BlockId,Col,Row,viability,AssayId,Size,RowSid,RowName,RowTarget,ColSid,ColName,ColTarget,RowIC50,ColIC50,RowConcs,ColConcs,RowConcUnit,ColConcUnit,sampleid,tissueid,tech_rep
1,1,1,14.474993,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
1,2,1,28.676052,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
1,3,1,48.732853,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
1,4,1,87.83152,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
1,5,1,95.498215,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
1,6,1,107.08472,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
1,1,2,27.756083,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
1,2,2,32.641487,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
1,3,2,58.319412,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
1,4,2,102.61983,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
1,5,2,121.307884,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
1,6,2,127.7844,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
1,1,3,29.385653,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
1,2,3,40.01661,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
1,3,3,47.64656,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
1,4,3,101.66422,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
1,5,3,104.186424,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
1,6,3,111.73902,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
1,1,4,23.841803,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
1,2,4,31.663637,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
1,3,4,55.086502,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
1,4,4,91.062355,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
1,5,4,107.619644,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
1,6,4,121.49063,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
1,1,5,26.949268,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
1,2,5,29.997416,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
1,3,5,63.292454,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
1,4,5,75.98061,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
1,5,5,99.06548,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
1,6,5,155.4477,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
1,1,6,25.806702,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
1,2,6,31.798246,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
1,3,6,52.973797,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
1,4,6,87.24015,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
1,5,6,121.06361,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
1,6,6,131.60458,241,6,NCGC00181170-01,Bendamustine,DNA Alkylating Drugs,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
2,1,1,29.801924,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
2,2,1,39.206524,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
2,3,1,62.363758,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
2,4,1,118.00928,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
2,5,1,108.924,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
2,6,1,110.91488,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
2,1,2,31.74158,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
2,2,2,36.245605,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
2,3,2,69.244606,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
2,4,2,106.69322,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
2,5,2,102.95666,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
2,6,2,120.22664,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
2,1,3,28.016712,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
2,2,3,41.870033,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
2,3,3,52.727165,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
2,4,3,95.64314,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
2,5,3,102.80574,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
2,6,3,115.9151,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
2,1,4,21.58653,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
2,2,4,34.21804,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
2,3,4,54.650093,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
2,4,4,111.27824,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
2,5,4,106.89332,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
2,6,4,135.62582,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
2,1,5,20.136543,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
2,2,5,38.628124,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
2,3,5,53.664227,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
2,4,5,101.9105,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
2,5,5,106.87818,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
2,6,5,121.9336,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
2,1,6,18.986855,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
2,2,6,30.399384,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
2,3,6,57.1681,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
2,4,6,107.812164,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
2,5,6,110.976845,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
2,6,6,127.42427,241,6,NCGC00015609-06,Lonidamine,Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
3,1,1,1.190721,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
3,2,1,5.45115,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
3,3,1,34.511883,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
3,4,1,62.129505,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
3,5,1,109.79749,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
3,6,1,121.42681,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
3,1,2,2.103873,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
3,2,2,5.844223,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
3,3,2,45.19304,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
3,4,2,63.733864,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
3,5,2,122.97624,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
3,6,2,121.80122,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
3,1,3,4.184669,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
3,2,3,10.824009,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
3,3,3,41.760242,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
3,4,3,95.623825,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
3,5,3,100.76559,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
3,6,3,103.04709,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
3,1,4,7.792697,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
3,2,4,16.02765,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
3,3,4,34.283543,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
3,4,4,104.51615,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
3,5,4,113.18016,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
3,6,4,102.914536,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
3,1,5,17.580656,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
3,2,5,31.49563,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
3,3,5,54.79558,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
3,4,5,107.15046,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
3,5,5,99.81724,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
3,6,5,120.697044,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
3,1,6,18.634737,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
3,2,6,35.88182,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
3,3,6,44.179775,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
3,4,6,105.03304,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
3,5,6,109.665634,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
3,6,6,120.70434,241,6,NCGC00167491-03,Lenalidomide,TNF-alpha Production Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
4,1,1,12.799044,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
4,2,1,19.575115,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
4,3,1,40.097553,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
4,4,1,69.11606,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
4,5,1,93.23787,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
4,6,1,103.0758,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
4,1,2,22.207022,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
4,2,2,31.705078,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
4,3,2,53.20959,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
4,4,2,96.614174,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
4,5,2,107.426125,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
4,6,2,109.19867,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
4,1,3,21.128227,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
4,2,3,25.887218,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
4,3,3,40.24586,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
4,4,3,82.91433,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
4,5,3,111.8516,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
4,6,3,120.221985,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
4,1,4,25.27073,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
4,2,4,31.52336,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
4,3,4,45.240524,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
4,4,4,80.97248,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
4,5,4,107.80447,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
4,6,4,122.52611,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
4,1,5,16.857117,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
4,2,5,35.09504,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
4,3,5,49.97621,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
4,4,5,75.57912,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
4,5,5,109.60606,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
4,6,5,118.48855,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
4,1,6,19.313986,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
4,2,6,34.623596,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
4,3,6,50.872105,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
4,4,6,84.63534,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
4,5,6,93.90398,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
4,6,6,104.35835,241,6,NCGC00022567-06,Cladribine,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
5,1,1,21.548607,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
5,2,1,25.239212,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
5,3,1,68.925896,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
5,4,1,99.63156,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
5,5,1,108.053566,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
5,6,1,105.06525,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
5,1,2,22.77298,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
5,2,2,32.914722,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
5,3,2,58.51257,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
5,4,2,93.51408,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
5,5,2,106.77318,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
5,6,2,100.57299,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
5,1,3,25.079494,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
5,2,3,29.045006,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
5,3,3,53.415234,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
5,4,3,87.410995,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
5,5,3,97.57086,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
5,6,3,99.27349,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
5,1,4,14.872461,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
5,2,4,31.565058,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
5,3,4,54.611244,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
5,4,4,69.65433,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
5,5,4,97.220604,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
5,6,4,99.77942,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
5,1,5,18.106356,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
5,2,5,29.591372,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
5,3,5,52.91111,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
5,4,5,85.77182,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
5,5,5,93.251625,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
5,6,5,99.444435,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
5,1,6,16.076849,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
5,2,6,29.057125,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
5,3,6,46.000217,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
5,4,6,81.53848,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
5,5,6,106.35091,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
5,6,6,102.915855,241,6,NCGC00182045-02,Pentostatin,Adenosine Deaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
6,1,1,26.128075,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
6,2,1,35.666027,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
6,3,1,58.12671,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
6,4,1,81.11758,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
6,5,1,90.26289,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
6,6,1,83.04601,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
6,1,2,30.931976,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
6,2,2,40.31774,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
6,3,2,60.48621,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
6,4,2,93.3162,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
6,5,2,94.85025,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
6,6,2,97.18974,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
6,1,3,19.626013,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
6,2,3,32.712337,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
6,3,3,51.044945,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
6,4,3,79.42058,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
6,5,3,98.67156,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
6,6,3,98.1773,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
6,1,4,28.84821,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
6,2,4,40.120857,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
6,3,4,55.165882,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
6,4,4,85.920265,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
6,5,4,104.84645,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
6,6,4,109.61235,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
6,1,5,34.72439,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
6,2,5,41.853745,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
6,3,5,43.14106,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
6,4,5,110.25843,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
6,5,5,132.80908,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
6,6,5,114.35211,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
6,1,6,35.43546,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
6,2,6,39.140656,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
6,3,6,46.291454,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
6,4,6,100.72871,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
6,5,6,113.32923,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
6,6,6,120.63585,241,6,NCGC00091641-03,6-Mercaptopurine monohydrate,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
7,1,1,14.439704,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
7,2,1,15.278762,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
7,3,1,20.408024,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
7,4,1,46.311577,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
7,5,1,65.06651,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
7,6,1,59.27867,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
7,1,2,11.079957,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
7,2,2,14.516161,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
7,3,2,28.643295,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
7,4,2,38.569836,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
7,5,2,51.35188,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
7,6,2,61.712933,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
7,1,3,10.328538,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
7,2,3,11.853755,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
7,3,3,26.986057,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
7,4,3,36.745625,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
7,5,3,44.163216,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
7,6,3,51.240192,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
7,1,4,9.814658,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
7,2,4,15.311415,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
7,3,4,18.450836,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
7,4,4,32.57938,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
7,5,4,49.66364,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
7,6,4,48.121227,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
7,1,5,10.156957,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
7,2,5,14.749002,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
7,3,5,17.429667,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
7,4,5,38.412632,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
7,5,5,41.247513,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
7,6,5,46.94222,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
7,1,6,28.104822,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
7,2,6,34.617764,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
7,3,6,54.821766,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
7,4,6,93.691444,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
7,5,6,116.779915,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
7,6,6,112.40249,241,6,NCGC00242507-01,Everolimus,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
8,1,1,21.197655,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
8,2,1,35.99878,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
8,3,1,50.27822,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
8,4,1,87.079994,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
8,5,1,111.97917,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
8,6,1,108.81846,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
8,1,2,22.087973,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
8,2,2,26.424858,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
8,3,2,57.266636,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
8,4,2,92.983604,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
8,5,2,111.79833,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
8,6,2,93.96965,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
8,1,3,19.445536,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
8,2,3,26.9313,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
8,3,3,51.843014,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
8,4,3,86.31994,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
8,5,3,110.35624,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
8,6,3,99.4149,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
8,1,4,27.782251,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
8,2,4,28.955685,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
8,3,4,41.221634,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
8,4,4,88.71548,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
8,5,4,97.98364,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
8,6,4,113.9349,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
8,1,5,25.694637,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
8,2,5,42.209106,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
8,3,5,71.14181,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
8,4,5,95.20246,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
8,5,5,132.17892,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
8,6,5,119.57787,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
8,1,6,30.787941,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
8,2,6,29.964596,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
8,3,6,53.461735,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
8,4,6,105.12927,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
8,5,6,111.3923,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
8,6,6,137.92578,241,6,NCGC00242510-01,Aminoglutethimide,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
9,1,1,27.973757,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
9,2,1,41.402912,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
9,3,1,59.2532,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
9,4,1,90.46126,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
9,5,1,100.4283,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
9,6,1,111.83955,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
9,1,2,30.206966,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
9,2,2,37.812187,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
9,3,2,71.8551,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
9,4,2,88.59775,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
9,5,2,113.80544,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
9,6,2,114.824715,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
9,1,3,24.408049,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
9,2,3,33.600307,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
9,3,3,53.184334,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
9,4,3,99.894585,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
9,5,3,113.50786,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
9,6,3,117.69093,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
9,1,4,19.692331,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
9,2,4,31.366262,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
9,3,4,44.849194,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
9,4,4,88.611046,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
9,5,4,113.67533,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
9,6,4,118.56876,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
9,1,5,17.682901,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
9,2,5,31.850082,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
9,3,5,44.168472,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
9,4,5,81.14715,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
9,5,5,112.52681,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
9,6,5,104.06654,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
9,1,6,22.381224,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
9,2,6,37.837887,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
9,3,6,47.628376,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
9,4,6,95.06108,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
9,5,6,113.75521,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
9,6,6,116.23054,241,6,NCGC00015070-04,4-Hydroxyandrostenedione,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
10,1,1,26.523907,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
10,2,1,29.607645,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
10,3,1,53.166756,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
10,4,1,104.99539,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
10,5,1,118.61184,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
10,6,1,111.780876,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
10,1,2,18.286346,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
10,2,2,32.166927,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
10,3,2,56.198128,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
10,4,2,81.27371,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
10,5,2,123.46991,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
10,6,2,107.65507,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
10,1,3,20.758806,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
10,2,3,25.504448,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
10,3,3,44.972336,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
10,4,3,91.22368,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
10,5,3,108.18309,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
10,6,3,107.12472,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
10,1,4,21.757551,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
10,2,4,21.563726,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
10,3,4,40.59952,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
10,4,4,84.50999,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
10,5,4,107.06331,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
10,6,4,113.23611,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
10,1,5,19.304108,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
10,2,5,28.870106,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
10,3,5,46.016808,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
10,4,5,83.60926,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
10,5,5,120.72137,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
10,6,5,106.238434,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
10,1,6,20.54171,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
10,2,6,30.033022,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
10,3,6,48.212456,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
10,4,6,87.73855,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
10,5,6,103.7352,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
10,6,6,102.24112,241,6,NCGC00016973-03,Letrozole,Aromatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
11,1,1,9.061117,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
11,2,1,14.064616,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
11,3,1,20.725775,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
11,4,1,39.078564,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
11,5,1,47.485584,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
11,6,1,42.38957,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
11,1,2,12.859485,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
11,2,2,20.261396,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
11,3,2,26.114681,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
11,4,2,50.401073,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
11,5,2,70.43093,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
11,6,2,65.13542,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
11,1,3,21.765053,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
11,2,3,37.548393,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
11,3,3,51.51926,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
11,4,3,102.42034,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
11,5,3,118.1117,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
11,6,3,123.325935,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
11,1,4,28.90594,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
11,2,4,32.910934,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
11,3,4,76.70259,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
11,4,4,104.86766,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
11,5,4,108.4861,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
11,6,4,132.68132,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
11,1,5,32.81769,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
11,2,5,43.22926,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
11,3,5,65.62405,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
11,4,5,108.62823,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
11,5,5,116.021286,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
11,6,5,120.68547,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
11,1,6,26.344854,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
11,2,6,37.099075,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
11,3,6,61.81077,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
11,4,6,112.0342,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
11,5,6,120.850655,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
11,6,6,132.1595,241,6,NCGC00242485-01,Pemetrexed disodium,thymidylate synthase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
12,1,1,8.187528,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
12,2,1,12.001366,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
12,3,1,18.081553,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
12,4,1,23.260708,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
12,5,1,41.93325,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
12,6,1,33.5005,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
12,1,2,12.594219,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
12,2,2,22.33298,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
12,3,2,25.621271,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
12,4,2,38.75196,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
12,5,2,54.773945,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
12,6,2,47.01898,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
12,1,3,13.946355,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
12,2,3,23.721497,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
12,3,3,32.128334,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
12,4,3,44.394737,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
12,5,3,63.326607,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
12,6,3,52.898277,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
12,1,4,15.968376,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
12,2,4,19.59004,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
12,3,4,35.295242,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
12,4,4,41.904762,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
12,5,4,80.48642,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
12,6,4,76.03816,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
12,1,5,20.195213,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
12,2,5,28.176748,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
12,3,5,45.827164,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
12,4,5,71.63027,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
12,5,5,93.5682,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
12,6,5,111.5816,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
12,1,6,28.598186,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
12,2,6,37.455116,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
12,3,6,54.0443,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
12,4,6,90.266495,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
12,5,6,112.9362,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
12,6,6,120.30409,241,6,NCGC00168784-02,Gemcitabine,Ribonucleotide reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
13,1,1,18.423336,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
13,2,1,30.731045,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
13,3,1,52.097023,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
13,4,1,81.04815,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
13,5,1,100.86715,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
13,6,1,113.5831,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
13,1,2,18.759073,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
13,2,2,29.40823,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
13,3,2,43.63179,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
13,4,2,62.209934,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
13,5,2,109.77385,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
13,6,2,113.796104,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
13,1,3,22.843315,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
13,2,3,32.458694,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
13,3,3,47.382397,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
13,4,3,84.06011,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
13,5,3,100.17637,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
13,6,3,113.16679,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
13,1,4,25.431416,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
13,2,4,47.364277,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
13,3,4,48.74076,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
13,4,4,85.08937,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
13,5,4,114.06472,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
13,6,4,123.57963,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
13,1,5,32.70125,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
13,2,5,38.087486,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
13,3,5,61.405758,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
13,4,5,110.014046,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
13,5,5,121.38621,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
13,6,5,113.904144,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
13,1,6,23.388485,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
13,2,6,33.613216,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
13,3,6,72.19201,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
13,4,6,94.427864,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
13,5,6,112.30405,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
13,6,6,111.42493,241,6,NCGC00024928-21,Tamoxifen,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
14,1,1,0.926228,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
14,2,1,-0.751313,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
14,3,1,0.239962,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
14,4,1,0.823376,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
14,5,1,1.367272,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
14,6,1,1.367469,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
14,1,2,-0.11161,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
14,2,2,-1.331089,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
14,3,2,-0.639354,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
14,4,2,-0.536775,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
14,5,2,-0.057032,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
14,6,2,0.092412,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
14,1,3,1.44676,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
14,2,3,-0.114958,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
14,3,3,0.695659,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
14,4,3,1.179494,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
14,5,3,3.43581,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
14,6,3,2.647451,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
14,1,4,5.799479,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
14,2,4,4.094469,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
14,3,4,10.956604,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
14,4,4,23.917246,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
14,5,4,26.305672,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
14,6,4,28.580626,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
14,1,5,9.829931,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
14,2,5,9.433266,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
14,3,5,15.551923,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
14,4,5,20.459797,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
14,5,5,33.813602,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
14,6,5,39.3313,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
14,1,6,22.311026,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
14,2,6,31.304474,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
14,3,6,51.53869,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
14,4,6,102.16524,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
14,5,6,117.19125,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
14,6,6,110.495056,241,6,NCGC00242508-01,Vincristine sulfate,Tubulin polymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
15,1,1,0.489274,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
15,2,1,-0.961971,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
15,3,1,-0.297889,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
15,4,1,0.595898,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
15,5,1,0.659461,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
15,6,1,0.623263,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
15,1,2,0.402816,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
15,2,2,-1.029822,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
15,3,2,-1.200858,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
15,4,2,-0.926076,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
15,5,2,-0.899454,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
15,6,2,-0.794466,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
15,1,3,0.091594,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
15,2,3,-1.040368,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
15,3,3,-1.656434,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
15,4,3,-1.028564,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
15,5,3,-0.886499,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
15,6,3,-0.939425,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
15,1,4,-0.254508,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
15,2,4,-0.942016,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
15,3,4,-0.94241,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
15,4,4,-0.843937,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
15,5,4,-0.839907,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
15,6,4,-0.49335,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
15,1,5,0.871786,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
15,2,5,-0.432302,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
15,3,5,0.032077,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
15,4,5,0.729327,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
15,5,5,1.538778,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
15,6,5,2.651163,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
15,1,6,21.146275,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
15,2,6,34.095898,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
15,3,6,41.09122,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
15,4,6,93.71493,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
15,5,6,93.23394,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
15,6,6,108.44731,241,6,NCGC00263098-01,Combretastatin A-4,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
16,1,1,-0.932349,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
16,2,1,-1.559809,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
16,3,1,-1.250966,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
16,4,1,-1.236874,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
16,5,1,-1.039989,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
16,6,1,-1.086612,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
16,1,2,-0.310131,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
16,2,2,-1.666479,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
16,3,2,-1.302316,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
16,4,2,-0.941349,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
16,5,2,-0.384649,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
16,6,2,-0.279888,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
16,1,3,1.361136,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
16,2,3,-0.531821,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
16,3,3,-0.519229,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
16,4,3,1.364394,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
16,5,3,5.522607,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
16,6,3,8.284319,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
16,1,4,4.632547,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
16,2,4,3.66203,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
16,3,4,8.439779,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
16,4,4,24.222649,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
16,5,4,36.622803,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
16,6,4,30.064978,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
16,1,5,12.109082,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
16,2,5,13.138661,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
16,3,5,18.857094,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
16,4,5,43.198746,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
16,5,5,74.60203,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
16,6,5,93.045105,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
16,1,6,28.8318,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
16,2,6,42.687847,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
16,3,6,57.39767,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
16,4,6,127.92144,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
16,5,6,133.84425,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
16,6,6,126.14696,241,6,NCGC00263169-01,Plinabulin,Tubulin polymerization Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
17,1,1,10.49068,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
17,2,1,13.327198,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
17,3,1,17.761406,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
17,4,1,31.484253,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
17,5,1,41.544903,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
17,6,1,42.61356,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
17,1,2,7.74365,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
17,2,2,9.280943,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
17,3,2,16.554804,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
17,4,2,27.58673,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
17,5,2,33.667946,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
17,6,2,35.451973,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
17,1,3,8.851777,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
17,2,3,10.486468,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
17,3,3,22.86721,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
17,4,3,27.083757,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
17,5,3,38.442314,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
17,6,3,44.724552,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
17,1,4,10.604547,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
17,2,4,9.90563,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
17,3,4,16.899998,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
17,4,4,28.905743,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
17,5,4,35.53728,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
17,6,4,35.08872,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
17,1,5,12.986232,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
17,2,5,12.416334,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
17,3,5,16.82154,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
17,4,5,34.45082,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
17,5,5,38.458664,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
17,6,5,42.203514,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
17,1,6,29.364408,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
17,2,6,42.29182,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
17,3,6,82.32468,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
17,4,6,121.982376,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
17,5,6,130.57625,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
17,6,6,121.06098,241,6,NCGC00242509-01,Docetaxel,Tubulin depolymerization inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
18,1,1,21.259216,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
18,2,1,39.2628,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
18,3,1,55.22566,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
18,4,1,93.38209,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
18,5,1,107.730194,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
18,6,1,110.44926,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
18,1,2,25.083586,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
18,2,2,27.903648,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
18,3,2,57.252045,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
18,4,2,91.235954,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
18,5,2,98.63863,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
18,6,2,104.7022,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
18,1,3,20.706987,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
18,2,3,39.370316,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
18,3,3,56.542793,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
18,4,3,93.4496,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
18,5,3,109.91404,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
18,6,3,117.29609,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
18,1,4,28.006683,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
18,2,4,34.744026,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
18,3,4,63.09404,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
18,4,4,98.17848,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
18,5,4,112.16524,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
18,6,4,106.10614,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
18,1,5,26.87569,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
18,2,5,40.44226,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
18,3,5,62.762997,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
18,4,5,105.770645,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
18,5,5,136.17027,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
18,6,5,113.275345,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
18,1,6,25.5938,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
18,2,6,39.44812,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
18,3,6,72.58332,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
18,4,6,107.840576,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
18,5,6,106.17411,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
18,6,6,102.668755,241,6,NCGC00025281-01,Blebbistatin,myosin II ATPase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
19,1,1,7.802637,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
19,2,1,6.831317,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
19,3,1,15.089589,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
19,4,1,24.503885,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
19,5,1,38.043076,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
19,6,1,45.790634,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
19,1,2,5.933393,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
19,2,2,6.551686,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
19,3,2,14.096026,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
19,4,2,23.261131,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
19,5,2,38.052074,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
19,6,2,39.37262,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
19,1,3,5.724235,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
19,2,3,7.612191,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
19,3,3,12.425198,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
19,4,3,25.934008,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
19,5,3,33.51744,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
19,6,3,39.23745,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
19,1,4,6.276571,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
19,2,4,7.064885,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
19,3,4,13.511189,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
19,4,4,29.103006,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
19,5,4,36.871628,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
19,6,4,39.754314,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
19,1,5,8.948099,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
19,2,5,14.99542,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
19,3,5,11.760282,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
19,4,5,28.036972,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
19,5,5,36.374866,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
19,6,5,40.77562,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
19,1,6,28.695145,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
19,2,6,46.666996,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
19,3,6,58.82688,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
19,4,6,118.13851,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
19,5,6,103.76006,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
19,6,6,122.956184,241,6,NCGC00263174-01,Ispinesib,Kinesin-Like Spindle Protein Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
20,1,1,-0.326632,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
20,2,1,-0.826088,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
20,3,1,-0.717554,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
20,4,1,0.422529,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
20,5,1,-0.056229,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
20,6,1,0.25263,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
20,1,2,-0.145505,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
20,2,2,-0.252114,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
20,3,2,-0.315086,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
20,4,2,0.205613,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
20,5,2,0.474591,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
20,6,2,-0.232053,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
20,1,3,-0.06126,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
20,2,3,0.411014,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
20,3,3,0.364254,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
20,4,3,5.670809,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
20,5,3,5.290341,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
20,6,3,10.269839,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
20,1,4,1.327014,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
20,2,4,3.413916,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
20,3,4,9.345672,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
20,4,4,25.844337,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
20,5,4,43.27052,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
20,6,4,50.195778,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
20,1,5,9.645106,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
20,2,5,9.873523,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
20,3,5,30.381989,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
20,4,5,81.52255,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
20,5,5,97.21404,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
20,6,5,106.43588,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
20,1,6,22.718327,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
20,2,6,31.925055,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
20,3,6,54.12703,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
20,4,6,82.67213,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
20,5,6,92.88483,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
20,6,6,102.92557,241,6,NCGC00024415-42,Doxorubicin,DNA Topoisomerase II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
21,1,1,-2.775577,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
21,2,1,-1.588234,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
21,3,1,-2.570024,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
21,4,1,-2.404367,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
21,5,1,-2.353835,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
21,6,1,-2.149692,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
21,1,2,-1.279239,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
21,2,2,-1.385091,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
21,3,2,0.536548,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
21,4,2,5.272659,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
21,5,2,5.246916,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
21,6,2,2.558251,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
21,1,3,3.159074,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
21,2,3,4.113393,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
21,3,3,4.843751,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
21,4,3,10.217247,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
21,5,3,15.903389,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
21,6,3,21.818842,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
21,1,4,6.495351,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
21,2,4,12.448517,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
21,3,4,18.341621,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
21,4,4,28.188599,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
21,5,4,26.208063,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
21,6,4,36.117558,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
21,1,5,14.766018,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
21,2,5,18.758347,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
21,3,5,30.281288,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
21,4,5,89.59246,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
21,5,5,75.6983,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
21,6,5,91.629616,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
21,1,6,39.90579,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
21,2,6,48.268898,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
21,3,6,79.06815,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
21,4,6,125.147194,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
21,5,6,115.60997,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
21,6,6,131.6862,241,6,NCGC00014925-04,Topotecan hydrochloride,DNA Topoisomerase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
22,1,1,30.891565,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
22,2,1,39.50958,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
22,3,1,55.184837,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
22,4,1,109.566956,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
22,5,1,136.96269,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
22,6,1,142.80092,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
22,1,2,29.964746,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
22,2,2,44.55908,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
22,3,2,71.00672,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
22,4,2,108.19806,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
22,5,2,120.89193,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
22,6,2,131.83694,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
22,1,3,30.553646,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
22,2,3,49.67773,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
22,3,3,67.27622,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
22,4,3,92.18627,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
22,5,3,124.58096,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
22,6,3,138.05379,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
22,1,4,32.522377,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
22,2,4,45.446926,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
22,3,4,69.75882,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
22,4,4,112.7483,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
22,5,4,131.37111,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
22,6,4,128.96548,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
22,1,5,30.674362,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
22,2,5,43.938892,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
22,3,5,72.2728,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
22,4,5,105.21393,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
22,5,5,121.43339,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
22,6,5,129.70496,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
22,1,6,37.709835,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
22,2,6,44.334267,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
22,3,6,69.351776,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
22,4,6,116.09494,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
22,5,6,135.43985,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
22,6,6,122.2194,241,6,NCGC00015209-06,Cyclophosphamide,Bcl-2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
23,1,1,22.970333,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
23,2,1,25.634438,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
23,3,1,53.126392,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
23,4,1,103.05665,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
23,5,1,116.608185,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
23,6,1,93.943665,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
23,1,2,20.639803,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
23,2,2,24.097569,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
23,3,2,46.36673,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
23,4,2,98.42743,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
23,5,2,112.49079,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
23,6,2,108.35863,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
23,1,3,22.310677,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
23,2,3,30.223969,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
23,3,3,59.459934,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
23,4,3,89.78772,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
23,5,3,113.02976,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
23,6,3,103.70823,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
23,1,4,23.252768,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
23,2,4,40.652966,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
23,3,4,68.01155,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
23,4,4,106.56349,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
23,5,4,104.82552,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
23,6,4,100.408875,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
23,1,5,32.73952,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
23,2,5,44.30257,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
23,3,5,74.41649,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
23,4,5,130.48701,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
23,5,5,135.58568,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
23,6,5,135.65071,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
23,1,6,30.084677,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
23,2,6,46.51325,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
23,3,6,81.997345,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
23,4,6,106.51512,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
23,5,6,115.81191,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
23,6,6,122.64599,241,6,NCGC00090851-08,5-Azacitidine,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
24,1,1,-0.354375,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
24,2,1,-0.976047,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
24,3,1,-0.556321,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
24,4,1,-0.399801,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
24,5,1,-0.150808,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
24,6,1,0.375331,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
24,1,2,-1.037095,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
24,2,2,-1.679616,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
24,3,2,-1.332514,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
24,4,2,-1.675237,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
24,5,2,-1.816318,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
24,6,2,-1.281451,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
24,1,3,-1.225465,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
24,2,3,-1.754285,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
24,3,3,-1.823803,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
24,4,3,-1.419562,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
24,5,3,-1.636145,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
24,6,3,-1.206055,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
24,1,4,-1.0944,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
24,2,4,-1.771452,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
24,3,4,-1.805787,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
24,4,4,-1.726618,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
24,5,4,-1.766937,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
24,6,4,-1.344287,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
24,1,5,-0.668446,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
24,2,5,-1.118416,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
24,3,5,-1.669949,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
24,4,5,-0.104988,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
24,5,5,0.077381,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
24,6,5,0.272403,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
24,1,6,29.985415,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
24,2,6,36.788063,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
24,3,6,1.671298,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
24,4,6,95.90076,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
24,5,6,121.57661,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
24,6,6,120.12531,241,6,NCGC00161622-04,Actinomycin D,DNA-Directed RNA Polymerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
25,1,1,-0.491243,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
25,2,1,-0.226947,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
25,3,1,-0.786738,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
25,4,1,0.275509,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
25,5,1,1.225147,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
25,6,1,1.255951,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
25,1,2,-1.194721,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
25,2,2,-1.137022,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
25,3,2,-1.127946,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
25,4,2,-0.93944,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
25,5,2,-0.589519,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
25,6,2,-0.343269,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
25,1,3,1.365288,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
25,2,3,1.11631,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
25,3,3,4.742414,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
25,4,3,7.884154,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
25,5,3,19.377033,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
25,6,3,12.369121,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
25,1,4,10.110895,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
25,2,4,12.467321,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
25,3,4,45.969383,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
25,4,4,72.450424,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
25,5,4,76.226006,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
25,6,4,92.58165,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
25,1,5,18.48502,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
25,2,5,33.794662,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
25,3,5,60.61,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
25,4,5,76.9013,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
25,5,5,106.717995,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
25,6,5,103.083466,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
25,1,6,25.781685,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
25,2,6,44.942635,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
25,3,6,64.60165,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
25,4,6,90.39822,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
25,5,6,110.23028,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
25,6,6,107.33271,241,6,NCGC00162423-03,Mithramycin,Alcohol Dehydrogenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
26,1,1,31.700047,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
26,2,1,40.76818,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
26,3,1,46.091537,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
26,4,1,81.701744,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
26,5,1,110.327324,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
26,6,1,131.48232,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
26,1,2,39.74457,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
26,2,2,42.590485,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
26,3,2,57.70304,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
26,4,2,97.90273,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
26,5,2,106.01185,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
26,6,2,123.041504,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
26,1,3,29.497929,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
26,2,3,43.019238,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
26,3,3,51.23192,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
26,4,3,95.16058,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
26,5,3,112.20667,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
26,6,3,123.13804,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
26,1,4,32.305447,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
26,2,4,45.912167,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
26,3,4,62.346012,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
26,4,4,92.72911,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
26,5,4,116.86286,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
26,6,4,142.57214,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
26,1,5,34.744846,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
26,2,5,41.34912,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
26,3,5,61.446728,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
26,4,5,99.23163,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
26,5,5,113.89253,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
26,6,5,132.68471,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
26,1,6,33.743435,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
26,2,6,44.911907,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
26,3,6,75.48333,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
26,4,6,103.523224,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
26,5,6,112.591934,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
26,6,6,122.22533,241,6,NCGC00018268-03,Itraconazole,cytochrome inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
27,1,1,28.885635,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
27,2,1,41.757713,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
27,3,1,59.370052,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
27,4,1,96.71298,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
27,5,1,118.59504,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
27,6,1,129.71658,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
27,1,2,34.749134,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
27,2,2,32.246277,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
27,3,2,4.206972,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
27,4,2,107.33274,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
27,5,2,134.14552,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
27,6,2,127.53427,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
27,1,3,27.951817,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
27,2,3,36.54616,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
27,3,3,59.47451,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
27,4,3,108.03867,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
27,5,3,115.32797,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
27,6,3,125.75653,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
27,1,4,35.606297,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
27,2,4,43.673367,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
27,3,4,74.53815,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
27,4,4,109.35156,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
27,5,4,135.1363,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
27,6,4,122.505455,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
27,1,5,31.183393,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
27,2,5,40.22557,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
27,3,5,70.02521,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
27,4,5,117.623055,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
27,5,5,128.56293,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
27,6,5,122.25539,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
27,1,6,29.897549,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
27,2,6,38.357265,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
27,3,6,61.67293,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
27,4,6,105.91112,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
27,5,6,116.03596,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
27,6,6,132.62851,241,6,NCGC00159483-02,Hydroxychloroquine sulfate,Autophagy Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
28,1,1,19.188528,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
28,2,1,29.663692,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
28,3,1,44.781525,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
28,4,1,95.36526,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
28,5,1,117.34373,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
28,6,1,117.41362,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
28,1,2,23.879698,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
28,2,2,27.552668,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
28,3,2,42.53292,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
28,4,2,80.07886,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
28,5,2,106.795044,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
28,6,2,102.22538,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
28,1,3,24.56219,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
28,2,3,35.15298,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
28,3,3,62.781437,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
28,4,3,76.204124,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
28,5,3,98.452675,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
28,6,3,117.40885,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
28,1,4,26.839039,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
28,2,4,30.13448,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
28,3,4,56.38571,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
28,4,4,109.11086,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
28,5,4,110.36909,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
28,6,4,107.201996,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
28,1,5,28.811104,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
28,2,5,45.907032,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
28,3,5,69.697014,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
28,4,5,116.88963,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
28,5,5,115.325645,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
28,6,5,115.74666,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
28,1,6,30.361715,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
28,2,6,48.670002,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
28,3,6,58.131573,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
28,4,6,89.62641,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
28,5,6,109.73514,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
28,6,6,108.140495,241,6,NCGC00025179-01,Mifepristone,Progesterone Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
29,1,1,23.170706,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
29,2,1,35.88173,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
29,3,1,57.326984,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
29,4,1,101.64111,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
29,5,1,116.37398,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
29,6,1,125.60565,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
29,1,2,21.886814,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
29,2,2,37.71705,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
29,3,2,55.95403,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
29,4,2,105.365234,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
29,5,2,136.15636,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
29,6,2,127.18905,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
29,1,3,26.560303,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
29,2,3,38.27184,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
29,3,3,51.977337,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
29,4,3,103.20851,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
29,5,3,119.64859,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
29,6,3,111.62158,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
29,1,4,27.512833,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
29,2,4,38.06724,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
29,3,4,64.0446,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
29,4,4,99.922874,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
29,5,4,120.386024,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
29,6,4,108.81361,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
29,1,5,26.917646,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
29,2,5,32.607155,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
29,3,5,62.573235,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
29,4,5,107.72445,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
29,5,5,112.87076,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
29,6,5,115.36502,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
29,1,6,36.38629,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
29,2,6,38.242172,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
29,3,6,47.810413,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
29,4,6,106.87385,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
29,5,6,111.525665,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
29,6,6,113.51416,241,6,NCGC00016564-05,Metformin,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
30,1,1,26.38878,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
30,2,1,36.86522,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
30,3,1,56.522488,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
30,4,1,95.77465,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
30,5,1,127.949196,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
30,6,1,116.44662,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
30,1,2,20.554527,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
30,2,2,30.911142,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
30,3,2,63.203556,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
30,4,2,91.00205,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
30,5,2,101.72431,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
30,6,2,113.37412,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
30,1,3,20.017479,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
30,2,3,34.494564,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
30,3,3,43.60376,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
30,4,3,104.995514,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
30,5,3,123.68128,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
30,6,3,106.20084,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
30,1,4,24.102098,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
30,2,4,33.227097,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
30,3,4,47.74203,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
30,4,4,103.79767,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
30,5,4,112.55028,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
30,6,4,119.05843,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
30,1,5,26.969467,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
30,2,5,31.949692,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
30,3,5,53.27902,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
30,4,5,87.48221,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
30,5,5,103.96386,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
30,6,5,110.196915,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
30,1,6,30.212255,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
30,2,6,39.964546,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
30,3,6,52.853428,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
30,4,6,88.747795,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
30,5,6,89.9239,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
30,6,6,103.647606,241,6,NCGC00165736-03,Acadesine,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
31,1,1,27.22334,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
31,2,1,36.70273,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
31,3,1,68.26463,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
31,4,1,98.19174,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
31,5,1,95.032715,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
31,6,1,108.085785,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
31,1,2,26.389782,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
31,2,2,38.747158,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
31,3,2,64.12511,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
31,4,2,94.32028,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
31,5,2,108.41673,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
31,6,2,117.63475,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
31,1,3,28.864378,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
31,2,3,38.459164,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
31,3,3,61.250507,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
31,4,3,106.60508,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
31,5,3,117.862785,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
31,6,3,110.3258,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
31,1,4,31.956177,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
31,2,4,45.15772,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
31,3,4,76.09803,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
31,4,4,118.39777,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
31,5,4,113.73964,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
31,6,4,109.941376,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
31,1,5,39.28575,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
31,2,5,45.629417,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
31,3,5,81.57509,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
31,4,5,103.16107,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
31,5,5,119.36226,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
31,6,5,126.90797,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
31,1,6,31.58374,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
31,2,6,41.716576,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
31,3,6,87.48213,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
31,4,6,115.08214,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
31,5,6,122.53637,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
31,6,6,133.42314,241,6,NCGC00250373-01,A-769662,AMPK Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
32,1,1,27.661854,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
32,2,1,31.865295,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
32,3,1,48.65721,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
32,4,1,104.56058,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
32,5,1,126.63944,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
32,6,1,108.28974,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
32,1,2,23.308784,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
32,2,2,32.699913,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
32,3,2,76.76469,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
32,4,2,82.75716,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
32,5,2,121.602516,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
32,6,2,118.83361,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
32,1,3,22.508636,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
32,2,3,34.22736,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
32,3,3,56.029106,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
32,4,3,102.965385,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
32,5,3,111.99299,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
32,6,3,112.26348,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
32,1,4,26.416615,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
32,2,4,39.99946,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
32,3,4,66.28563,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
32,4,4,104.75748,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
32,5,4,110.392525,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
32,6,4,122.132835,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
32,1,5,33.403194,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
32,2,5,35.043568,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
32,3,5,58.30535,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
32,4,5,108.820915,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
32,5,5,129.98015,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
32,6,5,108.2827,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
32,1,6,35.16151,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
32,2,6,35.16274,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
32,3,6,57.876003,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
32,4,6,104.80787,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
32,5,6,100.20071,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
32,6,6,123.057625,241,6,NCGC00159456-07,Imatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
33,1,1,24.679392,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
33,2,1,27.344387,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
33,3,1,41.517643,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
33,4,1,69.73397,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
33,5,1,94.49341,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
33,6,1,111.1045,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
33,1,2,21.981544,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
33,2,2,39.397606,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
33,3,2,49.44936,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
33,4,2,74.025795,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
33,5,2,109.26549,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
33,6,2,96.59264,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
33,1,3,28.726646,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
33,2,3,37.941982,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
33,3,3,55.91756,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
33,4,3,91.66195,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
33,5,3,102.99384,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
33,6,3,104.5383,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
33,1,4,20.781384,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
33,2,4,37.451145,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
33,3,4,53.990463,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
33,4,4,78.29927,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
33,5,4,104.636635,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
33,6,4,128.00429,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
33,1,5,37.978344,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
33,2,5,39.793877,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
33,3,5,73.675385,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
33,4,5,100.26849,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
33,5,5,122.832726,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
33,6,5,97.552765,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
33,1,6,26.933693,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
33,2,6,40.345757,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
33,3,6,74.3637,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
33,4,6,107.87841,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
33,5,6,114.48885,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
33,6,6,120.58051,241,6,NCGC00183285-04,Nilotinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
34,1,1,10.85204,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
34,2,1,5.078122,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
34,3,1,3.703774,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
34,4,1,7.619918,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
34,5,1,5.226991,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
34,6,1,13.557539,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
34,1,2,15.652881,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
34,2,2,8.068176,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
34,3,2,13.09372,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
34,4,2,9.478313,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
34,5,2,19.17018,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
34,6,2,47.183846,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
34,1,3,15.444737,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
34,2,3,15.94386,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
34,3,3,25.916918,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
34,4,3,52.57242,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
34,5,3,63.88493,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
34,6,3,99.277176,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
34,1,4,20.148863,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
34,2,4,26.854448,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
34,3,4,58.27923,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
34,4,4,99.934814,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
34,5,4,116.196686,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
34,6,4,103.916145,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
34,1,5,27.125698,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
34,2,5,40.75665,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
34,3,5,71.931175,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
34,4,5,111.91042,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
34,5,5,124.312515,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
34,6,5,106.32745,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
34,1,6,29.700224,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
34,2,6,39.50062,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
34,3,6,64.60748,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
34,4,6,105.81263,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
34,5,6,107.2353,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
34,6,6,116.67485,241,6,NCGC00263152-01,Ponatinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
35,1,1,5.676975,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
35,2,1,5.24837,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
35,3,1,4.813886,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
35,4,1,6.027457,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
35,5,1,4.857388,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
35,6,1,7.559477,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
35,1,2,5.727886,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
35,2,2,7.325924,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
35,3,2,10.3696,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
35,4,2,12.745527,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
35,5,2,18.326258,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
35,6,2,18.798819,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
35,1,3,8.487311,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
35,2,3,12.90085,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
35,3,3,24.478277,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
35,4,3,56.82021,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
35,5,3,61.134247,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
35,6,3,74.8142,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
35,1,4,16.418512,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
35,2,4,20.40519,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
35,3,4,44.561424,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
35,4,4,77.35157,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
35,5,4,104.58804,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
35,6,4,93.1583,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
35,1,5,15.177698,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
35,2,5,26.363022,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
35,3,5,46.764668,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
35,4,5,90.82747,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
35,5,5,102.743454,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
35,6,5,103.62852,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
35,1,6,22.953304,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
35,2,6,31.994768,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
35,3,6,53.921432,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
35,4,6,92.23764,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
35,5,6,97.5993,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
35,6,6,100.60485,241,6,NCGC00263172-01,DCC-2036,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
36,1,1,1.282767,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
36,2,1,1.077831,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
36,3,1,3.207967,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
36,4,1,2.550915,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
36,5,1,2.576279,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
36,6,1,3.094423,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
36,1,2,0.641177,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
36,2,2,0.974313,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
36,3,2,0.959443,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
36,4,2,0.876984,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
36,5,2,1.622827,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
36,6,2,2.782202,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
36,1,3,0.878616,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
36,2,3,1.112576,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
36,3,3,2.054225,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
36,4,3,2.074279,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
36,5,3,2.351791,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
36,6,3,2.348436,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
36,1,4,1.905272,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
36,2,4,1.474896,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
36,3,4,5.002708,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
36,4,4,3.992017,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
36,5,4,5.94407,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
36,6,4,9.356955,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
36,1,5,4.696083,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
36,2,5,6.516492,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
36,3,5,14.333151,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
36,4,5,26.637943,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
36,5,5,61.30163,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
36,6,5,47.84038,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
36,1,6,13.052519,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
36,2,6,24.712133,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
36,3,6,54.03843,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
36,4,6,82.92033,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
36,5,6,128.20325,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
36,6,6,108.848305,241,6,NCGC00181129-03,Dasatinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
37,1,1,5.883064,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
37,2,1,4.745447,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
37,3,1,5.940303,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
37,4,1,11.162584,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
37,5,1,14.122385,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
37,6,1,22.325205,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
37,1,2,25.74817,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
37,2,2,33.136497,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
37,3,2,55.204746,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
37,4,2,82.963264,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
37,5,2,80.10275,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
37,6,2,119.60951,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
37,1,3,25.789032,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
37,2,3,37.987923,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
37,3,3,47.973732,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
37,4,3,111.32488,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
37,5,3,127.52284,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
37,6,3,115.099945,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
37,1,4,23.125612,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
37,2,4,36.185413,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
37,3,4,54.52556,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
37,4,4,92.9303,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
37,5,4,124.237595,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
37,6,4,99.00481,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
37,1,5,19.06102,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
37,2,5,31.44185,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
37,3,5,52.43295,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
37,4,5,76.21628,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
37,5,5,121.58279,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
37,6,5,138.28201,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
37,1,6,14.686826,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
37,2,6,27.304234,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
37,3,6,50.154037,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
37,4,6,106.344666,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
37,5,6,118.03079,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
37,6,6,123.265594,241,6,NCGC00241107-01,Bosutinib,Bcr-Abl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
38,1,1,6.685249,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
38,2,1,9.368202,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
38,3,1,16.485512,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
38,4,1,43.3513,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
38,5,1,71.309715,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
38,6,1,81.81372,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
38,1,2,14.547469,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
38,2,2,23.432955,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
38,3,2,52.04026,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
38,4,2,99.51233,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
38,5,2,105.217834,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
38,6,2,113.412384,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
38,1,3,17.954416,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
38,2,3,37.77755,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
38,3,3,61.42156,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
38,4,3,94.718056,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
38,5,3,113.36856,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
38,6,3,120.9208,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
38,1,4,16.662197,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
38,2,4,28.55848,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
38,3,4,48.10019,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
38,4,4,91.33079,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
38,5,4,114.20151,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
38,6,4,113.54487,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
38,1,5,17.353224,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
38,2,5,38.20649,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
38,3,5,59.20907,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
38,4,5,106.38146,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
38,5,5,120.838165,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
38,6,5,131.79504,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
38,1,6,18.682108,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
38,2,6,38.386654,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
38,3,6,68.727425,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
38,4,6,121.73404,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
38,5,6,118.57726,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
38,6,6,112.3016,241,6,NCGC00241099-03,Saracatinib,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
39,1,1,1.626899,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
39,2,1,1.669285,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
39,3,1,2.763188,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
39,4,1,2.991659,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
39,5,1,2.018619,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
39,6,1,3.529946,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
39,1,2,0.429783,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
39,2,2,1.016215,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
39,3,2,2.27222,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
39,4,2,6.226155,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
39,5,2,5.589158,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
39,6,2,10.057829,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
39,1,3,2.731797,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
39,2,3,11.276774,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
39,3,3,15.055657,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
39,4,3,44.52949,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
39,5,3,73.095215,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
39,6,3,98.73237,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
39,1,4,12.93336,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
39,2,4,19.689838,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
39,3,4,36.245037,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
39,4,4,86.43685,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
39,5,4,117.46598,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
39,6,4,130.35901,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
39,1,5,16.25245,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
39,2,5,30.892729,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
39,3,5,40.00245,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
39,4,5,85.57872,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
39,5,5,90.60717,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
39,6,5,117.26793,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
39,1,6,20.242476,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
39,2,6,29.707684,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
39,3,6,44.441956,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
39,4,6,100.456635,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
39,5,6,109.75544,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
39,6,6,115.894485,241,6,NCGC00242490-02,PD-166285,cSRC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
40,1,1,10.168611,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
40,2,1,18.875814,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
40,3,1,38.899075,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
40,4,1,83.7948,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
40,5,1,121.51627,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
40,6,1,125.93868,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
40,1,2,17.083084,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
40,2,2,23.360952,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
40,3,2,41.805244,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
40,4,2,94.5617,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
40,5,2,124.3616,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
40,6,2,130.31094,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
40,1,3,18.390318,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
40,2,3,24.15232,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
40,3,3,52.587894,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
40,4,3,92.05763,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
40,5,3,110.87603,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
40,6,3,114.65291,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
40,1,4,20.916676,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
40,2,4,26.172375,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
40,3,4,52.72926,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
40,4,4,98.4314,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
40,5,4,118.563095,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
40,6,4,115.092125,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
40,1,5,14.323393,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
40,2,5,26.095854,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
40,3,5,53.852436,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
40,4,5,84.53156,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
40,5,5,120.471146,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
40,6,5,110.94776,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
40,1,6,18.74679,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
40,2,6,23.43925,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
40,3,6,44.61369,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
40,4,6,79.23757,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
40,5,6,111.004105,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
40,6,6,101.998024,241,6,NCGC00167513-03,Vandetanib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
41,1,1,15.372811,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
41,2,1,26.956335,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
41,3,1,43.13596,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
41,4,1,76.03093,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
41,5,1,97.93417,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
41,6,1,106.616066,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
41,1,2,12.518787,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
41,2,2,22.436703,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
41,3,2,44.7893,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
41,4,2,83.03263,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
41,5,2,115.80196,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
41,6,2,104.40847,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
41,1,3,20.31602,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
41,2,3,21.13363,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
41,3,3,44.236214,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
41,4,3,92.675835,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
41,5,3,121.04931,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
41,6,3,116.595055,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
41,1,4,17.504688,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
41,2,4,32.14834,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
41,3,4,46.840508,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
41,4,4,83.22341,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
41,5,4,127.08059,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
41,6,4,112.74146,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
41,1,5,25.9756,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
41,2,5,35.40479,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
41,3,5,50.762302,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
41,4,5,102.94732,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
41,5,5,128.9437,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
41,6,5,119.69798,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
41,1,6,22.892353,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
41,2,6,31.149218,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
41,3,6,54.744255,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
41,4,6,115.68521,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
41,5,6,130.78781,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
41,6,6,140.71803,241,6,NCGC00164574-03,Erlotinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
42,1,1,17.027584,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
42,2,1,20.17164,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
42,3,1,53.176083,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
42,4,1,115.514015,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
42,5,1,136.023,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
42,6,1,127.30278,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
42,1,2,25.283552,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
42,2,2,31.391983,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
42,3,2,66.23314,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
42,4,2,108.91503,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
42,5,2,110.65004,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
42,6,2,146.80978,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
42,1,3,29.493834,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
42,2,3,28.48804,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
42,3,3,56.914497,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
42,4,3,107.803276,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
42,5,3,129.32309,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
42,6,3,133.02252,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
42,1,4,25.862576,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
42,2,4,34.44465,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
42,3,4,58.251457,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
42,4,4,106.69214,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
42,5,4,117.42076,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
42,6,4,150.58585,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
42,1,5,26.230799,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
42,2,5,32.07761,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
42,3,5,56.32972,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
42,4,5,97.7915,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
42,5,5,147.92577,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
42,6,5,118.241135,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
42,1,6,33.482227,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
42,2,6,30.919598,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
42,3,6,67.0463,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
42,4,6,107.21441,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
42,5,6,122.76415,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
42,6,6,135.37248,241,6,NCGC00159455-08,Gefitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
43,1,1,20.77237,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
43,2,1,30.359337,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
43,3,1,43.633923,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
43,4,1,81.928505,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
43,5,1,122.18827,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
43,6,1,138.63918,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
43,1,2,18.624277,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
43,2,2,30.61075,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
43,3,2,42.000908,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
43,4,2,84.83385,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
43,5,2,123.95023,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
43,6,2,136.11955,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
43,1,3,24.43308,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
43,2,3,34.606354,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
43,3,3,44.913387,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
43,4,3,81.86931,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
43,5,3,123.853516,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
43,6,3,118.01247,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
43,1,4,34.76069,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
43,2,4,30.135818,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
43,3,4,55.28776,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
43,4,4,100.36523,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
43,5,4,117.425316,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
43,6,4,118.56838,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
43,1,5,26.09684,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
43,2,5,36.393005,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
43,3,5,60.14157,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
43,4,5,103.486,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
43,5,5,119.52708,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
43,6,5,141.50395,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
43,1,6,24.547934,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
43,2,6,41.583214,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
43,3,6,61.804543,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
43,4,6,99.74036,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
43,5,6,122.80386,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
43,6,6,145.11908,241,6,NCGC00167507-03,Lapatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
44,1,1,0.999372,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
44,2,1,1.030888,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
44,3,1,1.714721,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
44,4,1,2.580046,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
44,5,1,2.762668,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
44,6,1,3.037094,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
44,1,2,9.449962,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
44,2,2,12.627578,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
44,3,2,15.363089,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
44,4,2,29.340252,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
44,5,2,34.361866,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
44,6,2,39.705082,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
44,1,3,31.348324,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
44,2,3,38.23144,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
44,3,3,66.0279,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
44,4,3,86.72396,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
44,5,3,87.27432,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
44,6,3,89.3905,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
44,1,4,27.417635,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
44,2,4,40.932495,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
44,3,4,52.72621,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
44,4,4,85.27829,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
44,5,4,97.56182,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
44,6,4,108.62803,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
44,1,5,28.913391,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
44,2,5,48.396896,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
44,3,5,51.74117,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
44,4,5,99.4535,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
44,5,5,122.81106,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
44,6,5,122.04298,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
44,1,6,20.577835,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
44,2,6,40.07402,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
44,3,6,59.942913,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
44,4,6,108.33529,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
44,5,6,128.1021,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
44,6,6,139.78333,241,6,NCGC00241101-01,Neratinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
45,1,1,13.286711,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
45,2,1,33.808582,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
45,3,1,32.707737,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
45,4,1,35.68761,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
45,5,1,41.0434,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
45,6,1,46.980835,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
45,1,2,63.878338,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
45,2,2,121.64903,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
45,3,2,158.4078,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
45,4,2,148.9793,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
45,5,2,140.63225,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
45,6,2,151.47575,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
45,1,3,40.801746,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
45,2,3,100.395256,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
45,3,3,148.33612,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
45,4,3,135.38275,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
45,5,3,142.65184,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
45,6,3,181.184,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
45,1,4,27.161379,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
45,2,4,65.10792,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
45,3,4,118.55597,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
45,4,4,156.93535,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
45,5,4,178.45438,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
45,6,4,187.23946,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
45,1,5,26.562283,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
45,2,5,44.694195,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
45,3,5,97.06703,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
45,4,5,135.2814,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
45,5,5,136.33353,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
45,6,5,153.8751,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
45,1,6,23.027296,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
45,2,6,31.688921,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
45,3,6,40.31216,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
45,4,6,89.57034,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
45,5,6,95.24452,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
45,6,6,115.03824,241,6,NCGC00182713-02,Canertinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
46,1,1,1.067427,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
46,2,1,1.531399,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
46,3,1,4.029453,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
46,4,1,5.013309,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
46,5,1,5.430715,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
46,6,1,6.314408,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
46,1,2,12.571793,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
46,2,2,42.49198,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
46,3,2,108.74609,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
46,4,2,124.39858,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
46,5,2,134.17648,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
46,6,2,156.21252,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
46,1,3,23.749857,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
46,2,3,57.96546,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
46,3,3,117.40366,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
46,4,3,148.10863,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
46,5,3,168.99434,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
46,6,3,175.37262,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
46,1,4,23.657568,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
46,2,4,55.95703,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
46,3,4,96.724335,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
46,4,4,151.41562,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
46,5,4,141.43222,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
46,6,4,156.16422,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
46,1,5,29.073341,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
46,2,5,42.813694,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
46,3,5,87.637375,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
46,4,5,116.608475,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
46,5,5,152.82047,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
46,6,5,139.67792,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
46,1,6,29.413885,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
46,2,6,37.704975,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
46,3,6,61.31856,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
46,4,6,117.60096,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
46,5,6,137.33282,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
46,6,6,135.75519,241,6,NCGC00263195-01,AV-412,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
47,1,1,19.179068,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
47,2,1,30.218546,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
47,3,1,50.240192,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
47,4,1,113.43389,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
47,5,1,136.73949,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
47,6,1,133.79515,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
47,1,2,31.570517,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
47,2,2,42.61349,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
47,3,2,72.31768,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
47,4,2,131.41176,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
47,5,2,156.39967,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
47,6,2,160.07816,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
47,1,3,29.146473,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
47,2,3,38.56576,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
47,3,3,77.05222,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
47,4,3,131.71013,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
47,5,3,131.67828,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
47,6,3,146.13942,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
47,1,4,22.543001,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
47,2,4,31.84209,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
47,3,4,76.39583,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
47,4,4,131.05882,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
47,5,4,140.97234,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
47,6,4,148.87901,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
47,1,5,29.229828,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
47,2,5,37.097626,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
47,3,5,59.727016,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
47,4,5,111.83908,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
47,5,5,128.14871,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
47,6,5,126.42888,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
47,1,6,28.38255,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
47,2,6,40.659737,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
47,3,6,70.82511,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
47,4,6,92.73948,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
47,5,6,131.99046,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
47,6,6,133.80428,241,6,NCGC00263185-01,Dacomitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
48,1,1,29.108679,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
48,2,1,32.372326,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
48,3,1,42.084103,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
48,4,1,83.68156,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
48,5,1,124.814,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
48,6,1,123.08599,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
48,1,2,29.818521,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
48,2,2,30.727827,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
48,3,2,49.162094,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
48,4,2,98.783134,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
48,5,2,124.60901,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
48,6,2,120.891365,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
48,1,3,23.487736,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
48,2,3,33.442783,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
48,3,3,55.275024,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
48,4,3,96.726845,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
48,5,3,118.64417,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
48,6,3,117.88068,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
48,1,4,25.96577,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
48,2,4,35.12615,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
48,3,4,60.462635,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
48,4,4,123.63167,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
48,5,4,120.18219,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
48,6,4,119.00279,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
48,1,5,23.372522,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
48,2,5,34.51322,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
48,3,5,65.24284,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
48,4,5,100.4009,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
48,5,5,116.57773,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
48,6,5,156.96718,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
48,1,6,33.684616,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
48,2,6,36.82399,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
48,3,6,68.48914,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
48,4,6,116.27475,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
48,5,6,127.25202,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
48,6,6,139.55751,241,6,NCGC00263101-01,CP-724714,HER2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
49,1,1,0.864464,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
49,2,1,0.969093,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
49,3,1,2.807332,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
49,4,1,4.728317,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
49,5,1,5.30187,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
49,6,1,6.316632,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
49,1,2,18.69558,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
49,2,2,21.918972,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
49,3,2,72.13585,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
49,4,2,121.95051,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
49,5,2,127.18141,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
49,6,2,151.93279,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
49,1,3,25.988892,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
49,2,3,35.11996,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
49,3,3,62.921837,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
49,4,3,126.63317,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
49,5,3,127.68623,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
49,6,3,154.40402,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
49,1,4,23.59364,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
49,2,4,33.872402,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
49,3,4,70.84007,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
49,4,4,134.66322,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
49,5,4,130.30618,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
49,6,4,124.74089,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
49,1,5,26.818054,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
49,2,5,36.314224,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
49,3,5,73.10655,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
49,4,5,129.78333,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
49,5,5,118.45089,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
49,6,5,141.3396,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
49,1,6,29.37333,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
49,2,6,35.49211,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
49,3,6,61.388317,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
49,4,6,124.830414,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
49,5,6,132.87856,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
49,6,6,133.86928,241,6,NCGC00185000-02,Afatinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
50,1,1,17.672762,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
50,2,1,22.188663,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
50,3,1,29.405867,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
50,4,1,74.95685,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
50,5,1,114.46897,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
50,6,1,126.473274,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
50,1,2,27.410944,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
50,2,2,33.620686,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
50,3,2,49.12826,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
50,4,2,104.4554,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
50,5,2,132.2011,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
50,6,2,120.77271,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
50,1,3,27.884657,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
50,2,3,39.158722,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
50,3,3,66.53582,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
50,4,3,118.55789,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
50,5,3,130.93277,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
50,6,3,142.61092,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
50,1,4,23.680008,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
50,2,4,39.441883,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
50,3,4,67.18849,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
50,4,4,112.44458,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
50,5,4,120.217026,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
50,6,4,116.24572,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
50,1,5,19.928534,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
50,2,5,32.592545,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
50,3,5,56.711555,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
50,4,5,102.54015,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
50,5,5,121.64727,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
50,6,5,130.182,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
50,1,6,16.007673,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
50,2,6,31.51925,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
50,3,6,50.170273,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
50,4,6,104.001366,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
50,5,6,115.15173,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
50,6,6,110.057724,241,6,NCGC00263149-01,AEE-788,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
51,1,1,-1.099159,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
51,2,1,-1.294301,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
51,3,1,-1.222174,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
51,4,1,-1.231215,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
51,5,1,-1.166012,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
51,6,1,-0.845127,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
51,1,2,0.999605,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
51,2,2,-0.735798,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
51,3,2,-0.887029,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
51,4,2,-0.136576,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
51,5,2,0.949559,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
51,6,2,1.662343,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
51,1,3,3.204828,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
51,2,3,0.820122,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
51,3,3,5.443881,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
51,4,3,13.472813,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
51,5,3,25.55256,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
51,6,3,26.051296,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
51,1,4,9.75951,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
51,2,4,9.274909,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
51,3,4,25.892174,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
51,4,4,78.426865,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
51,5,4,71.42539,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
51,6,4,95.252525,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
51,1,5,17.307358,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
51,2,5,22.436255,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
51,3,5,39.94686,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
51,4,5,93.103195,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
51,5,5,123.13555,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
51,6,5,125.290855,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
51,1,6,29.121487,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
51,2,6,33.68856,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
51,3,6,69.15427,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
51,4,6,87.1009,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
51,5,6,133.19809,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
51,6,6,119.391,241,6,NCGC00263177-01,CUDC-101,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
52,1,1,9.078063,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
52,2,1,12.706952,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
52,3,1,28.352898,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
52,4,1,48.073856,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
52,5,1,54.45593,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
52,6,1,59.550636,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
52,1,2,32.693764,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
52,2,2,55.981068,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
52,3,2,80.542725,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
52,4,2,134.42358,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
52,5,2,148.04153,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
52,6,2,178.39006,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
52,1,3,30.616758,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
52,2,3,40.328213,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
52,3,3,86.66609,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
52,4,3,119.41172,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
52,5,3,147.1354,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
52,6,3,160.27771,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
52,1,4,26.06109,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
52,2,4,39.42558,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
52,3,4,85.48932,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
52,4,4,125.128105,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
52,5,4,147.31166,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
52,6,4,133.82101,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
52,1,5,24.330404,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
52,2,5,34.504345,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
52,3,5,51.73405,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
52,4,5,125.37763,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
52,5,5,139.15707,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
52,6,5,141.33191,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
52,1,6,35.07639,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
52,2,6,40.140766,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
52,3,6,62.31002,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
52,4,6,111.76025,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
52,5,6,137.34549,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
52,6,6,129.07404,241,6,NCGC00263103-01,Pelitinib,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
53,1,1,39.399982,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
53,2,1,66.1347,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
53,3,1,72.89324,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
53,4,1,78.80581,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
53,5,1,88.35081,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
53,6,1,74.0661,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
53,1,2,27.835058,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
53,2,2,50.404125,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
53,3,2,117.30768,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
53,4,2,132.20807,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
53,5,2,123.59911,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
53,6,2,131.022,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
53,1,3,29.22843,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
53,2,3,45.81981,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
53,3,3,78.394684,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
53,4,3,128.41263,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
53,5,3,133.62103,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
53,6,3,147.00232,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
53,1,4,22.768099,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
53,2,4,39.7825,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
53,3,4,82.39881,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
53,4,4,124.53163,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
53,5,4,132.22821,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
53,6,4,120.4727,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
53,1,5,28.341257,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
53,2,5,39.007187,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
53,3,5,72.02031,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
53,4,5,112.195465,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
53,5,5,139.58987,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
53,6,5,151.00922,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
53,1,6,40.275494,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
53,2,6,41.96078,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
53,3,6,60.045174,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
53,4,6,102.82294,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
53,5,6,134.36429,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
53,6,6,160.0777,241,6,NCGC00263144-01,WZ-4002,EGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
54,1,1,28.699883,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
54,2,1,30.186886,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
54,3,1,51.639896,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
54,4,1,115.69068,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
54,5,1,152.55782,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
54,6,1,152.7422,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
54,1,2,29.885212,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
54,2,2,42.4873,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
54,3,2,65.28286,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
54,4,2,130.34476,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
54,5,2,153.5152,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
54,6,2,149.55702,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
54,1,3,30.8013,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
54,2,3,44.46045,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
54,3,3,59.96745,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
54,4,3,113.8231,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
54,5,3,127.880226,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
54,6,3,142.913,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
54,1,4,24.405188,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
54,2,4,38.99395,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
54,3,4,69.66561,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
54,4,4,134.46306,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
54,5,4,135.93578,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
54,6,4,125.31252,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
54,1,5,20.909536,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
54,2,5,32.109306,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
54,3,5,59.20776,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
54,4,5,123.19397,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
54,5,5,122.22895,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
54,6,5,144.57639,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
54,1,6,28.335894,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
54,2,6,37.102882,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
54,3,6,52.945515,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
54,4,6,127.30368,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
54,5,6,119.069756,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
54,6,6,126.895584,241,6,NCGC00250403-01,Linifanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
55,1,1,33.413723,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
55,2,1,38.426888,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
55,3,1,58.33829,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
55,4,1,132.36732,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
55,5,1,155.2181,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
55,6,1,160.58891,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
55,1,2,29.504847,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
55,2,2,38.06091,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
55,3,2,60.714836,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
55,4,2,122.37479,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
55,5,2,124.572296,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
55,6,2,115.2858,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
55,1,3,25.179981,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
55,2,3,37.217342,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
55,3,3,59.643517,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
55,4,3,113.37305,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
55,5,3,115.621445,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
55,6,3,132.85751,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
55,1,4,28.29878,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
55,2,4,26.862629,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
55,3,4,54.217968,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
55,4,4,104.19954,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
55,5,4,137.58443,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
55,6,4,116.0737,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
55,1,5,28.433311,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
55,2,5,28.826412,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
55,3,5,40.206078,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
55,4,5,102.85926,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
55,5,5,113.479645,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
55,6,5,125.28102,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
55,1,6,21.084429,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
55,2,6,34.374783,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
55,3,6,44.01246,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
55,4,6,92.17182,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
55,5,6,118.173256,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
55,6,6,132.55281,241,6,NCGC00241108-01,Axitinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
56,1,1,15.701391,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
56,2,1,37.85886,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
56,3,1,46.941803,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
56,4,1,94.51405,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
56,5,1,115.23731,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
56,6,1,101.48498,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
56,1,2,25.297543,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
56,2,2,36.03271,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
56,3,2,62.10069,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
56,4,2,119.64591,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
56,5,2,122.105255,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
56,6,2,130.63995,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
56,1,3,28.021072,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
56,2,3,36.946163,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
56,3,3,67.0922,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
56,4,3,128.29198,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
56,5,3,121.2957,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
56,6,3,128.60031,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
56,1,4,33.09465,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
56,2,4,34.08028,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
56,3,4,49.0634,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
56,4,4,93.072685,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
56,5,4,118.750916,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
56,6,4,126.04432,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
56,1,5,27.026543,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
56,2,5,35.25033,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
56,3,5,60.8757,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
56,4,5,93.522415,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
56,5,5,121.30841,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
56,6,5,131.88376,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
56,1,6,31.815453,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
56,2,6,36.646374,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
56,3,6,59.39476,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
56,4,6,118.45888,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
56,5,6,117.675545,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
56,6,6,125.55747,241,6,NCGC00167488-05,Sorafenib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
57,1,1,29.895115,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
57,2,1,41.086613,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
57,3,1,61.781887,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
57,4,1,102.76306,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
57,5,1,137.43747,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
57,6,1,122.25349,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
57,1,2,32.579,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
57,2,2,36.509293,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
57,3,2,66.84214,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
57,4,2,126.1355,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
57,5,2,133.42296,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
57,6,2,132.2219,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
57,1,3,31.73538,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
57,2,3,38.089645,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
57,3,3,56.203777,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
57,4,3,102.78007,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
57,5,3,104.56424,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
57,6,3,136.12091,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
57,1,4,30.390118,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
57,2,4,38.167656,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
57,3,4,60.1705,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
57,4,4,120.9276,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
57,5,4,148.31416,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
57,6,4,133.11998,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
57,1,5,27.667164,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
57,2,5,29.774305,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
57,3,5,64.15612,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
57,4,5,103.782364,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
57,5,5,123.71764,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
57,6,5,125.837585,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
57,1,6,29.21268,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
57,2,6,34.995525,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
57,3,6,50.53096,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
57,4,6,102.4547,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
57,5,6,125.90946,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
57,6,6,132.31923,241,6,NCGC00181350-02,Vatalanib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
58,1,1,26.112553,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
58,2,1,40.93244,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
58,3,1,56.631786,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
58,4,1,105.81221,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
58,5,1,134.0693,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
58,6,1,126.906166,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
58,1,2,33.31991,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
58,2,2,42.25492,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
58,3,2,64.38312,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
58,4,2,106.27531,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
58,5,2,122.77409,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
58,6,2,128.39491,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
58,1,3,30.78435,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
58,2,3,38.9601,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
58,3,3,70.4043,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
58,4,3,95.95457,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
58,5,3,124.301025,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
58,6,3,124.2461,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
58,1,4,26.532991,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
58,2,4,35.800205,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
58,3,4,69.85258,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
58,4,4,111.658936,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
58,5,4,123.009445,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
58,6,4,115.90469,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
58,1,5,30.710484,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
58,2,5,32.65222,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
58,3,5,63.903145,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
58,4,5,133.63094,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
58,5,5,135.4772,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
58,6,5,129.62195,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
58,1,6,29.025162,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
58,2,6,34.32958,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
58,3,6,70.06063,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
58,4,6,111.44899,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
58,5,6,127.32626,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
58,6,6,142.94016,241,6,NCGC00263205-01,Motesanib,"VEGFR-1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
59,1,1,24.790144,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
59,2,1,28.373795,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
59,3,1,33.897087,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
59,4,1,64.72441,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
59,5,1,101.18192,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
59,6,1,93.38525,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
59,1,2,25.322243,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
59,2,2,31.115726,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
59,3,2,44.845406,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
59,4,2,84.2651,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
59,5,2,129.06755,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
59,6,2,139.42305,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
59,1,3,32.00491,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
59,2,3,38.923363,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
59,3,3,52.744686,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
59,4,3,92.8991,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
59,5,3,134.11542,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
59,6,3,133.49419,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
59,1,4,26.187317,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
59,2,4,34.88607,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
59,3,4,49.013947,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
59,4,4,115.7319,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
59,5,4,123.6133,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
59,6,4,124.77176,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
59,1,5,27.307032,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
59,2,5,35.93183,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
59,3,5,51.657562,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
59,4,5,114.797806,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
59,5,5,126.32895,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
59,6,5,123.48006,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
59,1,6,18.094492,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
59,2,6,25.341024,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
59,3,6,53.186523,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
59,4,6,116.05875,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
59,5,6,131.47958,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
59,6,6,147.05263,241,6,NCGC00249390-01,Tivozanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
60,1,1,1.953954,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
60,2,1,0.109473,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
60,3,1,0.664424,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
60,4,1,1.725053,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
60,5,1,1.913433,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
60,6,1,3.186048,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
60,1,2,2.949972,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
60,2,2,1.84484,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
60,3,2,2.666379,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
60,4,2,12.612421,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
60,5,2,27.660078,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
60,6,2,38.688812,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
60,1,3,9.99833,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
60,2,3,7.992608,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
60,3,3,19.364344,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
60,4,3,54.496933,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
60,5,3,73.546814,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
60,6,3,98.38847,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
60,1,4,16.848747,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
60,2,4,25.367876,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
60,3,4,48.57817,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
60,4,4,83.70115,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
60,5,4,113.39069,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
60,6,4,133.02658,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
60,1,5,17.310783,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
60,2,5,28.406174,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
60,3,5,53.902466,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
60,4,5,88.89955,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
60,5,5,110.16009,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
60,6,5,115.36117,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
60,1,6,23.794594,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
60,2,6,35.353867,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
60,3,6,58.770515,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
60,4,6,96.724625,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
60,5,6,107.53976,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
60,6,6,120.25623,241,6,NCGC00263156-01,Nintedanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
61,1,1,22.879438,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
61,2,1,27.487644,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
61,3,1,40.03739,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
61,4,1,67.51982,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
61,5,1,81.50871,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
61,6,1,102.77422,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
61,1,2,28.904352,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
61,2,2,32.311424,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
61,3,2,59.6821,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
61,4,2,91.430305,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
61,5,2,101.6365,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
61,6,2,115.67394,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
61,1,3,26.68677,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
61,2,3,31.893894,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
61,3,3,47.436447,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
61,4,3,111.35191,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
61,5,3,117.13048,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
61,6,3,109.79384,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
61,1,4,40.97219,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
61,2,4,34.98211,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
61,3,4,58.412014,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
61,4,4,106.62399,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
61,5,4,123.13149,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
61,6,4,116.28707,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
61,1,5,21.281527,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
61,2,5,37.308914,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
61,3,5,67.15072,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
61,4,5,115.53061,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
61,5,5,130.16983,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
61,6,5,118.34436,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
61,1,6,24.852873,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
61,2,6,32.01628,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
61,3,6,59.7983,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
61,4,6,124.430046,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
61,5,6,119.174835,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
61,6,6,139.24261,241,6,NCGC00263160-01,Brivanib,"VEGFR-2,3/FGFR1,2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
62,1,1,32.189613,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
62,2,1,38.23824,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
62,3,1,67.107506,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
62,4,1,120.36296,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
62,5,1,126.040245,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
62,6,1,152.13834,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
62,1,2,32.367554,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
62,2,2,38.2598,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
62,3,2,62.881924,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
62,4,2,119.07874,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
62,5,2,129.94464,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
62,6,2,128.02278,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
62,1,3,30.851185,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
62,2,3,35.282562,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
62,3,3,46.679554,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
62,4,3,97.364365,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
62,5,3,127.06362,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
62,6,3,134.20532,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
62,1,4,32.914864,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
62,2,4,35.08272,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
62,3,4,66.96062,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
62,4,4,104.553856,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
62,5,4,132.43767,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
62,6,4,135.85527,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
62,1,5,26.484974,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
62,2,5,42.49964,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
62,3,5,60.741203,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
62,4,5,102.42381,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
62,5,5,138.14873,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
62,6,5,140.83727,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
62,1,6,30.810843,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
62,2,6,34.89278,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
62,3,6,65.21732,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
62,4,6,95.434074,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
62,5,6,117.93034,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
62,6,6,136.24966,241,6,NCGC00249392-01,Telatinib,"VEGFR-2,3 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
63,1,1,27.031189,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
63,2,1,26.79341,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
63,3,1,41.609547,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
63,4,1,79.02599,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
63,5,1,107.07768,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
63,6,1,95.48017,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
63,1,2,28.94993,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
63,2,2,31.922916,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
63,3,2,48.25386,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
63,4,2,96.63734,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
63,5,2,122.61904,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
63,6,2,118.76835,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
63,1,3,31.754375,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
63,2,3,37.35087,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
63,3,3,54.573597,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
63,4,3,90.96332,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
63,5,3,112.230995,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
63,6,3,118.46905,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
63,1,4,24.64824,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
63,2,4,33.456524,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
63,3,4,53.886124,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
63,4,4,88.04858,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
63,5,4,123.69578,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
63,6,4,117.58126,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
63,1,5,30.035133,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
63,2,5,41.32974,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
63,3,5,63.507225,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
63,4,5,115.809395,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
63,5,5,121.74288,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
63,6,5,121.44863,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
63,1,6,24.078024,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
63,2,6,34.0584,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
63,3,6,60.306057,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
63,4,6,94.85309,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
63,5,6,141.17068,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
63,6,6,130.16005,241,6,NCGC00263164-01,Cabozantinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
64,1,1,27.315193,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
64,2,1,31.31417,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
64,3,1,53.269592,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
64,4,1,94.16659,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
64,5,1,133.0212,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
64,6,1,134.34843,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
64,1,2,24.259768,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
64,2,2,37.7136,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
64,3,2,52.931416,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
64,4,2,105.59379,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
64,5,2,121.823204,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
64,6,2,129.20897,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
64,1,3,23.376003,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
64,2,3,29.81235,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
64,3,3,51.304012,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
64,4,3,86.90205,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
64,5,3,118.343056,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
64,6,3,125.59941,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
64,1,4,29.288734,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
64,2,4,30.638033,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
64,3,4,57.60895,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
64,4,4,93.48042,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
64,5,4,121.44705,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
64,6,4,140.1103,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
64,1,5,26.09761,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
64,2,5,37.6653,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
64,3,5,59.770496,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
64,4,5,110.229744,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
64,5,5,124.89436,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
64,6,5,133.85751,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
64,1,6,32.881786,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
64,2,6,39.393597,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
64,3,6,60.149445,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
64,4,6,108.002975,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
64,5,6,120.19945,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
64,6,6,122.67757,241,6,NCGC00263097-01,Cediranib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
65,1,1,45.38278,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
65,2,1,47.43966,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
65,3,1,62.548626,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
65,4,1,115.44863,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
65,5,1,122.732475,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
65,6,1,121.438225,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
65,1,2,26.493061,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
65,2,2,36.386295,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
65,3,2,65.441055,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
65,4,2,88.03425,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
65,5,2,122.514084,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
65,6,2,133.74408,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
65,1,3,24.068983,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
65,2,3,40.63882,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
65,3,3,44.798588,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
65,4,3,102.32017,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
65,5,3,122.33241,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
65,6,3,129.11613,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
65,1,4,27.88611,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
65,2,4,33.409615,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
65,3,4,54.585186,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
65,4,4,112.848785,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
65,5,4,122.77226,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
65,6,4,121.07941,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
65,1,5,24.48831,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
65,2,5,31.241417,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
65,3,5,48.16681,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
65,4,5,115.228195,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
65,5,5,99.27744,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
65,6,5,127.181526,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
65,1,6,27.160805,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
65,2,6,29.501726,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
65,3,6,42.795307,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
65,4,6,89.1009,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
65,5,6,123.58379,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
65,6,6,108.45183,241,6,NCGC00263176-01,BMS-794833,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
66,1,1,19.45979,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
66,2,1,20.352272,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
66,3,1,37.154133,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
66,4,1,64.18584,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
66,5,1,70.46012,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
66,6,1,89.22243,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
66,1,2,23.184645,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
66,2,2,25.763685,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
66,3,2,42.667503,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
66,4,2,66.328964,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
66,5,2,95.43741,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
66,6,2,106.799545,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
66,1,3,20.854055,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
66,2,3,35.038525,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
66,3,3,46.443356,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
66,4,3,76.33947,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
66,5,3,113.49918,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
66,6,3,118.36494,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
66,1,4,23.350155,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
66,2,4,31.78259,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
66,3,4,52.3022,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
66,4,4,95.38067,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
66,5,4,114.536835,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
66,6,4,131.0876,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
66,1,5,29.094076,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
66,2,5,32.937946,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
66,3,5,60.242954,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
66,4,5,90.603424,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
66,5,5,114.327965,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
66,6,5,103.93058,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
66,1,6,34.52151,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
66,2,6,34.597744,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
66,3,6,73.60426,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
66,4,6,84.17219,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
66,5,6,108.37868,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
66,6,6,121.369705,241,6,NCGC00263198-01,Lenvatinib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
67,1,1,26.729355,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
67,2,1,33.33629,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
67,3,1,52.460106,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
67,4,1,86.017494,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
67,5,1,122.4101,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
67,6,1,136.05453,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
67,1,2,30.16344,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
67,2,2,47.752365,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
67,3,2,69.3986,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
67,4,2,87.61398,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
67,5,2,122.73877,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
67,6,2,132.85167,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
67,1,3,28.420792,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
67,2,3,29.816654,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
67,3,3,46.121464,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
67,4,3,78.2124,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
67,5,3,125.62463,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
67,6,3,115.3216,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
67,1,4,25.622105,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
67,2,4,29.817463,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
67,3,4,46.638783,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
67,4,4,97.045654,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
67,5,4,106.84995,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
67,6,4,118.85377,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
67,1,5,28.72451,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
67,2,5,31.139908,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
67,3,5,53.902355,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
67,4,5,97.77975,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
67,5,5,109.91246,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
67,6,5,112.37314,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
67,1,6,24.606806,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
67,2,6,29.00656,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
67,3,6,48.511604,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
67,4,6,91.26637,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
67,5,6,125.989395,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
67,6,6,139.51898,241,6,NCGC00263100-01,OSI-632,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
68,1,1,26.18486,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
68,2,1,15.217633,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
68,3,1,17.438444,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
68,4,1,44.90392,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
68,5,1,48.803394,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
68,6,1,70.30699,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
68,1,2,23.987457,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
68,2,2,26.052464,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
68,3,2,52.50314,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
68,4,2,85.003265,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
68,5,2,95.91518,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
68,6,2,124.23921,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
68,1,3,21.593925,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
68,2,3,36.957966,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
68,3,3,43.37103,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
68,4,3,85.92791,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
68,5,3,122.99723,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
68,6,3,114.449295,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
68,1,4,25.6472,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
68,2,4,36.24075,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
68,3,4,53.51487,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
68,4,4,84.67449,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
68,5,4,114.600204,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
68,6,4,122.214386,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
68,1,5,27.85696,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
68,2,5,34.63554,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
68,3,5,53.881763,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
68,4,5,106.26725,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
68,5,5,116.02001,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
68,6,5,128.05849,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
68,1,6,27.35374,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
68,2,6,36.82575,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
68,3,6,61.207474,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
68,4,6,99.2021,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
68,5,6,124.04412,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
68,6,6,123.67459,241,6,NCGC00263104-01,Foretinib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
69,1,1,34.997986,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
69,2,1,44.358974,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
69,3,1,53.681458,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
69,4,1,94.19905,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
69,5,1,108.671936,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
69,6,1,114.96807,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
69,1,2,33.138885,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
69,2,2,38.717655,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
69,3,2,55.33458,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
69,4,2,116.60774,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
69,5,2,131.51772,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
69,6,2,132.9699,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
69,1,3,22.209023,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
69,2,3,36.241955,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
69,3,3,48.829044,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
69,4,3,115.172775,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
69,5,3,120.83486,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
69,6,3,131.02095,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
69,1,4,32.271282,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
69,2,4,42.1514,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
69,3,4,53.998608,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
69,4,4,113.68647,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
69,5,4,121.37412,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
69,6,4,114.36698,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
69,1,5,22.628061,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
69,2,5,32.59622,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
69,3,5,52.442078,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
69,4,5,99.04459,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
69,5,5,123.309525,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
69,6,5,118.34068,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
69,1,6,30.221039,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
69,2,6,41.695755,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
69,3,6,56.315044,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
69,4,6,102.861755,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
69,5,6,121.73737,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
69,6,6,126.13262,241,6,NCGC00263138-01,Regorafenib,VEGFR-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
70,1,1,7.947352,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
70,2,1,8.569946,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
70,3,1,26.212233,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
70,4,1,49.882107,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
70,5,1,97.27925,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
70,6,1,103.46144,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
70,1,2,22.588041,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
70,2,2,36.86903,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
70,3,2,65.06752,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
70,4,2,121.85723,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
70,5,2,130.1527,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
70,6,2,126.98402,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
70,1,3,23.946686,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
70,2,3,28.849463,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
70,3,3,58.240585,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
70,4,3,90.55331,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
70,5,3,111.34983,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
70,6,3,131.8205,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
70,1,4,21.896818,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
70,2,4,35.030884,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
70,3,4,45.62341,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
70,4,4,86.518394,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
70,5,4,122.08832,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
70,6,4,130.82854,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
70,1,5,27.892712,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
70,2,5,24.582518,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
70,3,5,47.834393,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
70,4,5,76.95012,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
70,5,5,102.61504,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
70,6,5,104.59029,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
70,1,6,21.096159,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
70,2,6,26.385616,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
70,3,6,45.015167,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
70,4,6,85.900505,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
70,5,6,119.144806,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
70,6,6,114.71787,241,6,NCGC00249685-01,Dovitinib,FGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
71,1,1,6.977157,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
71,2,1,12.002084,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
71,3,1,23.492374,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
71,4,1,44.97156,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
71,5,1,97.91118,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
71,6,1,105.6279,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
71,1,2,8.841011,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
71,2,2,20.516508,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
71,3,2,29.306343,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
71,4,2,74.0052,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
71,5,2,112.48092,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
71,6,2,100.82493,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
71,1,3,10.859449,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
71,2,3,20.849339,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
71,3,3,42.838394,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
71,4,3,69.396645,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
71,5,3,107.53438,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
71,6,3,103.70435,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
71,1,4,11.737911,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
71,2,4,25.83503,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
71,3,4,45.358734,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
71,4,4,83.51781,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
71,5,4,108.67186,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
71,6,4,106.46319,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
71,1,5,14.198558,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
71,2,5,22.93872,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
71,3,5,47.036503,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
71,4,5,78.33509,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
71,5,5,102.60331,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
71,6,5,123.96852,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
71,1,6,14.370287,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
71,2,6,25.255589,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
71,3,6,54.56494,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
71,4,6,94.02422,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
71,5,6,115.176155,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
71,6,6,110.867905,241,6,NCGC00241103-04,Masitinib,FGFR 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
72,1,1,16.703562,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
72,2,1,24.722776,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
72,3,1,39.90212,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
72,4,1,67.29425,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
72,5,1,84.99988,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
72,6,1,123.78528,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
72,1,2,16.96061,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
72,2,2,30.275248,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
72,3,2,33.58175,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
72,4,2,86.30246,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
72,5,2,122.42869,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
72,6,2,109.31482,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
72,1,3,17.227024,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
72,2,3,22.91796,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
72,3,3,43.892876,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
72,4,3,92.16461,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
72,5,3,114.70608,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
72,6,3,106.77199,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
72,1,4,16.42175,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
72,2,4,25.993649,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
72,3,4,51.359623,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
72,4,4,89.51692,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
72,5,4,114.808266,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
72,6,4,104.36247,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
72,1,5,17.574837,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
72,2,5,30.089785,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
72,3,5,46.693027,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
72,4,5,91.47331,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
72,5,5,114.59761,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
72,6,5,109.67627,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
72,1,6,13.595506,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
72,2,6,26.767723,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
72,3,6,38.137062,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
72,4,6,85.46443,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
72,5,6,111.565094,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
72,6,6,108.37281,241,6,NCGC00165863-02,PD-173074,FGFR 1/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
73,1,1,16.079891,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
73,2,1,27.329237,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
73,3,1,39.23718,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
73,4,1,69.789825,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
73,5,1,98.4011,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
73,6,1,106.928474,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
73,1,2,21.881792,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
73,2,2,26.523,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
73,3,2,36.85574,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
73,4,2,84.79172,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
73,5,2,99.55269,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
73,6,2,121.90167,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
73,1,3,23.60454,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
73,2,3,30.89285,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
73,3,3,52.690876,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
73,4,3,83.988014,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
73,5,3,101.70836,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
73,6,3,120.20164,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
73,1,4,17.782228,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
73,2,4,24.429312,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
73,3,4,48.35365,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
73,4,4,91.166756,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
73,5,4,104.9896,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
73,6,4,113.38955,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
73,1,5,11.641498,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
73,2,5,27.75936,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
73,3,5,53.273823,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
73,4,5,93.723335,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
73,5,5,117.01068,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
73,6,5,122.839424,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
73,1,6,16.061596,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
73,2,6,31.55494,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
73,3,6,55.37164,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
73,4,6,112.54331,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
73,5,6,108.39226,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
73,6,6,113.25946,241,6,NCGC00263125-01,SG-00529,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
74,1,1,19.399406,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
74,2,1,22.272888,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
74,3,1,38.28609,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
74,4,1,92.2176,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
74,5,1,95.81156,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
74,6,1,105.76854,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
74,1,2,20.896832,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
74,2,2,27.239708,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
74,3,2,45.73893,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
74,4,2,97.89125,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
74,5,2,121.48791,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
74,6,2,108.15251,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
74,1,3,20.037819,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
74,2,3,21.123947,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
74,3,3,39.43764,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
74,4,3,92.68225,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
74,5,3,116.69951,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
74,6,3,127.13076,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
74,1,4,15.85982,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
74,2,4,26.352858,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
74,3,4,36.875317,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
74,4,4,89.15984,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
74,5,4,116.73236,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
74,6,4,111.84162,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
74,1,5,22.509958,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
74,2,5,25.968052,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
74,3,5,46.66674,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
74,4,5,98.2996,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
74,5,5,112.253,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
74,6,5,103.944244,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
74,1,6,17.114283,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
74,2,6,30.726772,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
74,3,6,41.855198,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
74,4,6,91.11713,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
74,5,6,113.24882,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
74,6,6,112.741455,241,6,NCGC00263158-01,Amuvatinib,PDGFR alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
75,1,1,1.617017,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
75,2,1,4.637768,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
75,3,1,10.405188,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
75,4,1,40.45111,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
75,5,1,106.109535,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
75,6,1,105.65898,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
75,1,2,13.08184,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
75,2,2,20.316093,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
75,3,2,30.07773,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
75,4,2,82.401184,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
75,5,2,105.306755,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
75,6,2,114.25201,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
75,1,3,14.24927,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
75,2,3,20.440409,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
75,3,3,45.560078,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
75,4,3,102.93724,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
75,5,3,106.44756,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
75,6,3,119.92106,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
75,1,4,14.7901,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
75,2,4,21.741854,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
75,3,4,43.644535,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
75,4,4,94.637474,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
75,5,4,117.98776,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
75,6,4,114.555,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
75,1,5,20.758223,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
75,2,5,25.715261,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
75,3,5,40.853893,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
75,4,5,85.148796,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
75,5,5,98.66904,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
75,6,5,117.37949,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
75,1,6,17.834606,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
75,2,6,18.119013,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
75,3,6,41.63703,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
75,4,6,79.832085,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
75,5,6,99.950966,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
75,6,6,102.37285,241,6,NCGC00263159-01,OSI-930,PDGFR beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
76,1,1,10.436274,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
76,2,1,13.789229,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
76,3,1,20.487886,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
76,4,1,48.8794,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
76,5,1,77.60448,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
76,6,1,95.186356,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
76,1,2,17.892378,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
76,2,2,30.607052,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
76,3,2,44.939114,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
76,4,2,80.39152,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
76,5,2,102.21453,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
76,6,2,102.73566,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
76,1,3,17.073544,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
76,2,3,26.427612,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
76,3,3,43.192562,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
76,4,3,82.1789,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
76,5,3,102.90338,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
76,6,3,113.902145,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
76,1,4,18.39138,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
76,2,4,21.64965,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
76,3,4,55.943974,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
76,4,4,100.799736,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
76,5,4,108.202995,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
76,6,4,113.708824,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
76,1,5,24.173527,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
76,2,5,32.17051,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
76,3,5,53.01506,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
76,4,5,108.94031,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
76,5,5,120.80325,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
76,6,5,116.64722,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
76,1,6,21.140802,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
76,2,6,27.354145,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
76,3,6,42.48298,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
76,4,6,118.1549,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
76,5,6,91.32725,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
76,6,6,116.459015,241,6,NCGC00250400-01,Crizotinib,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
77,1,1,27.922268,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
77,2,1,36.47077,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
77,3,1,50.53423,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
77,4,1,88.063675,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
77,5,1,132.74069,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
77,6,1,133.34782,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
77,1,2,24.152958,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
77,2,2,35.703358,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
77,3,2,47.793194,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
77,4,2,88.581726,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
77,5,2,120.38344,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
77,6,2,134.12692,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
77,1,3,22.689964,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
77,2,3,29.689276,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
77,3,3,46.232857,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
77,4,3,100.51642,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
77,5,3,113.55954,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
77,6,3,121.78259,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
77,1,4,24.410358,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
77,2,4,34.150017,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
77,3,4,57.66957,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
77,4,4,88.0472,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
77,5,4,118.332214,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
77,6,4,108.72292,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
77,1,5,26.314342,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
77,2,5,35.785793,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
77,3,5,56.749428,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
77,4,5,92.5418,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
77,5,5,120.500854,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
77,6,5,132.89404,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
77,1,6,19.603054,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
77,2,6,37.286983,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
77,3,6,56.164413,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
77,4,6,107.045,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
77,5,6,106.43858,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
77,6,6,118.65546,241,6,NCGC00242500-01,PHA-665752,HGFR (MET; c-Met) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
78,1,1,17.614262,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
78,2,1,31.001701,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
78,3,1,46.270412,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
78,4,1,89.57767,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
78,5,1,112.229996,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
78,6,1,129.88728,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
78,1,2,20.780952,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
78,2,2,22.80221,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
78,3,2,40.333954,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
78,4,2,98.9617,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
78,5,2,115.00304,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
78,6,2,122.742294,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
78,1,3,18.790577,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
78,2,3,29.937536,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
78,3,3,43.362885,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
78,4,3,77.19659,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
78,5,3,109.60712,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
78,6,3,123.5556,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
78,1,4,26.032019,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
78,2,4,29.010988,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
78,3,4,51.389782,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
78,4,4,76.81265,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
78,5,4,116.15153,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
78,6,4,115.44223,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
78,1,5,23.076721,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
78,2,5,39.270157,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
78,3,5,61.13365,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
78,4,5,85.31134,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
78,5,5,113.57007,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
78,6,5,125.79781,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
78,1,6,26.495005,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
78,2,6,33.141926,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
78,3,6,45.574276,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
78,4,6,105.29333,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
78,5,6,119.68762,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
78,6,6,125.6412,241,6,NCGC00263157-01,BMS-777607,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
79,1,1,17.958729,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
79,2,1,26.662731,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
79,3,1,45.88519,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
79,4,1,67.978714,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
79,5,1,119.11345,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
79,6,1,106.31124,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
79,1,2,21.583172,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
79,2,2,28.324505,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
79,3,2,49.228924,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
79,4,2,87.70412,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
79,5,2,110.11126,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
79,6,2,130.68166,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
79,1,3,29.70197,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
79,2,3,34.906292,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
79,3,3,54.02816,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
79,4,3,104.8542,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
79,5,3,118.78717,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
79,6,3,127.14124,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
79,1,4,17.43509,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
79,2,4,25.552656,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
79,3,4,43.348427,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
79,4,4,99.94977,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
79,5,4,119.51298,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
79,6,4,140.11877,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
79,1,5,21.753618,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
79,2,5,32.801205,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
79,3,5,47.207157,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
79,4,5,90.90898,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
79,5,5,115.160675,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
79,6,5,112.12361,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
79,1,6,22.216173,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
79,2,6,31.778597,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
79,3,6,43.56256,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
79,4,6,90.36173,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
79,5,6,115.69733,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
79,6,6,130.03964,241,6,NCGC00263161-01,PF-04217903,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
80,1,1,22.891546,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
80,2,1,25.531174,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
80,3,1,41.951977,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
80,4,1,85.63189,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
80,5,1,120.60953,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
80,6,1,120.815254,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
80,1,2,23.159369,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
80,2,2,31.170902,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
80,3,2,46.046307,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
80,4,2,103.9318,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
80,5,2,108.33732,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
80,6,2,122.0285,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
80,1,3,22.061363,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
80,2,3,31.15696,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
80,3,3,47.56366,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
80,4,3,76.752495,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
80,5,3,110.51295,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
80,6,3,123.14583,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
80,1,4,24.268131,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
80,2,4,32.0023,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
80,3,4,45.061954,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
80,4,4,98.28645,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
80,5,4,112.60045,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
80,6,4,115.55651,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
80,1,5,22.151167,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
80,2,5,24.02592,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
80,3,5,46.989532,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
80,4,5,86.14786,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
80,5,5,105.092575,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
80,6,5,111.78566,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
80,1,6,21.27826,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
80,2,6,27.070171,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
80,3,6,48.264233,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
80,4,6,82.595505,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
80,5,6,93.51018,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
80,6,6,105.12345,241,6,NCGC00263189-01,JNJ-38877605,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
81,1,1,12.122748,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
81,2,1,9.920143,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
81,3,1,33.815556,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
81,4,1,76.02202,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
81,5,1,94.36746,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
81,6,1,110.60032,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
81,1,2,19.23802,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
81,2,2,25.123573,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
81,3,2,41.671574,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
81,4,2,90.446144,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
81,5,2,107.65146,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
81,6,2,110.6687,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
81,1,3,15.831167,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
81,2,3,27.507368,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
81,3,3,43.426178,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
81,4,3,89.05219,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
81,5,3,107.677666,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
81,6,3,108.64613,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
81,1,4,19.648851,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
81,2,4,35.28167,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
81,3,4,50.398468,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
81,4,4,91.83843,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
81,5,4,131.01369,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
81,6,4,111.71986,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
81,1,5,20.5426,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
81,2,5,31.800125,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
81,3,5,49.484276,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
81,4,5,102.65826,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
81,5,5,119.47538,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
81,6,5,114.33276,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
81,1,6,25.60878,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
81,2,6,32.524082,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
81,3,6,59.964333,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
81,4,6,100.81972,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
81,5,6,115.91372,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
81,6,6,137.09818,241,6,NCGC00263163-01,SGX-523,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
82,1,1,16.095594,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
82,2,1,16.396984,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
82,3,1,22.470774,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
82,4,1,31.43429,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
82,5,1,39.819424,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
82,6,1,41.342026,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
82,1,2,23.141296,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
82,2,2,28.711952,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
82,3,2,52.228016,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
82,4,2,80.80234,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
82,5,2,102.34179,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
82,6,2,129.8242,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
82,1,3,23.246578,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
82,2,3,32.877033,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
82,3,3,47.34572,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
82,4,3,89.084206,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
82,5,3,123.335915,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
82,6,3,121.468796,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
82,1,4,21.608047,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
82,2,4,34.539383,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
82,3,4,74.01586,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
82,4,4,99.017044,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
82,5,4,120.088196,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
82,6,4,116.801125,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
82,1,5,24.001766,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
82,2,5,35.016216,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
82,3,5,47.076664,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
82,4,5,93.17013,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
82,5,5,121.65095,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
82,6,5,121.097824,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
82,1,6,22.62603,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
82,2,6,32.012592,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
82,3,6,54.5206,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
82,4,6,79.54397,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
82,5,6,112.88354,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
82,6,6,98.129135,241,6,NCGC00263201-01,AMG-51,HGFR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
83,1,1,0.816368,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
83,2,1,-0.811134,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
83,3,1,-0.625158,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
83,4,1,0.186776,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
83,5,1,0.743102,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
83,6,1,0.796551,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
83,1,2,0.333837,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
83,2,2,-1.699552,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
83,3,2,-1.933935,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
83,4,2,-2.105231,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
83,5,2,-0.992451,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
83,6,2,-0.500252,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
83,1,3,0.397563,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
83,2,3,-1.844869,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
83,3,3,-1.457935,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
83,4,3,-0.894837,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
83,5,3,-0.833464,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
83,6,3,-0.389079,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
83,1,4,1.349067,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
83,2,4,-0.431275,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
83,3,4,-0.150791,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
83,4,4,0.612624,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
83,5,4,1.105849,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
83,6,4,2.245729,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
83,1,5,6.916409,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
83,2,5,7.104769,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
83,3,5,8.836881,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
83,4,5,23.390438,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
83,5,5,35.449554,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
83,6,5,36.62848,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
83,1,6,27.272617,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
83,2,6,34.438824,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
83,3,6,57.637814,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
83,4,6,99.223236,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
83,5,6,110.20425,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
83,6,6,118.789635,241,6,NCGC00022001-07,Podofilox,Antimitotic Agent,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
84,1,1,25.599813,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
84,2,1,35.76351,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
84,3,1,46.885437,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
84,4,1,94.62288,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
84,5,1,107.20087,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
84,6,1,120.59458,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
84,1,2,28.242483,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
84,2,2,32.19612,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
84,3,2,52.79939,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
84,4,2,86.05396,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
84,5,2,118.48531,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
84,6,2,125.29494,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
84,1,3,28.699482,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
84,2,3,23.112019,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
84,3,3,64.502754,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
84,4,3,92.68521,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
84,5,3,116.85813,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
84,6,3,116.280754,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
84,1,4,20.988155,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
84,2,4,23.466314,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
84,3,4,27.367016,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
84,4,4,86.54222,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
84,5,4,107.796425,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
84,6,4,110.76192,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
84,1,5,21.942476,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
84,2,5,24.630894,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
84,3,5,51.95141,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
84,4,5,116.9008,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
84,5,5,121.27808,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
84,6,5,127.74396,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
84,1,6,27.17334,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
84,2,6,30.123129,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
84,3,6,59.56043,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
84,4,6,112.32263,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
84,5,6,125.19716,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
84,6,6,109.99571,241,6,NCGC00250375-02,Linsitinib,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
85,1,1,29.407207,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
85,2,1,38.238087,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
85,3,1,50.531155,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
85,4,1,84.12225,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
85,5,1,105.37531,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
85,6,1,118.27329,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
85,1,2,24.055647,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
85,2,2,38.001637,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
85,3,2,52.755737,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
85,4,2,111.83351,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
85,5,2,124.420876,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
85,6,2,123.62418,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
85,1,3,21.435213,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
85,2,3,28.653284,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
85,3,3,41.90415,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
85,4,3,102.618164,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
85,5,3,114.608955,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
85,6,3,120.687004,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
85,1,4,22.48678,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
85,2,4,28.376562,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
85,3,4,51.617664,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
85,4,4,105.59462,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
85,5,4,111.550354,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
85,6,4,110.08281,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
85,1,5,19.088894,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
85,2,5,34.69011,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
85,3,5,54.89588,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
85,4,5,101.07097,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
85,5,5,111.65456,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
85,6,5,110.47885,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
85,1,6,18.324917,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
85,2,6,26.915619,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
85,3,6,37.872074,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
85,4,6,91.8774,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
85,5,6,127.41648,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
85,6,6,115.63345,241,6,NCGC00253439-01,GSK-1904529A,IGF-1R Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
86,1,1,8.194499,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
86,2,1,12.78125,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
86,3,1,25.335657,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
86,4,1,79.06774,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
86,5,1,95.024315,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
86,6,1,110.84008,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
86,1,2,15.792973,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
86,2,2,24.765982,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
86,3,2,40.041718,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
86,4,2,70.62761,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
86,5,2,112.71835,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
86,6,2,109.731636,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
86,1,3,21.546595,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
86,2,3,28.321337,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
86,3,3,42.670174,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
86,4,3,91.88951,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
86,5,3,111.15248,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
86,6,3,123.38301,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
86,1,4,25.533863,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
86,2,4,25.806007,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
86,3,4,53.246,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
86,4,4,91.98607,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
86,5,4,114.14567,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
86,6,4,110.86559,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
86,1,5,25.784029,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
86,2,5,30.538525,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
86,3,5,58.618435,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
86,4,5,100.538956,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
86,5,5,115.866684,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
86,6,5,21.85938,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
86,1,6,25.784782,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
86,2,6,35.77075,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
86,3,6,50.13966,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
86,4,6,121.93402,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
86,5,6,106.04193,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
86,6,6,122.14014,241,6,NCGC00165869-02,Dorsomorphin,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
87,1,1,27.414972,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
87,2,1,38.06764,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
87,3,1,57.221214,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
87,4,1,115.01763,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
87,5,1,135.7382,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
87,6,1,118.48737,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
87,1,2,24.495295,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
87,2,2,43.45827,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
87,3,2,52.429855,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
87,4,2,109.66777,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
87,5,2,125.35115,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
87,6,2,121.389435,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
87,1,3,33.82148,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
87,2,3,33.804157,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
87,3,3,60.5107,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
87,4,3,87.13393,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
87,5,3,120.42645,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
87,6,3,127.24904,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
87,1,4,25.144913,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
87,2,4,43.56048,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
87,3,4,65.12348,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
87,4,4,87.27136,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
87,5,4,127.97764,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
87,6,4,122.99643,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
87,1,5,25.31973,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
87,2,5,30.862917,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
87,3,5,53.24421,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
87,4,5,96.85071,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
87,5,5,115.59087,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
87,6,5,124.7869,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
87,1,6,29.206585,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
87,2,6,30.643421,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
87,3,6,63.73257,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
87,4,6,94.73824,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
87,5,6,112.845184,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
87,6,6,130.12608,241,6,NCGC00249388-01,LY2157299,TGF-bR1 (ALK5) and TGFbR2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
88,1,1,21.115799,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
88,2,1,36.672485,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
88,3,1,49.23094,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
88,4,1,78.18131,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
88,5,1,114.781136,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
88,6,1,132.66898,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
88,1,2,21.50323,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
88,2,2,29.224113,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
88,3,2,54.632862,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
88,4,2,105.84549,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
88,5,2,117.21508,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
88,6,2,114.53496,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
88,1,3,27.172138,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
88,2,3,28.95906,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
88,3,3,45.689835,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
88,4,3,89.76259,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
88,5,3,116.32788,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
88,6,3,116.19076,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
88,1,4,20.439833,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
88,2,4,24.920774,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
88,3,4,62.109646,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
88,4,4,80.86649,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
88,5,4,106.92717,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
88,6,4,101.65467,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
88,1,5,23.057064,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
88,2,5,28.225723,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
88,3,5,52.095604,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
88,4,5,99.27086,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
88,5,5,113.13974,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
88,6,5,109.8858,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
88,1,6,30.45567,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
88,2,6,34.048256,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
88,3,6,53.807224,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
88,4,6,96.44841,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
88,5,6,113.601585,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
88,6,6,106.10171,241,6,NCGC00242598-01,LY-2109761,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
89,1,1,28.827143,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
89,2,1,33.678066,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
89,3,1,56.350903,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
89,4,1,95.46679,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
89,5,1,117.12749,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
89,6,1,106.87012,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
89,1,2,31.757866,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
89,2,2,34.272537,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
89,3,2,45.3053,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
89,4,2,94.35149,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
89,5,2,113.70501,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
89,6,2,112.67622,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
89,1,3,27.360851,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
89,2,3,35.89868,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
89,3,3,65.306915,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
89,4,3,100.00642,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
89,5,3,114.94489,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
89,6,3,119.43907,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
89,1,4,27.508825,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
89,2,4,39.946842,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
89,3,4,50.57407,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
89,4,4,99.64603,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
89,5,4,125.22083,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
89,6,4,128.02174,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
89,1,5,23.6407,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
89,2,5,35.26694,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
89,3,5,49.812,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
89,4,5,106.999954,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
89,5,5,129.9149,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
89,6,5,113.68169,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
89,1,6,28.126028,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
89,2,6,37.5557,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
89,3,6,53.983963,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
89,4,6,116.36657,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
89,5,6,115.83022,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
89,6,6,115.779396,241,6,NCGC00165721-02,A-83-01,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
90,1,1,30.697144,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
90,2,1,34.805573,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
90,3,1,52.67453,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
90,4,1,91.32132,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
90,5,1,93.58375,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
90,6,1,112.78781,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
90,1,2,32.701977,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
90,2,2,32.205246,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
90,3,2,50.699474,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
90,4,2,87.22133,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
90,5,2,113.31102,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
90,6,2,124.993675,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
90,1,3,28.129341,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
90,2,3,33.11055,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
90,3,3,57.208393,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
90,4,3,96.74498,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
90,5,3,113.69547,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
90,6,3,116.569244,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
90,1,4,24.317324,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
90,2,4,36.04803,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
90,3,4,46.85712,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
90,4,4,88.89847,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
90,5,4,114.19963,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
90,6,4,132.08644,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
90,1,5,22.878693,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
90,2,5,31.746164,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
90,3,5,55.37313,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
90,4,5,108.8162,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
90,5,5,120.73861,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
90,6,5,125.80575,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
90,1,6,20.134682,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
90,2,6,28.950497,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
90,3,6,50.353935,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
90,4,6,107.90832,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
90,5,6,113.83423,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
90,6,6,108.68619,241,6,NCGC00242054-02,SJN-2511,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
91,1,1,17.85588,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
91,2,1,29.35371,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
91,3,1,43.399715,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
91,4,1,68.84715,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
91,5,1,80.56259,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
91,6,1,113.76613,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
91,1,2,18.22615,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
91,2,2,24.576084,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
91,3,2,50.850426,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
91,4,2,81.54406,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
91,5,2,113.32544,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
91,6,2,106.812454,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
91,1,3,17.384907,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
91,2,3,37.77196,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
91,3,3,45.334324,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
91,4,3,92.18554,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
91,5,3,109.298584,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
91,6,3,109.62525,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
91,1,4,17.341143,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
91,2,4,26.40629,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
91,3,4,54.2178,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
91,4,4,93.211,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
91,5,4,111.86761,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
91,6,4,113.3465,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
91,1,5,21.95802,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
91,2,5,32.550446,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
91,3,5,46.294872,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
91,4,5,89.28961,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
91,5,5,129.50499,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
91,6,5,107.68988,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
91,1,6,26.759865,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
91,2,6,29.75233,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
91,3,6,71.00262,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
91,4,6,99.31456,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
91,5,6,125.43291,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
91,6,6,116.17611,241,6,NCGC00165898-02,SD-208,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
92,1,1,14.029902,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
92,2,1,19.578484,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
92,3,1,32.025352,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
92,4,1,75.5021,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
92,5,1,90.92551,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
92,6,1,103.16094,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
92,1,2,25.163864,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
92,2,2,37.612225,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
92,3,2,69.31835,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
92,4,2,68.8141,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
92,5,2,119.8431,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
92,6,2,124.273445,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
92,1,3,25.361221,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
92,2,3,39.665783,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
92,3,3,60.03667,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
92,4,3,116.3961,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
92,5,3,116.18143,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
92,6,3,141.76414,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
92,1,4,25.492756,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
92,2,4,28.394026,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
92,3,4,64.29512,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
92,4,4,110.266174,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
92,5,4,135.56154,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
92,6,4,92.84777,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
92,1,5,24.76278,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
92,2,5,28.63137,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
92,3,5,51.06744,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
92,4,5,104.59212,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
92,5,5,115.34503,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
92,6,5,123.30411,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
92,1,6,27.237322,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
92,2,6,29.658606,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
92,3,6,55.896095,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
92,4,6,102.69644,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
92,5,6,113.30436,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
92,6,6,119.68405,241,6,NCGC00238453-02,TAE-684,ALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
93,1,1,24.174248,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
93,2,1,35.31791,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
93,3,1,59.29741,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
93,4,1,96.07026,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
93,5,1,106.63778,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
93,6,1,103.6551,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
93,1,2,26.218042,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
93,2,2,39.00299,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
93,3,2,55.741177,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
93,4,2,92.758705,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
93,5,2,116.065,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
93,6,2,105.31423,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
93,1,3,30.251942,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
93,2,3,28.261724,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
93,3,3,50.76488,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
93,4,3,95.05857,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
93,5,3,108.63673,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
93,6,3,110.66485,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
93,1,4,22.345242,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
93,2,4,25.576012,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
93,3,4,58.851585,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
93,4,4,111.13004,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
93,5,4,113.15296,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
93,6,4,117.05174,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
93,1,5,23.813772,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
93,2,5,34.168587,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
93,3,5,59.49637,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
93,4,5,104.45237,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
93,5,5,120.20748,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
93,6,5,115.5822,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
93,1,6,25.988045,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
93,2,6,30.62266,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
93,3,6,50.121696,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
93,4,6,118.023705,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
93,5,6,114.606094,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
93,6,6,130.41953,241,6,NCGC00186024-01,SB-525334,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
94,1,1,37.38527,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
94,2,1,45.8825,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
94,3,1,66.764656,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
94,4,1,90.65766,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
94,5,1,119.971886,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
94,6,1,119.08115,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
94,1,2,26.03991,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
94,2,2,37.748096,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
94,3,2,63.96724,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
94,4,2,108.84237,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
94,5,2,106.86922,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
94,6,2,117.28805,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
94,1,3,28.78136,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
94,2,3,37.114964,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
94,3,3,60.255047,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
94,4,3,115.02988,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
94,5,3,122.60966,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
94,6,3,131.03877,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
94,1,4,21.409664,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
94,2,4,35.588696,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
94,3,4,56.36989,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
94,4,4,119.89186,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
94,5,4,120.92286,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
94,6,4,115.798386,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
94,1,5,22.78084,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
94,2,5,34.5442,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
94,3,5,36.733025,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
94,4,5,92.850395,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
94,5,5,119.28865,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
94,6,5,128.07184,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
94,1,6,24.190126,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
94,2,6,35.86004,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
94,3,6,49.935417,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
94,4,6,90.85012,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
94,5,6,111.05926,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
94,6,6,122.08282,241,6,NCGC00025230-01,SB-431542,TGF-bR1 (ALK5) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
95,1,1,25.889727,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
95,2,1,34.0945,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
95,3,1,50.454765,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
95,4,1,109.7504,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
95,5,1,125.44635,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
95,6,1,146.29947,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
95,1,2,22.603235,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
95,2,2,35.56582,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
95,3,2,49.023994,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
95,4,2,105.56621,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
95,5,2,132.89598,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
95,6,2,124.4097,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
95,1,3,24.346457,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
95,2,3,26.335073,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
95,3,3,46.9523,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
95,4,3,97.55397,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
95,5,3,112.27384,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
95,6,3,116.27017,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
95,1,4,25.304188,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
95,2,4,30.330202,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
95,3,4,60.458595,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
95,4,4,91.96759,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
95,5,4,114.24927,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
95,6,4,117.04358,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
95,1,5,23.115509,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
95,2,5,26.60832,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
95,3,5,45.611813,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
95,4,5,80.889404,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
95,5,5,116.02515,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
95,6,5,119.31005,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
95,1,6,22.524557,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
95,2,6,29.307337,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
95,3,6,52.71785,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
95,4,6,81.951294,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
95,5,6,111.03846,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
95,6,6,123.30944,241,6,NCGC00241097-02,Tandutinib,KIT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
96,1,1,18.915163,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
96,2,1,20.69629,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
96,3,1,34.45746,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
96,4,1,70.84743,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
96,5,1,72.92991,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
96,6,1,82.591,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
96,1,2,27.398598,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
96,2,2,28.508623,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
96,3,2,47.355164,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
96,4,2,87.89502,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
96,5,2,114.067345,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
96,6,2,108.415,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
96,1,3,19.602688,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
96,2,3,34.811382,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
96,3,3,40.513268,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
96,4,3,89.08858,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
96,5,3,111.64111,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
96,6,3,114.44533,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
96,1,4,27.83887,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
96,2,4,26.376469,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
96,3,4,48.071373,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
96,4,4,84.13345,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
96,5,4,100.45463,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
96,6,4,119.54381,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
96,1,5,23.929731,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
96,2,5,40.822357,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
96,3,5,51.33819,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
96,4,5,100.60694,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
96,5,5,115.141975,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
96,6,5,119.26419,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
96,1,6,23.948334,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
96,2,6,32.237915,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
96,3,6,47.312344,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
96,4,6,92.71963,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
96,5,6,106.90155,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
96,6,6,127.394615,241,6,NCGC00242493-02,Quizartinib,Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
97,1,1,13.024341,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
97,2,1,15.090818,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
97,3,1,33.333473,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
97,4,1,85.33542,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
97,5,1,115.07622,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
97,6,1,109.748764,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
97,1,2,23.580208,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
97,2,2,38.610195,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
97,3,2,51.053143,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
97,4,2,96.85827,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
97,5,2,117.13757,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
97,6,2,106.65485,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
97,1,3,26.003107,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
97,2,3,28.480515,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
97,3,3,49.88954,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
97,4,3,91.27386,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
97,5,3,114.588615,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
97,6,3,130.73415,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
97,1,4,23.943674,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
97,2,4,28.841677,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
97,3,4,46.70415,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
97,4,4,92.40417,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
97,5,4,111.10796,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
97,6,4,126.15134,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
97,1,5,24.012812,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
97,2,5,25.690048,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
97,3,5,46.233418,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
97,4,5,97.82264,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
97,5,5,114.26782,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
97,6,5,118.60033,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
97,1,6,25.372522,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
97,2,6,31.955175,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
97,3,6,54.939102,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
97,4,6,105.75972,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
97,5,6,98.26951,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
97,6,6,114.22459,241,6,NCGC00250381-01,AZ-23,Trk Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
98,1,1,28.984097,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
98,2,1,37.044388,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
98,3,1,46.269005,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
98,4,1,74.82797,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
98,5,1,104.700356,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
98,6,1,84.13055,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
98,1,2,25.102972,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
98,2,2,34.299175,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
98,3,2,52.5243,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
98,4,2,74.54556,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
98,5,2,116.84156,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
98,6,2,105.125595,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
98,1,3,22.607014,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
98,2,3,37.337612,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
98,3,3,49.48455,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
98,4,3,82.773346,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
98,5,3,113.369576,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
98,6,3,109.21546,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
98,1,4,26.372643,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
98,2,4,31.334452,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
98,3,4,62.069515,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
98,4,4,65.93471,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
98,5,4,104.90202,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
98,6,4,106.482124,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
98,1,5,27.195606,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
98,2,5,37.106705,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
98,3,5,52.828506,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
98,4,5,110.51588,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
98,5,5,120.646935,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
98,6,5,117.05004,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
98,1,6,21.556166,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
98,2,6,28.035666,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
98,3,6,52.740307,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
98,4,6,94.59946,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
98,5,6,126.16575,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
98,6,6,109.8657,241,6,NCGC00249389-01,LDN-193189,ALK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
99,1,1,6.181487,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
99,2,1,7.992836,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
99,3,1,8.265156,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
99,4,1,9.549056,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
99,5,1,12.620263,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
99,6,1,17.411688,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
99,1,2,14.991187,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
99,2,2,12.808095,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
99,3,2,23.44027,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
99,4,2,41.624046,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
99,5,2,59.823048,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
99,6,2,73.38497,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
99,1,3,24.95519,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
99,2,3,34.637814,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
99,3,3,40.437824,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
99,4,3,60.53945,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
99,5,3,96.576645,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
99,6,3,112.75357,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
99,1,4,22.198086,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
99,2,4,28.694248,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
99,3,4,51.07922,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
99,4,4,86.59516,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
99,5,4,114.74188,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
99,6,4,103.28601,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
99,1,5,23.283716,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
99,2,5,32.892414,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
99,3,5,48.254417,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
99,4,5,89.1597,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
99,5,5,113.91894,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
99,6,5,117.68326,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
99,1,6,18.070269,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
99,2,6,30.083366,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
99,3,6,51.222614,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
99,4,6,92.472374,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
99,5,6,113.90974,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
99,6,6,116.025276,241,6,NCGC00253909-02,PRT-060318,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
100,1,1,19.358204,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
100,2,1,16.101934,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
100,3,1,27.105036,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
100,4,1,57.166214,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
100,5,1,81.68152,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
100,6,1,71.67546,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
100,1,2,16.789873,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
100,2,2,29.942772,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
100,3,2,39.469273,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
100,4,2,85.82133,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
100,5,2,107.397995,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
100,6,2,117.81597,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
100,1,3,19.372387,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
100,2,3,30.927986,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
100,3,3,45.129906,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
100,4,3,90.32618,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
100,5,3,107.88243,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
100,6,3,111.3123,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
100,1,4,23.548944,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
100,2,4,32.634377,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
100,3,4,45.81801,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
100,4,4,89.35878,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
100,5,4,112.186455,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
100,6,4,114.32671,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
100,1,5,24.65505,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
100,2,5,54.74954,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
100,3,5,39.241535,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
100,4,5,89.10434,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
100,5,5,116.73241,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
100,6,5,115.724335,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
100,1,6,24.769054,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
100,2,6,27.95012,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
100,3,6,41.701782,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
100,4,6,96.169174,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
100,5,6,91.80731,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
100,6,6,106.434166,241,6,NCGC00182051-03,R-406,Syk Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
101,1,1,10.486762,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
101,2,1,14.306737,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
101,3,1,28.566635,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
101,4,1,51.832294,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
101,5,1,61.09533,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
101,6,1,73.79302,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
101,1,2,17.569921,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
101,2,2,20.57833,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
101,3,2,39.337276,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
101,4,2,66.537476,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
101,5,2,83.4771,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
101,6,2,83.859085,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
101,1,3,15.35816,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
101,2,3,27.317055,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
101,3,3,36.11214,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
101,4,3,69.6192,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
101,5,3,119.058655,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
101,6,3,102.68181,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
101,1,4,16.19489,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
101,2,4,33.56806,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
101,3,4,52.501553,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
101,4,4,76.976006,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
101,5,4,85.08181,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
101,6,4,102.03513,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
101,1,5,23.854546,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
101,2,5,27.501223,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
101,3,5,50.27662,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
101,4,5,121.11724,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
101,5,5,94.69546,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
101,6,5,97.40281,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
101,1,6,24.789993,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
101,2,6,28.536957,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
101,3,6,43.65068,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
101,4,6,104.28221,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
101,5,6,113.21353,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
101,6,6,82.70835,241,6,NCGC00187909-01,Perifosine,PI3K kinase activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
102,1,1,4.550143,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
102,2,1,3.581735,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
102,3,1,2.245329,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
102,4,1,4.386594,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
102,5,1,2.511967,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
102,6,1,4.713948,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
102,1,2,6.410603,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
102,2,2,3.523179,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
102,3,2,5.009271,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
102,4,2,7.86223,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
102,5,2,10.182123,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
102,6,2,12.987091,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
102,1,3,6.147023,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
102,2,3,8.935904,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
102,3,3,9.193801,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
102,4,3,13.189843,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
102,5,3,21.72274,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
102,6,3,23.949406,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
102,1,4,8.73208,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
102,2,4,8.826444,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
102,3,4,22.22581,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
102,4,4,33.5469,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
102,5,4,55.883224,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
102,6,4,55.758846,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
102,1,5,16.73327,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
102,2,5,13.844407,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
102,3,5,23.892899,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
102,4,5,51.18945,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
102,5,5,88.99197,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
102,6,5,81.95686,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
102,1,6,18.516302,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
102,2,6,30.668552,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
102,3,6,36.703156,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
102,4,6,75.05792,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
102,5,6,115.5394,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
102,6,6,120.75837,241,6,NCGC00187482-03,Pictilisib,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
103,1,1,3.064851,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
103,2,1,1.333044,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
103,3,1,1.654011,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
103,4,1,2.220277,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
103,5,1,2.222519,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
103,6,1,3.85748,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
103,1,2,3.431312,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
103,2,2,1.848935,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
103,3,2,1.115933,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
103,4,2,1.13772,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
103,5,2,1.60213,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
103,6,2,2.629718,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
103,1,3,3.682198,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
103,2,3,1.61484,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
103,3,3,0.818081,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
103,4,3,0.335358,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
103,5,3,2.275872,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
103,6,3,4.276862,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
103,1,4,4.070381,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
103,2,4,2.740859,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
103,3,4,2.804056,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
103,4,4,1.820585,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
103,5,4,2.158136,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
103,6,4,4.668919,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
103,1,5,4.241757,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
103,2,5,3.59651,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
103,3,5,4.334553,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
103,4,5,3.633327,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
103,5,5,4.276126,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
103,6,5,9.65341,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
103,1,6,21.972265,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
103,2,6,34.531315,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
103,3,6,42.861416,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
103,4,6,75.506325,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
103,5,6,107.93992,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
103,6,6,124.83397,241,6,NCGC00250408-01,GSK-2126458,PI3Kalpha/beta/delta/gamma Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
104,1,1,5.378885,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
104,2,1,5.362701,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
104,3,1,6.491233,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
104,4,1,15.571364,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
104,5,1,23.561207,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
104,6,1,42.21258,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
104,1,2,7.2206,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
104,2,2,7.516099,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
104,3,2,13.483085,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
104,4,2,33.212696,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
104,5,2,51.83793,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
104,6,2,51.358616,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
104,1,3,8.375688,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
104,2,3,10.347673,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
104,3,3,15.412073,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
104,4,3,37.887074,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
104,5,3,62.06574,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
104,6,3,68.658585,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
104,1,4,16.693796,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
104,2,4,19.634813,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
104,3,4,33.65668,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
104,4,4,68.31417,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
104,5,4,97.99176,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
104,6,4,113.99739,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
104,1,5,16.151878,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
104,2,5,18.588001,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
104,3,5,30.104256,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
104,4,5,53.38224,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
104,5,5,101.00909,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
104,6,5,93.595146,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
104,1,6,22.156513,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
104,2,6,26.421162,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
104,3,6,42.510464,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
104,4,6,85.89044,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
104,5,6,109.210785,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
104,6,6,111.89112,241,6,NCGC00168114-01,IC-87114,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
105,1,1,6.633572,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
105,2,1,6.430164,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
105,3,1,6.729473,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
105,4,1,8.474759,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
105,5,1,11.335946,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
105,6,1,13.428627,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
105,1,2,8.712022,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
105,2,2,4.800436,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
105,3,2,7.713184,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
105,4,2,8.449579,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
105,5,2,8.808468,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
105,6,2,10.884485,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
105,1,3,6.407337,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
105,2,3,6.772373,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
105,3,3,6.627457,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
105,4,3,11.266889,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
105,5,3,20.109869,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
105,6,3,20.956877,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
105,1,4,9.503179,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
105,2,4,16.644623,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
105,3,4,13.427859,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
105,4,4,36.476746,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
105,5,4,63.340736,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
105,6,4,68.09581,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
105,1,5,7.869017,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
105,2,5,8.348523,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
105,3,5,9.029724,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
105,4,5,21.000145,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
105,5,5,35.88197,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
105,6,5,33.919827,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
105,1,6,20.767202,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
105,2,6,28.328571,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
105,3,6,39.77041,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
105,4,6,79.40065,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
105,5,6,83.9685,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
105,6,6,94.57935,241,6,NCGC00238454-02,PIK-90,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
106,1,1,1.748436,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
106,2,1,1.429566,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
106,3,1,3.336595,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
106,4,1,5.238875,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
106,5,1,7.675781,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
106,6,1,7.703217,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
106,1,2,10.795664,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
106,2,2,15.668672,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
106,3,2,25.515661,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
106,4,2,47.00629,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
106,5,2,82.759315,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
106,6,2,63.55999,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
106,1,3,13.615979,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
106,2,3,25.924656,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
106,3,3,49.713306,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
106,4,3,77.767075,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
106,5,3,94.065994,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
106,6,3,101.56031,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
106,1,4,20.73818,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
106,2,4,32.60067,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
106,3,4,59.014626,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
106,4,4,81.27289,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
106,5,4,112.73928,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
106,6,4,112.9181,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
106,1,5,21.179161,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
106,2,5,22.766487,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
106,3,5,62.237938,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
106,4,5,97.919655,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
106,5,5,116.26681,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
106,6,5,132.70009,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
106,1,6,26.549026,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
106,2,6,42.378872,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
106,3,6,52.094505,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
106,4,6,91.76205,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
106,5,6,114.13429,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
106,6,6,122.41991,241,6,NCGC00262604-01,BKM-120,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
107,1,1,4.638784,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
107,2,1,8.739116,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
107,3,1,7.834541,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
107,4,1,15.667777,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
107,5,1,23.934225,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
107,6,1,26.945198,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
107,1,2,8.404495,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
107,2,2,11.57793,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
107,3,2,9.907872,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
107,4,2,18.867268,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
107,5,2,26.05528,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
107,6,2,30.080954,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
107,1,3,5.971701,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
107,2,3,9.63395,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
107,3,3,13.013611,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
107,4,3,24.826372,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
107,5,3,33.91946,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
107,6,3,30.897165,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
107,1,4,9.949587,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
107,2,4,12.234441,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
107,3,4,19.15776,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
107,4,4,31.150297,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
107,5,4,53.816856,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
107,6,4,57.167976,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
107,1,5,11.674912,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
107,2,5,15.376237,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
107,3,5,28.08022,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
107,4,5,49.79583,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
107,5,5,67.40522,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
107,6,5,66.54331,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
107,1,6,31.03069,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
107,2,6,39.22348,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
107,3,6,57.556423,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
107,4,6,101.427505,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
107,5,6,106.45454,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
107,6,6,114.48025,241,6,NCGC00262603-01,Idelalisib,PI3Kdelta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
108,1,1,9.20142,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
108,2,1,12.180464,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
108,3,1,12.034117,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
108,4,1,11.165127,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
108,5,1,17.554258,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
108,6,1,18.150146,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
108,1,2,11.089055,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
108,2,2,12.805639,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
108,3,2,24.05397,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
108,4,2,31.398985,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
108,5,2,43.616962,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
108,6,2,44.742435,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
108,1,3,13.276957,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
108,2,3,25.054482,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
108,3,3,42.266,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
108,4,3,56.08625,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
108,5,3,67.06453,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
108,6,3,78.17001,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
108,1,4,15.647457,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
108,2,4,22.769644,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
108,3,4,41.805912,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
108,4,4,82.71402,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
108,5,4,104.28055,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
108,6,4,108.836876,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
108,1,5,24.824568,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
108,2,5,37.374874,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
108,3,5,49.107723,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
108,4,5,86.825485,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
108,5,5,97.953514,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
108,6,5,112.04342,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
108,1,6,32.901222,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
108,2,6,39.88855,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
108,3,6,67.38299,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
108,4,6,99.62668,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
108,5,6,107.38362,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
108,6,6,120.42673,241,6,NCGC00263088-01,BAG-956,PI3K/PDK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
109,1,1,6.354928,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
109,2,1,8.432234,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
109,3,1,13.020713,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
109,4,1,18.105883,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
109,5,1,28.353474,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
109,6,1,27.378698,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
109,1,2,12.721055,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
109,2,2,14.327348,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
109,3,2,25.360043,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
109,4,2,39.197273,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
109,5,2,53.626488,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
109,6,2,87.737595,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
109,1,3,14.265009,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
109,2,3,17.000786,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
109,3,3,28.71075,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
109,4,3,62.74733,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
109,5,3,79.93011,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
109,6,3,96.04673,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
109,1,4,20.033564,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
109,2,4,27.437138,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
109,3,4,40.511173,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
109,4,4,86.89315,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
109,5,4,111.064835,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
109,6,4,105.14432,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
109,1,5,16.59158,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
109,2,5,29.341679,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
109,3,5,44.59841,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
109,4,5,84.93705,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
109,5,5,110.15876,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
109,6,5,112.23353,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
109,1,6,23.443317,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
109,2,6,27.891489,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
109,3,6,31.788994,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
109,4,6,92.50859,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
109,5,6,102.885765,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
109,6,6,109.701584,241,6,NCGC00263154-01,AZD-6482,PI3Kb/d Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
110,1,1,13.518981,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
110,2,1,12.743923,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
110,3,1,16.570288,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
110,4,1,16.002565,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
110,5,1,26.901358,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
110,6,1,33.894115,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
110,1,2,9.736835,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
110,2,2,12.505146,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
110,3,2,17.271322,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
110,4,2,29.105618,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
110,5,2,39.2443,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
110,6,2,45.717407,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
110,1,3,8.747736,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
110,2,3,17.203157,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
110,3,3,14.803506,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
110,4,3,30.111502,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
110,5,3,47.42782,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
110,6,3,44.06351,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
110,1,4,14.92407,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
110,2,4,17.808498,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
110,3,4,29.209095,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
110,4,4,40.28147,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
110,5,4,63.37909,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
110,6,4,62.716965,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
110,1,5,16.362772,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
110,2,5,24.248543,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
110,3,5,40.990627,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
110,4,5,66.81934,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
110,5,5,61.711975,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
110,6,5,92.3556,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
110,1,6,24.24959,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
110,2,6,29.227684,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
110,3,6,56.971687,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
110,4,6,75.13375,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
110,5,6,102.10943,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
110,6,6,103.55416,241,6,NCGC00263223-01,CAY-10626,PI3Kalpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
111,1,1,6.200584,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
111,2,1,5.57075,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
111,3,1,3.760476,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
111,4,1,6.080808,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
111,5,1,5.787341,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
111,6,1,6.333865,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
111,1,2,7.176163,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
111,2,2,6.338888,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
111,3,2,3.743343,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
111,4,2,8.37108,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
111,5,2,10.450344,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
111,6,2,12.781511,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
111,1,3,10.133507,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
111,2,3,9.839554,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
111,3,3,11.482237,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
111,4,3,22.065193,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
111,5,3,30.70502,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
111,6,3,28.98566,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
111,1,4,14.385468,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
111,2,4,15.58474,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
111,3,4,20.984879,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
111,4,4,44.905415,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
111,5,4,54.230965,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
111,6,4,57.10348,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
111,1,5,19.172039,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
111,2,5,21.707127,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
111,3,5,36.827953,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
111,4,5,80.85297,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
111,5,5,82.97167,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
111,6,5,94.335724,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
111,1,6,32.538498,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
111,2,6,48.275517,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
111,3,6,49.996716,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
111,4,6,92.174416,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
111,5,6,114.6766,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
111,6,6,121.1907,241,6,NCGC00187906-02,PI-103,"PI3Kalpha, beta, gamma Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
112,1,1,8.176006,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
112,2,1,10.062929,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
112,3,1,10.802022,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
112,4,1,13.42083,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
112,5,1,16.447235,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
112,6,1,19.892012,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
112,1,2,12.803803,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
112,2,2,13.568087,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
112,3,2,9.889601,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
112,4,2,24.894356,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
112,5,2,38.62498,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
112,6,2,43.517807,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
112,1,3,14.319578,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
112,2,3,16.043158,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
112,3,3,18.292397,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
112,4,3,31.566334,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
112,5,3,45.35244,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
112,6,3,54.219887,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
112,1,4,13.391679,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
112,2,4,16.597603,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
112,3,4,25.45733,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
112,4,4,37.810425,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
112,5,4,55.1075,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
112,6,4,60.90206,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
112,1,5,14.640057,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
112,2,5,14.70716,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
112,3,5,25.504583,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
112,4,5,49.62622,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
112,5,5,60.8493,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
112,6,5,68.619774,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
112,1,6,34.493023,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
112,2,6,26.789944,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
112,3,6,54.224045,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
112,4,6,118.17172,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
112,5,6,132.09819,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
112,6,6,121.97405,241,6,NCGC00016094-02,17_-hydroxy Wortmannin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
113,1,1,11.24041,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
113,2,1,18.793274,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
113,3,1,27.575958,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
113,4,1,59.695324,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
113,5,1,70.68205,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
113,6,1,85.5144,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
113,1,2,16.015417,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
113,2,2,19.180796,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
113,3,2,33.605946,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
113,4,2,61.547844,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
113,5,2,100.020805,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
113,6,2,105.088036,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
113,1,3,24.468912,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
113,2,3,24.90217,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
113,3,3,35.566162,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
113,4,3,74.674644,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
113,5,3,94.032974,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
113,6,3,103.011566,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
113,1,4,22.30602,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
113,2,4,27.89152,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
113,3,4,47.79704,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
113,4,4,93.44786,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
113,5,4,104.725006,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
113,6,4,107.76791,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
113,1,5,28.799358,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
113,2,5,32.034294,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
113,3,5,53.468384,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
113,4,5,93.96844,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
113,5,5,106.2467,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
113,6,5,119.305984,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
113,1,6,26.056541,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
113,2,6,30.02564,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
113,3,6,51.577133,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
113,4,6,86.96921,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
113,5,6,115.11317,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
113,6,6,107.047905,241,6,NCGC00025288-01,Deguelin,PI3K Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
114,1,1,8.733153,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
114,2,1,7.519131,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
114,3,1,14.152275,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
114,4,1,39.565872,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
114,5,1,61.683434,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
114,6,1,74.281235,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
114,1,2,9.595603,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
114,2,2,9.071067,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
114,3,2,20.249805,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
114,4,2,48.774742,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
114,5,2,83.47786,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
114,6,2,79.2898,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
114,1,3,10.030394,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
114,2,3,18.769085,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
114,3,3,29.584204,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
114,4,3,74.82131,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
114,5,3,96.00468,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
114,6,3,95.812325,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
114,1,4,13.976352,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
114,2,4,16.135073,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
114,3,4,36.350582,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
114,4,4,63.6084,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
114,5,4,102.49116,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
114,6,4,89.823715,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
114,1,5,18.06268,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
114,2,5,24.110846,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
114,3,5,37.6096,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
114,4,5,76.688705,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
114,5,5,99.89394,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
114,6,5,103.25831,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
114,1,6,24.32627,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
114,2,6,34.807796,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
114,3,6,52.19557,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
114,4,6,103.10148,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
114,5,6,106.23834,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
114,6,6,112.7662,241,6,NCGC00186465-02,MK-2206,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
115,1,1,1.035838,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
115,2,1,0.770263,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
115,3,1,1.95307,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
115,4,1,4.556885,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
115,5,1,9.896961,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
115,6,1,10.758622,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
115,1,2,16.665632,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
115,2,2,25.117048,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
115,3,2,39.30949,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
115,4,2,75.96642,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
115,5,2,116.96834,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
115,6,2,110.691444,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
115,1,3,25.095787,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
115,2,3,29.130049,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
115,3,3,46.029648,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
115,4,3,85.60582,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
115,5,3,100.16879,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
115,6,3,118.635,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
115,1,4,24.308832,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
115,2,4,33.207787,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
115,3,4,37.61019,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
115,4,4,80.25268,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
115,5,4,114.43228,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
115,6,4,122.565735,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
115,1,5,25.90112,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
115,2,5,32.088547,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
115,3,5,52.690243,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
115,4,5,110.80893,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
115,5,5,117.74657,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
115,6,5,129.23615,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
115,1,6,26.296333,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
115,2,6,33.00558,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
115,3,6,49.569756,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
115,4,6,77.291756,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
115,5,6,123.46562,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
115,6,6,102.54592,241,6,NCGC00263147-01,A-674563,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
116,1,1,6.849948,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
116,2,1,9.579017,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
116,3,1,20.788363,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
116,4,1,40.08892,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
116,5,1,48.421955,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
116,6,1,55.080837,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
116,1,2,11.167798,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
116,2,2,22.350058,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
116,3,2,40.97738,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
116,4,2,61.200764,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
116,5,2,95.86781,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
116,6,2,99.215805,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
116,1,3,15.862379,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
116,2,3,21.083227,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
116,3,3,34.316936,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
116,4,3,78.61874,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
116,5,3,114.8532,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
116,6,3,112.93832,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
116,1,4,23.280325,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
116,2,4,33.008736,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
116,3,4,55.41503,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
116,4,4,82.44456,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
116,5,4,102.18318,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
116,6,4,102.21534,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
116,1,5,27.434088,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
116,2,5,39.396656,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
116,3,5,50.130207,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
116,4,5,82.932144,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
116,5,5,128.80728,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
116,6,5,119.91716,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
116,1,6,29.727863,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
116,2,6,39.880295,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
116,3,6,47.774307,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
116,4,6,88.06983,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
116,5,6,111.771,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
116,6,6,108.814384,241,6,NCGC00263181-01,GSK-690693,AKT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
117,1,1,16.456764,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
117,2,1,21.053226,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
117,3,1,21.033089,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
117,4,1,25.903229,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
117,5,1,29.996353,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
117,6,1,29.807274,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
117,1,2,19.529741,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
117,2,2,20.902084,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
117,3,2,17.032986,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
117,4,2,25.060946,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
117,5,2,31.880924,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
117,6,2,41.598003,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
117,1,3,20.594748,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
117,2,3,17.583199,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
117,3,3,21.61767,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
117,4,3,30.578447,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
117,5,3,36.71044,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
117,6,3,45.97412,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
117,1,4,21.646883,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
117,2,4,22.357841,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
117,3,4,30.80264,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
117,4,4,39.258457,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
117,5,4,50.93698,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
117,6,4,61.10313,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
117,1,5,19.608303,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
117,2,5,19.075953,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
117,3,5,31.988333,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
117,4,5,64.22578,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
117,5,5,65.45007,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
117,6,5,63.563587,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
117,1,6,29.342255,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
117,2,6,36.154312,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
117,3,6,62.63487,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
117,4,6,73.26074,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
117,5,6,112.692825,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
117,6,6,108.697266,241,6,NCGC00187481-05,BEZ-235,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
118,1,1,8.681042,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
118,2,1,5.927345,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
118,3,1,8.640525,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
118,4,1,9.512884,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
118,5,1,11.985148,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
118,6,1,12.269146,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
118,1,2,12.452322,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
118,2,2,14.641847,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
118,3,2,14.286026,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
118,4,2,27.988989,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
118,5,2,30.06115,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
118,6,2,34.014515,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
118,1,3,12.96534,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
118,2,3,20.29445,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
118,3,3,19.460438,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
118,4,3,28.985994,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
118,5,3,39.489147,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
118,6,3,42.38388,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
118,1,4,18.247797,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
118,2,4,19.26403,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
118,3,4,24.015503,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
118,4,4,46.496155,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
118,5,4,51.609444,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
118,6,4,57.625744,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
118,1,5,29.234846,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
118,2,5,28.831785,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
118,3,5,38.233257,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
118,4,5,68.74972,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
118,5,5,70.896706,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
118,6,5,72.07576,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
118,1,6,25.47214,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
118,2,6,42.85556,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
118,3,6,55.771065,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
118,4,6,103.85892,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
118,5,6,111.3341,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
118,6,6,117.504456,241,6,NCGC00250398-01,PF-05212384,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
119,1,1,6.768368,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
119,2,1,5.574361,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
119,3,1,6.481122,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
119,4,1,6.921589,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
119,5,1,7.608313,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
119,6,1,6.406234,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
119,1,2,5.721725,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
119,2,2,7.124447,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
119,3,2,9.251193,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
119,4,2,7.255801,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
119,5,2,9.200691,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
119,6,2,11.598932,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
119,1,3,8.625608,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
119,2,3,8.670146,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
119,3,3,10.405669,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
119,4,3,17.122473,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
119,5,3,27.732517,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
119,6,3,25.947783,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
119,1,4,16.31268,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
119,2,4,17.746996,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
119,3,4,20.048573,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
119,4,4,42.041443,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
119,5,4,59.199608,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
119,6,4,51.3988,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
119,1,5,15.265551,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
119,2,5,19.481047,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
119,3,5,34.356342,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
119,4,5,58.890568,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
119,5,5,81.01425,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
119,6,5,93.16219,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
119,1,6,36.381054,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
119,2,6,32.53144,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
119,3,6,55.194874,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
119,4,6,98.26428,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
119,5,6,109.52058,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
119,6,6,126.79144,241,6,NCGC00263109-01,GDC-0980,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
120,1,1,20.593184,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
120,2,1,22.823256,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
120,3,1,26.805893,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
120,4,1,43.84886,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
120,5,1,49.9655,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
120,6,1,48.77852,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
120,1,2,22.213907,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
120,2,2,20.858835,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
120,3,2,21.150042,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
120,4,2,35.34033,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
120,5,2,44.311134,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
120,6,2,47.366085,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
120,1,3,15.398088,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
120,2,3,23.264072,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
120,3,3,26.821249,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
120,4,3,36.748924,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
120,5,3,52.21439,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
120,6,3,49.713642,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
120,1,4,16.371239,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
120,2,4,16.50373,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
120,3,4,31.347208,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
120,4,4,47.359043,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
120,5,4,56.24114,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
120,6,4,69.341385,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
120,1,5,19.89872,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
120,2,5,25.085241,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
120,3,5,32.9613,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
120,4,5,59.571606,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
120,5,5,80.48317,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
120,6,5,84.34057,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
120,1,6,29.638893,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
120,2,6,34.127598,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
120,3,6,52.07918,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
120,4,6,112.64791,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
120,5,6,114.45298,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
120,6,6,119.252754,241,6,NCGC00263215-01,Torin-1,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
121,1,1,1.913372,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
121,2,1,1.176373,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
121,3,1,0.730899,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
121,4,1,1.466198,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
121,5,1,1.505031,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
121,6,1,1.88278,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
121,1,2,5.752742,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
121,2,2,7.336577,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
121,3,2,5.116444,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
121,4,2,8.265948,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
121,5,2,12.938511,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
121,6,2,12.908981,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
121,1,3,10.39233,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
121,2,3,10.143659,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
121,3,3,11.795689,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
121,4,3,17.766026,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
121,5,3,29.297352,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
121,6,3,32.85855,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
121,1,4,13.052125,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
121,2,4,12.173544,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
121,3,4,17.42893,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
121,4,4,33.11962,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
121,5,4,40.494377,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
121,6,4,53.267815,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
121,1,5,13.003399,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
121,2,5,18.296022,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
121,3,5,25.470394,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
121,4,5,38.235653,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
121,5,5,47.518974,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
121,6,5,69.17135,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
121,1,6,28.955553,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
121,2,6,41.437634,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
121,3,6,68.36048,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
121,4,6,104.34735,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
121,5,6,147.44704,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
121,6,6,105.63069,241,6,NCGC00263216-01,Torin-2,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
122,1,1,19.863695,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
122,2,1,22.99531,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
122,3,1,28.628792,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
122,4,1,40.415756,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
122,5,1,50.68916,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
122,6,1,47.323277,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
122,1,2,20.111746,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
122,2,2,27.05467,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
122,3,2,35.79653,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
122,4,2,44.867447,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
122,5,2,48.324394,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
122,6,2,47.95252,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
122,1,3,21.887026,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
122,2,3,25.11682,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
122,3,3,32.986523,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
122,4,3,49.46403,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
122,5,3,55.153675,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
122,6,3,56.397,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
122,1,4,11.496759,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
122,2,4,22.024723,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
122,3,4,29.856775,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
122,4,4,50.172134,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
122,5,4,64.7282,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
122,6,4,58.633114,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
122,1,5,15.189783,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
122,2,5,22.44258,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
122,3,5,31.117748,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
122,4,5,64.4374,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
122,5,5,74.16058,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
122,6,5,73.19271,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
122,1,6,25.713543,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
122,2,6,39.95239,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
122,3,6,59.689922,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
122,4,6,80.503975,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
122,5,6,103.99393,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
122,6,6,114.79402,241,6,NCGC00250405-01,AZD-8055,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
123,1,1,7.737042,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
123,2,1,8.566289,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
123,3,1,13.72536,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
123,4,1,24.57764,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
123,5,1,31.634636,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
123,6,1,36.679348,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
123,1,2,9.378602,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
123,2,2,14.342568,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
123,3,2,20.076935,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
123,4,2,39.769337,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
123,5,2,54.8298,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
123,6,2,46.498066,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
123,1,3,21.950245,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
123,2,3,13.89934,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
123,3,3,34.83546,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
123,4,3,56.55916,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
123,5,3,76.96149,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
123,6,3,78.44488,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
123,1,4,20.009056,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
123,2,4,28.345736,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
123,3,4,43.775143,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
123,4,4,66.72174,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
123,5,4,95.99826,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
123,6,4,91.753975,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
123,1,5,18.333445,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
123,2,5,30.792702,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
123,3,5,44.5365,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
123,4,5,81.98184,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
123,5,5,109.2064,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
123,6,5,112.0017,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
123,1,6,28.597214,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
123,2,6,40.590996,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
123,3,6,59.02611,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
123,4,6,96.6631,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
123,5,6,124.57198,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
123,6,6,105.010056,241,6,NCGC00250395-01,OSI-027,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
124,1,1,15.835338,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
124,2,1,14.702744,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
124,3,1,18.008778,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
124,4,1,33.888668,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
124,5,1,39.856243,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
124,6,1,43.462585,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
124,1,2,13.837062,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
124,2,2,24.250622,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
124,3,2,35.423927,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
124,4,2,44.055515,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
124,5,2,71.23049,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
124,6,2,63.674805,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
124,1,3,22.065557,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
124,2,3,26.99579,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
124,3,3,37.037155,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
124,4,3,64.76881,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
124,5,3,69.77408,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
124,6,3,86.01888,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
124,1,4,23.548828,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
124,2,4,29.8672,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
124,3,4,53.908817,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
124,4,4,81.65208,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
124,5,4,109.53512,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
124,6,4,115.49091,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
124,1,5,26.121412,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
124,2,5,34.531704,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
124,3,5,49.57868,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
124,4,5,81.94555,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
124,5,5,108.73922,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
124,6,5,128.98833,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
124,1,6,26.71366,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
124,2,6,37.988396,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
124,3,6,48.68081,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
124,4,6,101.8985,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
124,5,6,124.648674,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
124,6,6,112.56142,241,6,NCGC00250396-01,KU-0063794,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
125,1,1,12.446131,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
125,2,1,19.630898,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
125,3,1,22.888765,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
125,4,1,42.345898,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
125,5,1,47.54917,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
125,6,1,57.10925,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
125,1,2,13.195467,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
125,2,2,19.858097,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
125,3,2,25.07213,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
125,4,2,58.452454,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
125,5,2,72.49163,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
125,6,2,81.429436,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
125,1,3,21.720951,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
125,2,3,23.734646,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
125,3,3,40.82261,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
125,4,3,66.60401,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
125,5,3,105.37387,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
125,6,3,98.77721,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
125,1,4,30.337591,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
125,2,4,34.516376,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
125,3,4,54.134773,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
125,4,4,83.74567,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
125,5,4,98.20009,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
125,6,4,97.234314,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
125,1,5,26.512516,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
125,2,5,41.311317,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
125,3,5,56.076717,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
125,4,5,108.336815,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
125,5,5,128.83447,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
125,6,5,122.918236,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
125,1,6,34.197556,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
125,2,6,39.864346,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
125,3,6,58.91708,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
125,4,6,103.10774,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
125,5,6,122.86688,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
125,6,6,129.93692,241,6,NCGC00242484-02,WYE-354,mTORC1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
126,1,1,18.609884,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
126,2,1,25.774742,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
126,3,1,37.971382,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
126,4,1,94.76947,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
126,5,1,102.42748,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
126,6,1,100.53068,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
126,1,2,24.60098,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
126,2,2,31.961973,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
126,3,2,48.413883,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
126,4,2,95.997154,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
126,5,2,104.265495,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
126,6,2,116.76134,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
126,1,3,22.276777,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
126,2,3,39.72524,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
126,3,3,55.124935,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
126,4,3,99.126076,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
126,5,3,90.59166,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
126,6,3,117.64442,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
126,1,4,32.347446,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
126,2,4,36.185116,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
126,3,4,67.06011,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
126,4,4,110.13539,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
126,5,4,105.25379,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
126,6,4,109.9532,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
126,1,5,29.729216,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
126,2,5,41.669262,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
126,3,5,66.11717,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
126,4,5,114.04085,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
126,5,5,104.41735,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
126,6,5,119.436035,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
126,1,6,21.17288,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
126,2,6,37.453403,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
126,3,6,68.298355,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
126,4,6,114.77403,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
126,5,6,112.93112,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
126,6,6,101.064835,241,6,NCGC00015448-04,Salirasib,mTOR Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
127,1,1,5.640994,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
127,2,1,5.626715,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
127,3,1,9.106485,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
127,4,1,15.215185,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
127,5,1,30.512877,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
127,6,1,42.1641,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
127,1,2,14.994406,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
127,2,2,20.001986,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
127,3,2,42.8616,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
127,4,2,65.45535,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
127,5,2,93.01557,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
127,6,2,98.32204,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
127,1,3,19.678608,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
127,2,3,29.49103,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
127,3,3,49.66106,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
127,4,3,85.88625,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
127,5,3,109.540794,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
127,6,3,120.20659,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
127,1,4,21.88182,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
127,2,4,31.870483,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
127,3,4,63.82285,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
127,4,4,93.16958,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
127,5,4,114.825676,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
127,6,4,125.03498,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
127,1,5,28.198933,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
127,2,5,32.662277,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
127,3,5,53.31525,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
127,4,5,90.20646,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
127,5,5,120.288895,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
127,6,5,107.087524,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
127,1,6,31.364796,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
127,2,6,36.635963,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
127,3,6,60.743683,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
127,4,6,107.71413,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
127,5,6,102.3334,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
127,6,6,108.83699,241,6,NCGC00250377-01,NU-7441,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
128,1,1,1.30885,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
128,2,1,1.505168,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
128,3,1,1.283736,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
128,4,1,2.157658,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
128,5,1,2.2754,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
128,6,1,2.484161,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
128,1,2,3.411104,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
128,2,2,2.433841,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
128,3,2,4.17554,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
128,4,2,3.868551,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
128,5,2,5.105063,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
128,6,2,8.040191,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
128,1,3,6.842725,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
128,2,3,5.703227,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
128,3,3,9.002128,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
128,4,3,12.139173,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
128,5,3,19.385124,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
128,6,3,22.19849,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
128,1,4,9.825548,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
128,2,4,12.428725,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
128,3,4,14.062758,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
128,4,4,34.714973,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
128,5,4,55.570316,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
128,6,4,52.039696,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
128,1,5,14.175872,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
128,2,5,24.229847,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
128,3,5,35.480743,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
128,4,5,52.274147,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
128,5,5,86.9536,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
128,6,5,87.388794,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
128,1,6,28.395752,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
128,2,6,41.67741,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
128,3,6,55.646633,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
128,4,6,102.85948,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
128,5,6,113.49141,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
128,6,6,114.970535,241,6,NCGC00250387-02,KU-0060648,DNA-PK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
129,1,1,24.651361,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
129,2,1,35.224228,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
129,3,1,53.664654,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
129,4,1,101.26331,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
129,5,1,117.514534,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
129,6,1,116.01023,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
129,1,2,29.053415,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
129,2,2,32.17102,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
129,3,2,46.05215,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
129,4,2,77.39479,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
129,5,2,108.88879,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
129,6,2,117.91582,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
129,1,3,29.887625,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
129,2,3,37.840805,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
129,3,3,50.165157,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
129,4,3,102.78138,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
129,5,3,110.34319,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
129,6,3,137.46085,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
129,1,4,30.895102,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
129,2,4,47.197433,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
129,3,4,60.604454,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
129,4,4,108.544304,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
129,5,4,117.54855,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
129,6,4,124.29275,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
129,1,5,30.90237,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
129,2,5,43.244114,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
129,3,5,55.692566,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
129,4,5,97.48506,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
129,5,5,107.9494,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
129,6,5,126.16791,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
129,1,6,26.174995,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
129,2,6,39.445732,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
129,3,6,56.50922,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
129,4,6,98.73569,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
129,5,6,104.31102,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
129,6,6,130.02522,241,6,NCGC00092318-02,NSC-23766,Rac1-GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
130,1,1,29.274513,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
130,2,1,31.617563,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
130,3,1,47.14611,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
130,4,1,71.941284,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
130,5,1,109.315414,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
130,6,1,111.809,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
130,1,2,23.67595,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
130,2,2,34.80382,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
130,3,2,46.314693,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
130,4,2,82.55482,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
130,5,2,103.42878,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
130,6,2,112.68166,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
130,1,3,32.832085,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
130,2,3,31.70585,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
130,3,3,46.333553,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
130,4,3,90.93057,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
130,5,3,102.758965,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
130,6,3,126.243,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
130,1,4,27.506912,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
130,2,4,36.976048,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
130,3,4,69.89979,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
130,4,4,94.731476,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
130,5,4,107.487686,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
130,6,4,125.76218,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
130,1,5,33.439842,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
130,2,5,40.288,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
130,3,5,66.478836,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
130,4,5,100.458084,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
130,5,5,134.84856,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
130,6,5,135.36029,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
130,1,6,30.996365,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
130,2,6,51.98616,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
130,3,6,54.546665,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
130,4,6,99.25227,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
130,5,6,117.49447,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
130,6,6,112.4534,241,6,NCGC00188866-01,NCGC00188866,Rac1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
131,1,1,25.623571,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
131,2,1,34.99967,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
131,3,1,48.242435,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
131,4,1,73.00207,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
131,5,1,92.9202,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
131,6,1,96.17538,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
131,1,2,24.216267,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
131,2,2,36.791763,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
131,3,2,52.02123,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
131,4,2,82.58863,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
131,5,2,107.11519,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
131,6,2,96.91079,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
131,1,3,26.877047,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
131,2,3,29.487904,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
131,3,3,51.269238,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
131,4,3,93.63832,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
131,5,3,102.00328,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
131,6,3,100.252525,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
131,1,4,27.95794,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
131,2,4,44.984325,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
131,3,4,56.333115,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
131,4,4,97.5646,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
131,5,4,100.10323,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
131,6,4,106.61712,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
131,1,5,27.163715,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
131,2,5,39.642124,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
131,3,5,48.301575,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
131,4,5,90.677376,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
131,5,5,117.79528,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
131,6,5,116.912025,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
131,1,6,32.518757,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
131,2,6,39.08111,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
131,3,6,73.18628,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
131,4,6,108.25522,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
131,5,6,118.42326,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
131,6,6,119.33963,241,6,NCGC00249684-01,VX-702,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
132,1,1,28.363443,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
132,2,1,55.846893,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
132,3,1,67.46613,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
132,4,1,102.68823,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
132,5,1,111.169846,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
132,6,1,107.36463,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
132,1,2,32.179672,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
132,2,2,42.15879,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
132,3,2,59.78193,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
132,4,2,102.70227,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
132,5,2,117.0627,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
132,6,2,116.494125,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
132,1,3,34.398605,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
132,2,3,39.016796,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
132,3,3,54.01682,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
132,4,3,84.18131,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
132,5,3,110.188255,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
132,6,3,106.57774,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
132,1,4,31.180557,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
132,2,4,41.06597,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
132,3,4,57.298405,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
132,4,4,106.881905,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
132,5,4,118.23705,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
132,6,4,106.780846,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
132,1,5,36.239002,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
132,2,5,45.033688,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
132,3,5,60.174973,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
132,4,5,108.52353,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
132,5,5,99.8707,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
132,6,5,122.00466,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
132,1,6,33.292843,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
132,2,6,45.70275,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
132,3,6,64.04623,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
132,4,6,88.5049,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
132,5,6,104.53588,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
132,6,6,131.01141,241,6,NCGC00025035-02,SB-203580,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
133,1,1,19.627924,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
133,2,1,32.649033,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
133,3,1,46.488537,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
133,4,1,85.436806,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
133,5,1,98.50005,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
133,6,1,114.10578,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
133,1,2,27.067858,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
133,2,2,34.03526,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
133,3,2,47.181892,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
133,4,2,88.549904,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
133,5,2,95.30868,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
133,6,2,106.86562,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
133,1,3,25.430986,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
133,2,3,43.577778,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
133,3,3,48.927505,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
133,4,3,95.54978,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
133,5,3,105.93026,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
133,6,3,119.6063,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
133,1,4,21.942686,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
133,2,4,33.34923,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
133,3,4,53.050964,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
133,4,4,87.00542,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
133,5,4,111.80639,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
133,6,4,130.37006,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
133,1,5,28.794607,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
133,2,5,41.424355,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
133,3,5,58.178867,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
133,4,5,111.28581,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
133,5,5,98.41507,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
133,6,5,132.49368,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
133,1,6,32.093098,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
133,2,6,36.920734,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
133,3,6,54.458557,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
133,4,6,107.07924,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
133,5,6,106.184044,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
133,6,6,126.9216,241,6,NCGC00241111-01,VX-745,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
134,1,1,25.980652,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
134,2,1,31.045986,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
134,3,1,45.5234,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
134,4,1,69.29196,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
134,5,1,115.727356,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
134,6,1,120.62578,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
134,1,2,25.636787,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
134,2,2,36.49344,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
134,3,2,47.614376,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
134,4,2,87.42945,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
134,5,2,107.563576,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
134,6,2,105.98827,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
134,1,3,32.23635,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
134,2,3,40.471386,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
134,3,3,59.547703,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
134,4,3,93.7165,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
134,5,3,104.559784,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
134,6,3,110.38764,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
134,1,4,29.12935,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
134,2,4,42.009865,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
134,3,4,70.36927,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
134,4,4,101.78055,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
134,5,4,115.80294,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
134,6,4,128.91962,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
134,1,5,33.72156,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
134,2,5,33.27457,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
134,3,5,53.04376,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
134,4,5,100.129456,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
134,5,5,109.42704,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
134,6,5,121.41228,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
134,1,6,36.9945,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
134,2,6,39.102974,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
134,3,6,58.759247,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
134,4,6,99.62192,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
134,5,6,110.67762,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
134,6,6,125.66911,241,6,NCGC00241104-01,Doramapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
135,1,1,24.764975,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
135,2,1,33.886395,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
135,3,1,52.53417,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
135,4,1,82.314735,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
135,5,1,92.88044,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
135,6,1,119.231995,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
135,1,2,23.606358,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
135,2,2,34.532387,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
135,3,2,51.21723,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
135,4,2,79.78827,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
135,5,2,103.25288,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
135,6,2,106.385765,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
135,1,3,25.74494,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
135,2,3,32.07812,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
135,3,3,45.744648,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
135,4,3,71.583244,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
135,5,3,101.73722,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
135,6,3,98.591515,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
135,1,4,27.94653,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
135,2,4,45.064068,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
135,3,4,54.80098,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
135,4,4,99.00845,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
135,5,4,108.05357,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
135,6,4,100.98943,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
135,1,5,30.760077,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
135,2,5,39.146435,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
135,3,5,54.015545,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
135,4,5,101.85957,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
135,5,5,107.27774,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
135,6,5,104.559265,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
135,1,6,27.287636,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
135,2,6,41.538258,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
135,3,6,60.95466,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
135,4,6,105.1476,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
135,5,6,118.710556,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
135,6,6,94.00517,241,6,NCGC00263165-01,PH-797804,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
136,1,1,13.139593,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
136,2,1,20.03015,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
136,3,1,30.774158,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
136,4,1,52.246044,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
136,5,1,78.76425,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
136,6,1,86.79915,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
136,1,2,19.708654,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
136,2,2,25.152512,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
136,3,2,39.6259,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
136,4,2,82.77589,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
136,5,2,94.56187,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
136,6,2,92.59551,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
136,1,3,25.654984,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
136,2,3,29.919933,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
136,3,3,54.357586,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
136,4,3,83.86875,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
136,5,3,92.444435,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
136,6,3,100.518295,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
136,1,4,26.373377,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
136,2,4,31.189024,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
136,3,4,73.88561,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
136,4,4,90.255,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
136,5,4,104.60443,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
136,6,4,111.9226,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
136,1,5,32.476646,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
136,2,5,39.940903,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
136,3,5,61.55616,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
136,4,5,106.59205,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
136,5,5,100.46198,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
136,6,5,107.95169,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
136,1,6,31.032982,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
136,2,6,40.292538,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
136,3,6,50.986362,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
136,4,6,92.154305,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
136,5,6,120.134735,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
136,6,6,106.68398,241,6,NCGC00241112-03,RWJ-67657,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
137,1,1,30.410872,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
137,2,1,33.238605,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
137,3,1,53.768208,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
137,4,1,74.18559,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
137,5,1,95.28384,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
137,6,1,100.98707,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
137,1,2,40.391083,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
137,2,2,49.048042,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
137,3,2,37.322216,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
137,4,2,81.35062,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
137,5,2,89.06799,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
137,6,2,102.98349,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
137,1,3,33.43327,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
137,2,3,39.4983,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
137,3,3,50.339985,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
137,4,3,81.83826,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
137,5,3,103.133255,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
137,6,3,108.05072,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
137,1,4,27.741652,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
137,2,4,33.762505,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
137,3,4,50.28598,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
137,4,4,87.366974,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
137,5,4,99.44428,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
137,6,4,104.40561,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
137,1,5,36.79407,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
137,2,5,39.801506,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
137,3,5,50.847767,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
137,4,5,91.43423,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
137,5,5,105.79605,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
137,6,5,107.78152,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
137,1,6,33.163918,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
137,2,6,34.63814,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
137,3,6,56.255085,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
137,4,6,104.68388,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
137,5,6,109.475876,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
137,6,6,103.771614,241,6,NCGC00263140-01,Talmapimod,p38 MAPK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
138,1,1,24.138311,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
138,2,1,31.957907,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
138,3,1,45.60437,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
138,4,1,73.81818,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
138,5,1,112.990456,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
138,6,1,112.790085,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
138,1,2,30.390415,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
138,2,2,35.66219,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
138,3,2,43.795948,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
138,4,2,95.37896,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
138,5,2,108.846375,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
138,6,2,118.74175,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
138,1,3,21.514072,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
138,2,3,36.97852,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
138,3,3,56.58294,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
138,4,3,88.805725,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
138,5,3,100.76239,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
138,6,3,122.8813,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
138,1,4,30.35398,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
138,2,4,33.442085,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
138,3,4,50.112164,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
138,4,4,92.21577,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
138,5,4,104.87817,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
138,6,4,102.414566,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
138,1,5,32.80306,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
138,2,5,39.57713,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
138,3,5,60.88994,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
138,4,5,104.338165,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
138,5,5,120.164116,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
138,6,5,122.05502,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
138,1,6,31.79851,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
138,2,6,43.74663,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
138,3,6,62.49851,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
138,4,6,108.55551,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
138,5,6,113.244576,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
138,6,6,116.21011,241,6,NCGC00263239-01,FMK,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
139,1,1,8.90258,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
139,2,1,10.950599,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
139,3,1,18.408894,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
139,4,1,49.22067,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
139,5,1,84.93486,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
139,6,1,95.77303,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
139,1,2,24.207556,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
139,2,2,32.69662,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
139,3,2,49.918278,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
139,4,2,91.52569,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
139,5,2,115.36938,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
139,6,2,99.59611,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
139,1,3,20.919474,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
139,2,3,36.270325,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
139,3,3,51.38065,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
139,4,3,99.73712,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
139,5,3,111.285194,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
139,6,3,121.871574,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
139,1,4,30.212824,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
139,2,4,35.035877,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
139,3,4,56.47884,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
139,4,4,100.9082,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
139,5,4,116.332756,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
139,6,4,125.240295,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
139,1,5,28.710009,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
139,2,5,41.88866,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
139,3,5,72.01968,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
139,4,5,103.12902,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
139,5,5,112.30461,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
139,6,5,114.65839,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
139,1,6,30.508247,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
139,2,6,41.20939,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
139,3,6,55.75463,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
139,4,6,100.01332,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
139,5,6,103.73612,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
139,6,6,111.7461,241,6,NCGC00263086-01,BI-D1870,RSK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
140,1,1,1.980294,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
140,2,1,0.594234,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
140,3,1,0.646147,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
140,4,1,1.03904,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
140,5,1,0.877215,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
140,6,1,2.155366,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
140,1,2,2.449289,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
140,2,2,2.14784,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
140,3,2,-0.118561,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
140,4,2,0.409479,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
140,5,2,1.303645,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
140,6,2,1.516443,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
140,1,3,2.923611,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
140,2,3,2.216992,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
140,3,3,2.326433,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
140,4,3,1.393875,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
140,5,3,2.683908,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
140,6,3,4.82589,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
140,1,4,6.797094,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
140,2,4,7.565824,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
140,3,4,9.028153,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
140,4,4,16.147942,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
140,5,4,26.51417,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
140,6,4,25.997875,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
140,1,5,10.026797,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
140,2,5,10.530452,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
140,3,5,14.249607,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
140,4,5,38.545147,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
140,5,5,55.128304,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
140,6,5,55.136013,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
140,1,6,31.811134,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
140,2,6,39.61733,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
140,3,6,55.349476,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
140,4,6,104.59772,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
140,5,6,103.33303,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
140,6,6,103.75877,241,6,NCGC00253463-01,NCGC00253463-01,Chk1/2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
141,1,1,14.403275,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
141,2,1,22.022806,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
141,3,1,42.397408,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
141,4,1,66.77203,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
141,5,1,83.957054,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
141,6,1,93.90456,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
141,1,2,20.465979,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
141,2,2,33.36816,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
141,3,2,51.943806,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
141,4,2,100.94538,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
141,5,2,97.304855,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
141,6,2,100.59975,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
141,1,3,23.95543,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
141,2,3,37.36941,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
141,3,3,55.109554,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
141,4,3,84.76415,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
141,5,3,95.24537,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
141,6,3,101.07227,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
141,1,4,25.412094,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
141,2,4,44.902374,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
141,3,4,66.88886,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
141,4,4,94.62113,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
141,5,4,101.1045,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
141,6,4,113.81013,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
141,1,5,24.2607,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
141,2,5,44.52974,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
141,3,5,60.265373,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
141,4,5,100.73548,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
141,5,5,98.33782,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
141,6,5,117.24822,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
141,1,6,25.648752,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
141,2,6,37.17639,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
141,3,6,62.956684,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
141,4,6,78.61456,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
141,5,6,100.17353,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
141,6,6,108.04502,241,6,NCGC00250384-01,PHA-408,IKK-beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
142,1,1,-1.131198,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
142,2,1,-0.803133,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
142,3,1,-0.505311,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
142,4,1,-0.156863,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
142,5,1,0.244782,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
142,6,1,0.303735,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
142,1,2,-1.101743,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
142,2,2,-0.789367,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
142,3,2,-0.459091,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
142,4,2,0.02634,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
142,5,2,0.103752,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
142,6,2,0.683964,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
142,1,3,0.561192,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
142,2,3,2.642955,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
142,3,3,2.000977,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
142,4,3,3.010509,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
142,5,3,3.844044,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
142,6,3,7.396582,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
142,1,4,9.268917,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
142,2,4,12.131865,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
142,3,4,24.94564,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
142,4,4,50.00277,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
142,5,4,60.022945,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
142,6,4,68.02213,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
142,1,5,13.571492,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
142,2,5,27.611692,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
142,3,5,30.656536,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
142,4,5,57.953568,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
142,5,5,91.25979,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
142,6,5,103.10067,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
142,1,6,27.760933,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
142,2,6,38.987907,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
142,3,6,59.40735,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
142,4,6,94.50409,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
142,5,6,123.61121,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
142,6,6,117.51386,241,6,NCGC00263238-01,Withaferin A,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
143,1,1,11.780029,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
143,2,1,13.330915,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
143,3,1,20.982874,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
143,4,1,37.55052,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
143,5,1,57.15081,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
143,6,1,84.058586,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
143,1,2,18.66939,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
143,2,2,27.36068,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
143,3,2,37.21581,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
143,4,2,71.22072,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
143,5,2,104.6138,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
143,6,2,103.2095,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
143,1,3,27.683994,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
143,2,3,39.83716,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
143,3,3,51.811905,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
143,4,3,94.03984,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
143,5,3,106.43694,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
143,6,3,105.03174,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
143,1,4,21.161196,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
143,2,4,36.67236,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
143,3,4,62.08876,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
143,4,4,107.242775,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
143,5,4,110.16698,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
143,6,4,111.53841,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
143,1,5,26.139034,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
143,2,5,39.6181,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
143,3,5,66.14509,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
143,4,5,95.50217,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
143,5,5,107.51882,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
143,6,5,103.10764,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
143,1,6,33.445072,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
143,2,6,37.269363,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
143,3,6,67.597946,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
143,4,6,99.07863,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
143,5,6,98.33672,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
143,6,6,112.6061,241,6,NCGC00250386-01,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
144,1,1,-1.267778,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
144,2,1,-0.948785,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
144,3,1,-0.585092,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
144,4,1,0.098972,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
144,5,1,0.333061,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
144,6,1,1.064939,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
144,1,2,2.937417,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
144,2,2,2.980107,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
144,3,2,5.457429,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
144,4,2,15.1928,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
144,5,2,25.121723,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
144,6,2,37.33921,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
144,1,3,9.004469,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
144,2,3,12.019486,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
144,3,3,27.10163,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
144,4,3,64.64265,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
144,5,3,77.89625,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
144,6,3,83.1304,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
144,1,4,17.071306,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
144,2,4,22.919456,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
144,3,4,34.192482,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
144,4,4,82.20678,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
144,5,4,108.84867,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
144,6,4,104.01765,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
144,1,5,19.003098,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
144,2,5,25.272083,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
144,3,5,43.015156,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
144,4,5,87.76705,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
144,5,5,106.97153,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
144,6,5,104.5739,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
144,1,6,27.704119,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
144,2,6,36.865868,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
144,3,6,55.522266,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
144,4,6,93.564285,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
144,5,6,105.562836,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
144,6,6,114.24578,241,6,NCGC00186460-01,Bardoxolone methyl,NF-kappaB signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
145,1,1,8.967091,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
145,2,1,12.684229,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
145,3,1,12.442676,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
145,4,1,29.728249,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
145,5,1,53.515305,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
145,6,1,74.26762,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
145,1,2,15.480301,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
145,2,2,21.776445,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
145,3,2,38.090527,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
145,4,2,82.79184,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
145,5,2,98.21368,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
145,6,2,104.9252,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
145,1,3,19.33488,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
145,2,3,26.54269,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
145,3,3,57.42341,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
145,4,3,95.40703,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
145,5,3,100.730354,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
145,6,3,111.43527,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
145,1,4,23.542746,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
145,2,4,27.942556,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
145,3,4,50.416313,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
145,4,4,91.344826,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
145,5,4,103.34123,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
145,6,4,110.11444,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
145,1,5,27.91257,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
145,2,5,32.708614,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
145,3,5,52.341415,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
145,4,5,101.805084,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
145,5,5,108.051926,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
145,6,5,117.50644,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
145,1,6,27.574198,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
145,2,6,37.35272,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
145,3,6,51.666695,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
145,4,6,84.41,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
145,5,6,115.72975,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
145,6,6,1.927555,241,6,NCGC00167767-01,IKK-16,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
146,1,1,23.73337,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
146,2,1,23.965506,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
146,3,1,42.411057,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
146,4,1,71.976,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
146,5,1,65.21813,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
146,6,1,71.92441,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
146,1,2,32.122402,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
146,2,2,37.03859,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
146,3,2,57.037395,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
146,4,2,98.590706,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
146,5,2,95.84183,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
146,6,2,106.76574,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
146,1,3,18.477617,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
146,2,3,37.432343,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
146,3,3,60.041836,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
146,4,3,112.51162,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
146,5,3,103.708336,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
146,6,3,107.2808,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
146,1,4,27.180405,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
146,2,4,41.91189,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
146,3,4,61.67187,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
146,4,4,108.706375,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
146,5,4,96.64805,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
146,6,4,109.323395,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
146,1,5,36.97694,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
146,2,5,36.84399,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
146,3,5,60.344822,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
146,4,5,109.68968,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
146,5,5,105.40491,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
146,6,5,111.70302,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
146,1,6,23.180086,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
146,2,6,40.576214,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
146,3,6,69.59298,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
146,4,6,94.39886,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
146,5,6,103.957115,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
146,6,6,111.91857,241,6,NCGC00263213-01,PF-184,IKK-2 (IKK-beta) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
147,1,1,0.017182,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
147,2,1,0.631743,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
147,3,1,1.804497,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
147,4,1,2.862474,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
147,5,1,3.383647,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
147,6,1,4.196612,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
147,1,2,30.727892,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
147,2,2,45.39517,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
147,3,2,64.402626,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
147,4,2,82.49602,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
147,5,2,85.04337,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
147,6,2,106.1761,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
147,1,3,36.266277,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
147,2,3,42.829914,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
147,3,3,64.021194,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
147,4,3,92.32214,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
147,5,3,112.152336,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
147,6,3,110.34654,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
147,1,4,26.518576,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
147,2,4,33.841793,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
147,3,4,43.96434,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
147,4,4,83.047676,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
147,5,4,113.36795,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
147,6,4,101.163536,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
147,1,5,28.595127,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
147,2,5,37.429802,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
147,3,5,58.630554,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
147,4,5,98.52542,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
147,5,5,111.117004,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
147,6,5,118.37029,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
147,1,6,29.030634,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
147,2,6,32.38981,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
147,3,6,59.61029,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
147,4,6,97.80471,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
147,5,6,112.30806,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
147,6,6,99.99855,241,6,NCGC00165811-02,IMD-0354,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
148,1,1,18.0724,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
148,2,1,27.808517,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
148,3,1,48.18294,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
148,4,1,79.340454,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
148,5,1,92.229034,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
148,6,1,102.43328,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
148,1,2,25.086441,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
148,2,2,31.08379,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
148,3,2,54.467216,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
148,4,2,88.938354,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
148,5,2,104.06724,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
148,6,2,97.97881,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
148,1,3,26.783567,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
148,2,3,33.42882,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
148,3,3,51.01427,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
148,4,3,96.51253,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
148,5,3,104.18263,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
148,6,3,105.9912,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
148,1,4,25.68214,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
148,2,4,36.5559,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
148,3,4,51.474033,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
148,4,4,101.647,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
148,5,4,107.93709,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
148,6,4,122.41631,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
148,1,5,29.355413,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
148,2,5,46.4822,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
148,3,5,44.591305,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
148,4,5,95.266396,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
148,5,5,113.16703,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
148,6,5,113.43819,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
148,1,6,26.609594,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
148,2,6,38.852345,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
148,3,6,59.404896,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
148,4,6,99.89514,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
148,5,6,108.91432,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
148,6,6,109.351654,241,6,NCGC00165873-02,PS-1145,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
149,1,1,25.844387,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
149,2,1,25.155169,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
149,3,1,48.491314,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
149,4,1,79.985634,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
149,5,1,103.42176,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
149,6,1,114.371956,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
149,1,2,24.7756,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
149,2,2,27.397154,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
149,3,2,43.820854,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
149,4,2,84.40207,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
149,5,2,106.36828,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
149,6,2,110.29622,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
149,1,3,29.664415,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
149,2,3,33.576557,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
149,3,3,64.099365,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
149,4,3,117.193375,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
149,5,3,111.76305,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
149,6,3,110.44319,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
149,1,4,33.59055,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
149,2,4,38.49448,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
149,3,4,56.804386,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
149,4,4,112.11207,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
149,5,4,121.13101,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
149,6,4,109.5431,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
149,1,5,24.95088,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
149,2,5,31.457458,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
149,3,5,57.108047,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
149,4,5,94.4083,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
149,5,5,116.213615,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
149,6,5,122.220276,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
149,1,6,30.151642,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
149,2,6,33.274933,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
149,3,6,52.56873,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
149,4,6,99.932304,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
149,5,6,109.74966,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
149,6,6,142.41805,241,6,NCGC00263021-01,MLN-120B,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
150,1,1,16.153212,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
150,2,1,27.654238,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
150,3,1,28.660381,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
150,4,1,25.252647,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
150,5,1,32.52719,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
150,6,1,34.23375,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
150,1,2,22.032667,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
150,2,2,22.820772,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
150,3,2,36.01842,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
150,4,2,50.97056,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
150,5,2,59.668537,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
150,6,2,59.810287,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
150,1,3,24.83408,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
150,2,3,31.833494,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
150,3,3,41.664436,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
150,4,3,65.851845,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
150,5,3,76.79052,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
150,6,3,76.84472,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
150,1,4,22.60563,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
150,2,4,31.088469,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
150,3,4,40.011032,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
150,4,4,74.62623,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
150,5,4,89.57847,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
150,6,4,89.732735,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
150,1,5,32.71562,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
150,2,5,37.67039,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
150,3,5,49.541756,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
150,4,5,84.579124,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
150,5,5,82.5828,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
150,6,5,122.278496,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
150,1,6,28.31423,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
150,2,6,37.807175,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
150,3,6,51.705956,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
150,4,6,85.25248,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
150,5,6,106.661285,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
150,6,6,115.3685,241,6,NCGC00169964-03,cycloheximide,GSK-3beta Inhibitor; tau Protein Kinase I Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
151,1,1,30.184225,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
151,2,1,58.788425,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
151,3,1,89.98354,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
151,4,1,134.10951,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
151,5,1,150.33058,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
151,6,1,132.27176,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
151,1,2,23.254772,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
151,2,2,40.40592,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
151,3,2,85.17431,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
151,4,2,106.497795,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
151,5,2,122.80135,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
151,6,2,133.9909,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
151,1,3,36.77384,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
151,2,3,42.610523,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
151,3,3,72.74962,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
151,4,3,110.570244,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
151,5,3,111.25186,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
151,6,3,100.98543,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
151,1,4,33.81871,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
151,2,4,45.349308,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
151,3,4,77.89942,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
151,4,4,105.55154,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
151,5,4,107.27347,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
151,6,4,115.40023,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
151,1,5,33.293835,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
151,2,5,40.377983,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
151,3,5,70.31072,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
151,4,5,111.67027,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
151,5,5,121.866745,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
151,6,5,98.56675,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
151,1,6,40.22804,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
151,2,6,48.010246,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
151,3,6,69.285576,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
151,4,6,112.24007,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
151,5,6,131.71907,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
151,6,6,122.77701,241,6,NCGC00250379-01,CT-99021,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
152,1,1,38.70028,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
152,2,1,64.78504,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
152,3,1,84.703705,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
152,4,1,118.7556,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
152,5,1,119.92019,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
152,6,1,183.47543,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
152,1,2,39.321156,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
152,2,2,49.909294,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
152,3,2,65.24143,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
152,4,2,113.53665,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
152,5,2,132.54938,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
152,6,2,138.72498,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
152,1,3,32.60782,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
152,2,3,45.65383,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
152,3,3,68.60158,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
152,4,3,103.996025,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
152,5,3,118.237,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
152,6,3,122.642006,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
152,1,4,34.851456,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
152,2,4,40.914658,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
152,3,4,53.91131,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
152,4,4,102.75027,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
152,5,4,116.520134,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
152,6,4,116.276344,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
152,1,5,32.717716,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
152,2,5,46.94693,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
152,3,5,57.685516,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
152,4,5,102.5747,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
152,5,5,104.49132,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
152,6,5,105.14788,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
152,1,6,29.687683,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
152,2,6,30.945889,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
152,3,6,59.158806,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
152,4,6,101.161316,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
152,5,6,103.14544,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
152,6,6,98.69967,241,6,NCGC00263194-01,SB-216763,GSK-3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
153,1,1,0.556613,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
153,2,1,-0.987728,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
153,3,1,-0.474493,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
153,4,1,0.230356,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
153,5,1,0.419071,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
153,6,1,0.809262,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
153,1,2,1.106437,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
153,2,2,-0.496412,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
153,3,2,0.168389,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
153,4,2,4.909858,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
153,5,2,9.832607,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
153,6,2,20.6171,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
153,1,3,2.48569,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
153,2,3,2.017829,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
153,3,3,6.387567,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
153,4,3,22.84437,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
153,5,3,35.29639,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
153,6,3,41.738777,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
153,1,4,6.648642,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
153,2,4,7.99488,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
153,3,4,19.556309,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
153,4,4,38.51,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
153,5,4,53.95717,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
153,6,4,56.30658,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
153,1,5,11.566782,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
153,2,5,13.236881,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
153,3,5,19.916311,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
153,4,5,58.65064,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
153,5,5,76.1292,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
153,6,5,99.28577,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
153,1,6,29.897673,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
153,2,6,39.565968,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
153,3,6,56.249004,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
153,4,6,83.308235,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
153,5,6,118.81622,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
153,6,6,116.84489,241,6,NCGC00161703-02,SPC-839,IKK beta Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
154,1,1,24.940474,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
154,2,1,36.292027,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
154,3,1,49.110054,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
154,4,1,81.569145,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
154,5,1,103.155014,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
154,6,1,104.164055,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
154,1,2,28.916117,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
154,2,2,30.970821,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
154,3,2,60.134148,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
154,4,2,88.616806,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
154,5,2,116.91985,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
154,6,2,122.82886,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
154,1,3,24.25519,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
154,2,3,39.784897,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
154,3,3,51.67182,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
154,4,3,83.378235,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
154,5,3,110.21499,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
154,6,3,121.98015,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
154,1,4,32.22195,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
154,2,4,35.86726,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
154,3,4,59.14085,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
154,4,4,93.407036,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
154,5,4,127.86975,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
154,6,4,138.52446,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
154,1,5,30.54443,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
154,2,5,35.874035,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
154,3,5,70.38018,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
154,4,5,87.28807,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
154,5,5,123.327866,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
154,6,5,108.60034,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
154,1,6,31.381224,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
154,2,6,38.18736,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
154,3,6,58.310314,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
154,4,6,114.06614,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
154,5,6,107.03991,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
154,6,6,116.14944,241,6,NCGC00263019-01,WAY-204688,NF-kappaB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
155,1,1,28.721357,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
155,2,1,39.534676,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
155,3,1,59.732903,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
155,4,1,107.40616,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
155,5,1,118.22469,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
155,6,1,114.332855,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
155,1,2,17.787453,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
155,2,2,40.30001,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
155,3,2,61.324066,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
155,4,2,104.34623,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
155,5,2,125.5055,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
155,6,2,116.09549,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
155,1,3,32.22353,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
155,2,3,41.15564,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
155,3,3,57.723816,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
155,4,3,115.58866,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
155,5,3,112.41585,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
155,6,3,103.70752,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
155,1,4,24.165417,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
155,2,4,35.03816,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
155,3,4,53.400414,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
155,4,4,87.187,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
155,5,4,106.56339,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
155,6,4,133.46071,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
155,1,5,35.206333,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
155,2,5,40.448536,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
155,3,5,64.0159,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
155,4,5,104.0648,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
155,5,5,109.4577,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
155,6,5,122.52088,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
155,1,6,31.075163,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
155,2,6,37.76724,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
155,3,6,62.227592,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
155,4,6,101.44279,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
155,5,6,107.30345,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
155,6,6,121.010216,241,6,NCGC00090903-02,Sulfasalazine,NFKB Activation Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
156,1,1,6.87472,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
156,2,1,8.9122,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
156,3,1,28.1374,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
156,4,1,57.0169,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
156,5,1,75.21944,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
156,6,1,89.31408,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
156,1,2,21.761187,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
156,2,2,29.015692,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
156,3,2,55.59335,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
156,4,2,103.62497,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
156,5,2,110.355675,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
156,6,2,118.42596,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
156,1,3,22.269686,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
156,2,3,34.52092,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
156,3,3,60.114998,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
156,4,3,102.696884,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
156,5,3,110.663284,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
156,6,3,117.133865,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
156,1,4,29.015219,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
156,2,4,36.493717,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
156,3,4,58.089733,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
156,4,4,105.88046,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
156,5,4,118.9587,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
156,6,4,111.763824,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
156,1,5,35.13973,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
156,2,5,46.408833,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
156,3,5,69.14613,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
156,4,5,107.604576,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
156,5,5,105.37129,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
156,6,5,109.166245,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
156,1,6,30.53896,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
156,2,6,40.222786,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
156,3,6,69.67652,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
156,4,6,107.80351,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
156,5,6,114.79377,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
156,6,6,122.26711,241,6,NCGC00263020-01,NCGC00263020,NFkappaB-inducing kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
157,1,1,16.648333,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,2
157,2,1,17.552202,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,2
157,3,1,26.054058,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,2
157,4,1,51.023354,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,2
157,5,1,81.03592,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,2
157,6,1,82.48407,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,2
157,1,2,37.19004,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,2
157,2,2,42.2647,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,2
157,3,2,70.02979,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,2
157,4,2,107.381065,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,2
157,5,2,104.87775,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,2
157,6,2,127.405754,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,2
157,1,3,30.575348,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,2
157,2,3,35.626953,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,2
157,3,3,59.55284,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,2
157,4,3,113.00068,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,2
157,5,3,115.91466,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,2
157,6,3,112.53839,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,2
157,1,4,31.722294,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,2
157,2,4,36.46069,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,2
157,3,4,58.371292,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,2
157,4,4,102.50881,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,2
157,5,4,111.60637,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,2
157,6,4,100.67013,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,2
157,1,5,31.903214,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,2
157,2,5,32.917194,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,2
157,3,5,54.94125,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,2
157,4,5,105.74766,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,2
157,5,5,119.8153,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,2
157,6,5,111.20694,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,2
157,1,6,30.53233,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,2
157,2,6,34.15704,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,2
157,3,6,42.387516,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,2
157,4,6,98.388954,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,2
157,5,6,117.16211,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,2
157,6,6,111.79421,241,6,NCGC00250386-02,BX-795,IKK-epsilon Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,2
158,1,1,23.385998,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
158,2,1,27.05963,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
158,3,1,38.81584,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
158,4,1,73.91229,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
158,5,1,88.10699,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
158,6,1,99.89872,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
158,1,2,27.713923,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
158,2,2,36.06282,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
158,3,2,50.878864,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
158,4,2,81.85728,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
158,5,2,101.94623,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
158,6,2,114.9892,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
158,1,3,23.805443,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
158,2,3,34.29823,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
158,3,3,53.42038,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
158,4,3,94.19386,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
158,5,3,109.2707,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
158,6,3,101.043755,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
158,1,4,30.895348,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
158,2,4,34.864532,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
158,3,4,50.998405,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
158,4,4,102.022606,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
158,5,4,100.88488,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
158,6,4,128.80101,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
158,1,5,29.440647,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
158,2,5,38.35586,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
158,3,5,56.4631,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
158,4,5,103.26463,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
158,5,5,103.22273,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
158,6,5,110.20197,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
158,1,6,24.461128,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
158,2,6,31.765886,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
158,3,6,50.74478,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
158,4,6,104.04874,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
158,5,6,113.214615,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
158,6,6,119.815544,241,6,NCGC00229735-01,KU-60019,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
159,1,1,29.160324,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
159,2,1,23.057688,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
159,3,1,32.529602,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
159,4,1,101.07771,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
159,5,1,106.47787,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
159,6,1,115.22923,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
159,1,2,27.636065,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
159,2,2,30.47718,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
159,3,2,50.75114,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
159,4,2,98.07503,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
159,5,2,104.59183,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
159,6,2,105.68278,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
159,1,3,28.4516,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
159,2,3,38.047535,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
159,3,3,56.610344,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
159,4,3,93.96901,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
159,5,3,115.94828,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
159,6,3,114.90926,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
159,1,4,31.412271,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
159,2,4,41.02378,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
159,3,4,52.90974,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
159,4,4,88.908646,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
159,5,4,108.49001,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
159,6,4,120.44143,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
159,1,5,29.305834,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
159,2,5,39.3008,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
159,3,5,60.368538,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
159,4,5,92.003784,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
159,5,5,127.01202,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
159,6,5,116.26156,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
159,1,6,28.440907,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
159,2,6,47.61727,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
159,3,6,61.104103,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
159,4,6,109.37489,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
159,5,6,115.39697,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
159,6,6,122.97113,241,6,NCGC00263190-01,KU-0064,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
160,1,1,39.531845,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
160,2,1,42.321186,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
160,3,1,81.0861,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
160,4,1,101.20285,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
160,5,1,109.138794,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
160,6,1,112.003624,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
160,1,2,23.150417,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
160,2,2,42.713455,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
160,3,2,52.401573,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
160,4,2,90.03891,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
160,5,2,105.11349,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
160,6,2,115.040276,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
160,1,3,26.096247,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
160,2,3,37.26457,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
160,3,3,45.10919,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
160,4,3,91.33541,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
160,5,3,109.73442,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
160,6,3,113.594055,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
160,1,4,25.881077,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
160,2,4,33.825157,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
160,3,4,48.476974,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
160,4,4,109.98322,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
160,5,4,116.30426,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
160,6,4,115.45835,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
160,1,5,25.511196,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
160,2,5,40.31916,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
160,3,5,57.428837,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
160,4,5,101.92717,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
160,5,5,120.66995,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
160,6,5,126.35319,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
160,1,6,35.070744,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
160,2,6,44.325565,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
160,3,6,62.832294,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
160,4,6,108.57554,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
160,5,6,118.52404,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
160,6,6,127.00138,241,6,NCGC00263099-01,CP-466722,ATM Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
161,1,1,38.049717,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
161,2,1,43.508392,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
161,3,1,75.40783,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
161,4,1,96.370735,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
161,5,1,106.53794,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
161,6,1,106.39455,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
161,1,2,53.607185,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
161,2,2,73.80712,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
161,3,2,72.68505,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
161,4,2,92.0372,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
161,5,2,113.74036,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
161,6,2,96.88954,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
161,1,3,58.810356,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
161,2,3,79.63703,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
161,3,3,78.69431,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
161,4,3,98.297134,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
161,5,3,103.01137,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
161,6,3,110.13057,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
161,1,4,62.685104,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
161,2,4,63.63093,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
161,3,4,88.22583,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
161,4,4,100.96756,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
161,5,4,101.928635,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
161,6,4,113.13689,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
161,1,5,58.43844,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
161,2,5,58.50374,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
161,3,5,71.225845,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
161,4,5,90.30634,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
161,5,5,114.95504,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
161,6,5,113.26275,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
161,1,6,37.530167,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
161,2,6,38.008835,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
161,3,6,74.349655,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
161,4,6,105.89818,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
161,5,6,111.02689,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
161,6,6,114.159515,241,6,NCGC00263236-01,SM-164,IAP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
162,1,1,26.906168,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
162,2,1,33.40168,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
162,3,1,40.702763,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
162,4,1,54.651943,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
162,5,1,56.549194,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
162,6,1,50.608173,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
162,1,2,36.692352,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
162,2,2,40.017994,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
162,3,2,63.321598,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
162,4,2,92.76952,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
162,5,2,122.68478,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
162,6,2,127.69865,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
162,1,3,34.693127,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
162,2,3,39.658005,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
162,3,3,70.101036,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
162,4,3,103.463165,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
162,5,3,111.7956,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
162,6,3,112.69382,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
162,1,4,28.770147,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
162,2,4,39.07877,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
162,3,4,48.38818,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
162,4,4,95.84144,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
162,5,4,111.83227,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
162,6,4,126.704636,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
162,1,5,30.37452,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
162,2,5,39.012466,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
162,3,5,57.444584,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
162,4,5,108.720024,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
162,5,5,112.48195,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
162,6,5,108.54442,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
162,1,6,29.710478,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
162,2,6,39.20919,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
162,3,6,65.82797,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
162,4,6,90.70264,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
162,5,6,107.945946,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
162,6,6,127.90278,241,6,NCGC00263208-01,TW-37,Bcl-xL Inhibitor/Mcl-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
163,1,1,21.420649,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
163,2,1,25.917751,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
163,3,1,33.624615,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
163,4,1,58.27381,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
163,5,1,69.77924,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
163,6,1,94.14152,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
163,1,2,29.930786,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
163,2,2,35.65839,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
163,3,2,55.706116,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
163,4,2,90.6674,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
163,5,2,104.77935,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
163,6,2,107.14164,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
163,1,3,27.606567,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
163,2,3,39.104305,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
163,3,3,47.863605,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
163,4,3,91.49628,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
163,5,3,105.90027,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
163,6,3,99.196335,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
163,1,4,33.24576,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
163,2,4,42.87873,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
163,3,4,54.979492,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
163,4,4,106.9698,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
163,5,4,118.69585,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
163,6,4,107.470695,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
163,1,5,34.118427,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
163,2,5,41.459156,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
163,3,5,64.842255,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
163,4,5,107.39354,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
163,5,5,113.6297,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
163,6,5,130.56258,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
163,1,6,29.534554,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
163,2,6,36.82925,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
163,3,6,62.472862,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
163,4,6,106.854485,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
163,5,6,103.054214,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
163,6,6,124.097275,241,6,NCGC00016423-09,(-)-Gossypol,Bcl-xl Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
164,1,1,9.899254,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
164,2,1,18.743572,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
164,3,1,21.322536,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
164,4,1,34.242805,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
164,5,1,48.429535,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
164,6,1,59.005386,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
164,1,2,26.76508,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
164,2,2,39.5493,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
164,3,2,44.82199,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
164,4,2,85.275116,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
164,5,2,112.176796,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
164,6,2,117.270775,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
164,1,3,21.610037,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
164,2,3,29.608921,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
164,3,3,67.89593,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
164,4,3,112.12096,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
164,5,3,118.56827,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
164,6,3,103.99435,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
164,1,4,29.952261,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
164,2,4,44.489704,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
164,3,4,66.2656,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
164,4,4,97.98425,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
164,5,4,111.01944,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
164,6,4,101.57186,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
164,1,5,29.003592,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
164,2,5,41.541622,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
164,3,5,60.09044,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
164,4,5,95.02174,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
164,5,5,100.774254,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
164,6,5,126.32202,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
164,1,6,33.23121,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
164,2,6,40.668167,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
164,3,6,60.74041,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
164,4,6,98.12969,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
164,5,6,107.33727,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
164,6,6,110.516785,241,6,NCGC00015225-03,Chelerythrine chloride,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
165,1,1,19.365713,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
165,2,1,23.217594,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
165,3,1,27.21299,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
165,4,1,44.741924,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
165,5,1,50.688915,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
165,6,1,44.24248,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
165,1,2,41.64421,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
165,2,2,53.43347,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
165,3,2,59.816673,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
165,4,2,88.73688,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
165,5,2,105.70149,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
165,6,2,103.307396,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
165,1,3,30.826132,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
165,2,3,41.74307,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
165,3,3,62.31151,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
165,4,3,103.92279,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
165,5,3,113.26414,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
165,6,3,102.60276,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
165,1,4,24.185686,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
165,2,4,38.38394,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
165,3,4,51.1707,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
165,4,4,83.00952,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
165,5,4,109.30041,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
165,6,4,101.65015,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
165,1,5,31.717571,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
165,2,5,40.256847,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
165,3,5,58.754047,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
165,4,5,96.29491,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
165,5,5,113.22896,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
165,6,5,117.45603,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
165,1,6,31.205427,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
165,2,6,38.562378,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
165,3,6,52.760174,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
165,4,6,97.74897,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
165,5,6,121.189705,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
165,6,6,127.664604,241,6,NCGC00263166-01,Obatoclax,Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
166,1,1,0.878951,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
166,2,1,-0.131025,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
166,3,1,2.20218,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
166,4,1,28.616444,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
166,5,1,31.228838,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
166,6,1,48.668575,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
166,1,2,2.644276,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
166,2,2,3.648855,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
166,3,2,15.40563,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
166,4,2,63.106617,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
166,5,2,56.88527,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
166,6,2,76.65702,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
166,1,3,7.379443,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
166,2,3,14.18278,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
166,3,3,20.351044,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
166,4,3,64.56575,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
166,5,3,82.89331,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
166,6,3,76.76014,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
166,1,4,13.279039,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
166,2,4,17.733065,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
166,3,4,29.980352,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
166,4,4,75.90394,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
166,5,4,90.54221,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
166,6,4,118.86961,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
166,1,5,15.235733,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
166,2,5,25.081919,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
166,3,5,51.996025,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
166,4,5,91.9674,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
166,5,5,94.77807,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
166,6,5,100.55907,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
166,1,6,27.871346,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
166,2,6,43.986774,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
166,3,6,60.70863,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
166,4,6,96.67967,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
166,5,6,107.14145,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
166,6,6,96.15333,241,6,NCGC00188344-01,Navitoclax (ABT-263),Bcl-xL Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
167,1,1,2.953207,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
167,2,1,4.407734,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
167,3,1,6.486181,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
167,4,1,42.1509,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
167,5,1,50.555035,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
167,6,1,61.538002,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
167,1,2,14.070573,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
167,2,2,26.128988,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
167,3,2,56.235413,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
167,4,2,76.64047,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
167,5,2,106.49423,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
167,6,2,117.783134,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
167,1,3,20.801666,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
167,2,3,28.854954,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
167,3,3,51.641933,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
167,4,3,94.58899,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
167,5,3,110.5766,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
167,6,3,117.83973,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
167,1,4,27.741383,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
167,2,4,35.030838,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
167,3,4,61.003624,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
167,4,4,99.2667,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
167,5,4,105.92061,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
167,6,4,114.8066,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
167,1,5,28.747396,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
167,2,5,34.790363,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
167,3,5,51.783035,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
167,4,5,95.56599,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
167,5,5,99.000404,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
167,6,5,107.35221,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
167,1,6,33.876446,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
167,2,6,38.628853,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
167,3,6,56.560852,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
167,4,6,113.89126,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
167,5,6,118.19702,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
167,6,6,100.479965,241,6,NCGC00263124-01,Nutlin-3,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
168,1,1,28.415356,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
168,2,1,29.473318,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
168,3,1,54.396065,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
168,4,1,107.7442,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
168,5,1,109.24865,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
168,6,1,103.03112,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
168,1,2,27.66565,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
168,2,2,41.003654,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
168,3,2,51.545662,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
168,4,2,96.02769,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
168,5,2,101.284615,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
168,6,2,97.884445,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
168,1,3,28.420681,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
168,2,3,35.649548,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
168,3,3,51.045776,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
168,4,3,94.46367,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
168,5,3,111.50833,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
168,6,3,113.16525,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
168,1,4,30.228695,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
168,2,4,43.47182,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
168,3,4,56.76847,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
168,4,4,95.55516,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
168,5,4,110.60464,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
168,6,4,120.10494,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
168,1,5,36.650986,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
168,2,5,41.88737,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
168,3,5,61.69277,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
168,4,5,113.16198,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
168,5,5,114.56505,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
168,6,5,106.90201,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
168,1,6,32.433285,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
168,2,6,43.024254,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
168,3,6,52.09267,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
168,4,6,98.49111,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
168,5,6,103.311516,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
168,6,6,121.04155,241,6,NCGC00263280-01,Ac-SAH-p53-8,HDM2/HDMX Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
169,1,1,1.707046,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
169,2,1,0.984297,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
169,3,1,1.789253,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
169,4,1,6.480324,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
169,5,1,25.164845,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
169,6,1,26.250639,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
169,1,2,18.505524,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
169,2,2,26.926895,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
169,3,2,36.798042,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
169,4,2,77.38058,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
169,5,2,109.161316,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
169,6,2,107.414986,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
169,1,3,24.772802,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
169,2,3,33.31525,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
169,3,3,51.852383,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
169,4,3,105.12295,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
169,5,3,111.31434,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
169,6,3,122.292206,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
169,1,4,30.475973,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
169,2,4,34.81993,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
169,3,4,57.353363,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
169,4,4,97.584816,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
169,5,4,107.163826,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
169,6,4,133.46698,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
169,1,5,32.389435,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
169,2,5,33.09032,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
169,3,5,62.169186,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
169,4,5,87.93526,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
169,5,5,106.11199,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
169,6,5,127.22192,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
169,1,6,31.04476,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
169,2,6,33.439747,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
169,3,6,60.844364,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
169,4,6,97.255936,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
169,5,6,103.22433,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
169,6,6,121.55374,241,6,NCGC00263171-01,Serdemetan,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
170,1,1,31.781963,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
170,2,1,39.786663,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
170,3,1,67.12742,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
170,4,1,99.99595,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
170,5,1,102.13922,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
170,6,1,106.89011,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
170,1,2,28.295355,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
170,2,2,41.727795,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
170,3,2,62.982956,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
170,4,2,103.61323,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
170,5,2,110.44015,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
170,6,2,109.71952,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
170,1,3,31.016827,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
170,2,3,37.98501,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
170,3,3,53.682274,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
170,4,3,101.15069,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
170,5,3,114.51424,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
170,6,3,124.628876,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
170,1,4,29.091238,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
170,2,4,29.603582,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
170,3,4,46.728676,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
170,4,4,89.3486,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
170,5,4,103.04931,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
170,6,4,104.85319,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
170,1,5,38.534,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
170,2,5,38.57745,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
170,3,5,53.290775,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
170,4,5,107.07958,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
170,5,5,104.46264,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
170,6,5,117.497856,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
170,1,6,24.991776,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
170,2,6,34.447224,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
170,3,6,50.942684,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
170,4,6,94.980545,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
170,5,6,116.37827,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
170,6,6,117.86749,241,6,NCGC00014873-04,HLI-373989,MDM2 (hdm2) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
171,1,1,22.047253,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
171,2,1,31.338432,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
171,3,1,42.907986,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
171,4,1,85.44537,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
171,5,1,96.76887,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
171,6,1,92.65567,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
171,1,2,24.180792,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
171,2,2,31.68223,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
171,3,2,46.852867,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
171,4,2,95.54254,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
171,5,2,97.34404,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
171,6,2,93.42893,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
171,1,3,30.15276,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
171,2,3,28.892044,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
171,3,3,57.563362,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
171,4,3,86.59256,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
171,5,3,97.262505,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
171,6,3,97.007706,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
171,1,4,24.672308,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
171,2,4,24.631212,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
171,3,4,55.12395,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
171,4,4,87.57207,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
171,5,4,89.59132,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
171,6,4,102.2133,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
171,1,5,29.347963,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
171,2,5,38.54531,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
171,3,5,54.98005,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
171,4,5,87.21973,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
171,5,5,99.934074,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
171,6,5,96.93898,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
171,1,6,29.943348,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
171,2,6,34.309826,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
171,3,6,57.111897,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
171,4,6,88.54073,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
171,5,6,82.389114,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
171,6,6,110.0197,241,6,NCGC00263212-01,SJ-172550,MDM4 (MDMX) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
172,1,1,1.544025,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
172,2,1,0.88432,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
172,3,1,0.768367,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
172,4,1,1.069461,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
172,5,1,1.50946,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
172,6,1,2.737937,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
172,1,2,3.255822,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
172,2,2,1.022896,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
172,3,2,1.317659,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
172,4,2,0.554231,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
172,5,2,0.371343,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
172,6,2,1.574772,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
172,1,3,4.756455,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
172,2,3,2.51371,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
172,3,3,3.012877,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
172,4,3,3.12718,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
172,5,3,6.25492,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
172,6,3,6.459755,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
172,1,4,7.382486,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
172,2,4,3.427815,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
172,3,4,8.645959,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
172,4,4,30.905165,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
172,5,4,47.549507,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
172,6,4,55.40838,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
172,1,5,10.206132,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
172,2,5,11.748751,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
172,3,5,23.39537,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
172,4,5,57.081753,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
172,5,5,65.326195,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
172,6,5,89.18367,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
172,1,6,30.980581,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
172,2,6,36.8877,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
172,3,6,50.230156,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
172,4,6,82.85281,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
172,5,6,98.69572,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
172,6,6,94.15076,241,6,NCGC00242481-01,AZD-7762,Chk1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
173,1,1,3.824694,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
173,2,1,1.951326,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
173,3,1,6.114607,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
173,4,1,11.396541,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
173,5,1,19.032293,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
173,6,1,27.770105,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
173,1,2,9.93801,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
173,2,2,18.310793,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
173,3,2,23.099373,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
173,4,2,31.634962,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
173,5,2,48.675938,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
173,6,2,60.272205,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
173,1,3,18.400206,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
173,2,3,24.950994,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
173,3,3,46.00475,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
173,4,3,58.20359,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
173,5,3,98.032524,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
173,6,3,98.76157,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
173,1,4,27.40914,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
173,2,4,34.12219,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
173,3,4,53.28773,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
173,4,4,86.11019,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
173,5,4,98.091835,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
173,6,4,103.017296,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
173,1,5,34.50506,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
173,2,5,34.198868,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
173,3,5,51.812077,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
173,4,5,76.41537,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
173,5,5,101.84513,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
173,6,5,113.281654,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
173,1,6,23.742226,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
173,2,6,38.318684,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
173,3,6,63.763134,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
173,4,6,96.89109,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
173,5,6,105.17975,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
173,6,6,99.048676,241,6,NCGC00263132-01,PF-477736,Chk1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
174,1,1,-1.034881,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
174,2,1,-1.666581,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
174,3,1,-1.11093,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
174,4,1,-0.640112,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
174,5,1,-0.209198,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
174,6,1,0.301912,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
174,1,2,1.685486,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
174,2,2,0.14815,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
174,3,2,-0.23505,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
174,4,2,0.313582,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
174,5,2,1.623849,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
174,6,2,3.310383,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
174,1,3,6.594253,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
174,2,3,4.704033,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
174,3,3,12.399226,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
174,4,3,31.276768,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
174,5,3,50.45748,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
174,6,3,62.146004,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
174,1,4,21.575401,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
174,2,4,27.996801,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
174,3,4,50.342995,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
174,4,4,72.889114,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
174,5,4,87.586235,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
174,6,4,108.56302,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
174,1,5,31.626005,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
174,2,5,33.73072,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
174,3,5,54.50431,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
174,4,5,76.17275,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
174,5,5,116.33756,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
174,6,5,101.66737,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
174,1,6,31.764395,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
174,2,6,36.71446,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
174,3,6,46.046017,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
174,4,6,90.3208,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
174,5,6,114.46042,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
174,6,6,123.67492,241,6,NCGC00250401-01,Flavopiridol,CDK1/2/4/6/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
175,1,1,31.937103,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
175,2,1,48.350887,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
175,3,1,59.065434,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
175,4,1,96.87446,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
175,5,1,101.10932,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
175,6,1,111.241646,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
175,1,2,30.206244,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
175,2,2,37.19297,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
175,3,2,45.844097,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
175,4,2,86.02418,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
175,5,2,106.57407,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
175,6,2,97.59988,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
175,1,3,20.394077,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
175,2,3,32.423153,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
175,3,3,53.844475,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
175,4,3,90.61636,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
175,5,3,104.8639,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
175,6,3,108.60086,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
175,1,4,25.135963,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
175,2,4,38.126698,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
175,3,4,43.75761,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
175,4,4,86.64252,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
175,5,4,84.50794,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
175,6,4,102.81518,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
175,1,5,30.61251,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
175,2,5,37.052097,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
175,3,5,61.211803,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
175,4,5,98.44569,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
175,5,5,101.97736,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
175,6,5,102.034996,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
175,1,6,25.816597,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
175,2,6,32.346527,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
175,3,6,57.028313,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
175,4,6,91.94321,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
175,5,6,105.36172,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
175,6,6,105.83846,241,6,NCGC00025220-01,Purvalanol B,CDK1/2/3/4/5 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
176,1,1,18.93222,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
176,2,1,26.943235,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
176,3,1,48.091187,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
176,4,1,74.782974,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
176,5,1,95.33202,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
176,6,1,115.077934,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
176,1,2,15.747395,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
176,2,2,34.4725,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
176,3,2,42.249798,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
176,4,2,86.56913,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
176,5,2,99.16731,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
176,6,2,117.972275,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
176,1,3,19.382063,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
176,2,3,35.171337,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
176,3,3,38.71479,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
176,4,3,102.37827,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
176,5,3,119.520966,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
176,6,3,117.681496,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
176,1,4,26.334011,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
176,2,4,33.072407,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
176,3,4,50.513256,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
176,4,4,80.24427,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
176,5,4,100.89451,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
176,6,4,113.31892,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
176,1,5,23.483278,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
176,2,5,27.922075,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
176,3,5,53.040344,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
176,4,5,101.670105,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
176,5,5,125.3937,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
176,6,5,118.77993,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
176,1,6,18.475641,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
176,2,6,32.928127,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
176,3,6,52.356304,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
176,4,6,97.38114,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
176,5,6,109.80183,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
176,6,6,96.26181,241,6,NCGC00094374-05,Seliciclib,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
177,1,1,-0.681283,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
177,2,1,-0.139445,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
177,3,1,3.046308,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
177,4,1,2.386729,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
177,5,1,3.02432,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
177,6,1,3.423196,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
177,1,2,-1.12936,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
177,2,2,-0.653128,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
177,3,2,0.868103,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
177,4,2,5.415914,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
177,5,2,13.350218,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
177,6,2,12.557226,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
177,1,3,3.272689,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
177,2,3,6.789691,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
177,3,3,16.937258,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
177,4,3,39.05761,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
177,5,3,68.907974,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
177,6,3,83.25058,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
177,1,4,9.562109,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
177,2,4,18.474728,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
177,3,4,35.301205,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
177,4,4,89.89017,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
177,5,4,96.78498,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
177,6,4,100.31736,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
177,1,5,16.709917,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
177,2,5,25.964308,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
177,3,5,53.149506,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
177,4,5,87.686386,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
177,5,5,104.71396,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
177,6,5,108.179085,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
177,1,6,18.756521,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
177,2,6,31.899368,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
177,3,6,52.03525,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
177,4,6,97.4112,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
177,5,6,100.4088,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
177,6,6,128.62561,241,6,NCGC00263191-01,PHA-690509,CDK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
178,1,1,-1.524988,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
178,2,1,-1.732269,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
178,3,1,-1.737837,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
178,4,1,0.081742,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
178,5,1,-0.037047,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
178,6,1,1.152726,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
178,1,2,0.35662,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
178,2,2,1.417455,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
178,3,2,6.467319,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
178,4,2,8.638549,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
178,5,2,15.328761,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
178,6,2,18.92957,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
178,1,3,13.375783,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
178,2,3,21.32112,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
178,3,3,38.889275,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
178,4,3,66.47883,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
178,5,3,91.02537,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
178,6,3,91.73914,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
178,1,4,17.460968,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
178,2,4,34.475178,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
178,3,4,51.30788,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
178,4,4,84.31895,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
178,5,4,107.894684,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
178,6,4,121.56907,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
178,1,5,20.446192,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
178,2,5,31.85572,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
178,3,5,47.25172,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
178,4,5,88.77117,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
178,5,5,101.937874,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
178,6,5,145.02467,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
178,1,6,24.05146,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
178,2,6,39.47527,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
178,3,6,55.562283,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
178,4,6,81.85184,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
178,5,6,102.88546,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
178,6,6,100.244736,241,6,NCGC00263091-01,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
179,1,1,-2.313878,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,2
179,2,1,-2.034225,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,2
179,3,1,-1.341626,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,2
179,4,1,-0.498445,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,2
179,5,1,-0.529983,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,2
179,6,1,-0.647335,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,2
179,1,2,-0.22912,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,2
179,2,2,1.1008,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,2
179,3,2,4.032541,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,2
179,4,2,9.634107,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,2
179,5,2,23.554213,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,2
179,6,2,14.817697,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,2
179,1,3,10.834387,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,2
179,2,3,20.289621,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,2
179,3,3,41.131603,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,2
179,4,3,58.501522,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,2
179,5,3,91.07644,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,2
179,6,3,96.52379,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,2
179,1,4,22.629904,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,2
179,2,4,28.109509,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,2
179,3,4,53.268387,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,2
179,4,4,98.65866,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,2
179,5,4,106.869064,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,2
179,6,4,115.22126,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,2
179,1,5,21.816437,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,2
179,2,5,29.101398,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,2
179,3,5,47.477608,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,2
179,4,5,88.46086,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,2
179,5,5,108.47361,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,2
179,6,5,132.3037,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,2
179,1,6,27.642675,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,2
179,2,6,27.032553,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,2
179,3,6,50.898647,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,2
179,4,6,89.661964,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,2
179,5,6,111.440544,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,2
179,6,6,123.741196,241,6,NCGC00263091-02,AT-7519,CDK1/2/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,2
180,1,1,-2.115548,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
180,2,1,-2.170317,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
180,3,1,-1.544911,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
180,4,1,-0.755002,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
180,5,1,-0.501574,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
180,6,1,-0.193795,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
180,1,2,-1.448515,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
180,2,2,-1.059997,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
180,3,2,-0.444035,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
180,4,2,0.608477,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
180,5,2,1.409402,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
180,6,2,2.135366,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
180,1,3,2.134124,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
180,2,3,5.833934,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
180,3,3,20.668995,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
180,4,3,77.12067,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
180,5,3,84.969154,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
180,6,3,89.03812,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
180,1,4,17.628313,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
180,2,4,20.662317,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
180,3,4,50.83054,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
180,4,4,85.56663,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
180,5,4,97.312096,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
180,6,4,115.94342,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
180,1,5,15.075541,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
180,2,5,24.44131,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
180,3,5,63.423748,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
180,4,5,96.7208,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
180,5,5,118.00055,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
180,6,5,115.11226,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
180,1,6,21.19808,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
180,2,6,25.974337,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
180,3,6,48.49701,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
180,4,6,84.35203,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
180,5,6,103.17779,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
180,6,6,121.80635,241,6,NCGC00263167-01,SNS-032,CDK 2/7/9 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
181,1,1,0.81049,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
181,2,1,0.216547,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
181,3,1,2.396294,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
181,4,1,9.754287,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
181,5,1,16.480095,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
181,6,1,15.793931,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
181,1,2,10.070059,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
181,2,2,15.285786,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
181,3,2,34.957516,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
181,4,2,75.622246,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
181,5,2,81.6212,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
181,6,2,101.36483,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
181,1,3,14.732961,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
181,2,3,26.244097,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
181,3,3,49.8438,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
181,4,3,95.30109,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
181,5,3,101.272514,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
181,6,3,116.60144,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
181,1,4,16.733149,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
181,2,4,39.656895,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
181,3,4,59.68059,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
181,4,4,98.6495,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
181,5,4,117.68364,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
181,6,4,116.93198,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
181,1,5,28.351202,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
181,2,5,36.860394,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
181,3,5,53.885098,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
181,4,5,117.78946,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
181,5,5,109.79367,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
181,6,5,139.15663,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
181,1,6,30.68391,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
181,2,6,34.53354,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
181,3,6,51.830856,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
181,4,6,81.08871,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
181,5,6,107.450676,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
181,6,6,110.981094,241,6,NCGC00263168-01,PHA-793887,CDK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
182,1,1,12.819186,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
182,2,1,13.999933,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
182,3,1,24.285446,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
182,4,1,54.1784,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
182,5,1,71.93852,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
182,6,1,83.41817,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
182,1,2,21.106218,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
182,2,2,25.818996,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
182,3,2,49.13469,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
182,4,2,74.07759,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
182,5,2,111.18544,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
182,6,2,111.63557,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
182,1,3,28.928696,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
182,2,3,38.128258,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
182,3,3,60.901093,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
182,4,3,72.46679,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
182,5,3,102.73303,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
182,6,3,109.45767,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
182,1,4,26.216583,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
182,2,4,30.95355,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
182,3,4,41.07815,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
182,4,4,70.22752,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
182,5,4,85.69202,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
182,6,4,106.217735,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
182,1,5,27.04848,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
182,2,5,33.045612,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
182,3,5,51.594315,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
182,4,5,90.990074,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
182,5,5,106.49221,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
182,6,5,103.30608,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
182,1,6,20.213314,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
182,2,6,40.42986,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
182,3,6,57.09004,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
182,4,6,114.83386,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
182,5,6,97.28566,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
182,6,6,108.175995,241,6,NCGC00263129-01,Palbociclib,CDK4/6 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
183,1,1,-0.359838,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
183,2,1,0.623281,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
183,3,1,0.811178,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
183,4,1,14.994174,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
183,5,1,5.792008,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
183,6,1,8.541868,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
183,1,2,18.10965,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
183,2,2,30.557802,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
183,3,2,43.532227,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
183,4,2,81.216805,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
183,5,2,105.315384,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
183,6,2,117.13828,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
183,1,3,24.459438,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
183,2,3,32.629044,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
183,3,3,46.113422,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
183,4,3,103.268616,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
183,5,3,115.78094,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
183,6,3,128.74945,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
183,1,4,23.24425,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
183,2,4,35.002197,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
183,3,4,50.929947,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
183,4,4,111.77065,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
183,5,4,120.5915,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
183,6,4,107.07404,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
183,1,5,30.651953,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
183,2,5,36.347805,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
183,3,5,58.628918,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
183,4,5,96.85735,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
183,5,5,121.43492,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
183,6,5,117.3707,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
183,1,6,23.653769,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
183,2,6,36.796375,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
183,3,6,49.34507,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
183,4,6,99.22581,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
183,5,6,114.231865,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
183,6,6,108.34011,241,6,NCGC00092289-01,DA-3003-1,CDC25 Phosphatase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
184,1,1,11.442849,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
184,2,1,11.078266,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
184,3,1,16.736036,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
184,4,1,50.603935,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
184,5,1,63.974613,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
184,6,1,71.68745,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
184,1,2,27.08114,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
184,2,2,30.2301,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
184,3,2,48.980064,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
184,4,2,97.05967,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
184,5,2,114.51465,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
184,6,2,123.99111,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
184,1,3,32.521408,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
184,2,3,39.37452,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
184,3,3,61.390873,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
184,4,3,127.74826,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
184,5,3,134.21094,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
184,6,3,158.19025,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
184,1,4,23.545277,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
184,2,4,44.961967,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
184,3,4,54.097137,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
184,4,4,112.04911,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
184,5,4,115.94634,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
184,6,4,134.79037,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
184,1,5,26.366642,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
184,2,5,35.369698,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
184,3,5,69.17977,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
184,4,5,101.00479,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
184,5,5,118.08657,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
184,6,5,125.332184,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
184,1,6,23.741138,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
184,2,6,29.954504,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
184,3,6,56.849136,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
184,4,6,95.04516,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
184,5,6,107.79251,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
184,6,6,130.88696,241,6,NCGC00263151-01,JNJ-7706621,Aurora Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
185,1,1,27.351871,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
185,2,1,30.144377,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
185,3,1,48.222668,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
185,4,1,99.136116,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
185,5,1,130.23175,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
185,6,1,122.64547,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
185,1,2,17.449682,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
185,2,2,25.534641,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
185,3,2,39.58671,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
185,4,2,89.61251,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
185,5,2,106.37854,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
185,6,2,130.09676,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
185,1,3,15.424258,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
185,2,3,20.860949,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
185,3,3,43.267212,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
185,4,3,96.13012,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
185,5,3,106.81794,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
185,6,3,113.98986,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
185,1,4,19.153465,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
185,2,4,21.094769,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
185,3,4,31.025099,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
185,4,4,89.06095,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
185,5,4,105.26966,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
185,6,4,107.428566,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
185,1,5,14.355954,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
185,2,5,21.552456,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
185,3,5,33.90084,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
185,4,5,87.75266,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
185,5,5,120.37518,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
185,6,5,134.93053,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
185,1,6,26.859894,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
185,2,6,32.172108,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
185,3,6,51.23045,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
185,4,6,87.830734,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
185,5,6,118.04464,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
185,6,6,98.7065,241,6,NCGC00242482-01,SNS-314,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
186,1,1,14.296964,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
186,2,1,16.138067,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
186,3,1,28.893684,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
186,4,1,82.76462,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
186,5,1,101.069725,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
186,6,1,106.359245,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
186,1,2,12.066025,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
186,2,2,27.555845,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
186,3,2,41.90683,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
186,4,2,81.0776,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
186,5,2,104.90949,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
186,6,2,103.971695,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
186,1,3,17.123491,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
186,2,3,27.378096,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
186,3,3,44.254505,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
186,4,3,80.440475,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
186,5,3,102.987946,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
186,6,3,102.832756,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
186,1,4,10.973832,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
186,2,4,21.229977,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
186,3,4,37.428936,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
186,4,4,81.78368,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
186,5,4,103.227936,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
186,6,4,116.05149,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
186,1,5,20.642172,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
186,2,5,25.380768,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
186,3,5,54.810917,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
186,4,5,86.32072,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
186,5,5,100.142426,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
186,6,5,130.76048,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
186,1,6,27.008095,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
186,2,6,38.926758,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
186,3,6,61.505604,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
186,4,6,96.25879,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
186,5,6,117.12942,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
186,6,6,108.74141,241,6,NCGC00168110-02,Tozasertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
187,1,1,11.70246,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
187,2,1,21.477867,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
187,3,1,36.222355,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
187,4,1,76.69176,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
187,5,1,97.13388,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
187,6,1,99.54155,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
187,1,2,16.631542,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
187,2,2,28.578735,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
187,3,2,47.14411,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
187,4,2,93.26581,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
187,5,2,109.49646,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
187,6,2,107.23986,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
187,1,3,22.167337,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
187,2,3,24.38241,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
187,3,3,49.836704,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
187,4,3,80.23753,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
187,5,3,111.809395,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
187,6,3,110.75178,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
187,1,4,9.511337,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
187,2,4,11.498501,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
187,3,4,20.270567,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
187,4,4,42.072514,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
187,5,4,75.67628,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
187,6,4,65.43585,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
187,1,5,12.546673,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
187,2,5,13.915122,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
187,3,5,29.424026,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
187,4,5,66.33771,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
187,5,5,89.52763,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
187,6,5,99.96443,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
187,1,6,26.734024,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
187,2,6,27.083265,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
187,3,6,41.655975,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
187,4,6,84.32298,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
187,5,6,123.1658,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
187,6,6,117.50107,241,6,NCGC00263271-01,Alisertib,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
188,1,1,7.508455,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
188,2,1,8.019609,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
188,3,1,12.451924,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
188,4,1,34.92285,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
188,5,1,46.20741,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
188,6,1,60.95691,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
188,1,2,15.420666,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
188,2,2,23.1003,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
188,3,2,31.519367,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
188,4,2,83.940094,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
188,5,2,117.12939,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
188,6,2,99.258545,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
188,1,3,17.860397,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
188,2,3,22.831963,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
188,3,3,44.37713,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
188,4,3,86.14896,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
188,5,3,113.99428,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
188,6,3,108.40901,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
188,1,4,21.281078,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
188,2,4,34.902866,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
188,3,4,50.441288,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
188,4,4,85.75863,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
188,5,4,114.71196,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
188,6,4,127.525955,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
188,1,5,35.094505,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
188,2,5,43.10163,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
188,3,5,60.180744,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
188,4,5,97.16446,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
188,5,5,129.94632,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
188,6,5,129.55838,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
188,1,6,27.016207,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
188,2,6,35.98162,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
188,3,6,50.433327,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
188,4,6,73.993614,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
188,5,6,105.3201,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
188,6,6,101.671364,241,6,NCGC00263203-01,Danusertib,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
189,1,1,8.732999,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
189,2,1,10.989818,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
189,3,1,9.95413,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
189,4,1,23.411686,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
189,5,1,37.260212,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
189,6,1,49.447975,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
189,1,2,16.388878,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
189,2,2,25.583828,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
189,3,2,41.432007,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
189,4,2,77.391815,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
189,5,2,96.978226,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
189,6,2,105.61312,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
189,1,3,29.757072,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
189,2,3,33.466206,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
189,3,3,54.48073,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
189,4,3,103.02098,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
189,5,3,112.94393,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
189,6,3,115.82253,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
189,1,4,26.953325,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
189,2,4,31.105806,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
189,3,4,54.740776,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
189,4,4,102.56692,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
189,5,4,111.38341,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
189,6,4,122.29015,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
189,1,5,32.15676,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
189,2,5,32.672436,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
189,3,5,51.0956,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
189,4,5,88.585304,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
189,5,5,114.3802,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
189,6,5,129.50726,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
189,1,6,25.14391,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
189,2,6,37.449112,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
189,3,6,47.345703,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
189,4,6,80.0635,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
189,5,6,115.04275,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
189,6,6,126.444,241,6,NCGC00263204-01,CYC-116,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
190,1,1,20.291433,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
190,2,1,24.992683,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
190,3,1,32.1137,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
190,4,1,66.694885,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
190,5,1,118.53686,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
190,6,1,119.73528,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
190,1,2,18.762823,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
190,2,2,24.206654,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
190,3,2,38.444492,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
190,4,2,102.711945,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
190,5,2,96.932465,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
190,6,2,112.52636,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
190,1,3,16.549309,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
190,2,3,27.903543,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
190,3,3,40.244568,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
190,4,3,92.3614,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
190,5,3,98.505,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
190,6,3,121.37797,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
190,1,4,18.154915,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
190,2,4,21.218151,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
190,3,4,35.68746,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
190,4,4,80.060265,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
190,5,4,107.172356,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
190,6,4,112.07004,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
190,1,5,14.447141,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
190,2,5,22.511864,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
190,3,5,58.909065,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
190,4,5,85.52036,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
190,5,5,113.01415,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
190,6,5,115.90925,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
190,1,6,18.039928,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
190,2,6,29.020435,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
190,3,6,45.901875,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
190,4,6,83.13381,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
190,5,6,107.91498,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
190,6,6,106.40562,241,6,NCGC00263089-01,Barasertib,Aurora-B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
191,1,1,20.775076,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
191,2,1,24.211607,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
191,3,1,39.975048,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
191,4,1,78.337616,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
191,5,1,99.342636,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
191,6,1,124.47782,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
191,1,2,23.07364,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
191,2,2,27.342232,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
191,3,2,39.709946,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
191,4,2,71.011,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
191,5,2,103.98726,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
191,6,2,104.001045,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
191,1,3,15.726274,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
191,2,3,24.002693,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
191,3,3,41.746834,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
191,4,3,95.69218,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
191,5,3,97.49119,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
191,6,3,85.76321,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
191,1,4,24.33767,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
191,2,4,22.680227,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
191,3,4,38.72853,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
191,4,4,93.888596,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
191,5,4,116.5046,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
191,6,4,123.06253,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
191,1,5,22.323263,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
191,2,5,24.480453,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
191,3,5,46.368484,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
191,4,5,81.46739,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
191,5,5,113.390976,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
191,6,5,124.23324,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
191,1,6,26.453503,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
191,2,6,35.493114,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
191,3,6,55.884983,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
191,4,6,71.29793,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
191,5,6,124.853676,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
191,6,6,122.76586,241,6,NCGC00263094-01,AMG-900,Aurora-A/B/C Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
192,1,1,15.158421,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
192,2,1,19.485495,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
192,3,1,33.52855,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
192,4,1,76.41206,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
192,5,1,98.21845,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
192,6,1,105.53648,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
192,1,2,33.181747,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
192,2,2,28.78199,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
192,3,2,54.921024,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
192,4,2,108.41068,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
192,5,2,112.700806,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
192,6,2,138.4299,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
192,1,3,22.041096,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
192,2,3,34.968353,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
192,3,3,59.549572,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
192,4,3,99.9489,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
192,5,3,113.06314,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
192,6,3,119.04137,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
192,1,4,27.244265,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
192,2,4,31.982382,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
192,3,4,50.276337,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
192,4,4,91.95421,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
192,5,4,131.4893,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
192,6,4,127.3769,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
192,1,5,28.34044,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
192,2,5,35.548794,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
192,3,5,59.368187,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
192,4,5,107.27753,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
192,5,5,119.60359,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
192,6,5,112.3921,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
192,1,6,31.210285,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
192,2,6,36.964394,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
192,3,6,57.525707,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
192,4,6,98.33436,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
192,5,6,120.580444,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
192,6,6,108.37798,241,6,NCGC00263178-01,ENMD-981693,Aurora-A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
193,1,1,11.940546,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
193,2,1,22.64167,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
193,3,1,33.36598,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
193,4,1,88.3597,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
193,5,1,104.411,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
193,6,1,99.403915,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
193,1,2,18.590479,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
193,2,2,23.297207,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
193,3,2,39.483685,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
193,4,2,66.451164,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
193,5,2,100.233986,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
193,6,2,110.69439,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
193,1,3,16.788965,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
193,2,3,29.387085,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
193,3,3,41.271408,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
193,4,3,74.8847,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
193,5,3,110.9477,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
193,6,3,111.9048,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
193,1,4,28.329767,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
193,2,4,37.54825,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
193,3,4,53.34652,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
193,4,4,95.69929,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
193,5,4,105.73863,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
193,6,4,103.38781,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
193,1,5,27.37597,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
193,2,5,34.56111,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
193,3,5,46.188667,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
193,4,5,116.49927,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
193,5,5,138.70001,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
193,6,5,118.41744,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
193,1,6,28.364628,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
193,2,6,33.126545,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
193,3,6,47.129337,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
193,4,6,96.75585,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
193,5,6,111.72101,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
193,6,6,113.328545,241,6,NCGC00250407-01,CHIR-265,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
194,1,1,16.724796,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
194,2,1,16.893818,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
194,3,1,23.124786,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
194,4,1,41.313786,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
194,5,1,63.209087,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
194,6,1,61.308502,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
194,1,2,24.738462,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
194,2,2,27.056232,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
194,3,2,42.351627,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
194,4,2,61.841194,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
194,5,2,95.53509,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
194,6,2,108.80079,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
194,1,3,27.227919,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
194,2,3,32.540253,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
194,3,3,44.890076,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
194,4,3,112.659515,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
194,5,3,112.57275,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
194,6,3,119.22016,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
194,1,4,20.230738,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
194,2,4,34.527954,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
194,3,4,59.781868,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
194,4,4,100.5312,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
194,5,4,125.05335,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
194,6,4,127.71989,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
194,1,5,34.973576,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
194,2,5,32.466503,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
194,3,5,59.620373,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
194,4,5,92.27735,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
194,5,5,111.558044,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
194,6,5,129.21492,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
194,1,6,27.142658,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
194,2,6,43.81797,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
194,3,6,56.00841,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
194,4,6,98.15451,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
194,5,6,130.69804,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
194,6,6,129.05682,241,6,NCGC00250380-01,AZ-628,Raf kinase B/C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
195,1,1,36.0138,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
195,2,1,42.47181,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
195,3,1,55.359806,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
195,4,1,99.44677,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
195,5,1,131.83034,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
195,6,1,125.52014,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
195,1,2,26.750324,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
195,2,2,37.643402,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
195,3,2,59.809723,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
195,4,2,98.86031,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
195,5,2,120.539665,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
195,6,2,131.6269,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
195,1,3,24.465935,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
195,2,3,32.14636,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
195,3,3,53.70917,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
195,4,3,103.52823,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
195,5,3,125.214966,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
195,6,3,126.87844,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
195,1,4,25.88791,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
195,2,4,33.30073,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
195,3,4,56.753475,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
195,4,4,96.95821,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
195,5,4,108.50726,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
195,6,4,133.84184,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
195,1,5,29.766308,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
195,2,5,34.748005,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
195,3,5,63.199795,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
195,4,5,96.17022,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
195,5,5,112.22421,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
195,6,5,134.73064,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
195,1,6,22.508423,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
195,2,6,31.895416,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
195,3,6,55.149544,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
195,4,6,103.3143,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
195,5,6,116.94651,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
195,6,6,131.5148,241,6,NCGC00250399-01,Vemurafenib,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
196,1,1,25.810522,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
196,2,1,29.95651,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
196,3,1,45.160194,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
196,4,1,67.02272,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
196,5,1,114.43252,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
196,6,1,95.01317,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
196,1,2,22.827486,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
196,2,2,31.240059,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
196,3,2,59.3359,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
196,4,2,91.34438,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
196,5,2,94.63555,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
196,6,2,112.13602,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
196,1,3,22.782118,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
196,2,3,30.645397,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
196,3,3,59.81077,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
196,4,3,91.632065,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
196,5,3,124.96668,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
196,6,3,123.03128,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
196,1,4,23.456455,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
196,2,4,32.485184,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
196,3,4,59.899906,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
196,4,4,100.65094,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
196,5,4,102.59382,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
196,6,4,122.77454,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
196,1,5,36.003742,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
196,2,5,30.699163,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
196,3,5,58.399826,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
196,4,5,105.19088,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
196,5,5,119.11235,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
196,6,5,116.460785,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
196,1,6,27.01504,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
196,2,6,33.945374,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
196,3,6,58.59585,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
196,4,6,118.63162,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
196,5,6,123.87379,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
196,6,6,133.733,241,6,NCGC00187911-02,PLX-4720,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
197,1,1,28.582478,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
197,2,1,40.044262,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
197,3,1,74.828384,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
197,4,1,110.873795,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
197,5,1,150.90295,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
197,6,1,148.05702,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
197,1,2,31.006987,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
197,2,2,38.214714,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
197,3,2,53.956554,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
197,4,2,120.80723,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
197,5,2,115.87473,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
197,6,2,120.15218,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
197,1,3,25.359901,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
197,2,3,31.273903,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
197,3,3,56.79639,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
197,4,3,110.88652,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
197,5,3,100.52113,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
197,6,3,120.760254,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
197,1,4,25.081627,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
197,2,4,42.67722,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
197,3,4,64.1504,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
197,4,4,106.83892,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
197,5,4,114.272194,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
197,6,4,115.54323,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
197,1,5,29.865322,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
197,2,5,34.42978,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
197,3,5,46.88775,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
197,4,5,94.49957,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
197,5,5,110.68493,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
197,6,5,126.36832,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
197,1,6,26.73064,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
197,2,6,38.98841,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
197,3,6,49.606236,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
197,4,6,85.78418,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
197,5,6,117.637955,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
197,6,6,117.246414,241,6,NCGC00263179-01,AR-00341677,Raf kinase B Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
198,1,1,34.718697,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
198,2,1,38.126713,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
198,3,1,53.76773,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
198,4,1,105.862206,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
198,5,1,109.75749,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
198,6,1,123.32259,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
198,1,2,28.649145,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
198,2,2,38.85795,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
198,3,2,55.66552,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
198,4,2,91.07361,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
198,5,2,118.31234,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
198,6,2,109.827034,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
198,1,3,28.919952,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
198,2,3,33.812393,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
198,3,3,53.475967,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
198,4,3,94.60593,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
198,5,3,120.742546,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
198,6,3,106.73066,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
198,1,4,28.097818,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
198,2,4,35.847923,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
198,3,4,54.052937,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
198,4,4,103.448586,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
198,5,4,122.371895,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
198,6,4,134.39919,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
198,1,5,31.767616,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
198,2,5,38.01366,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
198,3,5,56.842598,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
198,4,5,96.473236,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
198,5,5,112.805405,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
198,6,5,130.5178,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
198,1,6,29.468212,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
198,2,6,43.272945,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
198,3,6,51.45213,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
198,4,6,97.9823,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
198,5,6,120.101395,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
198,6,6,112.80384,241,6,NCGC00188380-01,Refametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
199,1,1,27.077232,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
199,2,1,29.768806,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
199,3,1,41.26828,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
199,4,1,82.48959,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
199,5,1,105.52366,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
199,6,1,103.705215,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
199,1,2,34.00007,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
199,2,2,25.387264,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
199,3,2,50.87856,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
199,4,2,79.50459,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
199,5,2,111.50697,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
199,6,2,93.90093,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
199,1,3,28.055637,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
199,2,3,31.384533,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
199,3,3,50.63929,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
199,4,3,76.0385,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
199,5,3,113.34969,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
199,6,3,121.855354,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
199,1,4,32.41509,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
199,2,4,34.702694,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
199,3,4,49.900887,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
199,4,4,94.3453,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
199,5,4,114.03164,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
199,6,4,114.84913,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
199,1,5,25.11752,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
199,2,5,35.11118,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
199,3,5,57.187035,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
199,4,5,99.55121,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
199,5,5,102.52788,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
199,6,5,118.92484,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
199,1,6,24.782784,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
199,2,6,44.913025,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
199,3,6,53.507908,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
199,4,6,100.0328,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
199,5,6,107.00064,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
199,6,6,112.897354,241,6,NCGC00189073-01,Selumetinib,Mek1/2 inibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
200,1,1,31.024904,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
200,2,1,30.005651,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
200,3,1,47.611946,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
200,4,1,85.61715,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
200,5,1,91.24843,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
200,6,1,113.02973,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
200,1,2,32.273247,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
200,2,2,36.92507,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
200,3,2,45.12876,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
200,4,2,82.92821,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
200,5,2,101.26464,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
200,6,2,101.49995,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
200,1,3,27.88184,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
200,2,3,31.13531,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
200,3,3,51.29005,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
200,4,3,83.58144,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
200,5,3,101.24884,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
200,6,3,108.76226,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
200,1,4,31.931475,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
200,2,4,30.311993,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
200,3,4,38.881775,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
200,4,4,62.80141,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
200,5,4,103.06075,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
200,6,4,99.14805,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
200,1,5,31.915264,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
200,2,5,34.49841,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
200,3,5,47.848553,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
200,4,5,75.706055,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
200,5,5,111.881424,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
200,6,5,111.08942,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
200,1,6,35.570393,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
200,2,6,42.236732,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
200,3,6,71.34798,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
200,4,6,91.28523,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
200,5,6,114.91848,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
200,6,6,131.49568,241,6,NCGC00189075-01,PD-0325901,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
201,1,1,14.935109,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
201,2,1,27.113531,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
201,3,1,36.316444,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
201,4,1,56.07463,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
201,5,1,78.820915,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
201,6,1,94.50815,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
201,1,2,19.997978,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
201,2,2,28.588196,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
201,3,2,36.557854,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
201,4,2,70.18907,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
201,5,2,91.812614,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
201,6,2,96.47686,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
201,1,3,20.183722,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
201,2,3,29.286093,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
201,3,3,49.043472,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
201,4,3,65.26759,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
201,5,3,100.86683,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
201,6,3,104.07441,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
201,1,4,27.849283,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
201,2,4,28.038319,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
201,3,4,39.562866,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
201,4,4,79.08193,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
201,5,4,101.37134,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
201,6,4,90.502045,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
201,1,5,22.496716,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
201,2,5,29.717974,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
201,3,5,49.649944,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
201,4,5,94.73055,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
201,5,5,90.32764,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
201,6,5,103.07628,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
201,1,6,29.917816,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
201,2,6,37.849304,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
201,3,6,55.784203,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
201,4,6,108.54774,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
201,5,6,115.61929,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
201,6,6,113.53081,241,6,NCGC00263180-01,Trametinib,Mek 1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
202,1,1,35.349056,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
202,2,1,34.240265,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
202,3,1,51.799004,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
202,4,1,85.34255,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
202,5,1,95.00173,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
202,6,1,102.71217,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
202,1,2,31.152016,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
202,2,2,45.05007,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
202,3,2,48.82139,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
202,4,2,80.450325,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
202,5,2,105.45763,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
202,6,2,110.940186,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
202,1,3,27.354073,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
202,2,3,34.897194,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
202,3,3,59.821114,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
202,4,3,91.24733,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
202,5,3,93.56576,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
202,6,3,104.16043,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
202,1,4,30.51869,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
202,2,4,36.4145,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
202,3,4,54.38616,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
202,4,4,80.2672,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
202,5,4,90.72064,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
202,6,4,110.281624,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
202,1,5,33.392876,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
202,2,5,38.009167,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
202,3,5,50.81059,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
202,4,5,82.88646,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
202,5,5,92.52779,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
202,6,5,84.296555,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
202,1,6,30.78815,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
202,2,6,38.394302,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
202,3,6,55.37853,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
202,4,6,101.6676,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
202,5,6,115.77242,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
202,6,6,102.63543,241,6,NCGC00263187-01,TAK-733,MEK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
203,1,1,22.100235,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
203,2,1,25.2875,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
203,3,1,42.578144,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
203,4,1,83.61478,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
203,5,1,116.3546,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
203,6,1,118.06268,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
203,1,2,29.56404,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
203,2,2,32.5554,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
203,3,2,53.996178,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
203,4,2,107.47244,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
203,5,2,118.38529,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
203,6,2,119.88924,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
203,1,3,25.556646,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
203,2,3,33.981987,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
203,3,3,59.51082,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
203,4,3,106.31575,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
203,5,3,135.13011,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
203,6,3,111.42055,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
203,1,4,29.249092,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
203,2,4,34.120876,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
203,3,4,59.33403,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
203,4,4,98.19618,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
203,5,4,111.25842,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
203,6,4,122.85769,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
203,1,5,34.436317,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
203,2,5,36.277035,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
203,3,5,65.66094,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
203,4,5,108.77289,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
203,5,5,120.16124,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
203,6,5,124.82646,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
203,1,6,28.698826,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
203,2,6,32.111004,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
203,3,6,65.04361,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
203,4,6,103.63723,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
203,5,6,116.972984,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
203,6,6,115.127396,241,6,NCGC00250385-01,XMD8-92,ERK5/BMK1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
204,1,1,39.066814,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
204,2,1,45.900036,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
204,3,1,55.153046,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
204,4,1,92.72451,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
204,5,1,102.49134,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
204,6,1,112.72616,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
204,1,2,34.442562,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
204,2,2,36.57462,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
204,3,2,51.706383,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
204,4,2,97.92177,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
204,5,2,126.27134,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
204,6,2,104.139206,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
204,1,3,34.256207,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
204,2,3,38.30762,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
204,3,3,61.601086,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
204,4,3,114.44147,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
204,5,3,124.68646,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
204,6,3,115.71385,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
204,1,4,30.912117,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
204,2,4,41.745365,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
204,3,4,54.503677,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
204,4,4,85.02757,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
204,5,4,125.95615,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
204,6,4,138.1184,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
204,1,5,34.03713,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
204,2,5,35.187805,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
204,3,5,53.404434,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
204,4,5,91.67185,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
204,5,5,141.18031,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
204,6,5,134.93802,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
204,1,6,25.81012,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
204,2,6,43.99018,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
204,3,6,54.448097,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
204,4,6,94.33765,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
204,5,6,121.194595,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
204,6,6,130.78795,241,6,NCGC00242487-01,NCGC00242487,ERK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
205,1,1,34.902134,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
205,2,1,37.344364,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
205,3,1,66.380424,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
205,4,1,102.936485,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
205,5,1,117.66279,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
205,6,1,128.96147,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
205,1,2,35.480404,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
205,2,2,35.108982,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
205,3,2,54.668434,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
205,4,2,84.42278,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
205,5,2,111.927475,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
205,6,2,125.541695,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
205,1,3,29.187946,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
205,2,3,34.590134,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
205,3,3,57.639122,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
205,4,3,99.23717,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
205,5,3,105.09637,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
205,6,3,123.95725,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
205,1,4,29.318785,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
205,2,4,40.097816,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
205,3,4,63.2156,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
205,4,4,94.61976,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
205,5,4,113.59423,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
205,6,4,111.18241,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
205,1,5,28.875422,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
205,2,5,40.564335,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
205,3,5,53.7602,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
205,4,5,92.50079,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
205,5,5,119.163124,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
205,6,5,116.05454,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
205,1,6,32.84128,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
205,2,6,38.027924,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
205,3,6,45.96597,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
205,4,6,101.4122,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
205,5,6,116.05317,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
205,6,6,117.06946,241,6,NCGC00263196-01,S6K-18,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
206,1,1,15.075661,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
206,2,1,24.89762,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
206,3,1,28.33267,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
206,4,1,61.03235,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
206,5,1,80.04947,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
206,6,1,85.37496,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
206,1,2,24.830143,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
206,2,2,24.898893,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
206,3,2,41.959908,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
206,4,2,76.45472,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
206,5,2,94.55937,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
206,6,2,95.86277,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
206,1,3,25.192331,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
206,2,3,33.193962,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
206,3,3,50.590523,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
206,4,3,74.87547,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
206,5,3,99.99021,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
206,6,3,92.52883,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
206,1,4,26.751596,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
206,2,4,32.87614,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
206,3,4,48.82197,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
206,4,4,89.49254,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
206,5,4,104.11744,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
206,6,4,106.609024,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
206,1,5,21.976866,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
206,2,5,42.123543,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
206,3,5,60.57929,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
206,4,5,88.293816,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
206,5,5,107.92381,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
206,6,5,113.484,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
206,1,6,25.071808,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
206,2,6,40.553753,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
206,3,6,63.049046,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
206,4,6,86.826065,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
206,5,6,97.317345,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
206,6,6,111.28749,241,6,NCGC00263134-01,PF-4708671,p70 ribosomal S6 kinase (S6K1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
207,1,1,10.17828,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
207,2,1,16.466637,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
207,3,1,28.821266,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
207,4,1,74.65779,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
207,5,1,114.1516,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
207,6,1,118.375275,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
207,1,2,31.481289,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
207,2,2,46.420048,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
207,3,2,70.64667,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
207,4,2,114.65267,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
207,5,2,146.00952,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
207,6,2,137.56087,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
207,1,3,35.268784,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
207,2,3,41.83697,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
207,3,3,68.86849,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
207,4,3,110.50032,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
207,5,3,141.77441,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
207,6,3,119.211945,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
207,1,4,33.97823,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
207,2,4,37.922802,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
207,3,4,61.91044,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
207,4,4,108.32773,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
207,5,4,144.77275,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
207,6,4,128.58298,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
207,1,5,26.39333,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
207,2,5,37.15328,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
207,3,5,55.165382,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
207,4,5,104.242424,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
207,5,5,107.24344,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
207,6,5,127.08976,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
207,1,6,26.244097,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
207,2,6,40.774506,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
207,3,6,60.341606,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
207,4,6,82.1155,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
207,5,6,110.48457,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
207,6,6,116.043755,241,6,NCGC00242495-01,PF-562271,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
208,1,1,16.042793,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
208,2,1,18.819164,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
208,3,1,18.766445,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
208,4,1,49.26138,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
208,5,1,83.33159,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
208,6,1,88.31044,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
208,1,2,29.50023,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
208,2,2,33.644657,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
208,3,2,49.23424,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
208,4,2,85.610596,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
208,5,2,107.128555,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
208,6,2,115.222725,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
208,1,3,31.943659,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
208,2,3,32.70206,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
208,3,3,46.48197,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
208,4,3,82.55786,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
208,5,3,112.05582,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
208,6,3,101.40308,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
208,1,4,25.90716,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
208,2,4,38.04864,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
208,3,4,53.90753,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
208,4,4,88.03085,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
208,5,4,102.632706,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
208,6,4,109.428894,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
208,1,5,25.173218,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
208,2,5,42.593758,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
208,3,5,55.0107,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
208,4,5,85.69242,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
208,5,5,106.08305,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
208,6,5,117.75435,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
208,1,6,28.673485,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
208,2,6,46.53616,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
208,3,6,53.113537,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
208,4,6,100.13111,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
208,5,6,106.61883,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
208,6,6,121.37971,241,6,NCGC00263133-01,PF-573228,Focal Adhesion Kinase (FAK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
209,1,1,17.370905,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
209,2,1,13.585086,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
209,3,1,14.651743,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
209,4,1,16.264923,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
209,5,1,17.615786,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
209,6,1,15.195243,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
209,1,2,18.819866,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
209,2,2,20.138756,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
209,3,2,19.672523,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
209,4,2,16.67401,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
209,5,2,20.377562,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
209,6,2,21.345263,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
209,1,3,29.628569,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
209,2,3,23.902555,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
209,3,3,23.159693,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
209,4,3,18.3927,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
209,5,3,28.952599,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
209,6,3,26.98416,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
209,1,4,22.378527,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
209,2,4,21.55636,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
209,3,4,22.359278,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
209,4,4,36.791645,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
209,5,4,27.99807,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
209,6,4,23.441906,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
209,1,5,30.759155,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
209,2,5,27.436771,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
209,3,5,28.300295,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
209,4,5,29.445072,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
209,5,5,28.074991,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
209,6,5,33.780914,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
209,1,6,27.818628,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
209,2,6,28.916435,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
209,3,6,52.10376,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
209,4,6,97.19099,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
209,5,6,94.12215,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
209,6,6,121.36278,241,6,NCGC00187912-01,Ibrutinib (PCI-32765),BTK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
210,1,1,0.693003,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
210,2,1,-1.087314,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
210,3,1,-0.884314,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
210,4,1,-1.274283,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
210,5,1,-0.078778,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
210,6,1,0.65928,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
210,1,2,1.576374,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
210,2,2,-0.610932,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
210,3,2,0.509447,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
210,4,2,1.499991,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
210,5,2,16.206472,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
210,6,2,15.47536,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
210,1,3,3.804858,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
210,2,3,4.104284,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
210,3,3,11.981784,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
210,4,3,43.736588,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
210,5,3,88.65301,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
210,6,3,90.72634,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
210,1,4,6.766356,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
210,2,4,13.745501,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
210,3,4,37.54874,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
210,4,4,86.419685,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
210,5,4,109.72218,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
210,6,4,102.78727,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
210,1,5,20.80323,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
210,2,5,30.289974,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
210,3,5,54.89902,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
210,4,5,78.732185,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
210,5,5,107.864044,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
210,6,5,109.088455,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
210,1,6,29.211058,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
210,2,6,33.355473,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
210,3,6,60.624973,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
210,4,6,115.809845,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
210,5,6,124.93391,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
210,6,6,103.1593,241,6,NCGC00188382-02,NCGC00188382-01,ITK inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
211,1,1,11.677426,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
211,2,1,20.640207,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
211,3,1,38.097218,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
211,4,1,74.69594,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
211,5,1,93.20067,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
211,6,1,96.76557,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
211,1,2,18.038515,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
211,2,2,25.927422,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
211,3,2,43.784595,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
211,4,2,82.826805,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
211,5,2,88.26418,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
211,6,2,115.43519,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
211,1,3,16.71292,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
211,2,3,34.54165,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
211,3,3,51.757484,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
211,4,3,90.77674,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
211,5,3,84.73694,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
211,6,3,103.58224,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
211,1,4,19.26299,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
211,2,4,25.524801,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
211,3,4,58.14285,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
211,4,4,86.812614,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
211,5,4,106.453156,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
211,6,4,98.349335,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
211,1,5,24.25498,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
211,2,5,27.423538,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
211,3,5,55.645767,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
211,4,5,81.94645,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
211,5,5,100.4164,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
211,6,5,107.5423,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
211,1,6,21.574793,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
211,2,6,34.942112,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
211,3,6,40.076305,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
211,4,6,96.4753,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
211,5,6,100.81355,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
211,6,6,104.19663,241,6,NCGC00229512-01,BMS-509744,ITK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
212,1,1,4.365413,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
212,2,1,4.724478,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
212,3,1,5.08923,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
212,4,1,10.630517,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
212,5,1,16.253332,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
212,6,1,19.898968,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
212,1,2,13.969752,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
212,2,2,18.476612,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
212,3,2,33.033714,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
212,4,2,75.64203,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
212,5,2,90.72322,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
212,6,2,94.73241,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
212,1,3,20.199131,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
212,2,3,26.564234,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
212,3,3,38.642673,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
212,4,3,76.98059,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
212,5,3,93.36561,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
212,6,3,92.7634,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
212,1,4,22.956493,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
212,2,4,30.415615,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
212,3,4,51.912933,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
212,4,4,95.06907,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
212,5,4,96.83293,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
212,6,4,113.22029,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
212,1,5,31.102571,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
212,2,5,33.670654,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
212,3,5,56.411156,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
212,4,5,89.49439,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
212,5,5,96.19438,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
212,6,5,123.82411,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
212,1,6,24.834238,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
212,2,6,35.659863,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
212,3,6,50.439625,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
212,4,6,85.89931,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
212,5,6,99.335464,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
212,6,6,114.54429,241,6,NCGC00241102-01,Midostaurin,PKC/flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
213,1,1,34.95023,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
213,2,1,40.31523,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
213,3,1,49.877663,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
213,4,1,76.50594,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
213,5,1,79.44673,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
213,6,1,93.273544,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
213,1,2,24.121115,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
213,2,2,36.421864,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
213,3,2,49.291542,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
213,4,2,86.31096,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
213,5,2,96.890045,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
213,6,2,117.98718,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
213,1,3,23.973064,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
213,2,3,41.074734,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
213,3,3,60.562126,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
213,4,3,99.42335,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
213,5,3,106.48385,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
213,6,3,114.27814,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
213,1,4,26.439516,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
213,2,4,40.24003,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
213,3,4,59.093395,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
213,4,4,100.23193,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
213,5,4,106.71004,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
213,6,4,108.87367,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
213,1,5,24.384403,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
213,2,5,34.525623,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
213,3,5,56.50212,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
213,4,5,96.729324,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
213,5,5,103.06741,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
213,6,5,112.02325,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
213,1,6,25.33989,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
213,2,6,40.89853,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
213,3,6,59.516956,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
213,4,6,88.31641,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
213,5,6,104.84229,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
213,6,6,115.91172,241,6,NCGC00238452-02,Enzastaurin,"PKCa, PKCb, PKCg inhbitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
214,1,1,19.0854,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
214,2,1,27.284025,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
214,3,1,38.252666,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
214,4,1,49.21357,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
214,5,1,56.29866,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
214,6,1,50.98639,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
214,1,2,27.399109,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
214,2,2,24.403828,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
214,3,2,28.367626,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
214,4,2,49.053833,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
214,5,2,58.075607,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
214,6,2,70.71797,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
214,1,3,19.483536,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
214,2,3,31.342554,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
214,3,3,43.833523,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
214,4,3,64.12697,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
214,5,3,98.26903,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
214,6,3,78.32977,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
214,1,4,23.374056,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
214,2,4,37.360878,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
214,3,4,50.91146,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
214,4,4,95.61031,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
214,5,4,104.43455,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
214,6,4,101.62408,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
214,1,5,28.225864,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
214,2,5,28.071918,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
214,3,5,57.07734,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
214,4,5,92.038246,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
214,5,5,107.601814,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
214,6,5,107.016685,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
214,1,6,26.862894,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
214,2,6,30.120863,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
214,3,6,51.495502,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
214,4,6,85.856865,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
214,5,6,105.844666,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
214,6,6,112.17213,241,6,NCGC00263095-01,Sotrastaurin,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
215,1,1,9.476851,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
215,2,1,16.380701,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
215,3,1,24.185255,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
215,4,1,31.475767,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
215,5,1,40.34084,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
215,6,1,53.21334,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
215,1,2,18.296785,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
215,2,2,30.008984,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
215,3,2,36.194244,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
215,4,2,67.60925,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
215,5,2,94.77448,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
215,6,2,96.42255,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
215,1,3,20.925863,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
215,2,3,33.48359,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
215,3,3,53.06895,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
215,4,3,81.14929,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
215,5,3,105.35312,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
215,6,3,106.58468,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
215,1,4,26.145391,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
215,2,4,37.348736,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
215,3,4,59.279167,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
215,4,4,87.817535,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
215,5,4,94.72463,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
215,6,4,117.47705,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
215,1,5,20.165903,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
215,2,5,33.28746,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
215,3,5,50.777187,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
215,4,5,97.91487,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
215,5,5,108.530334,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
215,6,5,112.65286,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
215,1,6,28.90644,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
215,2,6,47.366623,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
215,3,6,57.71508,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
215,4,6,108.5736,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
215,5,6,112.59967,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
215,6,6,119.72839,241,6,NCGC00263119-01,Ruboxistaurin mesylate,PKC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
216,1,1,20.609045,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
216,2,1,41.000748,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
216,3,1,64.14724,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
216,4,1,94.79847,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
216,5,1,100.59726,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
216,6,1,110.721054,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
216,1,2,26.154345,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
216,2,2,33.002903,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
216,3,2,59.05597,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
216,4,2,89.434006,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
216,5,2,100.90479,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
216,6,2,109.52844,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
216,1,3,21.648935,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
216,2,3,34.322186,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
216,3,3,52.595104,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
216,4,3,97.09715,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
216,5,3,89.03093,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
216,6,3,114.27821,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
216,1,4,23.80827,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
216,2,4,30.196012,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
216,3,4,46.800095,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
216,4,4,87.41911,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
216,5,4,109.44706,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
216,6,4,100.21869,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
216,1,5,30.651207,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
216,2,5,38.121925,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
216,3,5,52.80489,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
216,4,5,102.20813,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
216,5,5,126.456696,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
216,6,5,123.56632,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
216,1,6,32.049507,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
216,2,6,29.218971,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
216,3,6,40.221077,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
216,4,6,97.118484,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
216,5,6,114.544685,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
216,6,6,121.657104,241,6,NCGC00263018-01,NCGC00263018-01,Brk/PTK6 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
217,1,1,12.813641,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
217,2,1,17.760456,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
217,3,1,19.709244,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
217,4,1,33.408543,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
217,5,1,48.638363,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
217,6,1,69.37324,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
217,1,2,24.974995,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
217,2,2,38.553013,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
217,3,2,50.459194,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
217,4,2,87.31184,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
217,5,2,105.331055,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
217,6,2,97.94743,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
217,1,3,31.785828,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
217,2,3,33.047832,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
217,3,3,63.298615,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
217,4,3,100.46195,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
217,5,3,117.51063,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
217,6,3,110.30243,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
217,1,4,28.252413,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
217,2,4,43.304485,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
217,3,4,54.430824,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
217,4,4,98.61856,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
217,5,4,119.09792,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
217,6,4,107.23855,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
217,1,5,26.164867,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
217,2,5,38.721664,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
217,3,5,58.520634,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
217,4,5,96.66857,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
217,5,5,106.03256,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
217,6,5,105.77052,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
217,1,6,25.818756,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
217,2,6,30.864496,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
217,3,6,47.86902,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
217,4,6,84.30751,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
217,5,6,99.66081,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
217,6,6,102.4015,241,6,NCGC00242217-04,GW-843682X,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
218,1,1,1.493882,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
218,2,1,0.166585,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
218,3,1,0.970205,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
218,4,1,2.232379,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
218,5,1,3.459782,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
218,6,1,4.672414,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
218,1,2,8.402949,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
218,2,2,7.505579,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
218,3,2,12.81253,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
218,4,2,37.78181,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
218,5,2,53.074444,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
218,6,2,55.758774,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
218,1,3,10.074474,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
218,2,3,11.167828,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
218,3,3,15.572063,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
218,4,3,34.654926,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
218,5,3,50.797684,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
218,6,3,52.967373,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
218,1,4,20.19215,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
218,2,4,16.402452,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
218,3,4,27.689821,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
218,4,4,68.56248,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
218,5,4,87.82235,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
218,6,4,98.76523,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
218,1,5,18.748543,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
218,2,5,23.359179,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
218,3,5,60.412376,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
218,4,5,91.86801,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
218,5,5,94.40353,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
218,6,5,111.42178,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
218,1,6,28.32168,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
218,2,6,31.496264,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
218,3,6,55.863632,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
218,4,6,93.376015,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
218,5,6,101.62879,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
218,6,6,132.42981,241,6,NCGC00253438-01,BI-2536,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
219,1,1,0.810613,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
219,2,1,0.785332,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
219,3,1,1.836909,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
219,4,1,4.611055,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
219,5,1,6.515976,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
219,6,1,6.709149,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
219,1,2,4.857208,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
219,2,2,8.357538,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
219,3,2,15.809575,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
219,4,2,28.73626,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
219,5,2,41.54244,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
219,6,2,45.3607,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
219,1,3,11.851737,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
219,2,3,17.961105,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
219,3,3,19.298141,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
219,4,3,36.69659,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
219,5,3,59.023277,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
219,6,3,75.85911,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
219,1,4,30.181856,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
219,2,4,34.267117,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
219,3,4,43.637512,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
219,4,4,72.33472,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
219,5,4,100.5317,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
219,6,4,105.099724,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
219,1,5,26.587214,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
219,2,5,31.019188,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
219,3,5,53.217052,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
219,4,5,90.80031,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
219,5,5,106.71623,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
219,6,5,114.05371,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
219,1,6,26.90815,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
219,2,6,35.834316,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
219,3,6,62.827015,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
219,4,6,102.020134,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
219,5,6,118.61992,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
219,6,6,139.74521,241,6,NCGC00263087-01,Volasertib,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
220,1,1,16.432491,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
220,2,1,19.770407,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
220,3,1,22.298258,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
220,4,1,40.01542,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
220,5,1,68.467545,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
220,6,1,82.21217,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
220,1,2,7.681275,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
220,2,2,17.531387,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
220,3,2,16.654867,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
220,4,2,35.70194,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
220,5,2,54.405674,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
220,6,2,65.30238,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
220,1,3,9.082191,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
220,2,3,9.495478,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
220,3,3,18.56341,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
220,4,3,30.42287,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
220,5,3,42.38096,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
220,6,3,56.754505,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
220,1,4,17.590525,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
220,2,4,32.723118,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
220,3,4,51.096714,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
220,4,4,76.086754,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
220,5,4,96.47856,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
220,6,4,95.37305,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
220,1,5,21.883022,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
220,2,5,30.064655,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
220,3,5,35.731537,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
220,4,5,91.08399,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
220,5,5,103.85847,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
220,6,5,96.186066,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
220,1,6,22.91792,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
220,2,6,30.948965,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
220,3,6,53.962032,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
220,4,6,103.130974,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
220,5,6,119.103096,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
220,6,6,122.101135,241,6,NCGC00263112-01,GSK-461364A,Polo-like Kinase-1 (Plk-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
221,1,1,19.252234,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
221,2,1,21.397528,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
221,3,1,33.25558,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
221,4,1,70.86926,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
221,5,1,93.06812,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
221,6,1,91.062996,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
221,1,2,22.314623,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
221,2,2,29.238317,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
221,3,2,50.114456,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
221,4,2,97.04235,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
221,5,2,93.56971,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
221,6,2,112.12931,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
221,1,3,20.483688,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
221,2,3,25.85562,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
221,3,3,50.51501,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
221,4,3,89.58978,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
221,5,3,113.47564,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
221,6,3,114.71584,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
221,1,4,21.979778,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
221,2,4,34.290985,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
221,3,4,54.479424,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
221,4,4,100.42446,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
221,5,4,105.88283,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
221,6,4,113.16026,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
221,1,5,24.358404,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
221,2,5,38.619797,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
221,3,5,58.178677,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
221,4,5,99.09165,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
221,5,5,95.06284,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
221,6,5,106.75933,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
221,1,6,26.642101,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
221,2,6,29.957062,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
221,3,6,66.46924,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
221,4,6,79.61244,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
221,5,6,107.76619,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
221,6,6,115.65327,241,6,NCGC00250376-01,KN-93,CaMK-II Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
222,1,1,30.881607,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
222,2,1,40.539448,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
222,3,1,61.187397,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
222,4,1,97.41521,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
222,5,1,104.20611,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
222,6,1,112.73084,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
222,1,2,29.639538,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
222,2,2,33.298035,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
222,3,2,73.45311,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
222,4,2,95.0596,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
222,5,2,118.677315,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
222,6,2,123.88556,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
222,1,3,30.488085,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
222,2,3,34.0301,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
222,3,3,49.858906,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
222,4,3,101.80394,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
222,5,3,105.15154,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
222,6,3,107.25671,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
222,1,4,32.67134,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
222,2,4,31.710325,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
222,3,4,54.51456,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
222,4,4,93.6907,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
222,5,4,106.13287,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
222,6,4,106.08529,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
222,1,5,25.12588,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
222,2,5,37.324684,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
222,3,5,52.0368,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
222,4,5,103.36452,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
222,5,5,103.026505,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
222,6,5,114.591255,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
222,1,6,35.848854,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
222,2,6,38.966312,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
222,3,6,33.814537,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
222,4,6,89.2571,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
222,5,6,103.15644,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
222,6,6,121.60167,241,6,NCGC00162398-03,KN-62,Ca2+/calmodulin dependent protein kinase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
223,1,1,22.097946,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
223,2,1,21.025404,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
223,3,1,31.548027,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
223,4,1,69.3164,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
223,5,1,100.544876,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
223,6,1,110.461105,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
223,1,2,19.45406,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
223,2,2,33.722866,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
223,3,2,50.548042,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
223,4,2,79.33131,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
223,5,2,130.44258,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
223,6,2,119.924614,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
223,1,3,27.846275,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
223,2,3,32.37396,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
223,3,3,51.97765,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
223,4,3,92.33003,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
223,5,3,103.139084,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
223,6,3,125.8741,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
223,1,4,30.42491,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
223,2,4,35.240093,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
223,3,4,48.51114,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
223,4,4,109.06749,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
223,5,4,105.91109,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
223,6,4,131.98988,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
223,1,5,26.811106,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
223,2,5,37.975338,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
223,3,5,60.65798,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
223,4,5,100.93255,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
223,5,5,113.004395,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
223,6,5,113.31153,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
223,1,6,27.47636,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
223,2,6,27.101818,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
223,3,6,58.29928,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
223,4,6,90.958046,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
223,5,6,109.59043,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
223,6,6,98.80828,241,6,NCGC00241982-03,GSK-269962A,"ROCK 1, ROCK 2 Inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
224,1,1,25.865108,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
224,2,1,41.598686,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
224,3,1,42.28198,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
224,4,1,96.64453,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
224,5,1,103.442635,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
224,6,1,104.79866,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
224,1,2,24.528793,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
224,2,2,39.804535,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
224,3,2,61.347485,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
224,4,2,99.32336,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
224,5,2,120.42437,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
224,6,2,94.09292,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
224,1,3,36.812523,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
224,2,3,33.063084,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
224,3,3,56.99079,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
224,4,3,100.089355,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
224,5,3,109.35986,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
224,6,3,108.50347,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
224,1,4,31.819395,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
224,2,4,36.774025,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
224,3,4,57.422836,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
224,4,4,104.0482,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
224,5,4,113.69951,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
224,6,4,121.07245,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
224,1,5,31.037043,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
224,2,5,45.79865,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
224,3,5,54.779575,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
224,4,5,108.128845,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
224,5,5,116.27738,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
224,6,5,132.3464,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
224,1,6,28.136297,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
224,2,6,37.387493,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
224,3,6,57.067886,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
224,4,6,99.5368,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
224,5,6,109.56778,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
224,6,6,118.800255,241,6,NCGC00092276-10,Y-27632,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
225,1,1,21.553865,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
225,2,1,31.791748,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
225,3,1,51.413242,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
225,4,1,70.28323,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
225,5,1,98.48288,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
225,6,1,108.546776,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
225,1,2,29.53192,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
225,2,2,35.720425,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
225,3,2,55.22209,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
225,4,2,106.31332,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
225,5,2,119.81826,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
225,6,2,99.06287,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
225,1,3,27.502935,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
225,2,3,41.046303,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
225,3,3,58.0774,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
225,4,3,92.512856,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
225,5,3,105.13311,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
225,6,3,131.12761,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
225,1,4,25.386818,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
225,2,4,38.786774,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
225,3,4,55.935425,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
225,4,4,112.40792,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
225,5,4,102.81161,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
225,6,4,114.44531,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
225,1,5,29.257233,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
225,2,5,31.149603,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
225,3,5,51.085052,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
225,4,5,89.22835,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
225,5,5,100.98933,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
225,6,5,106.79798,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
225,1,6,33.117893,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
225,2,6,36.668823,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
225,3,6,63.019978,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
225,4,6,106.425255,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
225,5,6,110.4781,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
225,6,6,133.95726,241,6,NCGC00242475-01,GSK-650394,SGK1 and SGK2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
226,1,1,16.16736,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
226,2,1,25.03353,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
226,3,1,46.315254,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
226,4,1,83.84635,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
226,5,1,97.490944,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
226,6,1,93.699684,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
226,1,2,19.25873,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
226,2,2,33.273315,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
226,3,2,45.192726,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
226,4,2,91.246864,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
226,5,2,95.52912,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
226,6,2,92.23563,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
226,1,3,24.587837,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
226,2,3,29.734007,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
226,3,3,60.88935,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
226,4,3,95.410095,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
226,5,3,100.215706,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
226,6,3,104.18018,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
226,1,4,27.706003,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
226,2,4,32.42937,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
226,3,4,62.3571,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
226,4,4,99.99633,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
226,5,4,101.29343,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
226,6,4,102.72889,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
226,1,5,21.829468,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
226,2,5,37.46043,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
226,3,5,56.90824,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
226,4,5,101.265076,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
226,5,5,119.979225,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
226,6,5,106.95474,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
226,1,6,29.49341,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
226,2,6,39.507023,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
226,3,6,64.526,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
226,4,6,120.96842,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
226,5,6,91.841934,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
226,6,6,100.6544,241,6,NCGC00242486-02,AZD-1480,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
227,1,1,29.432444,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
227,2,1,39.77856,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
227,3,1,59.34446,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
227,4,1,98.564545,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
227,5,1,101.59,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
227,6,1,97.3924,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
227,1,2,29.341805,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
227,2,2,41.748,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
227,3,2,53.59246,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
227,4,2,103.41004,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
227,5,2,103.40437,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
227,6,2,105.14046,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
227,1,3,22.718353,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
227,2,3,33.40849,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
227,3,3,63.90225,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
227,4,3,87.338394,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
227,5,3,108.85608,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
227,6,3,107.85406,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
227,1,4,24.970629,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
227,2,4,31.991392,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
227,3,4,59.072807,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
227,4,4,105.27108,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
227,5,4,104.1598,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
227,6,4,111.7762,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
227,1,5,27.652777,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
227,2,5,38.075752,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
227,3,5,67.48424,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
227,4,5,104.51562,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
227,5,5,109.00061,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
227,6,5,121.2042,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
227,1,6,26.73891,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
227,2,6,35.426662,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
227,3,6,55.995686,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
227,4,6,94.54338,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
227,5,6,104.36046,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
227,6,6,120.24535,241,6,NCGC00229511-02,Tofacitinib,Jak1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
228,1,1,31.607138,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
228,2,1,38.561512,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
228,3,1,50.504917,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
228,4,1,84.993675,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
228,5,1,116.10078,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
228,6,1,107.06933,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
228,1,2,28.35143,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
228,2,2,35.596127,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
228,3,2,53.34836,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
228,4,2,98.774414,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
228,5,2,109.495514,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
228,6,2,115.281784,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
228,1,3,22.716185,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
228,2,3,39.67672,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
228,3,3,52.39444,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
228,4,3,90.94212,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
228,5,3,100.23073,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
228,6,3,109.83124,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
228,1,4,27.673836,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
228,2,4,34.213955,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
228,3,4,46.497578,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
228,4,4,91.51453,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
228,5,4,114.40939,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
228,6,4,108.71697,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
228,1,5,36.070534,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
228,2,5,35.10586,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
228,3,5,48.925102,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
228,4,5,89.82631,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
228,5,5,103.75623,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
228,6,5,119.79057,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
228,1,6,23.880281,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
228,2,6,35.69589,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
228,3,6,51.677513,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
228,4,6,77.38736,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
228,5,6,104.7617,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
228,6,6,124.6217,241,6,NCGC00244253-02,Ruxolitinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
229,1,1,9.443714,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
229,2,1,6.306659,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
229,3,1,7.37681,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
229,4,1,21.874826,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
229,5,1,27.552792,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
229,6,1,35.07344,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
229,1,2,21.74428,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
229,2,2,20.273928,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
229,3,2,36.411613,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
229,4,2,87.60927,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
229,5,2,86.4804,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
229,6,2,98.929955,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
229,1,3,26.03219,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
229,2,3,28.783018,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
229,3,3,52.593796,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
229,4,3,81.62693,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
229,5,3,109.415794,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
229,6,3,122.74811,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
229,1,4,30.800486,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
229,2,4,33.818836,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
229,3,4,46.636623,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
229,4,4,93.31245,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
229,5,4,117.71128,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
229,6,4,111.27126,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
229,1,5,27.567287,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
229,2,5,33.307186,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
229,3,5,46.799183,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
229,4,5,90.31875,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
229,5,5,106.48277,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
229,6,5,136.13637,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
229,1,6,24.130682,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
229,2,6,40.024464,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
229,3,6,52.65752,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
229,4,6,96.06321,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
229,5,6,127.21154,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
229,6,6,117.261406,241,6,NCGC00244257-01,Momelotinib,Jak1/2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
230,1,1,5.723768,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
230,2,1,2.659953,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
230,3,1,3.864467,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
230,4,1,5.399695,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
230,5,1,5.733075,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
230,6,1,3.534355,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
230,1,2,6.147695,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
230,2,2,4.633878,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
230,3,2,7.149755,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
230,4,2,11.810561,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
230,5,2,18.840881,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
230,6,2,18.210943,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
230,1,3,5.692552,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
230,2,3,7.007888,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
230,3,3,14.044992,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
230,4,3,30.281017,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
230,5,3,39.4159,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
230,6,3,50.92341,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
230,1,4,11.827633,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
230,2,4,14.936179,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
230,3,4,23.708742,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
230,4,4,54.4417,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
230,5,4,71.59726,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
230,6,4,71.847275,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
230,1,5,17.87874,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
230,2,5,20.249718,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
230,3,5,30.295984,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
230,4,5,72.83009,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
230,5,5,76.61464,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
230,6,5,110.703575,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
230,1,6,29.528025,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
230,2,6,38.909843,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
230,3,6,55.49432,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
230,4,6,112.28756,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
230,5,6,113.66156,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
230,6,6,121.221924,241,6,NCGC00244256-01,Lestaurtinib,Jak/Tyk/Flt Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
231,1,1,2.428362,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
231,2,1,0.713595,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
231,3,1,1.422001,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
231,4,1,3.40956,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
231,5,1,7.594519,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
231,6,1,12.023394,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
231,1,2,14.118533,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
231,2,2,17.508734,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
231,3,2,34.31377,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
231,4,2,60.908,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
231,5,2,89.68404,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
231,6,2,93.48338,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
231,1,3,18.887323,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
231,2,3,27.808525,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
231,3,3,47.669415,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
231,4,3,87.072495,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
231,5,3,102.50213,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
231,6,3,99.87536,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
231,1,4,30.679401,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
231,2,4,28.679295,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
231,3,4,50.281395,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
231,4,4,72.93283,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
231,5,4,96.21182,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
231,6,4,111.99132,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
231,1,5,28.427744,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
231,2,5,34.86521,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
231,3,5,55.88732,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
231,4,5,82.16973,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
231,5,5,103.65733,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
231,6,5,113.9764,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
231,1,6,34.12827,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
231,2,6,35.58351,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
231,3,6,66.020355,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
231,4,6,84.247,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
231,5,6,103.07275,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
231,6,6,117.903564,241,6,NCGC00249346-01,SB1518,Jak2 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
232,1,1,30.740917,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
232,2,1,37.649616,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
232,3,1,51.651695,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
232,4,1,113.15482,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
232,5,1,104.76982,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
232,6,1,105.05979,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
232,1,2,28.580029,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
232,2,2,37.553516,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
232,3,2,69.60412,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
232,4,2,108.9014,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
232,5,2,104.89197,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
232,6,2,108.65821,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
232,1,3,33.21082,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
232,2,3,39.07332,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
232,3,3,64.911316,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
232,4,3,91.9071,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
232,5,3,107.69456,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
232,6,3,106.43382,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
232,1,4,32.7227,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
232,2,4,30.324612,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
232,3,4,59.985836,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
232,4,4,87.97342,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
232,5,4,112.902245,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
232,6,4,106.53072,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
232,1,5,29.918043,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
232,2,5,37.73976,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
232,3,5,49.21043,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
232,4,5,80.654724,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
232,5,5,108.123566,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
232,6,5,127.22634,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
232,1,6,26.47817,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
232,2,6,38.896942,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
232,3,6,52.986862,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
232,4,6,85.86723,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
232,5,6,104.77248,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
232,6,6,130.02332,241,6,NCGC00015610-14,Leflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
233,1,1,23.788963,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
233,2,1,27.361238,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
233,3,1,42.895096,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
233,4,1,78.68988,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
233,5,1,108.106316,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
233,6,1,109.65562,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
233,1,2,27.818186,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
233,2,2,33.0691,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
233,3,2,44.503445,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
233,4,2,101.84245,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
233,5,2,104.24285,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
233,6,2,132.35388,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
233,1,3,28.159277,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
233,2,3,36.602383,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
233,3,3,58.407616,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
233,4,3,97.540215,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
233,5,3,104.94711,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
233,6,3,119.89267,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
233,1,4,35.494232,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
233,2,4,41.227936,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
233,3,4,56.457676,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
233,4,4,101.93317,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
233,5,4,107.627785,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
233,6,4,125.970375,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
233,1,5,27.187437,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
233,2,5,34.89062,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
233,3,5,59.049133,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
233,4,5,90.15643,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
233,5,5,109.36548,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
233,6,5,122.772285,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
233,1,6,28.966923,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
233,2,6,38.753845,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
233,3,6,53.4745,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
233,4,6,91.864586,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
233,5,6,109.09826,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
233,6,6,111.50654,241,6,NCGC00263202-01,NVP-BSK805,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
234,1,1,-0.316112,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
234,2,1,-0.414437,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
234,3,1,0.823358,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
234,4,1,2.8777,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
234,5,1,5.3215,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
234,6,1,2.988339,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
234,1,2,18.617525,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
234,2,2,29.133966,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
234,3,2,44.202965,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
234,4,2,86.64824,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
234,5,2,94.19694,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
234,6,2,111.12695,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
234,1,3,30.454687,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
234,2,3,43.88893,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
234,3,3,58.28755,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
234,4,3,97.263695,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
234,5,3,109.37187,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
234,6,3,117.18637,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
234,1,4,33.441536,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
234,2,4,42.74706,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
234,3,4,62.810047,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
234,4,4,103.52015,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
234,5,4,113.27392,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
234,6,4,130.79224,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
234,1,5,31.879616,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
234,2,5,41.36316,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
234,3,5,62.601357,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
234,4,5,107.23244,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
234,5,5,104.87122,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
234,6,5,114.818665,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
234,1,6,40.11185,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
234,2,6,41.397903,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
234,3,6,52.315685,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
234,4,6,99.41687,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
234,5,6,110.05757,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
234,6,6,117.161476,241,6,NCGC00263102-01,Degrasyn,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
235,1,1,16.995253,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
235,2,1,22.249395,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
235,3,1,33.332977,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
235,4,1,64.234024,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
235,5,1,85.334496,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
235,6,1,101.33093,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
235,1,2,9.07278,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
235,2,2,14.012012,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
235,3,2,22.84996,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
235,4,2,46.856228,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
235,5,2,65.937164,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
235,6,2,77.40983,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
235,1,3,20.927929,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
235,2,3,27.762892,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
235,3,3,47.81221,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
235,4,3,76.79281,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
235,5,3,109.068634,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
235,6,3,98.21265,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
235,1,4,27.78982,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
235,2,4,28.127369,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
235,3,4,51.41706,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
235,4,4,96.23261,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
235,5,4,116.9952,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
235,6,4,106.07448,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
235,1,5,24.363123,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
235,2,5,37.252567,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
235,3,5,56.84236,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
235,4,5,81.73146,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
235,5,5,105.20906,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
235,6,5,132.2986,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
235,1,6,29.897652,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
235,2,6,38.792904,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
235,3,6,56.606182,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
235,4,6,104.17777,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
235,5,6,113.28652,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
235,6,6,109.90201,241,6,NCGC00263200-01,RO495,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
236,1,1,15.104843,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
236,2,1,18.391882,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
236,3,1,28.42633,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
236,4,1,62.456944,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
236,5,1,81.26577,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
236,6,1,98.59835,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
236,1,2,26.150005,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
236,2,2,27.696697,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
236,3,2,49.203804,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
236,4,2,90.491486,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
236,5,2,101.43455,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
236,6,2,107.260185,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
236,1,3,27.786434,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
236,2,3,28.637426,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
236,3,3,42.902283,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
236,4,3,103.15525,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
236,5,3,104.40281,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
236,6,3,83.9117,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
236,1,4,26.582912,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
236,2,4,33.140327,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
236,3,4,50.208347,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
236,4,4,88.64309,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
236,5,4,100.713806,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
236,6,4,108.29116,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
236,1,5,28.056076,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
236,2,5,34.569542,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
236,3,5,51.667774,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
236,4,5,93.58688,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
236,5,5,101.72083,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
236,6,5,103.61192,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
236,1,6,26.079014,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
236,2,6,35.893753,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
236,3,6,55.86902,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
236,4,6,105.73006,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
236,5,6,93.29157,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
236,6,6,113.498665,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
237,1,1,19.261227,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,2
237,2,1,28.080914,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,2
237,3,1,41.802734,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,2
237,4,1,82.88129,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,2
237,5,1,98.47898,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,2
237,6,1,114.45752,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,2
237,1,2,34.34156,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,2
237,2,2,40.44204,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,2
237,3,2,55.63339,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,2
237,4,2,100.160164,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,2
237,5,2,108.67105,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,2
237,6,2,115.46892,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,2
237,1,3,31.768978,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,2
237,2,3,38.00276,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,2
237,3,3,54.393963,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,2
237,4,3,112.084465,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,2
237,5,3,103.470695,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,2
237,6,3,114.14035,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,2
237,1,4,32.063614,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,2
237,2,4,29.481907,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,2
237,3,4,51.27816,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,2
237,4,4,69.31603,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,2
237,5,4,105.58302,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,2
237,6,4,111.904205,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,2
237,1,5,26.798738,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,2
237,2,5,34.16031,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,2
237,3,5,55.418594,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,2
237,4,5,103.77815,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,2
237,5,5,115.31344,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,2
237,6,5,92.886986,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,2
237,1,6,27.720148,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,2
237,2,6,38.500454,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,2
237,3,6,45.77061,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,2
237,4,6,102.069084,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,2
237,5,6,98.27913,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,2
237,6,6,107.958435,241,6,NCGC00244250-01,NCGC00244250,Tyk 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,2
238,1,1,29.321165,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
238,2,1,29.993074,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
238,3,1,39.114037,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
238,4,1,74.90658,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
238,5,1,68.2596,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
238,6,1,81.47458,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
238,1,2,28.262203,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
238,2,2,47.41918,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
238,3,2,56.051018,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
238,4,2,97.06767,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
238,5,2,109.88112,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
238,6,2,132.22298,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
238,1,3,27.01386,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
238,2,3,34.765747,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
238,3,3,58.782524,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
238,4,3,91.4924,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
238,5,3,122.48865,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
238,6,3,123.665825,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
238,1,4,31.311836,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
238,2,4,35.424232,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
238,3,4,68.04384,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
238,4,4,97.930336,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
238,5,4,121.83955,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
238,6,4,124.16083,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
238,1,5,32.921597,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
238,2,5,33.995132,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
238,3,5,54.811157,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
238,4,5,102.757545,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
238,5,5,116.62678,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
238,6,5,119.93587,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
238,1,6,38.780174,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
238,2,6,36.3021,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
238,3,6,69.22554,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
238,4,6,95.42043,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
238,5,6,109.02814,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
238,6,6,103.95632,241,6,NCGC00263116-01,ICG-001,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
239,1,1,45.157497,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
239,2,1,43.354107,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
239,3,1,58.366337,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
239,4,1,89.835976,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
239,5,1,135.73996,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
239,6,1,149.53473,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
239,1,2,29.754072,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
239,2,2,35.04215,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
239,3,2,52.706867,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
239,4,2,106.74478,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
239,5,2,114.18182,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
239,6,2,114.94896,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
239,1,3,28.580368,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
239,2,3,34.53804,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
239,3,3,51.82535,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
239,4,3,112.585815,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
239,5,3,104.01278,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
239,6,3,125.831764,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
239,1,4,28.319628,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
239,2,4,44.565807,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
239,3,4,53.958218,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
239,4,4,97.74608,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
239,5,4,133.9864,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
239,6,4,126.942215,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
239,1,5,29.32523,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
239,2,5,35.337776,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
239,3,5,56.051304,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
239,4,5,101.40077,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
239,5,5,128.27478,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
239,6,5,116.43594,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
239,1,6,29.926476,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
239,2,6,47.58568,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
239,3,6,47.817802,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
239,4,6,99.7823,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
239,5,6,113.36812,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
239,6,6,99.89606,241,6,NCGC00263085-01,Wnt-C59,Wnt Signaling Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
240,1,1,40.152187,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
240,2,1,59.7726,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
240,3,1,69.86656,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
240,4,1,105.98327,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
240,5,1,116.05054,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
240,6,1,133.00961,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
240,1,2,33.033035,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
240,2,2,42.53826,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
240,3,2,57.993374,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
240,4,2,95.587296,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
240,5,2,112.442955,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
240,6,2,124.668175,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
240,1,3,25.458801,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
240,2,3,36.83137,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
240,3,3,54.225388,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
240,4,3,94.97243,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
240,5,3,102.74085,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
240,6,3,119.40928,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
240,1,4,26.67499,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
240,2,4,43.54571,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
240,3,4,60.86313,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
240,4,4,106.36877,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
240,5,4,116.28462,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
240,6,4,102.52264,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
240,1,5,35.902225,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
240,2,5,35.702503,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
240,3,5,60.32337,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
240,4,5,101.48443,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
240,5,5,101.070435,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
240,6,5,121.30753,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
240,1,6,32.71675,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
240,2,6,37.17764,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
240,3,6,64.342674,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
240,4,6,108.10639,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
240,5,6,127.78709,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
240,6,6,123.353386,241,6,NCGC00242498-01,D-4476,Casein Kinase 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
241,1,1,8.499862,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
241,2,1,10.175257,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
241,3,1,18.942617,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
241,4,1,42.022823,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
241,5,1,55.14873,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
241,6,1,67.181725,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
241,1,2,16.847034,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
241,2,2,26.042896,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
241,3,2,44.76736,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
241,4,2,87.271324,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
241,5,2,100.58198,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
241,6,2,97.02719,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
241,1,3,22.94963,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
241,2,3,38.077557,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
241,3,3,47.819973,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
241,4,3,85.97961,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
241,5,3,97.62116,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
241,6,3,100.48348,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
241,1,4,27.381538,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
241,2,4,38.069115,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
241,3,4,51.136593,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
241,4,4,83.34806,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
241,5,4,121.99136,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
241,6,4,97.66638,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
241,1,5,30.215868,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
241,2,5,33.319344,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
241,3,5,44.633797,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
241,4,5,103.82874,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
241,5,5,103.0317,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
241,6,5,117.09329,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
241,1,6,34.548695,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
241,2,6,40.962658,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
241,3,6,74.72423,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
241,4,6,64.1275,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
241,5,6,95.67346,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
241,6,6,89.56871,241,6,NCGC00263192-01,Silmitasertib,Casein Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
242,1,1,41.96154,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
242,2,1,34.324932,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
242,3,1,47.21975,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
242,4,1,68.516754,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
242,5,1,97.2645,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
242,6,1,113.403564,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
242,1,2,33.492386,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
242,2,2,37.596992,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
242,3,2,56.64886,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
242,4,2,97.201485,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
242,5,2,105.955894,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
242,6,2,104.00997,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
242,1,3,31.00571,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
242,2,3,35.073963,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
242,3,3,47.700787,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
242,4,3,101.35485,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
242,5,3,96.98873,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
242,6,3,99.416885,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
242,1,4,26.667252,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
242,2,4,34.045147,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
242,3,4,57.76884,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
242,4,4,94.041115,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
242,5,4,105.55638,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
242,6,4,92.294304,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
242,1,5,22.03302,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
242,2,5,38.043587,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
242,3,5,50.812992,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
242,4,5,91.930786,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
242,5,5,96.56977,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
242,6,5,98.37344,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
242,1,6,32.788933,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
242,2,6,32.03905,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
242,3,6,50.401443,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
242,4,6,90.08262,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
242,5,6,108.80032,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
242,6,6,96.96139,241,6,NCGC00250382-01,Sonidegib,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
243,1,1,23.352146,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
243,2,1,36.53309,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
243,3,1,48.810753,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
243,4,1,83.4467,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
243,5,1,100.09721,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
243,6,1,90.91097,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
243,1,2,25.739033,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
243,2,2,30.681664,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
243,3,2,49.472298,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
243,4,2,90.43704,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
243,5,2,97.739006,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
243,6,2,108.73402,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
243,1,3,22.733309,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
243,2,3,43.62334,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
243,3,3,50.660576,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
243,4,3,87.55256,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
243,5,3,103.5492,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
243,6,3,110.33835,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
243,1,4,32.720505,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
243,2,4,34.26164,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
243,3,4,55.494724,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
243,4,4,97.65071,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
243,5,4,107.662834,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
243,6,4,124.18022,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
243,1,5,32.405987,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
243,2,5,39.576878,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
243,3,5,49.276367,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
243,4,5,112.92067,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
243,5,5,97.18079,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
243,6,5,126.98254,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
243,1,6,29.22156,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
243,2,6,39.255642,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
243,3,6,55.643703,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
243,4,6,98.030495,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
243,5,6,105.92855,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
243,6,6,123.08274,241,6,NCGC00163474-05,Cyclopamine,Smo Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
244,1,1,24.002436,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
244,2,1,33.983997,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
244,3,1,37.468655,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
244,4,1,72.17271,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
244,5,1,97.85659,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
244,6,1,124.10229,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
244,1,2,25.413706,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
244,2,2,28.92163,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
244,3,2,47.877007,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
244,4,2,88.58014,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
244,5,2,107.96509,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
244,6,2,117.56705,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
244,1,3,26.446785,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
244,2,3,33.404125,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
244,3,3,58.727978,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
244,4,3,105.651665,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
244,5,3,110.64032,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
244,6,3,91.88615,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
244,1,4,26.850922,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
244,2,4,34.549335,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
244,3,4,61.33253,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
244,4,4,107.36213,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
244,5,4,97.84652,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
244,6,4,97.51214,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
244,1,5,35.112617,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
244,2,5,31.895994,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
244,3,5,47.522552,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
244,4,5,106.13594,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
244,5,5,110.45809,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
244,6,5,123.7829,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
244,1,6,34.308018,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
244,2,6,36.43181,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
244,3,6,53.711884,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
244,4,6,96.23955,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
244,5,6,118.764175,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
244,6,6,144.70943,241,6,NCGC00263170-01,Taladegib,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
245,1,1,34.595306,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
245,2,1,44.4335,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
245,3,1,53.93665,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
245,4,1,91.430405,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
245,5,1,105.537704,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
245,6,1,119.50215,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
245,1,2,33.115894,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
245,2,2,35.03569,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
245,3,2,56.26483,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
245,4,2,87.88332,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
245,5,2,100.154076,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
245,6,2,112.14146,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
245,1,3,25.824272,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
245,2,3,36.48616,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
245,3,3,61.703583,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
245,4,3,86.68353,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
245,5,3,113.418915,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
245,6,3,121.2625,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
245,1,4,28.639727,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
245,2,4,35.58411,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
245,3,4,60.795,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
245,4,4,85.553894,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
245,5,4,95.253624,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
245,6,4,120.71207,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
245,1,5,30.043373,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
245,2,5,42.338387,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
245,3,5,50.963173,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
245,4,5,101.43403,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
245,5,5,99.98566,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
245,6,5,116.75284,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
245,1,6,28.00077,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
245,2,6,40.630833,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
245,3,6,69.22089,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
245,4,6,108.89517,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
245,5,6,117.85733,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
245,6,6,116.19831,241,6,NCGC00263210-01,SANT-2,Smoothened (Smo) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
246,1,1,10.91747,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
246,2,1,19.726366,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
246,3,1,30.110905,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
246,4,1,63.470303,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
246,5,1,84.56115,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
246,6,1,100.083336,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
246,1,2,14.687244,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
246,2,2,30.309677,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
246,3,2,45.19064,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
246,4,2,78.28071,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
246,5,2,96.4141,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
246,6,2,92.276085,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
246,1,3,18.90943,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
246,2,3,21.774769,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
246,3,3,45.717674,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
246,4,3,80.993706,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
246,5,3,98.97638,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
246,6,3,105.8781,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
246,1,4,22.67141,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
246,2,4,35.428192,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
246,3,4,66.84325,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
246,4,4,100.22361,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
246,5,4,113.03535,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
246,6,4,94.23251,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
246,1,5,29.166912,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
246,2,5,35.82196,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
246,3,5,63.263958,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
246,4,5,103.624626,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
246,5,5,98.093414,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
246,6,5,103.94334,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
246,1,6,24.452509,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
246,2,6,34.451298,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
246,3,6,63.87739,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
246,4,6,97.2061,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
246,5,6,106.184555,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
246,6,6,106.620705,241,6,NCGC00263084-01,Hh-Ag1.5,Smoothened (Smo) receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
247,1,1,30.74094,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
247,2,1,31.929144,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
247,3,1,61.61842,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
247,4,1,102.09686,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
247,5,1,117.88129,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
247,6,1,112.89675,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
247,1,2,26.82822,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
247,2,2,35.44992,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
247,3,2,62.80913,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
247,4,2,95.48968,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
247,5,2,116.81249,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
247,6,2,117.69686,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
247,1,3,20.510565,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
247,2,3,40.003983,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
247,3,3,63.498093,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
247,4,3,92.56261,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
247,5,3,106.385445,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
247,6,3,92.97859,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
247,1,4,23.327068,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
247,2,4,37.264038,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
247,3,4,50.77938,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
247,4,4,90.2572,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
247,5,4,102.263535,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
247,6,4,99.77974,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
247,1,5,25.447868,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
247,2,5,33.674973,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
247,3,5,68.219536,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
247,4,5,104.69813,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
247,5,5,106.46493,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
247,6,5,133.50696,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
247,1,6,25.732658,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
247,2,6,33.893085,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
247,3,6,43.84648,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
247,4,6,101.77084,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
247,5,6,113.376724,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
247,6,6,132.64162,241,6,NCGC00242497-02,Vismodegib,Hedgehog Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
248,1,1,25.733786,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
248,2,1,35.524734,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
248,3,1,53.06521,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
248,4,1,80.5158,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
248,5,1,92.82536,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
248,6,1,111.36173,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
248,1,2,24.469849,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
248,2,2,39.5643,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
248,3,2,51.908897,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
248,4,2,80.0538,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
248,5,2,111.59506,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
248,6,2,112.96383,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
248,1,3,28.440796,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
248,2,3,33.872498,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
248,3,3,79.35518,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
248,4,3,80.24928,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
248,5,3,103.96044,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
248,6,3,113.92251,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
248,1,4,29.758087,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
248,2,4,35.97405,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
248,3,4,54.73087,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
248,4,4,91.96444,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
248,5,4,108.302925,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
248,6,4,120.72311,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
248,1,5,32.561596,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
248,2,5,46.005592,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
248,3,5,83.30089,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
248,4,5,111.60836,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
248,5,5,107.329185,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
248,6,5,115.03341,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
248,1,6,30.367832,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
248,2,6,35.019592,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
248,3,6,33.11984,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
248,4,6,86.512375,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
248,5,6,103.55076,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
248,6,6,125.14053,241,6,NCGC00263162-01,RO-4929097,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
249,1,1,26.796638,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
249,2,1,37.424545,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
249,3,1,39.421623,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
249,4,1,84.07338,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
249,5,1,102.41186,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
249,6,1,108.9871,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
249,1,2,26.150953,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
249,2,2,32.610012,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
249,3,2,55.65696,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
249,4,2,100.77204,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
249,5,2,101.40949,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
249,6,2,108.945145,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
249,1,3,24.356028,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
249,2,3,36.647877,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
249,3,3,51.55538,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
249,4,3,91.46567,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
249,5,3,101.711975,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
249,6,3,126.01336,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
249,1,4,33.561104,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
249,2,4,36.238625,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
249,3,4,60.256607,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
249,4,4,93.32052,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
249,5,4,104.85582,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
249,6,4,115.36213,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
249,1,5,28.49298,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
249,2,5,34.539185,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
249,3,5,60.575443,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
249,4,5,94.78389,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
249,5,5,106.253204,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
249,6,5,127.948,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
249,1,6,25.982622,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
249,2,6,36.649685,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
249,3,6,55.164356,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
249,4,6,86.864876,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
249,5,6,105.115906,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
249,6,6,109.3403,241,6,NCGC00263184-01,MK-0752,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
250,1,1,27.71151,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
250,2,1,37.58348,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
250,3,1,54.727016,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
250,4,1,74.10187,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
250,5,1,104.16904,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
250,6,1,101.541214,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
250,1,2,17.33976,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
250,2,2,34.20209,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
250,3,2,50.206467,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
250,4,2,97.26329,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
250,5,2,103.52541,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
250,6,2,101.10084,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
250,1,3,21.18681,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
250,2,3,34.65705,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
250,3,3,47.848595,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
250,4,3,87.22267,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
250,5,3,102.81265,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
250,6,3,114.60859,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
250,1,4,20.065147,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
250,2,4,42.63083,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
250,3,4,43.01299,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
250,4,4,79.217186,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
250,5,4,103.17279,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
250,6,4,105.25851,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
250,1,5,19.706284,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
250,2,5,32.881985,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
250,3,5,55.889923,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
250,4,5,96.08384,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
250,5,5,107.95315,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
250,6,5,112.14013,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
250,1,6,23.239212,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
250,2,6,31.928476,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
250,3,6,45.552544,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
250,4,6,84.87385,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
250,5,6,105.485916,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
250,6,6,111.733116,241,6,NCGC00263188-01,YO-01027,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
251,1,1,20.316208,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
251,2,1,37.727062,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
251,3,1,61.11338,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
251,4,1,75.09965,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
251,5,1,95.345474,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
251,6,1,88.86016,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
251,1,2,30.652416,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
251,2,2,30.987522,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
251,3,2,60.5941,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
251,4,2,84.9335,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
251,5,2,118.94675,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
251,6,2,128.31157,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
251,1,3,22.445276,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
251,2,3,29.2236,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
251,3,3,54.80706,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
251,4,3,99.36746,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
251,5,3,117.96665,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
251,6,3,104.78393,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
251,1,4,23.598759,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
251,2,4,38.14823,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
251,3,4,60.38135,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
251,4,4,87.88063,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
251,5,4,97.979965,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
251,6,4,105.79365,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
251,1,5,28.190033,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
251,2,5,32.297302,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
251,3,5,54.410244,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
251,4,5,101.84877,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
251,5,5,98.07895,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
251,6,5,98.4568,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
251,1,6,24.121729,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
251,2,6,35.249294,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
251,3,6,52.747055,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
251,4,6,108.70137,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
251,5,6,101.98967,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
251,6,6,142.16847,241,6,NCGC00167803-01,GSI-IX,g-Secretase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
252,1,1,36.43071,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
252,2,1,42.685116,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
252,3,1,61.64824,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
252,4,1,104.8017,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
252,5,1,109.80189,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
252,6,1,124.40132,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
252,1,2,34.27492,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
252,2,2,38.855865,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
252,3,2,63.57126,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
252,4,2,106.59425,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
252,5,2,120.84629,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
252,6,2,123.368935,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
252,1,3,35.88065,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
252,2,3,46.301155,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
252,3,3,57.89917,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
252,4,3,108.103615,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
252,5,3,108.05182,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
252,6,3,108.623505,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
252,1,4,29.318335,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
252,2,4,40.17729,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
252,3,4,59.168575,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
252,4,4,96.24557,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
252,5,4,113.71865,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
252,6,4,125.34599,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
252,1,5,26.53713,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
252,2,5,37.553764,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
252,3,5,62.58967,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
252,4,5,109.11187,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
252,5,5,109.76077,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
252,6,5,116.48725,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
252,1,6,30.59521,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
252,2,6,35.452705,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
252,3,6,55.774025,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
252,4,6,99.51212,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
252,5,6,116.7826,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
252,6,6,123.648834,241,6,NCGC00250397-01,NVP-XAV-939,TNKS1/TNKS2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
253,1,1,19.889748,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
253,2,1,27.816896,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
253,3,1,47.282955,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
253,4,1,83.8716,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
253,5,1,106.647545,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
253,6,1,116.02437,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
253,1,2,26.169346,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
253,2,2,40.41722,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
253,3,2,58.331306,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
253,4,2,93.68747,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
253,5,2,127.2514,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
253,6,2,136.99306,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
253,1,3,31.7727,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
253,2,3,41.950817,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
253,3,3,56.93068,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
253,4,3,99.25644,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
253,5,3,110.498184,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
253,6,3,114.6251,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
253,1,4,34.01298,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
253,2,4,40.75037,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
253,3,4,58.591198,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
253,4,4,119.54123,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
253,5,4,125.33453,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
253,6,4,135.05574,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
253,1,5,29.245401,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
253,2,5,39.004025,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
253,3,5,61.86004,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
253,4,5,110.98517,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
253,5,5,126.14596,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
253,6,5,95.81876,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
253,1,6,28.805485,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
253,2,6,42.678577,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
253,3,6,51.3765,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
253,4,6,107.267654,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
253,5,6,114.89696,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
253,6,6,131.04924,241,6,NCGC00263015-01,NCGC00263015,TLR4 (LPS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
254,1,1,5.982758,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
254,2,1,6.322578,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
254,3,1,12.809989,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
254,4,1,42.00383,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
254,5,1,64.72486,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
254,6,1,63.62177,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
254,1,2,31.024813,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
254,2,2,40.392708,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
254,3,2,52.13236,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
254,4,2,98.82347,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
254,5,2,109.77285,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
254,6,2,125.832375,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
254,1,3,31.904528,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
254,2,3,43.04955,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
254,3,3,55.945396,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
254,4,3,98.97292,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
254,5,3,107.13046,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
254,6,3,125.96546,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
254,1,4,30.7636,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
254,2,4,43.497784,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
254,3,4,57.73749,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
254,4,4,104.01354,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
254,5,4,106.19923,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
254,6,4,125.18272,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
254,1,5,29.485582,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
254,2,5,40.174004,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
254,3,5,61.253586,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
254,4,5,105.37561,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
254,5,5,109.60904,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
254,6,5,127.21989,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
254,1,6,28.63244,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
254,2,6,33.396374,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
254,3,6,52.81164,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
254,4,6,79.225914,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
254,5,6,111.4441,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
254,6,6,104.10241,241,6,NCGC00263017-01,CPG-52364,"TLR 7, 8 and 9 Antagonist",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
255,1,1,25.289185,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
255,2,1,34.595085,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
255,3,1,57.405262,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
255,4,1,97.45075,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
255,5,1,123.50045,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
255,6,1,138.19571,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
255,1,2,24.606716,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
255,2,2,38.609238,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
255,3,2,49.816227,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
255,4,2,94.38387,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
255,5,2,106.63747,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
255,6,2,129.89381,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
255,1,3,33.050316,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
255,2,3,34.48054,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
255,3,3,56.895657,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
255,4,3,110.47367,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
255,5,3,100.48794,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
255,6,3,114.37235,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
255,1,4,31.845171,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
255,2,4,32.3559,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
255,3,4,52.130283,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
255,4,4,83.3852,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
255,5,4,101.81913,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
255,6,4,104.807,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
255,1,5,33.46271,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
255,2,5,34.692116,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
255,3,5,49.478764,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
255,4,5,94.05115,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
255,5,5,109.75513,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
255,6,5,112.6872,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
255,1,6,24.801916,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
255,2,6,28.783165,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
255,3,6,41.79366,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
255,4,6,96.37438,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
255,5,6,116.90875,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
255,6,6,110.38313,241,6,NCGC00186035-01,IRAK-1-4 Inhibitor I,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
256,1,1,11.009401,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
256,2,1,22.024256,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
256,3,1,31.874384,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
256,4,1,90.5315,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
256,5,1,87.68039,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
256,6,1,90.544945,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
256,1,2,23.884897,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
256,2,2,34.872955,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
256,3,2,67.76573,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
256,4,2,77.38755,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
256,5,2,93.673775,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
256,6,2,96.0608,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
256,1,3,25.50592,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
256,2,3,41.726643,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
256,3,3,58.27662,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
256,4,3,90.2289,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
256,5,3,101.96484,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
256,6,3,113.95919,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
256,1,4,27.580332,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
256,2,4,46.072018,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
256,3,4,58.283108,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
256,4,4,101.44789,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
256,5,4,102.69456,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
256,6,4,116.37468,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
256,1,5,35.84622,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
256,2,5,48.375034,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
256,3,5,85.34754,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
256,4,5,109.81838,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
256,5,5,97.31796,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
256,6,5,133.76656,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
256,1,6,27.801216,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
256,2,6,47.652252,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
256,3,6,63.819252,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
256,4,6,91.65801,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
256,5,6,144.63383,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
256,6,6,132.86731,241,6,NCGC00241410-01,NCGC00241410,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
257,1,1,23.24557,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
257,2,1,41.961414,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
257,3,1,63.03821,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
257,4,1,100.081276,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
257,5,1,115.18631,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
257,6,1,130.16104,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
257,1,2,34.177296,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
257,2,2,36.363365,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
257,3,2,67.49167,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
257,4,2,113.81317,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
257,5,2,110.69896,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
257,6,2,121.308586,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
257,1,3,29.19218,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
257,2,3,33.434006,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
257,3,3,54.22266,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
257,4,3,100.485344,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
257,5,3,114.03083,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
257,6,3,111.780945,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
257,1,4,29.042316,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
257,2,4,39.042366,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
257,3,4,72.22624,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
257,4,4,101.21365,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
257,5,4,112.12334,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
257,6,4,119.74643,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
257,1,5,26.515657,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
257,2,5,34.261906,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
257,3,5,59.28994,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
257,4,5,90.712746,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
257,5,5,112.30796,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
257,6,5,125.49814,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
257,1,6,25.900087,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
257,2,6,37.55937,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
257,3,6,50.46941,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
257,4,6,91.12185,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
257,5,6,107.32022,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
257,6,6,122.8964,241,6,NCGC00241411-01,NCGC00241411,IRAK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
258,1,1,0.922014,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
258,2,1,-0.196668,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
258,3,1,0.18293,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
258,4,1,2.11628,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
258,5,1,3.117806,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
258,6,1,4.258955,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
258,1,2,28.846642,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
258,2,2,33.638573,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
258,3,2,38.646732,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
258,4,2,103.49546,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
258,5,2,132.19566,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
258,6,2,132.05241,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
258,1,3,25.036703,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
258,2,3,37.501717,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
258,3,3,59.714176,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
258,4,3,112.24873,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
258,5,3,131.67569,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
258,6,3,136.43256,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
258,1,4,30.166185,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
258,2,4,39.109295,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
258,3,4,62.961765,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
258,4,4,105.48092,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
258,5,4,112.2098,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
258,6,4,120.27585,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
258,1,5,29.283386,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
258,2,5,38.022938,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
258,3,5,55.91678,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
258,4,5,102.03198,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
258,5,5,130.63919,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
258,6,5,136.52379,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
258,1,6,31.106474,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
258,2,6,34.610455,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
258,3,6,49.511307,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
258,4,6,83.49635,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
258,5,6,116.54346,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
258,6,6,115.31347,241,6,NCGC00263145-01,BI-78D3,SAPK1 (JNK) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
259,1,1,-0.519563,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
259,2,1,-1.519947,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
259,3,1,-1.19194,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
259,4,1,-0.717505,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
259,5,1,-0.268399,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
259,6,1,0.27249,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
259,1,2,0.061461,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
259,2,2,-1.478613,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
259,3,2,-1.413165,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
259,4,2,-1.096718,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
259,5,2,-1.159631,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
259,6,2,-0.624507,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
259,1,3,0.312387,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
259,2,3,-1.204374,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
259,3,3,-1.082357,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
259,4,3,-0.755401,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
259,5,3,-0.66015,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
259,6,3,-0.263968,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
259,1,4,1.046758,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
259,2,4,-0.59571,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
259,3,4,-0.226902,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
259,4,4,1.718572,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
259,5,4,1.655303,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
259,6,4,2.232369,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
259,1,5,5.802778,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
259,2,5,7.420629,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
259,3,5,9.488209,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
259,4,5,30.871094,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
259,5,5,57.295975,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
259,6,5,48.104324,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
259,1,6,32.328915,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
259,2,6,30.519522,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
259,3,6,62.88064,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
259,4,6,96.88147,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
259,5,6,130.47496,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
259,6,6,107.99136,241,6,NCGC00263146-01,SR-3306,JNK 1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
260,1,1,24.961252,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
260,2,1,34.625454,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
260,3,1,52.967896,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
260,4,1,66.96673,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
260,5,1,110.251366,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
260,6,1,114.25546,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
260,1,2,33.431084,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
260,2,2,43.90871,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
260,3,2,68.95865,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
260,4,2,103.75245,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
260,5,2,125.40389,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
260,6,2,116.46816,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
260,1,3,29.131878,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
260,2,3,55.775894,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
260,3,3,54.45288,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
260,4,3,106.02446,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
260,5,3,112.13041,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
260,6,3,108.07018,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
260,1,4,29.105215,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
260,2,4,38.037758,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
260,3,4,61.299618,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
260,4,4,91.912506,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
260,5,4,128.461,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
260,6,4,129.76741,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
260,1,5,26.357077,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
260,2,5,41.348038,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
260,3,5,41.559437,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
260,4,5,83.54028,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
260,5,5,116.57668,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
260,6,5,106.63206,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
260,1,6,26.566343,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
260,2,6,34.716972,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
260,3,6,51.483517,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
260,4,6,111.33695,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
260,5,6,110.289925,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
260,6,6,117.38412,241,6,NCGC00263141-01,STF-083010,Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
261,1,1,26.470158,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
261,2,1,36.816994,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
261,3,1,56.102062,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
261,4,1,100.19455,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
261,5,1,94.66731,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
261,6,1,103.14792,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
261,1,2,28.55598,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
261,2,2,43.23644,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
261,3,2,60.80356,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
261,4,2,96.09668,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
261,5,2,104.154915,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
261,6,2,119.946365,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
261,1,3,32.608486,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
261,2,3,34.64389,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
261,3,3,56.41178,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
261,4,3,109.68329,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
261,5,3,110.15,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
261,6,3,112.91293,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
261,1,4,28.386152,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
261,2,4,37.783707,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
261,3,4,51.551025,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
261,4,4,86.42775,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
261,5,4,114.057625,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
261,6,4,117.0959,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
261,1,5,30.366781,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
261,2,5,51.180527,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
261,3,5,53.94009,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
261,4,5,99.57862,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
261,5,5,132.00894,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
261,6,5,122.77152,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
261,1,6,26.711746,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
261,2,6,43.475285,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
261,3,6,67.5843,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
261,4,6,101.936775,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
261,5,6,119.67444,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
261,6,6,143.65222,241,6,NCGC00250383-01,Irestatin 9389,IRE1alpha/XBP-1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
262,1,1,34.269318,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
262,2,1,52.44663,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
262,3,1,55.99131,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
262,4,1,118.03275,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
262,5,1,128.0215,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
262,6,1,126.00822,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
262,1,2,37.055515,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
262,2,2,52.542267,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
262,3,2,63.760532,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
262,4,2,114.2498,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
262,5,2,118.239586,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
262,6,2,128.6529,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
262,1,3,33.459747,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
262,2,3,39.248653,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
262,3,3,53.710003,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
262,4,3,99.666595,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
262,5,3,118.99197,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
262,6,3,140.3224,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
262,1,4,30.458475,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
262,2,4,30.64059,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
262,3,4,69.67559,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
262,4,4,107.001015,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
262,5,4,98.157814,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
262,6,4,116.58793,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
262,1,5,22.881327,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
262,2,5,36.397423,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
262,3,5,55.594177,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
262,4,5,95.33081,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
262,5,5,105.509865,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
262,6,5,114.91496,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
262,1,6,31.602262,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
262,2,6,35.060703,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
262,3,6,65.51189,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
262,4,6,106.545135,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
262,5,6,107.07712,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
262,6,6,137.88211,241,6,NCGC00242491-01,SB-265610,CXCR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
263,1,1,50.56309,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
263,2,1,58.329453,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
263,3,1,72.82967,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
263,4,1,95.08008,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
263,5,1,106.40378,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
263,6,1,101.744316,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
263,1,2,38.758835,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
263,2,2,48.071854,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
263,3,2,54.39997,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
263,4,2,98.082954,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
263,5,2,111.04284,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
263,6,2,122.71866,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
263,1,3,41.340317,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
263,2,3,43.37643,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
263,3,3,57.902653,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
263,4,3,97.97681,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
263,5,3,113.34774,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
263,6,3,108.80986,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
263,1,4,28.841438,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
263,2,4,39.097557,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
263,3,4,50.799435,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
263,4,4,118.38712,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
263,5,4,123.9198,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
263,6,4,140.95091,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
263,1,5,28.862574,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
263,2,5,40.82649,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
263,3,5,59.499905,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
263,4,5,94.8087,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
263,5,5,107.24492,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
263,6,5,107.20267,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
263,1,6,30.211418,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
263,2,6,42.62364,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
263,3,6,59.018414,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
263,4,6,98.549385,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
263,5,6,111.349815,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
263,6,6,119.37672,241,6,NCGC00263093-01,Apilimod,PIKFyve Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
264,1,1,36.80955,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
264,2,1,27.881351,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
264,3,1,36.18552,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
264,4,1,92.50616,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
264,5,1,91.62926,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
264,6,1,107.99213,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
264,1,2,32.36645,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
264,2,2,27.688463,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
264,3,2,48.922905,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
264,4,2,95.71953,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
264,5,2,126.655174,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
264,6,2,136.27785,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
264,1,3,35.76803,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
264,2,3,40.80005,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
264,3,3,51.888622,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
264,4,3,88.03408,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
264,5,3,110.367035,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
264,6,3,123.17133,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
264,1,4,30.613247,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
264,2,4,44.923767,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
264,3,4,47.10004,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
264,4,4,109.231995,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
264,5,4,116.26276,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
264,6,4,137.0332,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
264,1,5,28.114952,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
264,2,5,39.081802,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
264,3,5,53.21079,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
264,4,5,87.10777,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
264,5,5,129.0923,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
264,6,5,120.803696,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
264,1,6,44.96196,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
264,2,6,43.318676,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
264,3,6,52.9502,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
264,4,6,110.40158,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
264,5,6,118.909966,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
264,6,6,132.272,241,6,NCGC00263128-01,PD-0220245,CXCR1/CXCR2 Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
265,1,1,33.066784,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
265,2,1,38.725136,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
265,3,1,57.96279,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
265,4,1,120.77437,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
265,5,1,126.87331,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
265,6,1,119.296555,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
265,1,2,34.21235,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
265,2,2,37.725327,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
265,3,2,49.35006,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
265,4,2,90.02631,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
265,5,2,122.85029,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
265,6,2,113.54872,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
265,1,3,27.654167,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
265,2,3,25.883532,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
265,3,3,45.938335,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
265,4,3,87.25028,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
265,5,3,114.4063,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
265,6,3,123.677635,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
265,1,4,29.587341,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
265,2,4,33.024708,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
265,3,4,58.23158,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
265,4,4,88.08397,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
265,5,4,120.1972,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
265,6,4,117.84031,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
265,1,5,25.228361,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
265,2,5,25.749304,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
265,3,5,58.44031,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
265,4,5,103.56398,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
265,5,5,119.611015,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
265,6,5,117.95148,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
265,1,6,27.65408,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
265,2,6,35.757103,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
265,3,6,51.818047,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
265,4,6,99.86795,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
265,5,6,105.53432,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
265,6,6,106.87615,241,6,NCGC00250388-01,KRP-203,S1P1/3/4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
266,1,1,5.972651,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
266,2,1,6.353731,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
266,3,1,8.70253,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
266,4,1,10.453291,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
266,5,1,8.537133,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
266,6,1,9.647115,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
266,1,2,11.4785,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
266,2,2,11.543444,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
266,3,2,29.300623,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
266,4,2,63.659428,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
266,5,2,73.31376,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
266,6,2,68.18117,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
266,1,3,16.39676,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
266,2,3,20.412258,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
266,3,3,47.595654,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
266,4,3,65.08984,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
266,5,3,103.60268,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
266,6,3,108.284325,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
266,1,4,21.399572,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
266,2,4,25.28133,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
266,3,4,44.577873,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
266,4,4,96.56115,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
266,5,4,115.68966,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
266,6,4,108.36579,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
266,1,5,25.785288,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
266,2,5,33.450424,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
266,3,5,53.949238,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
266,4,5,86.96244,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
266,5,5,119.81566,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
266,6,5,104.29015,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
266,1,6,23.369514,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
266,2,6,40.302925,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
266,3,6,58.779358,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
266,4,6,100.35946,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
266,5,6,119.78655,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
266,6,6,103.86596,241,6,NCGC00263206-01,AMG-47a,Lck Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
267,1,1,27.948963,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
267,2,1,37.983517,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
267,3,1,58.770943,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
267,4,1,98.61222,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
267,5,1,118.66677,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
267,6,1,149.71584,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
267,1,2,31.396317,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
267,2,2,40.86649,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
267,3,2,59.511124,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
267,4,2,106.31895,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
267,5,2,144.43861,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
267,6,2,113.405846,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
267,1,3,30.232002,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
267,2,3,35.304577,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
267,3,3,55.49694,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
267,4,3,83.22614,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
267,5,3,102.359856,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
267,6,3,120.984985,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
267,1,4,28.351147,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
267,2,4,39.95823,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
267,3,4,68.308266,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
267,4,4,92.663345,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
267,5,4,127.78133,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
267,6,4,108.8968,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
267,1,5,25.164352,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
267,2,5,29.76661,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
267,3,5,58.435966,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
267,4,5,100.566986,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
267,5,5,112.467224,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
267,6,5,117.581955,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
267,1,6,27.056961,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
267,2,6,36.68063,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
267,3,6,62.307945,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
267,4,6,102.30235,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
267,5,6,118.09947,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
267,6,6,117.98294,241,6,NCGC00242499-01,Pim 1 Inhibitor 2,Pim-1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
268,1,1,18.445208,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
268,2,1,24.507374,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
268,3,1,34.85969,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
268,4,1,71.82022,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
268,5,1,92.03301,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
268,6,1,109.51509,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
268,1,2,31.30655,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
268,2,2,35.660786,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
268,3,2,56.19545,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
268,4,2,97.32433,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
268,5,2,125.11298,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
268,6,2,129.2711,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
268,1,3,32.39134,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
268,2,3,39.817078,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
268,3,3,52.46099,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
268,4,3,83.99107,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
268,5,3,113.388214,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
268,6,3,129.68674,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
268,1,4,28.730537,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
268,2,4,36.407326,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
268,3,4,67.54461,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
268,4,4,117.079735,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
268,5,4,122.77154,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
268,6,4,123.44077,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
268,1,5,27.746885,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
268,2,5,38.383194,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
268,3,5,52.485428,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
268,4,5,107.109566,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
268,5,5,102.21392,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
268,6,5,163.0363,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
268,1,6,33.99656,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
268,2,6,38.97671,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
268,3,6,60.417946,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
268,4,6,105.63319,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
268,5,6,104.01623,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
268,6,6,130.31726,241,6,NCGC00263186-01,SGI-1776,Pim-1/Flt3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
269,1,1,34.129383,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
269,2,1,42.1201,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
269,3,1,53.12175,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
269,4,1,81.72364,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
269,5,1,99.812935,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
269,6,1,118.570145,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
269,1,2,28.81912,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
269,2,2,32.85919,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
269,3,2,52.62821,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
269,4,2,106.6236,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
269,5,2,125.25503,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
269,6,2,115.09245,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
269,1,3,31.86143,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
269,2,3,37.121777,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
269,3,3,57.387966,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
269,4,3,118.973885,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
269,5,3,115.515045,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
269,6,3,138.01875,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
269,1,4,30.248825,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
269,2,4,45.578094,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
269,3,4,56.829987,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
269,4,4,107.62075,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
269,5,4,113.197334,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
269,6,4,106.29866,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
269,1,5,28.39684,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
269,2,5,36.831474,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
269,3,5,67.01585,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
269,4,5,101.11436,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
269,5,5,114.473816,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
269,6,5,124.50468,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
269,1,6,28.79019,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
269,2,6,37.628788,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
269,3,6,60.129284,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
269,4,6,94.719864,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
269,5,6,105.84137,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
269,6,6,138.59172,241,6,NCGC00263193-01,KI-20227,CSF1R (c-FMS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
270,1,1,25.089834,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
270,2,1,49.180412,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
270,3,1,67.60361,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
270,4,1,110.151306,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
270,5,1,128.154,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
270,6,1,132.58168,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
270,1,2,26.446207,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
270,2,2,42.454403,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
270,3,2,61.691322,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
270,4,2,107.771324,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
270,5,2,114.69353,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
270,6,2,115.632774,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
270,1,3,27.966837,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
270,2,3,33.78153,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
270,3,3,53.52869,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
270,4,3,91.645355,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
270,5,3,109.918564,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
270,6,3,105.90755,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
270,1,4,34.15803,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
270,2,4,32.826824,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
270,3,4,56.533176,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
270,4,4,96.52269,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
270,5,4,110.7944,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
270,6,4,107.53583,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
270,1,5,28.105497,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
270,2,5,32.43885,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
270,3,5,45.75741,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
270,4,5,86.29432,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
270,5,5,116.77418,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
270,6,5,115.64001,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
270,1,6,34.75091,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
270,2,6,31.64133,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
270,3,6,48.025196,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
270,4,6,84.97747,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
270,5,6,67.13866,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
270,6,6,113.65005,241,6,NCGC00092381-02,ABT-702,Adenosine Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
271,1,1,16.068886,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
271,2,1,21.12342,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
271,3,1,27.957026,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
271,4,1,61.071945,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
271,5,1,94.80602,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
271,6,1,101.672935,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
271,1,2,24.451693,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
271,2,2,30.178679,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
271,3,2,44.550278,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
271,4,2,87.03955,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
271,5,2,101.30995,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
271,6,2,104.12312,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
271,1,3,24.181484,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
271,2,3,28.767307,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
271,3,3,52.46548,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
271,4,3,76.45441,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
271,5,3,108.602196,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
271,6,3,119.4323,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
271,1,4,26.790161,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
271,2,4,36.708164,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
271,3,4,59.64464,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
271,4,4,79.27346,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
271,5,4,113.98234,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
271,6,4,104.39107,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
271,1,5,32.723137,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
271,2,5,44.43736,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
271,3,5,63.516586,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
271,4,5,101.738655,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
271,5,5,106.03706,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
271,6,5,101.45917,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
271,1,6,26.59041,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
271,2,6,39.04437,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
271,3,6,67.66538,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
271,4,6,96.091576,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
271,5,6,125.308945,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
271,6,6,130.10309,241,6,NCGC00263090-01,AZ-3146,MPS1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
272,1,1,6.711186,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
272,2,1,4.210299,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
272,3,1,11.389132,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
272,4,1,16.249207,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
272,5,1,21.376822,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
272,6,1,22.45872,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
272,1,2,13.275279,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
272,2,2,17.86411,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
272,3,2,35.555058,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
272,4,2,27.877617,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
272,5,2,36.753635,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
272,6,2,44.43893,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
272,1,3,8.790875,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
272,2,3,10.703343,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
272,3,3,16.503246,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
272,4,3,38.294125,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
272,5,3,41.47776,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
272,6,3,57.898117,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
272,1,4,10.077236,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
272,2,4,14.957837,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
272,3,4,20.99426,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
272,4,4,49.39974,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
272,5,4,61.304417,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
272,6,4,55.96527,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
272,1,5,27.035828,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
272,2,5,35.94261,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
272,3,5,49.114388,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
272,4,5,96.582596,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
272,5,5,102.64211,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
272,6,5,110.45309,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
272,1,6,35.83128,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
272,2,6,34.39599,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
272,3,6,57.284725,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
272,4,6,99.00879,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
272,5,6,113.76796,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
272,6,6,123.4496,241,6,NCGC00263183-01,MK-1775,Wee1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
273,1,1,25.074644,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
273,2,1,33.628242,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
273,3,1,44.43518,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
273,4,1,103.81074,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
273,5,1,110.1174,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
273,6,1,118.216034,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
273,1,2,35.383465,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
273,2,2,34.09722,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
273,3,2,65.52699,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
273,4,2,117.795296,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
273,5,2,106.293015,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
273,6,2,125.89016,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
273,1,3,11.793821,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
273,2,3,11.415676,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
273,3,3,20.302485,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
273,4,3,38.79955,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
273,5,3,56.583775,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
273,6,3,63.305157,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
273,1,4,23.178358,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
273,2,4,29.125237,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
273,3,4,52.140865,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
273,4,4,83.55272,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
273,5,4,104.31686,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
273,6,4,107.30415,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
273,1,5,25.102121,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
273,2,5,43.474724,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
273,3,5,54.13986,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
273,4,5,97.74137,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
273,5,5,111.076035,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
273,6,5,104.24929,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
273,1,6,27.059242,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
273,2,6,34.968193,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
273,3,6,50.906467,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
273,4,6,92.262,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
273,5,6,113.604324,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
273,6,6,107.16248,241,6,NCGC00263197-01,BMS-5,LIMK1/LIMK2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
274,1,1,16.325905,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
274,2,1,17.40128,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
274,3,1,14.02004,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
274,4,1,21.86381,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
274,5,1,18.746552,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
274,6,1,22.928116,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
274,1,2,21.785675,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
274,2,2,24.746977,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
274,3,2,38.569252,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
274,4,2,106.52636,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
274,5,2,96.152756,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
274,6,2,103.156075,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
274,1,3,9.66075,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
274,2,3,14.371508,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
274,3,3,21.039227,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
274,4,3,33.772877,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
274,5,3,46.04451,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
274,6,3,59.68319,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
274,1,4,20.131159,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
274,2,4,30.770847,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
274,3,4,48.48367,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
274,4,4,94.070076,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
274,5,4,95.04575,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
274,6,4,106.551865,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
274,1,5,28.46399,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
274,2,5,37.991444,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
274,3,5,52.36168,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
274,4,5,104.24605,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
274,5,5,116.550964,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
274,6,5,114.86811,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
274,1,6,32.224518,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
274,2,6,31.430035,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
274,3,6,43.249184,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
274,4,6,103.27355,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
274,5,6,111.49108,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
274,6,6,117.25094,241,6,NCGC00263199-01,AMG-Tie2-1,Tie-2 kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
275,1,1,20.36507,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
275,2,1,18.7435,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
275,3,1,27.004318,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
275,4,1,55.30558,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
275,5,1,84.54845,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
275,6,1,97.30499,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
275,1,2,23.031961,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
275,2,2,31.508568,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
275,3,2,53.1953,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
275,4,2,101.52211,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
275,5,2,127.18384,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
275,6,2,105.23987,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
275,1,3,27.286722,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
275,2,3,26.733889,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
275,3,3,55.958347,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
275,4,3,98.50328,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
275,5,3,110.23266,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
275,6,3,124.60017,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
275,1,4,32.83468,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
275,2,4,37.156487,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
275,3,4,45.446102,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
275,4,4,60.07568,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
275,5,4,119.744865,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
275,6,4,104.43293,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
275,1,5,28.067171,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
275,2,5,34.192783,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
275,3,5,53.339104,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
275,4,5,97.919334,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
275,5,5,107.232765,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
275,6,5,105.14084,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
275,1,6,31.13521,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
275,2,6,40.855984,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
275,3,6,49.02669,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
275,4,6,87.55009,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
275,5,6,104.731865,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
275,6,6,113.28982,241,6,NCGC00263217-01,NVP-231,Ceramide kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
276,1,1,24.627583,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
276,2,1,32.383556,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
276,3,1,48.46307,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
276,4,1,67.89402,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
276,5,1,92.560135,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
276,6,1,89.255486,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
276,1,2,25.943274,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
276,2,2,29.988428,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
276,3,2,37.718006,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
276,4,2,75.72052,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
276,5,2,96.390686,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
276,6,2,88.276054,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
276,1,3,24.31023,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
276,2,3,28.150848,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
276,3,3,40.686302,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
276,4,3,81.168526,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
276,5,3,101.35191,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
276,6,3,97.16405,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
276,1,4,23.686377,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
276,2,4,33.803627,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
276,3,4,48.02127,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
276,4,4,76.72555,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
276,5,4,99.719536,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
276,6,4,105.02107,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
276,1,5,31.423943,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
276,2,5,30.934006,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
276,3,5,58.103024,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
276,4,5,82.12728,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
276,5,5,111.96239,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
276,6,5,100.13894,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
276,1,6,26.346851,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
276,2,6,38.787453,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
276,3,6,56.14553,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
276,4,6,97.104355,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
276,5,6,94.2086,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
276,6,6,111.92647,241,6,NCGC00263224-01,D-NMAPPD,Ceramidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
277,1,1,25.597658,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
277,2,1,37.983517,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
277,3,1,50.92419,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
277,4,1,66.63955,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
277,5,1,104.16122,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
277,6,1,101.740715,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
277,1,2,31.766651,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
277,2,2,38.940044,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
277,3,2,64.23746,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
277,4,2,69.945145,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
277,5,2,107.35005,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
277,6,2,111.133286,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
277,1,3,37.05704,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
277,2,3,42.368607,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
277,3,3,46.731056,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
277,4,3,83.25812,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
277,5,3,113.94161,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
277,6,3,108.94468,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
277,1,4,39.657017,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
277,2,4,34.879047,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
277,3,4,54.607357,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
277,4,4,114.56239,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
277,5,4,103.53681,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
277,6,4,102.37038,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
277,1,5,32.266117,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
277,2,5,24.096296,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
277,3,5,61.332207,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
277,4,5,117.84803,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
277,5,5,109.30528,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
277,6,5,99.80668,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
277,1,6,27.462835,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
277,2,6,30.638308,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
277,3,6,51.670597,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
277,4,6,100.156624,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
277,5,6,107.0799,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
277,6,6,110.63594,241,6,NCGC00188865-01,Pazopanib,VEGFR-1/2/3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
278,1,1,25.574228,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
278,2,1,30.218782,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
278,3,1,44.2398,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
278,4,1,100.64851,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
278,5,1,105.44286,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
278,6,1,119.89742,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
278,1,2,30.049578,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
278,2,2,34.507587,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
278,3,2,47.745743,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
278,4,2,88.453606,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
278,5,2,109.657875,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
278,6,2,109.34203,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
278,1,3,32.057903,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
278,2,3,39.231033,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
278,3,3,51.589634,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
278,4,3,100.56435,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
278,5,3,102.10365,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
278,6,3,108.608406,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
278,1,4,30.957615,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
278,2,4,33.77698,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
278,3,4,50.033775,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
278,4,4,107.458275,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
278,5,4,107.19487,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
278,6,4,101.59556,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
278,1,5,24.998362,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
278,2,5,32.774937,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
278,3,5,50.96867,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
278,4,5,100.520744,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
278,5,5,91.8158,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
278,6,5,107.79739,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
278,1,6,30.002285,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
278,2,6,38.73929,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
278,3,6,69.85167,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
278,4,6,95.59975,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
278,5,6,105.032555,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
278,6,6,95.61221,241,6,NCGC00244252-01,TG-101348,Jak2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
279,1,1,3.388013,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
279,2,1,2.027431,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
279,3,1,3.270057,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
279,4,1,5.604317,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
279,5,1,5.292582,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
279,6,1,4.945871,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
279,1,2,7.609265,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
279,2,2,4.625718,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
279,3,2,4.550134,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
279,4,2,7.617238,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
279,5,2,11.418433,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
279,6,2,8.85441,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
279,1,3,27.274658,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
279,2,3,32.929928,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
279,3,3,60.35435,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
279,4,3,87.91724,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
279,5,3,107.32083,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
279,6,3,116.80293,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
279,1,4,29.751759,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
279,2,4,42.532036,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
279,3,4,50.250023,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
279,4,4,79.18851,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
279,5,4,108.5832,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
279,6,4,105.13295,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
279,1,5,28.916758,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
279,2,5,44.861816,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
279,3,5,59.125908,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
279,4,5,82.84303,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
279,5,5,110.7067,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
279,6,5,118.87305,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
279,1,6,30.266846,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
279,2,6,30.989168,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
279,3,6,52.59485,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
279,4,6,99.9589,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
279,5,6,96.02729,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
279,6,6,103.269615,241,6,NCGC00242478-02,Alvespimycin hydrochloride,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
280,1,1,29.060799,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
280,2,1,35.42889,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
280,3,1,57.712624,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
280,4,1,79.465385,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
280,5,1,99.91284,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
280,6,1,103.71619,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
280,1,2,33.84108,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
280,2,2,37.089706,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
280,3,2,66.0095,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
280,4,2,101.10156,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
280,5,2,104.36851,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
280,6,2,107.688156,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
280,1,3,27.994595,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
280,2,3,48.570057,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
280,3,3,50.88006,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
280,4,3,91.72064,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
280,5,3,100.93036,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
280,6,3,101.28441,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
280,1,4,23.025309,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
280,2,4,37.311344,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
280,3,4,49.890476,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
280,4,4,81.70881,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
280,5,4,104.54287,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
280,6,4,106.23484,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
280,1,5,30.041767,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
280,2,5,33.61299,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
280,3,5,61.63154,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
280,4,5,91.22722,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
280,5,5,107.40172,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
280,6,5,84.487015,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
280,1,6,29.570475,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
280,2,6,32.656017,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
280,3,6,43.71735,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
280,4,6,79.69645,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
280,5,6,104.293396,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
280,6,6,104.658356,241,6,NCGC00161410-01,CCT-018159,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
281,1,1,-0.866553,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
281,2,1,0.986374,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
281,3,1,1.050871,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
281,4,1,2.696421,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
281,5,1,4.115591,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
281,6,1,5.297668,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
281,1,2,0.358837,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
281,2,2,1.961989,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
281,3,2,4.112508,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
281,4,2,8.469618,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
281,5,2,9.29527,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
281,6,2,9.88218,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
281,1,3,10.059508,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
281,2,3,8.834453,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
281,3,3,24.750854,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
281,4,3,47.8579,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
281,5,3,50.372047,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
281,6,3,55.081474,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
281,1,4,13.065027,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
281,2,4,20.439987,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
281,3,4,43.08098,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
281,4,4,79.01325,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
281,5,4,102.07737,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
281,6,4,97.49307,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
281,1,5,17.324507,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
281,2,5,18.743296,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
281,3,5,72.308044,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
281,4,5,92.10848,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
281,5,5,108.383514,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
281,6,5,114.18958,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
281,1,6,22.134893,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
281,2,6,28.024052,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
281,3,6,51.885002,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
281,4,6,108.049934,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
281,5,6,101.42641,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
281,6,6,122.37963,241,6,NCGC00247877-01,CNF-2024,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
282,1,1,1.163259,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
282,2,1,2.730027,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
282,3,1,5.428111,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
282,4,1,4.637455,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
282,5,1,5.782858,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
282,6,1,7.090174,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
282,1,2,2.194305,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
282,2,2,2.560071,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
282,3,2,4.351249,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
282,4,2,7.723374,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
282,5,2,6.749285,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
282,6,2,8.771574,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
282,1,3,2.226096,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
282,2,3,3.815756,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
282,3,3,6.184566,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
282,4,3,8.367852,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
282,5,3,8.019393,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
282,6,3,7.943145,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
282,1,4,1.321769,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
282,2,4,2.485441,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
282,3,4,4.37721,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
282,4,4,6.745287,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
282,5,4,8.770048,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
282,6,4,9.613632,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
282,1,5,0.581279,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
282,2,5,2.286472,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
282,3,5,5.669661,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
282,4,5,6.261608,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
282,5,5,9.167574,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
282,6,5,8.098236,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
282,1,6,21.930447,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
282,2,6,31.79216,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
282,3,6,48.699833,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
282,4,6,96.91472,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
282,5,6,115.325096,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
282,6,6,98.91552,241,6,NCGC00247878-01,NVP-AUY922,Heat Shock Protein 90 (hsp90) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
283,1,1,18.997559,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
283,2,1,25.926476,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
283,3,1,31.69346,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
283,4,1,33.880486,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
283,5,1,11.156057,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
283,6,1,54.93469,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
283,1,2,0.407828,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
283,2,2,8.739768,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
283,3,2,6.601413,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
283,4,2,18.970911,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
283,5,2,32.541515,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
283,6,2,26.576906,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
283,1,3,4.863895,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
283,2,3,19.710424,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
283,3,3,5.327444,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
283,4,3,17.15339,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
283,5,3,28.57769,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
283,6,3,17.931807,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
283,1,4,15.202222,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
283,2,4,18.108646,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
283,3,4,33.486774,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
283,4,4,37.80564,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
283,5,4,52.717415,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
283,6,4,61.39189,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
283,1,5,20.904802,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
283,2,5,17.933424,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
283,3,5,43.269188,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
283,4,5,57.02605,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
283,5,5,69.26366,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
283,6,5,73.03786,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
283,1,6,22.31419,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
283,2,6,23.880745,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
283,3,6,50.89629,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
283,4,6,92.89349,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
283,5,6,106.85764,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
283,6,6,106.24215,241,6,NCGC00183656-02,Elesclomol (STA-4783),Copper Chelator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
284,1,1,15.716501,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
284,2,1,23.693375,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
284,3,1,34.47721,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
284,4,1,70.243835,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
284,5,1,110.55056,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
284,6,1,109.69069,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
284,1,2,26.845316,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
284,2,2,32.006832,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
284,3,2,43.569405,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
284,4,2,70.86948,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
284,5,2,115.3263,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
284,6,2,112.29435,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
284,1,3,27.346195,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
284,2,3,31.27254,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
284,3,3,57.145046,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
284,4,3,106.30781,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
284,5,3,114.55903,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
284,6,3,125.76325,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
284,1,4,22.296486,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
284,2,4,28.94956,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
284,3,4,49.107555,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
284,4,4,114.78727,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
284,5,4,122.983696,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
284,6,4,124.19073,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
284,1,5,25.58844,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
284,2,5,22.898857,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
284,3,5,58.095543,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
284,4,5,103.83949,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
284,5,5,107.03743,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
284,6,5,103.803825,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
284,1,6,21.337614,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
284,2,6,27.157665,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
284,3,6,49.12114,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
284,4,6,94.533966,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
284,5,6,110.95042,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
284,6,6,118.296135,241,6,NCGC00263143-01,VER-155008,Heat Shock Protein 70 (hsp70) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
285,1,1,-0.739743,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
285,2,1,-0.206325,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
285,3,1,0.047388,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
285,4,1,0.884944,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
285,5,1,1.595399,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
285,6,1,1.529407,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
285,1,2,1.381886,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
285,2,2,2.208041,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
285,3,2,5.849171,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
285,4,2,16.517244,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
285,5,2,26.0305,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
285,6,2,31.338638,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
285,1,3,4.710468,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
285,2,3,6.92385,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
285,3,3,14.616762,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
285,4,3,40.628017,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
285,5,3,53.757816,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
285,6,3,83.621895,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
285,1,4,12.290808,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
285,2,4,13.235563,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
285,3,4,25.242376,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
285,4,4,79.6543,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
285,5,4,106.12341,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
285,6,4,111.821075,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
285,1,5,19.533615,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
285,2,5,22.246046,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
285,3,5,51.973656,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
285,4,5,94.8735,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
285,5,5,101.25468,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
285,6,5,107.6977,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
285,1,6,22.88674,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
285,2,6,27.81997,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
285,3,6,40.68995,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
285,4,6,90.28881,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
285,5,6,101.862114,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
285,6,6,110.07492,241,6,NCGC00250390-01,ISOX,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
286,1,1,-1.668564,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
286,2,1,-1.41827,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
286,3,1,-1.251244,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
286,4,1,-0.775379,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
286,5,1,-0.323338,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
286,6,1,-0.262184,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
286,1,2,2.931209,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
286,2,2,2.699442,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
286,3,2,6.343411,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
286,4,2,27.365807,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
286,5,2,38.8282,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
286,6,2,36.653492,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
286,1,3,10.420756,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
286,2,3,15.00014,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
286,3,3,26.681328,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
286,4,3,65.196815,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
286,5,3,80.72814,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
286,6,3,86.20729,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
286,1,4,15.143357,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
286,2,4,25.492199,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
286,3,4,47.13366,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
286,4,4,80.603134,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
286,5,4,106.50354,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
286,6,4,99.6241,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
286,1,5,21.742374,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
286,2,5,30.354477,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
286,3,5,54.990852,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
286,4,5,101.98134,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
286,5,5,111.9221,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
286,6,5,115.49763,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
286,1,6,23.270071,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
286,2,6,35.247032,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
286,3,6,51.806126,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
286,4,6,112.62083,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
286,5,6,136.2986,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
286,6,6,118.698166,241,6,NCGC00168085-04,Vorinostat (SAHA),HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
287,1,1,-1.639842,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
287,2,1,-1.834858,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
287,3,1,-1.050261,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
287,4,1,-0.411765,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
287,5,1,0.338401,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
287,6,1,0.167255,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
287,1,2,0.121347,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
287,2,2,-0.520674,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
287,3,2,1.226627,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
287,4,2,2.319056,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
287,5,2,3.467328,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
287,6,2,4.206658,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
287,1,3,3.054998,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
287,2,3,7.825766,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
287,3,3,11.98908,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
287,4,3,37.10414,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
287,5,3,46.572987,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
287,6,3,39.666306,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
287,1,4,13.286156,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
287,2,4,22.514944,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
287,3,4,41.94536,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
287,4,4,63.942303,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
287,5,4,89.909996,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
287,6,4,105.02151,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
287,1,5,21.887423,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
287,2,5,31.148003,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
287,3,5,47.90524,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
287,4,5,76.09742,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
287,5,5,113.26968,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
287,6,5,107.67858,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
287,1,6,29.810055,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
287,2,6,30.534079,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
287,3,6,53.877453,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
287,4,6,97.19487,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
287,5,6,111.49626,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
287,6,6,124.77613,241,6,NCGC00263153-01,AR-42,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
288,1,1,0.104681,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
288,2,1,-0.553823,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
288,3,1,0.44409,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
288,4,1,2.319254,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
288,5,1,2.228141,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
288,6,1,2.770975,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
288,1,2,2.476924,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
288,2,2,2.766488,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
288,3,2,9.336477,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
288,4,2,40.867386,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
288,5,2,49.217075,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
288,6,2,51.01323,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
288,1,3,6.4404,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
288,2,3,12.649309,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
288,3,3,21.918665,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
288,4,3,56.94298,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
288,5,3,67.496086,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
288,6,3,100.804756,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
288,1,4,14.51991,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
288,2,4,27.546614,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
288,3,4,38.287304,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
288,4,4,83.10939,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
288,5,4,108.51678,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
288,6,4,106.87063,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
288,1,5,21.5335,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
288,2,5,27.869661,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
288,3,5,54.18893,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
288,4,5,84.45272,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
288,5,5,106.529495,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
288,6,5,116.63047,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
288,1,6,30.444567,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
288,2,6,33.56081,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
288,3,6,53.65974,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
288,4,6,97.259445,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
288,5,6,102.06771,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
288,6,6,119.66991,241,6,NCGC00263155-01,Belinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
289,1,1,1.942545,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
289,2,1,0.878488,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
289,3,1,1.593385,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
289,4,1,3.031754,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
289,5,1,4.463104,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
289,6,1,5.151627,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
289,1,2,40.454872,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
289,2,2,40.040512,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
289,3,2,56.12371,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
289,4,2,78.73355,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
289,5,2,86.438126,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
289,6,2,93.068275,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
289,1,3,55.71721,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
289,2,3,61.10729,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
289,3,3,69.42798,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
289,4,3,107.79303,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
289,5,3,110.180046,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
289,6,3,111.38633,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
289,1,4,43.761734,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
289,2,4,39.704964,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
289,3,4,58.83428,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
289,4,4,101.366,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
289,5,4,120.29562,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
289,6,4,126.222786,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
289,1,5,42.47267,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
289,2,5,43.4286,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
289,3,5,59.267,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
289,4,5,113.18864,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
289,5,5,119.39696,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
289,6,5,131.24109,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
289,1,6,25.08727,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
289,2,6,37.482822,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
289,3,6,60.145866,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
289,4,6,113.4235,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
289,5,6,111.42528,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
289,6,6,120.00408,241,6,NCGC00263182-01,Mocetinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
290,1,1,-0.623111,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
290,2,1,-0.786627,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
290,3,1,-0.216642,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
290,4,1,0.575311,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
290,5,1,0.413612,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
290,6,1,0.538668,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
290,1,2,-1.398323,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
290,2,2,-1.784646,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
290,3,2,-1.54183,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
290,4,2,-1.381184,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
290,5,2,-1.071932,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
290,6,2,-1.315741,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
290,1,3,-0.932073,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
290,2,3,-1.534626,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
290,3,3,-1.367478,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
290,4,3,-1.190975,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
290,5,3,-1.028741,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
290,6,3,-0.70664,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
290,1,4,0.207134,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
290,2,4,-0.770083,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
290,3,4,-0.86782,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
290,4,4,0.327825,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
290,5,4,2.292821,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
290,6,4,3.439506,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
290,1,5,1.182337,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
290,2,5,1.313573,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
290,3,5,1.938883,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
290,4,5,11.954695,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
290,5,5,18.093445,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
290,6,5,19.398396,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
290,1,6,28.044655,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
290,2,6,26.803804,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
290,3,6,47.874275,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
290,4,6,100.52197,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
290,5,6,102.9188,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
290,6,6,116.48271,241,6,NCGC00263117-01,Panobinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
291,1,1,-2.362354,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
291,2,1,-2.027081,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
291,3,1,-1.652219,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
291,4,1,-1.590973,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
291,5,1,-1.831729,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
291,6,1,-1.270733,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
291,1,2,-1.326683,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
291,2,2,-1.408075,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
291,3,2,-1.51967,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
291,4,2,-0.955515,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
291,5,2,0.033836,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
291,6,2,0.558951,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
291,1,3,0.33979,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
291,2,3,-0.322636,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
291,3,3,1.864817,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
291,4,3,10.117335,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
291,5,3,29.379168,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
291,6,3,43.180504,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
291,1,4,10.014958,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
291,2,4,12.469783,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
291,3,4,24.50993,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
291,4,4,67.62687,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
291,5,4,83.322105,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
291,6,4,81.56313,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
291,1,5,13.669549,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
291,2,5,14.659113,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
291,3,5,34.700783,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
291,4,5,93.40306,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
291,5,5,115.47425,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
291,6,5,110.43663,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
291,1,6,33.714043,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
291,2,6,31.979149,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
291,3,6,47.51916,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
291,4,6,98.55992,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
291,5,6,155.25748,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
291,6,6,100.14552,241,6,NCGC00263136-01,Pracinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
292,1,1,-0.308564,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
292,2,1,-1.460728,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
292,3,1,-1.566493,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
292,4,1,-0.646477,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
292,5,1,0.797722,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
292,6,1,0.308107,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
292,1,2,-2.20566,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
292,2,2,-1.633294,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
292,3,2,-1.541387,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
292,4,2,-1.48994,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
292,5,2,-1.357848,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
292,6,2,-0.933614,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
292,1,3,-0.782262,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
292,2,3,-1.343471,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
292,3,3,-1.596986,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
292,4,3,-1.448,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
292,5,3,-1.277067,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
292,6,3,-0.795616,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
292,1,4,-0.41062,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
292,2,4,-1.976259,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
292,3,4,-1.207275,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
292,4,4,-1.104333,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
292,5,4,-1.066423,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
292,6,4,-0.49975,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
292,1,5,0.323368,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
292,2,5,-0.557867,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
292,3,5,0.188698,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
292,4,5,1.178414,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
292,5,5,1.455066,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
292,6,5,1.732557,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
292,1,6,23.74705,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
292,2,6,36.088924,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
292,3,6,54.77398,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
292,4,6,107.11702,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
292,5,6,120.902176,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
292,6,6,106.84551,241,6,NCGC00263220-01,Romidepsin,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
293,1,1,17.837214,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
293,2,1,25.138565,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
293,3,1,41.39204,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
293,4,1,77.32098,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
293,5,1,109.946205,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
293,6,1,121.175606,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
293,1,2,20.783653,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
293,2,2,31.45234,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
293,3,2,57.45128,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
293,4,2,103.88073,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
293,5,2,124.14644,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
293,6,2,116.27669,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
293,1,3,23.45732,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
293,2,3,31.547115,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
293,3,3,54.876434,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
293,4,3,111.26907,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
293,5,3,105.360214,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
293,6,3,112.75416,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
293,1,4,27.673225,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
293,2,4,34.242573,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
293,3,4,51.971825,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
293,4,4,88.60815,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
293,5,4,126.22935,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
293,6,4,116.16801,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
293,1,5,25.459995,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
293,2,5,31.437428,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
293,3,5,49.714672,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
293,4,5,98.95441,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
293,5,5,123.14033,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
293,6,5,113.526024,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
293,1,6,26.20673,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
293,2,6,26.896427,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
293,3,6,61.90579,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
293,4,6,86.82843,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
293,5,6,106.569534,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
293,6,6,113.79237,241,6,NCGC00182052-02,SRT-1720,Histone Deacetylase/SIRT1 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
294,1,1,23.912062,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
294,2,1,35.10745,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
294,3,1,46.572132,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
294,4,1,93.819496,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
294,5,1,111.186035,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
294,6,1,114.7934,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
294,1,2,24.497278,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
294,2,2,35.411007,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
294,3,2,62.84105,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
294,4,2,117.81483,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
294,5,2,120.560646,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
294,6,2,126.357086,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
294,1,3,27.799778,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
294,2,3,36.14463,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
294,3,3,62.6937,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
294,4,3,113.519646,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
294,5,3,120.0819,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
294,6,3,134.66685,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
294,1,4,27.976692,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
294,2,4,28.431421,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
294,3,4,52.459473,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
294,4,4,103.05511,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
294,5,4,119.12031,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
294,6,4,110.789604,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
294,1,5,33.314148,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
294,2,5,33.672894,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
294,3,5,68.913826,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
294,4,5,100.68335,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
294,5,5,114.39612,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
294,6,5,117.52004,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
294,1,6,29.37323,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
294,2,6,36.937515,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
294,3,6,57.682495,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
294,4,6,109.07742,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
294,5,6,113.19483,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
294,6,6,121.35535,241,6,NCGC00242458-01,Selisistat,Histone Deacetylase SIRT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
295,1,1,0.440274,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
295,2,1,0.96603,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
295,3,1,1.243857,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
295,4,1,3.229182,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
295,5,1,4.016206,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
295,6,1,6.329172,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
295,1,2,11.665697,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
295,2,2,17.38531,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
295,3,2,26.884676,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
295,4,2,49.62771,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
295,5,2,66.40463,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
295,6,2,75.25357,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
295,1,3,31.240686,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
295,2,3,43.189613,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
295,3,3,50.998898,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
295,4,3,86.25736,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
295,5,3,110.85821,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
295,6,3,105.46425,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
295,1,4,37.62967,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
295,2,4,44.077793,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
295,3,4,60.307827,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
295,4,4,111.60949,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
295,5,4,112.507065,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
295,6,4,110.08545,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
295,1,5,32.309093,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
295,2,5,38.218,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
295,3,5,56.88996,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
295,4,5,96.86297,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
295,5,5,112.7418,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
295,6,5,129.22021,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
295,1,6,32.404266,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
295,2,6,30.923317,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
295,3,6,51.22613,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
295,4,6,91.11791,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
295,5,6,113.26873,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
295,6,6,126.19954,241,6,NCGC00165833-04,Entinostat,HDAC Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
296,1,1,20.036081,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
296,2,1,25.18336,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
296,3,1,35.127823,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
296,4,1,81.43535,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
296,5,1,106.3539,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
296,6,1,98.311104,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
296,1,2,24.641502,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
296,2,2,23.653633,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
296,3,2,55.445793,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
296,4,2,76.3433,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
296,5,2,87.74013,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
296,6,2,106.10917,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
296,1,3,26.447348,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
296,2,3,30.019844,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
296,3,3,46.468456,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
296,4,3,81.68945,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
296,5,3,112.14132,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
296,6,3,113.83102,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
296,1,4,31.674978,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
296,2,4,39.18241,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
296,3,4,60.94078,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
296,4,4,114.61856,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
296,5,4,99.05512,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
296,6,4,111.00445,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
296,1,5,25.70666,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
296,2,5,30.958038,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
296,3,5,54.557247,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
296,4,5,98.27731,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
296,5,5,118.38051,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
296,6,5,131.10028,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
296,1,6,17.810322,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
296,2,6,30.4042,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
296,3,6,62.246677,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
296,4,6,115.75975,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
296,5,6,125.30601,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
296,6,6,132.92412,241,6,NCGC00263121-01,MG-149,Histone acetyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
297,1,1,25.78898,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
297,2,1,35.86305,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
297,3,1,60.454018,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
297,4,1,94.41257,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
297,5,1,115.70605,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
297,6,1,125.861855,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
297,1,2,23.072582,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
297,2,2,33.876396,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
297,3,2,74.85416,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
297,4,2,122.21375,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
297,5,2,107.81739,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
297,6,2,105.46182,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
297,1,3,30.89319,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
297,2,3,35.51273,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
297,3,3,59.837273,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
297,4,3,111.065735,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
297,5,3,127.76544,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
297,6,3,113.83324,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
297,1,4,24.136213,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
297,2,4,39.016563,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
297,3,4,49.790432,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
297,4,4,100.34495,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
297,5,4,110.71093,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
297,6,4,119.26661,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
297,1,5,26.647507,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
297,2,5,39.413616,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
297,3,5,48.84392,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
297,4,5,90.65063,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
297,5,5,108.566376,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
297,6,5,122.88647,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
297,1,6,30.403345,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
297,2,6,35.358383,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
297,3,6,53.774982,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
297,4,6,97.58107,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
297,5,6,119.32682,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
297,6,6,106.03149,241,6,NCGC00250404-01,Veliparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
298,1,1,25.098383,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
298,2,1,31.826681,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
298,3,1,49.97945,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
298,4,1,82.11903,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
298,5,1,115.91214,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
298,6,1,120.096886,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
298,1,2,26.72284,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
298,2,2,40.247814,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
298,3,2,57.214367,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
298,4,2,97.681145,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
298,5,2,124.65693,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
298,6,2,112.83451,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
298,1,3,36.02235,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
298,2,3,34.406044,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
298,3,3,49.87707,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
298,4,3,97.52346,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
298,5,3,114.25094,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
298,6,3,116.04939,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
298,1,4,25.142763,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
298,2,4,36.44735,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
298,3,4,64.2852,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
298,4,4,88.883865,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
298,5,4,118.07247,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
298,6,4,107.17714,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
298,1,5,24.32984,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
298,2,5,32.969627,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
298,3,5,41.291786,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
298,4,5,103.10095,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
298,5,5,115.51578,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
298,6,5,126.08366,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
298,1,6,30.93522,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
298,2,6,28.830229,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
298,3,6,49.026924,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
298,4,6,117.15446,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
298,5,6,130.54886,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
298,6,6,124.2065,241,6,NCGC00238451-02,Olaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
299,1,1,28.04644,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
299,2,1,36.07325,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
299,3,1,48.75502,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
299,4,1,106.251945,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
299,5,1,121.96382,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
299,6,1,125.02958,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
299,1,2,27.166685,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
299,2,2,35.79208,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
299,3,2,55.38137,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
299,4,2,117.07926,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
299,5,2,118.35148,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
299,6,2,125.456566,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
299,1,3,34.616276,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
299,2,3,35.07691,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
299,3,3,58.23258,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
299,4,3,100.632225,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
299,5,3,112.61106,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
299,6,3,118.88409,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
299,1,4,29.340464,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
299,2,4,36.528893,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
299,3,4,56.21093,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
299,4,4,86.90904,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
299,5,4,131.38185,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
299,6,4,106.67604,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
299,1,5,30.267057,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
299,2,5,39.489635,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
299,3,5,58.279877,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
299,4,5,86.52893,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
299,5,5,115.25953,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
299,6,5,124.78147,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
299,1,6,23.492254,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
299,2,6,38.131054,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
299,3,6,58.803295,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
299,4,6,87.92109,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
299,5,6,106.96364,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
299,6,6,107.549355,241,6,NCGC00168108-03,AG-14361,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
300,1,1,18.542007,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
300,2,1,32.62651,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
300,3,1,52.120567,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
300,4,1,116.94701,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
300,5,1,115.74725,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
300,6,1,121.82621,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
300,1,2,26.507158,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
300,2,2,38.956448,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
300,3,2,52.418083,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
300,4,2,81.57487,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
300,5,2,117.683174,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
300,6,2,120.1169,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
300,1,3,24.149628,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
300,2,3,30.566677,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
300,3,3,50.1605,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
300,4,3,90.13819,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
300,5,3,109.52794,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
300,6,3,123.32614,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
300,1,4,25.01223,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
300,2,4,31.138357,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
300,3,4,60.44918,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
300,4,4,120.56959,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
300,5,4,112.97117,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
300,6,4,130.2629,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
300,1,5,27.907465,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
300,2,5,30.976793,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
300,3,5,56.864414,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
300,4,5,91.21898,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
300,5,5,118.9598,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
300,6,5,115.91139,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
300,1,6,25.669268,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
300,2,6,32.827785,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
300,3,6,46.212563,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
300,4,6,107.53368,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
300,5,6,116.87854,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
300,6,6,122.40506,241,6,NCGC00263173-01,Rucaparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
301,1,1,17.067238,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
301,2,1,24.22461,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
301,3,1,38.797325,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
301,4,1,80.32085,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
301,5,1,76.89584,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
301,6,1,106.578735,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
301,1,2,15.035868,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
301,2,2,31.96288,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
301,3,2,42.176655,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
301,4,2,87.21306,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
301,5,2,112.867325,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
301,6,2,106.09565,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
301,1,3,27.97909,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
301,2,3,33.77625,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
301,3,3,59.136356,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
301,4,3,89.37278,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
301,5,3,106.97342,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
301,6,3,111.68247,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
301,1,4,27.78824,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
301,2,4,27.55951,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
301,3,4,49.766533,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
301,4,4,86.67638,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
301,5,4,113.967186,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
301,6,4,116.61205,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
301,1,5,29.230974,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
301,2,5,38.636147,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
301,3,5,58.56292,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
301,4,5,97.33385,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
301,5,5,115.10783,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
301,6,5,116.62638,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
301,1,6,28.848604,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
301,2,6,32.68301,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
301,3,6,50.902336,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
301,4,6,108.55702,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
301,5,6,121.831184,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
301,6,6,147.49013,241,6,NCGC00263096-01,Iniparib,PARP Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
302,1,1,1.015525,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
302,2,1,-1.129164,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
302,3,1,-0.716133,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
302,4,1,0.339638,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
302,5,1,0.131038,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
302,6,1,0.666287,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
302,1,2,2.400569,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
302,2,2,0.842928,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
302,3,2,1.666733,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
302,4,2,3.410798,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
302,5,2,7.031447,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
302,6,2,5.324499,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
302,1,3,13.22929,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
302,2,3,14.373655,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
302,3,3,20.0205,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
302,4,3,31.626842,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
302,5,3,28.837751,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
302,6,3,29.654247,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
302,1,4,29.82724,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
302,2,4,41.051685,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
302,3,4,54.056137,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
302,4,4,108.63681,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
302,5,4,94.826546,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
302,6,4,113.19062,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
302,1,5,34.019367,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
302,2,5,34.646923,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
302,3,5,61.29153,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
302,4,5,104.31213,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
302,5,5,124.924995,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
302,6,5,116.28171,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
302,1,6,28.565268,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
302,2,6,32.282616,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
302,3,6,53.245136,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
302,4,6,104.44076,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
302,5,6,125.44066,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
302,6,6,118.375275,241,6,NCGC00249611-01,Ixazomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
303,1,1,0.868446,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
303,2,1,-0.766695,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
303,3,1,-0.184882,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
303,4,1,0.027395,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
303,5,1,-0.077729,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
303,6,1,0.493645,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
303,1,2,-0.856084,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
303,2,2,-2.493346,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
303,3,2,-2.557995,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
303,4,2,-2.466226,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
303,5,2,-2.532737,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
303,6,2,-2.185896,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
303,1,3,-0.708898,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
303,2,3,-2.50316,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
303,3,3,-2.407422,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
303,4,3,-2.305763,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
303,5,3,-2.217534,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
303,6,3,-1.98009,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
303,1,4,2.560132,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
303,2,4,1.521364,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
303,3,4,0.734798,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
303,4,4,0.391131,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
303,5,4,2.19371,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
303,6,4,5.509213,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
303,1,5,5.502849,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
303,2,5,6.848213,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
303,3,5,7.519246,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
303,4,5,18.478807,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
303,5,5,25.917791,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
303,6,5,39.228474,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
303,1,6,29.309666,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
303,2,6,32.831738,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
303,3,6,68.281265,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
303,4,6,97.0448,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
303,5,6,112.41365,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
303,6,6,106.768456,241,6,NCGC00249613-01,Carfilzomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
304,1,1,0.63001,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
304,2,1,-1.169898,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
304,3,1,-0.915162,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
304,4,1,-0.423929,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
304,5,1,-0.427332,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
304,6,1,-0.244037,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
304,1,2,0.176641,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
304,2,2,-1.578306,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
304,3,2,-1.755801,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
304,4,2,-1.468008,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
304,5,2,-1.802655,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
304,6,2,-1.345776,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
304,1,3,-0.019062,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
304,2,3,-1.638926,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
304,3,3,-1.685749,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
304,4,3,-1.796917,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
304,5,3,-1.610905,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
304,6,3,-1.270321,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
304,1,4,0.310976,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
304,2,4,-1.356612,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
304,3,4,-1.119427,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
304,4,4,-0.253729,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
304,5,4,-1.010534,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
304,6,4,-0.333441,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
304,1,5,2.839897,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
304,2,5,1.278395,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
304,3,5,3.712433,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
304,4,5,2.26918,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
304,5,5,4.029926,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
304,6,5,6.349608,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
304,1,6,27.271702,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
304,2,6,33.76906,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
304,3,6,53.066666,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
304,4,6,115.81502,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
304,5,6,133.24504,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
304,6,6,121.81346,241,6,NCGC00242506-01,Bortezomib,Proteasome Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
305,1,1,61.570087,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
305,2,1,63.60625,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
305,3,1,75.66949,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
305,4,1,88.73781,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
305,5,1,102.35455,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
305,6,1,125.486336,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
305,1,2,38.96812,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
305,2,2,42.58303,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
305,3,2,65.52506,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
305,4,2,94.95591,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
305,5,2,115.17713,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
305,6,2,110.318,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
305,1,3,27.970406,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
305,2,3,33.492622,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
305,3,3,43.08936,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
305,4,3,81.876335,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
305,5,3,112.05909,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
305,6,3,115.458954,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
305,1,4,27.098831,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
305,2,4,35.830463,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
305,3,4,51.679256,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
305,4,4,110.18926,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
305,5,4,123.37784,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
305,6,4,106.65576,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
305,1,5,22.920681,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
305,2,5,36.747673,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
305,3,5,48.71015,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
305,4,5,88.547585,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
305,5,5,112.84922,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
305,6,5,128.90665,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
305,1,6,28.780842,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
305,2,6,32.100327,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
305,3,6,52.6111,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
305,4,6,97.988686,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
305,5,6,116.04295,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
305,6,6,110.090416,241,6,NCGC00263175-01,Tosedostat,Aminopeptidase N Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
306,1,1,13.056175,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
306,2,1,20.270641,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
306,3,1,33.043617,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
306,4,1,63.06543,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
306,5,1,93.71738,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
306,6,1,112.64862,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
306,1,2,20.80821,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
306,2,2,29.957302,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
306,3,2,34.167534,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
306,4,2,74.8247,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
306,5,2,110.334694,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
306,6,2,102.4935,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
306,1,3,22.03096,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
306,2,3,26.92915,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
306,3,3,48.197002,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
306,4,3,85.60347,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
306,5,3,107.66772,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
306,6,3,107.40941,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
306,1,4,26.244165,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
306,2,4,31.155985,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
306,3,4,54.648224,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
306,4,4,106.20326,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
306,5,4,102.070885,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
306,6,4,106.42761,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
306,1,5,24.517408,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
306,2,5,27.003445,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
306,3,5,47.334415,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
306,4,5,117.649475,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
306,5,5,105.29878,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
306,6,5,129.75029,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
306,1,6,30.209045,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
306,2,6,33.668148,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
306,3,6,52.730766,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
306,4,6,94.63223,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
306,5,6,112.55925,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
306,6,6,108.49897,241,6,NCGC00263218-01,Teriflunomide,DHODH Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
307,1,1,29.91199,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
307,2,1,37.186253,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
307,3,1,51.15356,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
307,4,1,109.19906,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
307,5,1,111.84293,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
307,6,1,128.74255,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
307,1,2,27.121372,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
307,2,2,39.984364,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
307,3,2,79.69321,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
307,4,2,116.915855,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
307,5,2,113.28976,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
307,6,2,104.08031,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
307,1,3,25.522814,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
307,2,3,33.229614,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
307,3,3,53.804745,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
307,4,3,98.05311,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
307,5,3,119.47362,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
307,6,3,123.37227,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
307,1,4,31.889042,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
307,2,4,36.590874,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
307,3,4,59.220753,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
307,4,4,86.412544,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
307,5,4,121.52296,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
307,6,4,117.82342,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
307,1,5,31.92944,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
307,2,5,31.098248,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
307,3,5,60.879276,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
307,4,5,95.31221,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
307,5,5,113.083405,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
307,6,5,112.143715,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
307,1,6,28.63515,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
307,2,6,31.011866,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
307,3,6,49.514496,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
307,4,6,103.38116,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
307,5,6,117.420044,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
307,6,6,107.47551,241,6,NCGC00263127-01,PD-166793,MMP13 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
308,1,1,17.07563,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
308,2,1,21.153618,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
308,3,1,46.568058,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
308,4,1,74.49248,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
308,5,1,105.62435,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
308,6,1,111.87192,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
308,1,2,27.64722,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
308,2,2,32.412983,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
308,3,2,52.994293,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
308,4,2,82.19719,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
308,5,2,116.530525,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
308,6,2,122.47681,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
308,1,3,24.57751,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
308,2,3,34.040874,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
308,3,3,50.044266,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
308,4,3,87.85117,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
308,5,3,115.729935,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
308,6,3,107.350845,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
308,1,4,24.329214,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
308,2,4,30.960434,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
308,3,4,56.5542,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
308,4,4,112.23176,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
308,5,4,116.31782,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
308,6,4,117.83906,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
308,1,5,23.605892,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
308,2,5,29.252096,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
308,3,5,54.064487,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
308,4,5,102.51395,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
308,5,5,111.69816,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
308,6,5,117.07032,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
308,1,6,22.677134,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
308,2,6,23.961555,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
308,3,6,50.3159,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
308,4,6,85.48568,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
308,5,6,109.47014,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
308,6,6,122.00709,241,6,NCGC00167751-01,SSR-69071,Leukocyte Elastase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
309,1,1,20.22101,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
309,2,1,31.14057,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
309,3,1,52.76863,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
309,4,1,93.72064,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
309,5,1,108.18085,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
309,6,1,113.79405,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
309,1,2,25.756214,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
309,2,2,30.458319,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
309,3,2,56.347904,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
309,4,2,104.36445,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
309,5,2,114.87737,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
309,6,2,102.07978,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
309,1,3,26.224234,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
309,2,3,36.849926,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
309,3,3,50.9849,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
309,4,3,101.95514,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
309,5,3,110.16827,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
309,6,3,107.60931,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
309,1,4,31.874237,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
309,2,4,35.55563,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
309,3,4,47.72019,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
309,4,4,117.9921,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
309,5,4,117.28292,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
309,6,4,115.283325,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
309,1,5,27.972649,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
309,2,5,29.94758,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
309,3,5,52.635044,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
309,4,5,99.97784,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
309,5,5,113.420906,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
309,6,5,118.64643,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
309,1,6,22.420916,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
309,2,6,29.634224,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
309,3,6,58.668304,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
309,4,6,107.82032,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
309,5,6,119.49102,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
309,6,6,101.39054,241,6,NCGC00014891-03,RG-108,DNA Methyltransferase (DNMT) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
310,1,1,31.793472,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
310,2,1,27.221704,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
310,3,1,32.72803,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
310,4,1,66.4021,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
310,5,1,65.38477,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
310,6,1,62.432613,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
310,1,2,34.959194,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
310,2,2,28.832197,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
310,3,2,41.32939,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
310,4,2,97.70356,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
310,5,2,118.48706,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
310,6,2,122.102066,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
310,1,3,28.103565,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
310,2,3,29.23015,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
310,3,3,47.62447,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
310,4,3,97.477165,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
310,5,3,112.32486,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
310,6,3,119.86497,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
310,1,4,24.49456,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
310,2,4,39.935616,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
310,3,4,52.874825,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
310,4,4,106.05,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
310,5,4,112.20064,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
310,6,4,121.20184,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
310,1,5,25.567043,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
310,2,5,28.871923,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
310,3,5,51.329422,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
310,4,5,92.50955,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
310,5,5,108.32324,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
310,6,5,108.83643,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
310,1,6,26.103588,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
310,2,6,35.233437,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
310,3,6,49.584015,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
310,4,6,99.04958,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
310,5,6,106.69987,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
310,6,6,122.45988,241,6,NCGC00185850-02,BIX-01294,EHMT2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
311,1,1,0.506618,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
311,2,1,-1.210068,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
311,3,1,-0.76813,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
311,4,1,-0.778264,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
311,5,1,-0.162279,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
311,6,1,0.732173,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
311,1,2,0.986878,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
311,2,2,-0.273996,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
311,3,2,-0.176503,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
311,4,2,1.598314,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
311,5,2,2.472575,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
311,6,2,5.115274,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
311,1,3,3.675958,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
311,2,3,2.756598,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
311,3,3,5.286802,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
311,4,3,17.232172,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
311,5,3,29.774221,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
311,6,3,24.331015,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
311,1,4,12.330336,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
311,2,4,17.107788,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
311,3,4,28.706745,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
311,4,4,57.53621,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
311,5,4,85.49575,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
311,6,4,91.19494,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
311,1,5,23.613035,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
311,2,5,25.811722,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
311,3,5,30.585678,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
311,4,5,81.91829,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
311,5,5,90.38162,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
311,6,5,102.9626,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
311,1,6,29.376772,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
311,2,6,39.53185,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
311,3,6,47.08049,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
311,4,6,102.447395,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
311,5,6,95.78219,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
311,6,6,105.899796,241,6,NCGC00250412-01,JQ1,Brd4 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
312,1,1,26.762245,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
312,2,1,21.202715,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
312,3,1,49.600544,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
312,4,1,95.64695,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
312,5,1,121.26007,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
312,6,1,113.246216,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
312,1,2,27.8495,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
312,2,2,30.826984,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
312,3,2,44.666275,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
312,4,2,91.15077,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
312,5,2,107.70394,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
312,6,2,109.563286,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
312,1,3,23.215008,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
312,2,3,23.860277,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
312,3,3,62.375,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
312,4,3,86.35658,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
312,5,3,102.072044,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
312,6,3,121.41588,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
312,1,4,19.554676,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
312,2,4,31.30813,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
312,3,4,47.725792,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
312,4,4,87.24363,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
312,5,4,112.03993,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
312,6,4,111.67577,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
312,1,5,25.537344,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
312,2,5,30.923698,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
312,3,5,47.83096,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
312,4,5,83.82423,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
312,5,5,100.087524,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
312,6,5,93.29148,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
312,1,6,29.766193,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
312,2,6,26.040955,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
312,3,6,43.51858,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
312,4,6,81.41154,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
312,5,6,106.18029,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
312,6,6,109.92474,241,6,NCGC00185090-04,NCGC00185090-04,APE1 inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
313,1,1,30.471535,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
313,2,1,28.42005,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
313,3,1,49.713192,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
313,4,1,86.52779,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
313,5,1,109.580956,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
313,6,1,109.93604,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
313,1,2,27.201496,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
313,2,2,34.348186,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
313,3,2,46.575016,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
313,4,2,74.43386,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
313,5,2,110.721794,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
313,6,2,106.408424,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
313,1,3,24.678146,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
313,2,3,24.688662,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
313,3,3,52.950905,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
313,4,3,69.51652,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
313,5,3,105.801445,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
313,6,3,106.906525,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
313,1,4,20.061874,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
313,2,4,20.845602,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
313,3,4,50.396557,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
313,4,4,88.35544,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
313,5,4,118.94116,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
313,6,4,109.843185,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
313,1,5,21.248697,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
313,2,5,30.016151,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
313,3,5,45.783993,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
313,4,5,76.48461,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
313,5,5,108.91705,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
313,6,5,101.25204,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
313,1,6,26.77879,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
313,2,6,31.918436,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
313,3,6,45.77551,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
313,4,6,82.36948,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
313,5,6,104.17653,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
313,6,6,106.05429,241,6,NCGC00189393-02,NCGC00189393,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
314,1,1,25.216692,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
314,2,1,33.384842,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
314,3,1,45.029278,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
314,4,1,105.08661,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
314,5,1,106.13817,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
314,6,1,113.73255,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
314,1,2,30.48965,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
314,2,2,28.601238,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
314,3,2,48.16631,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
314,4,2,86.895004,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
314,5,2,95.09282,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
314,6,2,102.698784,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
314,1,3,25.968231,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
314,2,3,27.946962,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
314,3,3,45.513706,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
314,4,3,63.971085,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
314,5,3,114.43101,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
314,6,3,109.74427,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
314,1,4,26.119446,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
314,2,4,33.522243,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
314,3,4,49.66342,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
314,4,4,87.14386,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
314,5,4,92.15214,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
314,6,4,109.80816,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
314,1,5,26.09344,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
314,2,5,29.704153,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
314,3,5,47.735558,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
314,4,5,91.29266,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
314,5,5,117.09596,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
314,6,5,111.12123,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
314,1,6,22.909983,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
314,2,6,36.00581,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
314,3,6,53.719112,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
314,4,6,94.51226,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
314,5,6,111.37878,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
314,6,6,122.76028,241,6,NCGC00247866-02,NCGC00247866,BLM Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
315,1,1,22.956898,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
315,2,1,29.07518,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
315,3,1,37.42597,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
315,4,1,98.11029,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
315,5,1,101.253456,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
315,6,1,107.28684,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
315,1,2,20.245962,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
315,2,2,29.83533,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
315,3,2,51.431725,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
315,4,2,95.70951,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
315,5,2,105.46184,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
315,6,2,106.989586,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
315,1,3,26.880632,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
315,2,3,30.328104,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
315,3,3,41.600212,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
315,4,3,95.86469,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
315,5,3,103.61983,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
315,6,3,110.09547,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
315,1,4,25.454868,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
315,2,4,26.124926,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
315,3,4,59.603966,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
315,4,4,77.11926,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
315,5,4,103.19005,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
315,6,4,105.84413,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
315,1,5,26.311228,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
315,2,5,31.82685,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
315,3,5,54.22472,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
315,4,5,83.934875,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
315,5,5,106.087456,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
315,6,5,100.30101,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
315,1,6,22.261812,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
315,2,6,30.715267,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
315,3,6,45.216373,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
315,4,6,83.19939,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
315,5,6,99.04841,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
315,6,6,108.77539,241,6,NCGC00241036-01,NCGC00241036,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
316,1,1,12.400668,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
316,2,1,21.592842,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
316,3,1,44.457573,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
316,4,1,96.74851,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
316,5,1,101.99519,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
316,6,1,110.48418,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
316,1,2,20.15609,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
316,2,2,28.334698,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
316,3,2,43.84948,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
316,4,2,72.474266,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
316,5,2,103.84122,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
316,6,2,111.84832,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
316,1,3,19.78143,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
316,2,3,26.820358,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
316,3,3,54.92342,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
316,4,3,85.07351,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
316,5,3,103.17676,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
316,6,3,117.99012,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
316,1,4,22.836075,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
316,2,4,31.231668,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
316,3,4,51.294758,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
316,4,4,88.47994,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
316,5,4,99.96066,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
316,6,4,100.81375,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
316,1,5,17.20451,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
316,2,5,37.881977,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
316,3,5,54.92841,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
316,4,5,106.48238,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
316,5,5,108.86507,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
316,6,5,129.29878,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
316,1,6,23.859648,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
316,2,6,35.079845,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
316,3,6,53.703064,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
316,4,6,104.58259,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
316,5,6,112.45708,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
316,6,6,108.5584,241,6,NCGC00183808-01,ML324,JMJ Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
317,1,1,6.833532,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
317,2,1,7.225058,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
317,3,1,10.994211,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
317,4,1,33.358974,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
317,5,1,65.35471,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
317,6,1,66.50346,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
317,1,2,6.236525,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
317,2,2,17.774471,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
317,3,2,30.485125,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
317,4,2,58.517128,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
317,5,2,80.48552,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
317,6,2,83.30498,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
317,1,3,10.109951,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
317,2,3,15.663226,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
317,3,3,26.61223,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
317,4,3,60.652843,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
317,5,3,83.765015,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
317,6,3,102.80093,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
317,1,4,16.644684,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
317,2,4,16.008394,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
317,3,4,38.320633,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
317,4,4,51.47473,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
317,5,4,88.29462,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
317,6,4,101.11949,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
317,1,5,16.667072,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
317,2,5,20.754894,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
317,3,5,42.649857,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
317,4,5,76.38476,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
317,5,5,87.00695,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
317,6,5,103.79304,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
317,1,6,21.61582,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
317,2,6,36.24841,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
317,3,6,44.527325,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
317,4,6,82.240555,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
317,5,6,106.787766,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
317,6,6,112.96737,241,6,NCGC00250406-01,Tipifarnib,Farnesyltransferase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
318,1,1,24.407524,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
318,2,1,35.5666,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
318,3,1,54.266987,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
318,4,1,79.100945,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
318,5,1,114.12459,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
318,6,1,139.22719,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
318,1,2,20.7955,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
318,2,2,27.184048,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
318,3,2,59.5386,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
318,4,2,99.42061,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
318,5,2,120.15442,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
318,6,2,133.46623,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
318,1,3,23.546888,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
318,2,3,35.43255,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
318,3,3,57.28994,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
318,4,3,109.177635,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
318,5,3,123.01072,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
318,6,3,127.82475,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
318,1,4,21.324884,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
318,2,4,35.75897,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
318,3,4,62.656597,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
318,4,4,106.09933,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
318,5,4,131.3697,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
318,6,4,132.4195,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
318,1,5,30.256407,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
318,2,5,32.11245,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
318,3,5,51.507343,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
318,4,5,101.42945,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
318,5,5,115.28766,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
318,6,5,135.56985,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
318,1,6,25.517153,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
318,2,6,33.721397,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
318,3,6,53.269897,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
318,4,6,86.57319,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
318,5,6,108.27305,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
318,6,6,115.20198,241,6,NCGC00242489-01,LG-100268,RXR Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
319,1,1,5.112906,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
319,2,1,9.128204,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
319,3,1,11.595734,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
319,4,1,22.847004,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
319,5,1,28.243065,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
319,6,1,27.693045,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
319,1,2,13.399252,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
319,2,2,16.539549,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
319,3,2,19.791653,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
319,4,2,24.321629,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
319,5,2,32.25465,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
319,6,2,27.47468,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
319,1,3,20.916739,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
319,2,3,29.076094,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
319,3,3,34.51798,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
319,4,3,57.737526,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
319,5,3,73.89156,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
319,6,3,101.168236,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
319,1,4,28.0427,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
319,2,4,42.517475,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
319,3,4,57.411037,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
319,4,4,97.12617,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
319,5,4,113.155495,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
319,6,4,114.14746,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
319,1,5,25.939133,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
319,2,5,41.023598,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
319,3,5,46.044292,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
319,4,5,94.23299,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
319,5,5,118.12673,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
319,6,5,132.31631,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
319,1,6,30.282604,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
319,2,6,40.111153,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
319,3,6,49.785294,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
319,4,6,103.33707,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
319,5,6,120.18085,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
319,6,6,111.09289,241,6,NCGC00092284-02,AHPN,RARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
320,1,1,30.296953,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
320,2,1,43.33998,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
320,3,1,55.59961,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
320,4,1,105.310555,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
320,5,1,111.88628,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
320,6,1,114.12591,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
320,1,2,32.762413,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
320,2,2,39.734253,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
320,3,2,57.118435,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
320,4,2,88.02167,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
320,5,2,111.36207,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
320,6,2,110.36133,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
320,1,3,34.081593,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
320,2,3,36.41944,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
320,3,3,58.23472,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
320,4,3,96.22268,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
320,5,3,109.64315,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
320,6,3,113.16694,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
320,1,4,21.734325,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
320,2,4,29.086891,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
320,3,4,56.37018,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
320,4,4,91.667786,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
320,5,4,119.919464,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
320,6,4,108.74072,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
320,1,5,27.581856,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
320,2,5,34.671238,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
320,3,5,48.2711,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
320,4,5,109.87231,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
320,5,5,113.798225,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
320,6,5,117.35137,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
320,1,6,21.30418,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
320,2,6,34.785778,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
320,3,6,49.720303,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
320,4,6,83.77581,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
320,5,6,114.14991,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
320,6,6,117.63109,241,6,NCGC00242477-01,AC-261066,RARbeta2 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
321,1,1,29.785957,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
321,2,1,36.89517,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
321,3,1,46.48111,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
321,4,1,82.580505,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
321,5,1,108.47216,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
321,6,1,108.8139,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
321,1,2,29.948479,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
321,2,2,32.578197,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
321,3,2,46.432728,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
321,4,2,86.76042,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
321,5,2,110.62079,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
321,6,2,104.841675,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
321,1,3,28.360119,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
321,2,3,36.61561,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
321,3,3,49.982407,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
321,4,3,85.98012,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
321,5,3,102.98372,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
321,6,3,98.62363,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
321,1,4,27.417194,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
321,2,4,4.083136,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
321,3,4,49.223312,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
321,4,4,87.84506,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
321,5,4,105.99905,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
321,6,4,110.01846,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
321,1,5,24.4414,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
321,2,5,35.3673,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
321,3,5,62.017075,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
321,4,5,102.4655,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
321,5,5,97.79741,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
321,6,5,107.1784,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
321,1,6,28.319386,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
321,2,6,35.16386,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
321,3,6,71.50737,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
321,4,6,109.0956,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
321,5,6,98.10022,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
321,6,6,108.52165,241,6,NCGC00090752-10,Fenretinide,RARbeta/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
322,1,1,17.188564,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
322,2,1,22.860647,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
322,3,1,30.767979,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
322,4,1,47.975002,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
322,5,1,51.88449,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
322,6,1,104.29015,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
322,1,2,23.628918,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
322,2,2,28.749674,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
322,3,2,46.463642,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
322,4,2,44.972626,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
322,5,2,83.684456,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
322,6,2,106.1282,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
322,1,3,18.72831,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
322,2,3,32.980274,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
322,3,3,56.853844,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
322,4,3,79.91629,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
322,5,3,92.28116,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
322,6,3,97.00241,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
322,1,4,31.510984,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
322,2,4,30.909231,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
322,3,4,51.55639,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
322,4,4,86.72128,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
322,5,4,117.20174,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
322,6,4,99.13009,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
322,1,5,32.58175,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
322,2,5,30.455778,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
322,3,5,53.774654,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
322,4,5,78.965805,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
322,5,5,73.984474,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
322,6,5,107.53649,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
322,1,6,29.315653,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
322,2,6,37.41774,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
322,3,6,50.459816,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
322,4,6,114.06026,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
322,5,6,114.20623,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
322,6,6,114.83776,241,6,NCGC00022848-12,Hydrocortisone,immunosuppressant,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
323,1,1,17.16632,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
323,2,1,15.717418,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
323,3,1,28.11537,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
323,4,1,45.01028,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
323,5,1,53.96724,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
323,6,1,54.97809,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
323,1,2,15.300198,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
323,2,2,19.090631,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
323,3,2,30.78723,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
323,4,2,50.86632,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
323,5,2,70.090904,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
323,6,2,78.64682,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
323,1,3,15.560477,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
323,2,3,21.115074,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
323,3,3,34.503944,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
323,4,3,47.372044,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
323,5,3,82.721214,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
323,6,3,75.71794,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
323,1,4,19.000982,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
323,2,4,21.871468,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
323,3,4,39.051647,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
323,4,4,54.24122,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
323,5,4,83.91777,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
323,6,4,84.58675,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
323,1,5,18.701178,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
323,2,5,26.822515,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
323,3,5,40.509453,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
323,4,5,71.276726,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
323,5,5,70.682335,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
323,6,5,96.67655,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
323,1,6,29.235106,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
323,2,6,36.41549,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
323,3,6,57.677498,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
323,4,6,93.70665,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
323,5,6,99.11086,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
323,6,6,112.989136,241,6,NCGC00242502-01,Dexamethasone,Antiinflammatory; glucocorticoid receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
324,1,1,30.625689,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
324,2,1,27.024633,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
324,3,1,26.733355,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
324,4,1,77.466965,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
324,5,1,87.32279,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
324,6,1,76.34943,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
324,1,2,25.907398,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
324,2,2,24.017984,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
324,3,2,32.802486,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
324,4,2,64.15805,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
324,5,2,77.15258,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
324,6,2,95.59612,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
324,1,3,20.511467,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
324,2,3,22.404593,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
324,3,3,27.924522,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
324,4,3,62.830536,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
324,5,3,89.803604,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
324,6,3,86.7864,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
324,1,4,17.879162,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
324,2,4,20.38091,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
324,3,4,28.185823,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
324,4,4,57.601707,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
324,5,4,80.148346,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
324,6,4,72.70531,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
324,1,5,18.314554,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
324,2,5,18.039597,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
324,3,5,29.71723,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
324,4,5,47.169823,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
324,5,5,71.653946,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
324,6,5,103.67219,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
324,1,6,28.838188,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
324,2,6,36.91773,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
324,3,6,61.114967,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
324,4,6,80.061874,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
324,5,6,117.05125,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
324,6,6,142.42885,241,6,NCGC00242504-01,Cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
325,1,1,41.503376,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
325,2,1,42.05607,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
325,3,1,43.21769,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
325,4,1,70.425,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
325,5,1,84.04819,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
325,6,1,103.680885,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
325,1,2,24.559275,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
325,2,2,25.09782,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
325,3,2,34.236996,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
325,4,2,64.634155,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
325,5,2,85.57912,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
325,6,2,96.187325,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
325,1,3,20.373995,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
325,2,3,15.48187,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
325,3,3,29.387386,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
325,4,3,45.709835,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
325,5,3,62.036182,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
325,6,3,91.03253,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
325,1,4,15.501209,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
325,2,4,14.181368,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
325,3,4,27.681383,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
325,4,4,43.915333,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
325,5,4,68.56167,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
325,6,4,74.07493,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
325,1,5,14.897027,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
325,2,5,16.40685,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
325,3,5,26.67948,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
325,4,5,48.263393,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
325,5,5,73.59041,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
325,6,5,81.71587,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
325,1,6,24.63482,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
325,2,6,29.969528,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
325,3,6,54.506546,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
325,4,6,82.87664,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
325,5,6,114.194824,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
325,6,6,108.11691,241,6,NCGC00242505-01,Deacetyl cortivazol,Glucocorticoid Receptor (GR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
326,1,1,25.672283,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
326,2,1,26.302576,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
326,3,1,53.100864,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
326,4,1,76.72268,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
326,5,1,110.080864,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
326,6,1,114.93025,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
326,1,2,22.22302,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
326,2,2,27.644331,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
326,3,2,40.122295,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
326,4,2,82.64887,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
326,5,2,111.894646,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
326,6,2,116.28246,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
326,1,3,22.540497,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
326,2,3,35.039528,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
326,3,3,47.73073,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
326,4,3,86.030655,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
326,5,3,110.52437,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
326,6,3,100.49225,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
326,1,4,28.14204,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
326,2,4,28.56714,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
326,3,4,56.64495,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
326,4,4,91.67367,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
326,5,4,117.21443,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
326,6,4,114.90548,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
326,1,5,24.09721,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
326,2,5,32.282246,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
326,3,5,63.153214,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
326,4,5,112.81049,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
326,5,5,126.253174,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
326,6,5,114.44203,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
326,1,6,31.225155,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
326,2,6,38.4104,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
326,3,6,82.45945,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
326,4,6,98.262,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
326,5,6,108.47398,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
326,6,6,110.43663,241,6,NCGC00263148-01,Abiraterone,Androgen Biosynthesis Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
327,1,1,9.28585,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
327,2,1,20.11793,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
327,3,1,25.885199,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
327,4,1,44.970913,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
327,5,1,70.25892,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
327,6,1,79.66569,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
327,1,2,17.745657,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
327,2,2,22.226873,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
327,3,2,36.032303,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
327,4,2,63.03281,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
327,5,2,97.44354,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
327,6,2,107.02592,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
327,1,3,20.672361,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
327,2,3,30.705158,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
327,3,3,57.945713,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
327,4,3,97.496925,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
327,5,3,117.16785,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
327,6,3,117.58585,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
327,1,4,26.500654,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
327,2,4,36.71357,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
327,3,4,47.062706,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
327,4,4,106.86899,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
327,5,4,146.46199,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
327,6,4,113.55762,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
327,1,5,30.064426,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
327,2,5,42.801304,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
327,3,5,48.041748,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
327,4,5,99.40039,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
327,5,5,135.7845,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
327,6,5,110.800285,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
327,1,6,23.80077,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
327,2,6,38.070232,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
327,3,6,56.019993,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
327,4,6,87.32255,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
327,5,6,115.05994,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
327,6,6,125.46565,241,6,NCGC00094082-03,2-Methoxyestradiol,Hypoxia Inducible Factor 1-alpha Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
328,1,1,29.213867,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
328,2,1,37.973984,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
328,3,1,57.77612,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
328,4,1,110.90216,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
328,5,1,128.39294,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
328,6,1,119.355064,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
328,1,2,37.40533,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
328,2,2,34.619534,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
328,3,2,58.318146,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
328,4,2,90.151566,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
328,5,2,123.38851,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
328,6,2,124.87894,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
328,1,3,31.84452,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
328,2,3,40.82286,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
328,3,3,60.213367,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
328,4,3,88.52983,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
328,5,3,141.67204,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
328,6,3,118.59155,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
328,1,4,35.308693,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
328,2,4,36.859524,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
328,3,4,65.47121,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
328,4,4,123.02505,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
328,5,4,104.062614,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
328,6,4,127.73279,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
328,1,5,30.651842,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
328,2,5,36.119522,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
328,3,5,57.248615,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
328,4,5,111.661545,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
328,5,5,124.84017,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
328,6,5,102.78087,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
328,1,6,33.551617,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
328,2,6,34.815395,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
328,3,6,65.95143,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
328,4,6,94.26658,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
328,5,6,124.39523,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
328,6,6,107.0058,241,6,NCGC00015870-19,Quercetin,Flavone,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
329,1,1,26.465355,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
329,2,1,35.823715,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
329,3,1,60.00596,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
329,4,1,86.91322,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
329,5,1,95.00277,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
329,6,1,104.208145,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
329,1,2,24.33382,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
329,2,2,33.978527,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
329,3,2,48.84575,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
329,4,2,89.95524,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
329,5,2,110.38077,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
329,6,2,140.20543,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
329,1,3,23.939047,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
329,2,3,37.86918,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
329,3,3,58.226208,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
329,4,3,120.22884,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
329,5,3,133.5869,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
329,6,3,128.32806,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
329,1,4,29.562502,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
329,2,4,38.14917,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
329,3,4,58.994637,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
329,4,4,94.38527,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
329,5,4,129.47665,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
329,6,4,125.80211,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
329,1,5,29.671118,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
329,2,5,29.413671,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
329,3,5,62.07706,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
329,4,5,112.578514,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
329,5,5,131.2447,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
329,6,5,116.244705,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
329,1,6,30.163364,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
329,2,6,31.752758,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
329,3,6,58.92877,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
329,4,6,94.97488,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
329,5,6,112.29194,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
329,6,6,117.62959,241,6,NCGC00182058-03,Doxercalciferol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
330,1,1,27.070457,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
330,2,1,31.898067,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
330,3,1,47.94675,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
330,4,1,83.68584,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
330,5,1,93.88617,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
330,6,1,109.87496,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
330,1,2,28.605185,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
330,2,2,40.93363,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
330,3,2,51.523144,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
330,4,2,82.02689,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
330,5,2,105.85404,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
330,6,2,120.25017,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
330,1,3,32.04293,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
330,2,3,29.725122,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
330,3,3,57.946762,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
330,4,3,96.965675,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
330,5,3,119.24251,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
330,6,3,131.52498,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
330,1,4,24.502321,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
330,2,4,31.207138,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
330,3,4,43.288403,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
330,4,4,112.005775,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
330,5,4,122.41487,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
330,6,4,115.597115,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
330,1,5,31.833954,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
330,2,5,38.450256,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
330,3,5,53.59738,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
330,4,5,102.79185,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
330,5,5,107.67821,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
330,6,5,136.00009,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
330,1,6,32.301743,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
330,2,6,36.771557,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
330,3,6,55.236137,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
330,4,6,98.46171,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
330,5,6,101.24159,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
330,6,6,124.59072,241,6,NCGC00242511-02,Seocalcitol,Vitamin D Analog,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
331,1,1,25.248075,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
331,2,1,30.194666,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
331,3,1,41.62207,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
331,4,1,77.655266,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
331,5,1,117.09341,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
331,6,1,117.21385,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
331,1,2,27.87726,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
331,2,2,30.310139,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
331,3,2,45.522655,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
331,4,2,71.91221,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
331,5,2,117.849236,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
331,6,2,103.05594,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
331,1,3,24.320852,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
331,2,3,32.633625,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
331,3,3,50.24381,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
331,4,3,95.02829,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
331,5,3,124.08906,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
331,6,3,111.96257,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
331,1,4,28.697912,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
331,2,4,32.750694,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
331,3,4,44.74057,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
331,4,4,92.043724,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
331,5,4,118.08873,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
331,6,4,113.45546,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
331,1,5,30.319557,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
331,2,5,42.963264,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
331,3,5,62.592094,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
331,4,5,101.76196,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
331,5,5,109.60465,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
331,6,5,114.565346,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
331,1,6,35.49633,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
331,2,6,42.620712,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
331,3,6,64.89921,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
331,4,6,84.36815,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
331,5,6,122.30482,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
331,6,6,129.02486,241,6,NCGC00242512-01,methyl jasmonate,cytochrome c release inducer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
332,1,1,28.863724,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
332,2,1,37.353798,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
332,3,1,61.264633,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
332,4,1,103.3554,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
332,5,1,115.96185,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
332,6,1,134.24414,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
332,1,2,31.279564,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
332,2,2,40.46886,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
332,3,2,67.68961,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
332,4,2,98.5698,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
332,5,2,119.12179,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
332,6,2,114.455894,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
332,1,3,35.910114,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
332,2,3,34.4503,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
332,3,3,62.71624,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
332,4,3,105.1492,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
332,5,3,120.53552,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
332,6,3,113.713165,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
332,1,4,26.682613,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
332,2,4,33.28589,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
332,3,4,59.785423,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
332,4,4,89.15941,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
332,5,4,121.01371,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
332,6,4,111.322296,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
332,1,5,29.056524,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
332,2,5,49.05224,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
332,3,5,75.77439,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
332,4,5,108.28558,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
332,5,5,130.78938,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
332,6,5,113.63668,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
332,1,6,27.752327,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
332,2,6,35.127323,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
332,3,6,64.32693,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
332,4,6,107.555084,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
332,5,6,120.17783,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
332,6,6,128.18158,241,6,NCGC00167977-02,Bicalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
333,1,1,28.458195,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
333,2,1,43.556664,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
333,3,1,65.750786,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
333,4,1,91.28838,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
333,5,1,137.77896,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
333,6,1,126.04959,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
333,1,2,31.848145,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
333,2,2,35.539005,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
333,3,2,54.142197,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
333,4,2,114.231606,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
333,5,2,116.94844,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
333,6,2,127.49792,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
333,1,3,32.5145,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
333,2,3,40.54163,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
333,3,3,64.58226,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
333,4,3,111.000496,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
333,5,3,136.17162,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
333,6,3,113.7417,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
333,1,4,31.731176,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
333,2,4,38.011986,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
333,3,4,73.14065,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
333,4,4,118.61515,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
333,5,4,113.65202,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
333,6,4,118.25851,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
333,1,5,30.18519,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
333,2,5,36.482838,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
333,3,5,54.31484,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
333,4,5,107.29993,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
333,5,5,106.290474,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
333,6,5,132.23047,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
333,1,6,34.316723,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
333,2,6,38.486805,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
333,3,6,60.410122,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
333,4,6,91.760254,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
333,5,6,101.491936,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
333,6,6,125.05575,241,6,NCGC00263150-01,Andarine,Selective Androgen Receptor Modulators (SARM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
334,1,1,25.484543,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
334,2,1,38.58159,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
334,3,1,61.092854,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
334,4,1,84.454445,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
334,5,1,110.12407,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
334,6,1,107.351845,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
334,1,2,27.72094,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
334,2,2,40.012447,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
334,3,2,63.66999,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
334,4,2,87.9415,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
334,5,2,116.909996,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
334,6,2,121.92197,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
334,1,3,29.164652,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
334,2,3,34.392067,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
334,3,3,63.080345,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
334,4,3,100.35206,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
334,5,3,119.12057,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
334,6,3,135.8969,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
334,1,4,27.173264,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
334,2,4,38.595737,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
334,3,4,55.92485,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
334,4,4,112.22614,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
334,5,4,119.513374,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
334,6,4,116.18073,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
334,1,5,30.656673,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
334,2,5,40.026867,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
334,3,5,56.529865,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
334,4,5,109.90984,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
334,5,5,111.29462,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
334,6,5,139.00266,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
334,1,6,29.559698,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
334,2,6,42.848293,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
334,3,6,52.49602,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
334,4,6,102.089935,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
334,5,6,130.77191,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
334,6,6,111.266335,241,6,NCGC00263120-01,Enzalutamide,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
335,1,1,27.119589,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
335,2,1,33.96911,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
335,3,1,59.058605,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
335,4,1,103.9178,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
335,5,1,122.08397,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
335,6,1,138.142,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
335,1,2,32.231186,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
335,2,2,33.901012,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
335,3,2,60.687138,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
335,4,2,97.10333,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
335,5,2,109.23682,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
335,6,2,129.75282,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
335,1,3,32.46491,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
335,2,3,36.06898,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
335,3,3,52.51878,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
335,4,3,88.46138,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
335,5,3,110.76662,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
335,6,3,133.12836,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
335,1,4,24.677668,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
335,2,4,38.223076,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
335,3,4,56.59683,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
335,4,4,90.324295,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
335,5,4,115.736885,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
335,6,4,120.668884,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
335,1,5,33.676407,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
335,2,5,39.950993,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
335,3,5,57.583218,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
335,4,5,91.98875,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
335,5,5,114.17809,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
335,6,5,120.83511,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
335,1,6,28.705029,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
335,2,6,32.359615,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
335,3,6,52.823,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
335,4,6,104.643265,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
335,5,6,119.03403,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
335,6,6,113.297264,241,6,NCGC00263137-01,RD-162,Androgen Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
336,1,1,24.528233,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
336,2,1,28.904243,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
336,3,1,43.49038,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
336,4,1,75.23598,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
336,5,1,94.418686,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
336,6,1,108.24103,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
336,1,2,22.32219,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
336,2,2,35.386208,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
336,3,2,40.548172,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
336,4,2,75.35512,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
336,5,2,102.06055,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
336,6,2,111.7847,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
336,1,3,25.455915,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
336,2,3,35.225414,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
336,3,3,65.981155,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
336,4,3,95.58832,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
336,5,3,105.11411,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
336,6,3,126.60333,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
336,1,4,25.697617,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
336,2,4,48.176517,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
336,3,4,46.763275,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
336,4,4,103.785774,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
336,5,4,108.1025,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
336,6,4,109.666306,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
336,1,5,34.50475,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
336,2,5,24.950958,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
336,3,5,82.383286,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
336,4,5,103.59736,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
336,5,5,113.0056,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
336,6,5,113.706245,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
336,1,6,28.378782,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
336,2,6,41.444958,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
336,3,6,55.93756,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
336,4,6,96.90738,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
336,5,6,111.66722,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
336,6,6,116.338524,241,6,NCGC00163107-06,CITCO,Constitutive androstane receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
337,1,1,31.16882,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
337,2,1,43.896683,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
337,3,1,50.770176,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
337,4,1,100.46766,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
337,5,1,128.87395,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
337,6,1,137.40283,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
337,1,2,35.137188,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
337,2,2,40.520767,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
337,3,2,63.367283,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
337,4,2,104.415764,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
337,5,2,107.96782,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
337,6,2,133.26706,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
337,1,3,23.178642,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
337,2,3,36.68842,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
337,3,3,50.29327,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
337,4,3,116.760315,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
337,5,3,131.10909,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
337,6,3,150.4298,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
337,1,4,27.969702,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
337,2,4,38.032215,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
337,3,4,59.574345,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
337,4,4,112.29007,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
337,5,4,130.02051,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
337,6,4,119.51373,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
337,1,5,28.872078,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
337,2,5,34.753197,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
337,3,5,59.22636,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
337,4,5,120.66144,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
337,5,5,113.89144,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
337,6,5,128.78177,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
337,1,6,32.68313,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
337,2,6,32.48843,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
337,3,6,23.910147,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
337,4,6,102.43673,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
337,5,6,109.0947,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
337,6,6,118.15934,241,6,NCGC00015205-06,PK-11195,Pregnane X Receptor (PXR) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
338,1,1,26.152782,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
338,2,1,34.00372,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
338,3,1,53.51236,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
338,4,1,97.833916,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
338,5,1,136.94621,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
338,6,1,103.46768,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
338,1,2,31.092054,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
338,2,2,41.70286,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
338,3,2,61.197903,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
338,4,2,103.15,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
338,5,2,122.16792,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
338,6,2,113.22082,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
338,1,3,28.88302,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
338,2,3,37.404438,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
338,3,3,73.371765,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
338,4,3,93.01364,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
338,5,3,114.24261,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
338,6,3,122.59334,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
338,1,4,29.93548,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
338,2,4,39.32884,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
338,3,4,55.999935,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
338,4,4,118.592735,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
338,5,4,121.67231,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
338,6,4,109.85885,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
338,1,5,31.181026,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
338,2,5,40.788967,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
338,3,5,52.113495,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
338,4,5,106.66827,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
338,5,5,114.53312,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
338,6,5,125.07722,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
338,1,6,25.886723,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
338,2,6,43.849552,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
338,3,6,50.889614,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
338,4,6,105.73378,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
338,5,6,113.13558,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
338,6,6,116.21301,241,6,NCGC00163128-06,Pioglitazone hydrochloride,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
339,1,1,28.029026,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
339,2,1,32.178505,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
339,3,1,33.266235,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
339,4,1,57.75416,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
339,5,1,3.232262,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
339,6,1,1.33248,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
339,1,2,26.512516,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
339,2,2,31.273409,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
339,3,2,51.985687,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
339,4,2,104.83872,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
339,5,2,112.65156,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
339,6,2,122.40021,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
339,1,3,29.774124,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
339,2,3,43.8086,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
339,3,3,58.37681,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
339,4,3,79.47929,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
339,5,3,112.989265,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
339,6,3,139.16982,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
339,1,4,31.055805,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
339,2,4,37.695747,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
339,3,4,47.291435,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
339,4,4,123.49117,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
339,5,4,116.81431,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
339,6,4,132.6698,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
339,1,5,34.688377,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
339,2,5,36.833412,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
339,3,5,58.78743,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
339,4,5,106.809494,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
339,5,5,116.871994,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
339,6,5,129.73491,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
339,1,6,29.965084,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
339,2,6,34.965263,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
339,3,6,58.912075,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
339,4,6,100.64992,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
339,5,6,124.78746,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
339,6,6,136.80891,241,6,NCGC00015480-10,GW-7647,PPARalpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
340,1,1,24.6981,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
340,2,1,37.704357,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
340,3,1,52.3912,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
340,4,1,86.83092,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
340,5,1,126.36281,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
340,6,1,105.36265,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
340,1,2,29.051908,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
340,2,2,38.148235,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
340,3,2,50.879192,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
340,4,2,93.65608,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
340,5,2,114.607864,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
340,6,2,119.72429,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
340,1,3,28.22663,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
340,2,3,35.142895,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
340,3,3,62.43448,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
340,4,3,106.03409,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
340,5,3,114.22502,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
340,6,3,126.515884,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
340,1,4,29.786303,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
340,2,4,37.282036,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
340,3,4,52.029224,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
340,4,4,107.0694,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
340,5,4,108.79755,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
340,6,4,106.714165,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
340,1,5,31.661009,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
340,2,5,34.322517,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
340,3,5,61.94357,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
340,4,5,94.61105,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
340,5,5,119.77708,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
340,6,5,117.82652,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
340,1,6,25.316689,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
340,2,6,32.656876,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
340,3,6,55.22705,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
340,4,6,100.05421,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
340,5,6,109.4672,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
340,6,6,113.13653,241,6,NCGC00092344-01,GW-0742,PPARgamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
341,1,1,20.8466,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
341,2,1,24.747633,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
341,3,1,42.091454,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
341,4,1,81.493576,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
341,5,1,93.52195,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
341,6,1,100.52454,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
341,1,2,26.221554,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
341,2,2,25.528643,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
341,3,2,46.2911,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
341,4,2,77.595795,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
341,5,2,102.361145,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
341,6,2,95.68931,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
341,1,3,27.650946,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
341,2,3,29.92182,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
341,3,3,53.34261,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
341,4,3,80.82105,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
341,5,3,100.0596,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
341,6,3,104.12229,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
341,1,4,32.743233,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
341,2,4,36.781536,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
341,3,4,53.851852,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
341,4,4,83.16073,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
341,5,4,102.108055,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
341,6,4,116.979416,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
341,1,5,26.406979,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
341,2,5,31.91706,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
341,3,5,44.740154,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
341,4,5,92.5526,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
341,5,5,129.0114,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
341,6,5,108.10227,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
341,1,6,32.958145,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
341,2,6,36.774994,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
341,3,6,52.41086,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
341,4,6,93.75424,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
341,5,6,108.212036,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
341,6,6,116.90868,241,6,NCGC00241455-02,GW-501516,PPARdelta Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
342,1,1,27.664259,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
342,2,1,35.22232,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
342,3,1,47.875175,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
342,4,1,115.09362,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
342,5,1,114.49646,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
342,6,1,126.01236,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
342,1,2,34.595825,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
342,2,2,47.36481,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
342,3,2,51.35266,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
342,4,2,114.05172,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
342,5,2,114.97543,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
342,6,2,129.6357,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
342,1,3,30.482637,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
342,2,3,42.133987,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
342,3,3,61.424175,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
342,4,3,116.439995,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
342,5,3,116.01478,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
342,6,3,109.18056,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
342,1,4,27.96382,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
342,2,4,33.886276,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
342,3,4,51.752483,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
342,4,4,116.75649,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
342,5,4,114.02786,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
342,6,4,104.425934,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
342,1,5,31.11424,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
342,2,5,40.17376,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
342,3,5,59.780922,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
342,4,5,111.356735,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
342,5,5,111.650085,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
342,6,5,119.95091,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
342,1,6,31.56138,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
342,2,6,40.73324,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
342,3,6,42.2866,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
342,4,6,105.05368,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
342,5,6,119.64364,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
342,6,6,108.210686,241,6,NCGC00161599-08,Troglitazone,CCL2 Expression Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
343,1,1,30.091125,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
343,2,1,50.46656,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
343,3,1,70.23189,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
343,4,1,101.179306,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
343,5,1,117.168724,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
343,6,1,108.88243,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
343,1,2,32.463917,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
343,2,2,49.192066,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
343,3,2,63.040806,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
343,4,2,97.711006,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
343,5,2,117.812225,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
343,6,2,110.52102,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
343,1,3,28.419128,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
343,2,3,39.502113,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
343,3,3,62.116528,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
343,4,3,91.52764,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
343,5,3,119.88527,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
343,6,3,106.60014,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
343,1,4,32.413506,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
343,2,4,36.690044,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
343,3,4,61.047302,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
343,4,4,112.79373,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
343,5,4,133.07141,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
343,6,4,107.86402,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
343,1,5,33.29634,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
343,2,5,37.697758,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
343,3,5,55.488636,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
343,4,5,87.15645,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
343,5,5,106.083626,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
343,6,5,127.19296,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
343,1,6,25.726547,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
343,2,6,37.533585,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
343,3,6,50.34621,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
343,4,6,85.20736,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
343,5,6,104.42685,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
343,6,6,114.50693,241,6,NCGC00095150-06,Telmisartan,Angiotensin AT1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
344,1,1,30.718128,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
344,2,1,32.78243,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
344,3,1,47.967354,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
344,4,1,90.0642,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
344,5,1,113.29193,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
344,6,1,113.91433,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
344,1,2,28.115484,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
344,2,2,37.817043,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
344,3,2,59.04276,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
344,4,2,89.08734,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
344,5,2,104.05588,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
344,6,2,109.89203,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
344,1,3,34.808468,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
344,2,3,36.95842,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
344,3,3,56.034702,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
344,4,3,100.103096,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
344,5,3,109.885025,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
344,6,3,116.888885,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
344,1,4,26.480179,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
344,2,4,30.599016,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
344,3,4,57.69714,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
344,4,4,108.337776,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
344,5,4,113.01729,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
344,6,4,123.18417,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
344,1,5,29.235537,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
344,2,5,41.30159,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
344,3,5,51.675903,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
344,4,5,106.74321,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
344,5,5,95.52758,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
344,6,5,119.959274,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
344,1,6,27.547937,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
344,2,6,35.083874,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
344,3,6,55.549286,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
344,4,6,97.15595,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
344,5,6,113.67707,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
344,6,6,108.90141,241,6,NCGC00263111-01,GSK-3787,PPARdelta Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
345,1,1,25.364656,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
345,2,1,33.1387,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
345,3,1,40.37566,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
345,4,1,77.06963,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
345,5,1,116.985954,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
345,6,1,121.01251,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
345,1,2,30.539965,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
345,2,2,37.491226,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
345,3,2,59.505116,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
345,4,2,86.86997,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
345,5,2,107.48504,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
345,6,2,110.61102,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
345,1,3,24.165607,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
345,2,3,36.725388,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
345,3,3,51.570366,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
345,4,3,76.330734,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
345,5,3,110.4012,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
345,6,3,125.941475,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
345,1,4,29.185268,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
345,2,4,36.269016,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
345,3,4,45.947784,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
345,4,4,101.074486,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
345,5,4,112.11121,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
345,6,4,108.11383,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
345,1,5,29.640663,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
345,2,5,35.624947,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
345,3,5,50.980877,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
345,4,5,101.67133,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
345,5,5,112.9518,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
345,6,5,121.93982,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
345,1,6,28.039824,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
345,2,6,32.641605,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
345,3,6,54.876648,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
345,4,6,91.79466,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
345,5,6,119.43061,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
345,6,6,123.20166,241,6,NCGC00263123-01,MK-767,PPARalpha/gamma Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
346,1,1,21.052183,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
346,2,1,26.212093,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
346,3,1,37.236183,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
346,4,1,65.80308,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
346,5,1,98.73383,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
346,6,1,96.220436,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
346,1,2,20.655209,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
346,2,2,29.2762,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
346,3,2,41.48483,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
346,4,2,67.229805,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
346,5,2,94.164314,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
346,6,2,99.856026,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
346,1,3,21.533934,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
346,2,3,25.002707,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
346,3,3,44.670734,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
346,4,3,70.21835,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
346,5,3,81.30191,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
346,6,3,102.749405,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
346,1,4,22.31034,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
346,2,4,23.78787,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
346,3,4,40.158947,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
346,4,4,72.28983,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
346,5,4,99.53302,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
346,6,4,104.91277,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
346,1,5,21.06593,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
346,2,5,37.151737,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
346,3,5,46.94972,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
346,4,5,81.721115,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
346,5,5,111.01213,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
346,6,5,106.23146,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
346,1,6,28.374914,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
346,2,6,30.915644,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
346,3,6,59.594547,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
346,4,6,82.84577,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
346,5,6,85.94968,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
346,6,6,102.26137,241,6,NCGC00081778-02,SID-7969543,SF1 (NR5A1) Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
347,1,1,20.845709,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
347,2,1,22.78253,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
347,3,1,50.253815,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
347,4,1,100.48003,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
347,5,1,113.61533,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
347,6,1,111.267044,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
347,1,2,31.19667,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
347,2,2,41.480488,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
347,3,2,53.95309,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
347,4,2,105.96743,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
347,5,2,121.671265,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
347,6,2,107.05651,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
347,1,3,26.934883,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
347,2,3,32.853153,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
347,3,3,53.53373,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
347,4,3,100.00259,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
347,5,3,109.32522,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
347,6,3,119.895996,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
347,1,4,24.36209,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
347,2,4,32.414944,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
347,3,4,42.56554,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
347,4,4,86.699646,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
347,5,4,109.65552,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
347,6,4,111.54585,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
347,1,5,28.143608,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
347,2,5,24.288572,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
347,3,5,55.499393,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
347,4,5,115.33573,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
347,5,5,101.011024,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
347,6,5,105.66431,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
347,1,6,26.890411,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
347,2,6,32.718674,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
347,3,6,45.013313,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
347,4,6,79.77228,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
347,5,6,102.65255,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
347,6,6,119.11884,241,6,NCGC00182055-02,Bazedoxifene,Selective Estrogen Receptor Modulators (SERM),NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
348,1,1,0.244606,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
348,2,1,-1.586964,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
348,3,1,-1.016729,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
348,4,1,-1.128651,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
348,5,1,-0.965686,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
348,6,1,0.821987,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
348,1,2,-0.529975,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
348,2,2,-1.193843,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
348,3,2,-1.435257,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
348,4,2,-2.024544,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
348,5,2,-1.611465,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
348,6,2,-0.007146,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
348,1,3,0.479076,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
348,2,3,-1.181794,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
348,3,3,-1.200256,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
348,4,3,-1.288669,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
348,5,3,-1.123374,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
348,6,3,0.352071,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
348,1,4,1.696557,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
348,2,4,-0.099499,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
348,3,4,0.753776,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
348,4,4,2.468033,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
348,5,4,5.580105,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
348,6,4,16.997776,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
348,1,5,5.231226,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
348,2,5,9.416348,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
348,3,5,14.208615,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
348,4,5,36.45017,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
348,5,5,63.372128,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
348,6,5,68.74093,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
348,1,6,28.534658,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
348,2,6,29.252316,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
348,3,6,49.04315,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
348,4,6,98.04335,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
348,5,6,109.63369,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
348,6,6,114.37539,241,6,NCGC00163411-02,Triptolide,Inhibition of RNA polymerase II mediated transcription,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
349,1,1,15.260456,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
349,2,1,28.368717,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
349,3,1,42.44541,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
349,4,1,69.257706,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
349,5,1,87.58856,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
349,6,1,95.70832,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
349,1,2,24.992914,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
349,2,2,31.23,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
349,3,2,59.427902,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
349,4,2,92.45355,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
349,5,2,108.24017,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
349,6,2,103.798515,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
349,1,3,25.788935,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
349,2,3,38.048855,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
349,3,3,56.214603,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
349,4,3,90.71192,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
349,5,3,111.018005,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
349,6,3,126.296364,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
349,1,4,30.871603,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
349,2,4,39.555542,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
349,3,4,52.33727,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
349,4,4,83.19212,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
349,5,4,113.86618,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
349,6,4,104.74687,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
349,1,5,33.0176,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
349,2,5,36.883278,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
349,3,5,61.62457,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
349,4,5,95.01158,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
349,5,5,117.29301,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
349,6,5,124.45126,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
349,1,6,27.12836,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
349,2,6,38.200977,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
349,3,6,47.142708,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
349,4,6,105.3121,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
349,5,6,117.30734,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
349,6,6,109.685585,241,6,NCGC00263092-01,Apratastat,TNF-alpha-Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
350,1,1,17.77427,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
350,2,1,25.806017,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
350,3,1,37.23838,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
350,4,1,79.76778,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
350,5,1,98.47177,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
350,6,1,101.56498,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
350,1,2,24.843035,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
350,2,2,34.024094,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
350,3,2,47.822205,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
350,4,2,81.46776,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
350,5,2,93.30351,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
350,6,2,104.34797,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
350,1,3,26.059795,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
350,2,3,35.403187,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
350,3,3,46.312263,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
350,4,3,91.413475,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
350,5,3,109.43032,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
350,6,3,107.408646,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
350,1,4,25.72383,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
350,2,4,32.63604,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
350,3,4,59.745636,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
350,4,4,69.815186,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
350,5,4,105.532295,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
350,6,4,105.3135,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
350,1,5,24.319529,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
350,2,5,31.211006,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
350,3,5,45.674767,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
350,4,5,86.214554,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
350,5,5,93.226295,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
350,6,5,104.82472,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
350,1,6,20.420525,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
350,2,6,31.347933,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
350,3,6,43.368866,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
350,4,6,68.24533,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
350,5,6,96.091805,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
350,6,6,109.946785,241,6,NCGC00263214-01,HC-067047,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
351,1,1,-0.850495,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
351,2,1,17.552444,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
351,3,1,31.904854,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
351,4,1,57.390705,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
351,5,1,81.76156,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
351,6,1,96.5117,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
351,1,2,17.14378,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
351,2,2,20.804375,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
351,3,2,43.6352,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
351,4,2,91.56905,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
351,5,2,99.59891,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
351,6,2,106.00068,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
351,1,3,16.703299,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
351,2,3,30.64415,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
351,3,3,44.47192,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
351,4,3,74.05554,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
351,5,3,103.44006,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
351,6,3,97.238075,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
351,1,4,22.86615,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
351,2,4,27.73369,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
351,3,4,49.68059,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
351,4,4,91.41661,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
351,5,4,105.6148,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
351,6,4,100.10427,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
351,1,5,18.268322,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
351,2,5,27.799807,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
351,3,5,55.42469,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
351,4,5,96.21222,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
351,5,5,102.634605,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
351,6,5,101.787025,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
351,1,6,27.302958,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
351,2,6,37.09933,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
351,3,6,54.88351,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
351,4,6,107.15616,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
351,5,6,102.96593,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
351,6,6,100.69356,241,6,NCGC00263016-01,DE-096,TRPV4 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
352,1,1,22.216053,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
352,2,1,36.452347,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
352,3,1,64.92252,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
352,4,1,113.0614,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
352,5,1,105.89771,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
352,6,1,114.4212,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
352,1,2,20.203924,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
352,2,2,37.755795,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
352,3,2,64.887405,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
352,4,2,115.12158,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
352,5,2,130.62103,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
352,6,2,101.85623,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
352,1,3,17.914396,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
352,2,3,36.460876,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
352,3,3,55.75049,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
352,4,3,101.81277,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
352,5,3,119.2481,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
352,6,3,104.56945,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
352,1,4,26.200342,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
352,2,4,31.434813,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
352,3,4,58.8126,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
352,4,4,102.3557,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
352,5,4,107.72063,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
352,6,4,106.52441,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
352,1,5,26.617607,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
352,2,5,28.559397,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
352,3,5,44.467148,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
352,4,5,112.14051,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
352,5,5,113.34453,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
352,6,5,118.32577,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
352,1,6,23.895327,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
352,2,6,36.494503,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
352,3,6,53.23994,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
352,4,6,102.03443,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
352,5,6,105.87441,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
352,6,6,116.574036,241,6,NCGC00161825-02,GSK-3965,ABCA1 Expression Enhancer,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
353,1,1,30.006355,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
353,2,1,43.013077,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
353,3,1,51.679966,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
353,4,1,85.181366,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
353,5,1,103.068,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
353,6,1,95.78911,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
353,1,2,23.303644,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
353,2,2,42.295235,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
353,3,2,66.960014,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
353,4,2,95.44276,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
353,5,2,111.710976,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
353,6,2,117.14459,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
353,1,3,31.715567,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
353,2,3,45.275517,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
353,3,3,92.38824,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
353,4,3,104.271736,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
353,5,3,116.72662,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
353,6,3,114.62171,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
353,1,4,30.09614,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
353,2,4,40.599773,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
353,3,4,65.930756,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
353,4,4,110.79435,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
353,5,4,116.80123,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
353,6,4,122.28812,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
353,1,5,25.7016,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
353,2,5,36.165096,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
353,3,5,70.77714,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
353,4,5,97.576965,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
353,5,5,115.05228,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
353,6,5,125.00689,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
353,1,6,37.558723,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
353,2,6,44.469505,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
353,3,6,88.05157,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
353,4,6,107.75223,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
353,5,6,106.359535,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
353,6,6,111.975464,241,6,NCGC00016925-07,Omeprazole,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
354,1,1,29.5567,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
354,2,1,46.098614,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
354,3,1,51.764954,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
354,4,1,83.89109,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
354,5,1,108.34463,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
354,6,1,125.17399,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
354,1,2,28.101068,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
354,2,2,42.708263,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
354,3,2,54.6403,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
354,4,2,85.84465,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
354,5,2,107.901665,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
354,6,2,109.99121,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
354,1,3,25.822483,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
354,2,3,31.068949,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
354,3,3,49.77422,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
354,4,3,89.40965,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
354,5,3,111.835266,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
354,6,3,119.98271,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
354,1,4,22.805462,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
354,2,4,33.66625,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
354,3,4,51.094597,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
354,4,4,101.253746,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
354,5,4,102.45486,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
354,6,4,120.29396,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
354,1,5,32.39998,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
354,2,5,40.12502,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
354,3,5,60.491493,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
354,4,5,93.5842,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
354,5,5,107.82727,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
354,6,5,103.90709,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
354,1,6,24.370317,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
354,2,6,36.45437,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
354,3,6,57.12063,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
354,4,6,100.27425,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
354,5,6,105.84628,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
354,6,6,99.64278,241,6,NCGC00263219-01,Elacridar,P-Glycoprotein (MDR-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
355,1,1,21.542809,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
355,2,1,39.75113,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
355,3,1,55.18072,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
355,4,1,86.018745,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
355,5,1,107.01058,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
355,6,1,135.73021,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
355,1,2,20.548971,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
355,2,2,28.53939,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
355,3,2,47.187298,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
355,4,2,112.033,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
355,5,2,109.65624,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
355,6,2,110.52214,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
355,1,3,22.106112,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
355,2,3,35.04816,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
355,3,3,62.808224,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
355,4,3,97.577354,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
355,5,3,104.74346,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
355,6,3,116.39099,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
355,1,4,20.350733,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
355,2,4,28.487331,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
355,3,4,42.29957,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
355,4,4,99.7552,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
355,5,4,110.65784,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
355,6,4,103.74781,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
355,1,5,24.99947,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
355,2,5,31.739653,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
355,3,5,57.331577,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
355,4,5,107.74667,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
355,5,5,109.462425,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
355,6,5,120.465065,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
355,1,6,29.64031,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
355,2,6,41.14818,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
355,3,6,63.974766,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
355,4,6,104.245346,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
355,5,6,108.42539,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
355,6,6,116.92924,241,6,NCGC00168109-03,Secin H3,GEF Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
356,1,1,6.155263,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
356,2,1,13.881386,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
356,3,1,17.272295,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
356,4,1,61.897797,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
356,5,1,64.69101,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
356,6,1,76.90178,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
356,1,2,15.263001,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
356,2,2,26.316063,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
356,3,2,46.90406,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
356,4,2,78.41891,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
356,5,2,102.20188,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
356,6,2,103.95024,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
356,1,3,17.79619,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
356,2,3,29.895615,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
356,3,3,46.75787,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
356,4,3,81.11828,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
356,5,3,104.40659,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
356,6,3,107.841644,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
356,1,4,26.21106,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
356,2,4,30.878202,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
356,3,4,58.34135,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
356,4,4,83.61169,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
356,5,4,94.24291,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
356,6,4,104.49486,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
356,1,5,27.227146,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
356,2,5,32.133644,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
356,3,5,49.91286,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
356,4,5,124.49219,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
356,5,5,111.953766,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
356,6,5,101.070015,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
356,1,6,26.979038,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
356,2,6,45.025864,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
356,3,6,68.23273,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
356,4,6,114.63253,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
356,5,6,115.445305,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
356,6,6,86.57112,241,6,NCGC00250389-01,CDIBA,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
357,1,1,22.374813,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
357,2,1,15.845087,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
357,3,1,38.25371,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
357,4,1,56.18909,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
357,5,1,75.63957,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
357,6,1,103.366455,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
357,1,2,21.229551,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
357,2,2,33.42886,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
357,3,2,56.45674,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
357,4,2,103.1155,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
357,5,2,103.412735,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
357,6,2,119.88823,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
357,1,3,29.402302,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
357,2,3,33.44039,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
357,3,3,56.232624,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
357,4,3,90.92861,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
357,5,3,109.07389,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
357,6,3,134.05042,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
357,1,4,27.114077,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
357,2,4,46.723347,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
357,3,4,65.85086,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
357,4,4,83.27152,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
357,5,4,112.54975,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
357,6,4,114.42428,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
357,1,5,25.902489,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
357,2,5,37.393143,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
357,3,5,64.44068,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
357,4,5,101.434586,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
357,5,5,103.55159,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
357,6,5,114.748955,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
357,1,6,26.891542,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
357,2,6,25.96121,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
357,3,6,66.4277,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
357,4,6,99.168945,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
357,5,6,108.08096,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
357,6,6,111.7176,241,6,NCGC00025091-04,U-73122,Phospholipase C Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
358,1,1,28.373657,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
358,2,1,38.811024,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
358,3,1,64.0522,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
358,4,1,97.991844,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
358,5,1,127.560394,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
358,6,1,133.12093,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
358,1,2,35.330765,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
358,2,2,42.035442,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
358,3,2,66.29576,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
358,4,2,99.36215,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
358,5,2,135.61192,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
358,6,2,132.94713,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
358,1,3,24.582134,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
358,2,3,43.212154,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
358,3,3,68.077286,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
358,4,3,119.84545,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
358,5,3,118.96112,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
358,6,3,121.02994,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
358,1,4,40.495304,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
358,2,4,36.370308,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
358,3,4,71.10066,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
358,4,4,116.689255,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
358,5,4,114.0643,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
358,6,4,110.62664,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
358,1,5,26.742237,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
358,2,5,41.992165,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
358,3,5,68.581894,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
358,4,5,96.27818,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
358,5,5,134.12277,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
358,6,5,114.86754,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
358,1,6,30.896763,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
358,2,6,37.504852,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
358,3,6,55.181126,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
358,4,6,92.60488,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
358,5,6,136.64053,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
358,6,6,139.51343,241,6,NCGC00263226-01,BAY-60-7550,Phosphodiesterase II (PDE2A) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
359,1,1,26.26068,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
359,2,1,34.99704,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
359,3,1,56.185642,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
359,4,1,112.66432,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
359,5,1,115.733505,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
359,6,1,127.55968,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
359,1,2,22.877583,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
359,2,2,36.400204,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
359,3,2,71.268585,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
359,4,2,103.80179,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
359,5,2,122.10385,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
359,6,2,116.94795,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
359,1,3,28.271784,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
359,2,3,41.86777,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
359,3,3,68.29848,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
359,4,3,120.587425,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
359,5,3,120.82607,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
359,6,3,128.0462,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
359,1,4,27.388475,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
359,2,4,42.61802,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
359,3,4,54.874294,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
359,4,4,101.61052,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
359,5,4,107.133545,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
359,6,4,117.167725,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
359,1,5,35.367058,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
359,2,5,46.158035,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
359,3,5,65.26992,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
359,4,5,101.71356,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
359,5,5,120.41159,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
359,6,5,110.138794,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
359,1,6,29.98903,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
359,2,6,41.22692,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
359,3,6,49.588676,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
359,4,6,96.80925,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
359,5,6,142.68692,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
359,6,6,113.853775,241,6,NCGC00161408-01,Anagrelide,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
360,1,1,31.444717,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
360,2,1,34.577488,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
360,3,1,61.58582,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
360,4,1,100.96995,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
360,5,1,130.28233,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
360,6,1,118.71216,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
360,1,2,28.622383,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
360,2,2,36.291424,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
360,3,2,68.20374,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
360,4,2,113.9713,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
360,5,2,112.57472,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
360,6,2,119.45235,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
360,1,3,23.663588,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
360,2,3,45.75145,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
360,3,3,69.33245,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
360,4,3,108.87468,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
360,5,3,114.26372,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
360,6,3,116.458305,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
360,1,4,26.097301,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
360,2,4,34.873123,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
360,3,4,57.04587,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
360,4,4,99.99945,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
360,5,4,122.50165,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
360,6,4,115.735016,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
360,1,5,27.44898,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
360,2,5,37.281757,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
360,3,5,55.769203,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
360,4,5,118.0902,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
360,5,5,120.4143,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
360,6,5,123.02808,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
360,1,6,32.793324,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
360,2,6,37.283524,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
360,3,6,56.02479,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
360,4,6,105.60776,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
360,5,6,119.71902,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
360,6,6,125.53369,241,6,NCGC00162385-03,Olprinone,Phosphodiesterase III (PDE3) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
361,1,1,13.614492,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
361,2,1,11.043088,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
361,3,1,20.55938,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
361,4,1,25.859547,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
361,5,1,42.273884,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
361,6,1,40.76294,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
361,1,2,24.206423,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
361,2,2,21.173115,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
361,3,2,52.362118,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
361,4,2,78.00776,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
361,5,2,93.70198,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
361,6,2,73.600624,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
361,1,3,26.868423,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
361,2,3,32.80954,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
361,3,3,53.702393,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
361,4,3,87.04983,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
361,5,3,107.5171,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
361,6,3,99.99258,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
361,1,4,21.032072,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
361,2,4,32.270435,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
361,3,4,57.502037,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
361,4,4,97.54516,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
361,5,4,110.025276,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
361,6,4,107.71966,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
361,1,5,28.216665,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
361,2,5,38.673878,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
361,3,5,62.712887,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
361,4,5,84.82309,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
361,5,5,107.04362,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
361,6,5,117.7723,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
361,1,6,29.424017,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
361,2,6,40.725357,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
361,3,6,69.63766,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
361,4,6,124.90419,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
361,5,6,108.44067,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
361,6,6,92.79003,241,6,NCGC00168459-03,NCGC00168459-01,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
362,1,1,43.701836,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
362,2,1,34.144455,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
362,3,1,55.727047,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
362,4,1,93.83473,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
362,5,1,113.15135,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
362,6,1,125.23469,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
362,1,2,30.631468,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
362,2,2,35.638493,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
362,3,2,66.58958,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
362,4,2,98.9307,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
362,5,2,131.29187,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
362,6,2,139.06091,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
362,1,3,37.005196,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
362,2,3,40.617786,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
362,3,3,62.787476,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
362,4,3,101.44855,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
362,5,3,104.96992,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
362,6,3,108.01712,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
362,1,4,36.93539,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
362,2,4,41.85269,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
362,3,4,66.22907,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
362,4,4,107.42019,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
362,5,4,112.24514,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
362,6,4,106.15388,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
362,1,5,24.22233,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
362,2,5,44.357334,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
362,3,5,76.30803,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
362,4,5,118.232605,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
362,5,5,103.60705,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
362,6,5,120.437584,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
362,1,6,28.775997,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
362,2,6,35.45653,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
362,3,6,64.605545,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
362,4,6,96.33807,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
362,5,6,119.86102,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
362,6,6,110.13548,241,6,NCGC00249759-01,NCGC00249759,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
363,1,1,32.923508,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
363,2,1,43.346996,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
363,3,1,63.95799,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
363,4,1,109.86462,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
363,5,1,109.66245,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
363,6,1,131.10551,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
363,1,2,31.838512,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
363,2,2,38.709118,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
363,3,2,60.32168,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
363,4,2,116.82403,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
363,5,2,111.56042,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
363,6,2,133.86214,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
363,1,3,35.08939,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
363,2,3,40.363434,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
363,3,3,61.03281,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
363,4,3,114.02793,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
363,5,3,110.83899,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
363,6,3,107.69923,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
363,1,4,29.833399,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
363,2,4,41.246758,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
363,3,4,75.890526,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
363,4,4,113.737045,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
363,5,4,119.572174,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
363,6,4,124.71725,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
363,1,5,31.859077,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
363,2,5,44.197617,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
363,3,5,65.60732,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
363,4,5,108.150925,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
363,5,5,130.22243,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
363,6,5,134.53746,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
363,1,6,33.69913,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
363,2,6,40.310997,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
363,3,6,72.902954,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
363,4,6,111.9109,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
363,5,6,124.538956,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
363,6,6,126.2954,241,6,NCGC00250085-01,NVP-ABE171,Phosphodiesterase IIII (PDE4) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
364,1,1,27.3824,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
364,2,1,41.572598,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
364,3,1,57.57966,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
364,4,1,108.67422,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
364,5,1,119.202484,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
364,6,1,117.14956,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
364,1,2,31.844826,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
364,2,2,36.53768,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
364,3,2,68.008644,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
364,4,2,96.95916,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
364,5,2,132.64468,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
364,6,2,122.50367,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
364,1,3,28.388472,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
364,2,3,43.995228,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
364,3,3,70.88895,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
364,4,3,120.7489,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
364,5,3,129.64307,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
364,6,3,120.15514,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
364,1,4,36.39016,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
364,2,4,37.58177,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
364,3,4,61.308727,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
364,4,4,102.94197,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
364,5,4,142.15013,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
364,6,4,130.99173,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
364,1,5,28.011524,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
364,2,5,36.2687,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
364,3,5,61.02667,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
364,4,5,113.8596,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
364,5,5,142.5331,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
364,6,5,108.49668,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
364,1,6,36.0349,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
364,2,6,21.753475,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
364,3,6,73.74358,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
364,4,6,114.91627,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
364,5,6,110.545204,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
364,6,6,126.83323,241,6,NCGC00263118-01,Lirimilast,Phosphodiesterase IIII (PDE4) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
365,1,1,31.184418,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
365,2,1,41.257683,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
365,3,1,59.290623,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
365,4,1,100.12872,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
365,5,1,106.46615,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
365,6,1,125.19326,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
365,1,2,31.073465,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
365,2,2,40.787098,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
365,3,2,55.95824,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
365,4,2,101.62979,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
365,5,2,128.46649,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
365,6,2,138.51025,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
365,1,3,6.567562,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
365,2,3,47.314243,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
365,3,3,63.006153,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
365,4,3,119.51445,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
365,5,3,118.44525,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
365,6,3,116.583664,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
365,1,4,32.57814,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
365,2,4,53.863316,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
365,3,4,75.90283,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
365,4,4,94.14932,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
365,5,4,109.18539,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
365,6,4,126.558,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
365,1,5,34.861874,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
365,2,5,38.83772,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
365,3,5,74.592804,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
365,4,5,105.31732,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
365,5,5,119.77405,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
365,6,5,128.20648,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
365,1,6,38.09018,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
365,2,6,46.225204,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
365,3,6,59.230522,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
365,4,6,119.59834,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
365,5,6,115.92874,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
365,6,6,135.19931,241,6,NCGC00159496-02,Sildenafil citrate,Phosphodiesterase V (PDE5) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
366,1,1,22.67024,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
366,2,1,32.361973,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
366,3,1,57.44159,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
366,4,1,96.73487,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
366,5,1,100.859764,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
366,6,1,99.06083,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
366,1,2,23.07603,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
366,2,2,37.573814,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
366,3,2,56.77578,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
366,4,2,95.26749,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
366,5,2,106.88571,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
366,6,2,112.07441,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
366,1,3,29.061493,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
366,2,3,20.691711,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
366,3,3,53.405113,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
366,4,3,84.07499,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
366,5,3,94.43894,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
366,6,3,107.33603,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
366,1,4,30.080048,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
366,2,4,42.684067,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
366,3,4,60.744343,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
366,4,4,103.3385,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
366,5,4,105.634254,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
366,6,4,102.27365,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
366,1,5,30.09273,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
366,2,5,43.420338,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
366,3,5,61.69932,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
366,4,5,89.45745,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
366,5,5,113.1425,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
366,6,5,114.284485,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
366,1,6,27.075514,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
366,2,6,40.09626,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
366,3,6,61.007027,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
366,4,6,112.1204,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
366,5,6,119.520676,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
366,6,6,115.455246,241,6,NCGC00182037-01,Alacepril,Angiotensin-I Converting Enzyme Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
367,1,1,35.594753,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
367,2,1,44.297543,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
367,3,1,75.45385,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
367,4,1,110.29474,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
367,5,1,109.81808,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
367,6,1,107.063805,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
367,1,2,33.996536,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
367,2,2,32.90948,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
367,3,2,52.771275,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
367,4,2,100.68942,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
367,5,2,110.274086,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
367,6,2,127.936195,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
367,1,3,31.715664,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
367,2,3,39.131336,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
367,3,3,74.359764,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
367,4,3,107.75149,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
367,5,3,108.556305,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
367,6,3,132.06927,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
367,1,4,30.948893,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
367,2,4,36.535282,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
367,3,4,61.168945,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
367,4,4,115.438805,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
367,5,4,112.498,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
367,6,4,106.434586,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
367,1,5,31.773363,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
367,2,5,32.52946,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
367,3,5,58.113148,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
367,4,5,110.3677,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
367,5,5,113.10597,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
367,6,5,128.82886,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
367,1,6,28.2996,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
367,2,6,43.88819,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
367,3,6,65.54846,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
367,4,6,100.27427,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
367,5,6,122.99121,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
367,6,6,143.58582,241,6,NCGC00025323-06,Ubenimex,Leukotriene A4 Hydrolase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
368,1,1,30.083626,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
368,2,1,46.71148,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
368,3,1,64.67542,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
368,4,1,116.559265,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
368,5,1,111.02043,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
368,6,1,108.963135,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
368,1,2,31.931255,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
368,2,2,31.76743,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
368,3,2,63.929398,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
368,4,2,100.16063,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
368,5,2,119.20829,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
368,6,2,123.51887,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
368,1,3,29.266027,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
368,2,3,42.913486,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
368,3,3,55.527336,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
368,4,3,113.32421,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
368,5,3,118.11213,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
368,6,3,117.251686,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
368,1,4,30.252361,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
368,2,4,46.67005,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
368,3,4,64.21149,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
368,4,4,103.84574,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
368,5,4,128.67018,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
368,6,4,134.32036,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
368,1,5,32.473064,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
368,2,5,38.10536,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
368,3,5,68.48994,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
368,4,5,108.768105,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
368,5,5,111.73742,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
368,6,5,110.06015,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
368,1,6,34.795197,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
368,2,6,37.30709,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
368,3,6,58.453636,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
368,4,6,114.347374,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
368,5,6,115.14604,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
368,6,6,112.66358,241,6,NCGC00263227-01,BAY-41-8543,Soluble Guanylate Cyclase (sGC) Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
369,1,1,32.3301,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
369,2,1,33.47371,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
369,3,1,53.14703,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
369,4,1,88.65521,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
369,5,1,108.04593,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
369,6,1,143.74161,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
369,1,2,33.792507,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
369,2,2,32.04713,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
369,3,2,51.810238,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
369,4,2,108.2862,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
369,5,2,115.15474,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
369,6,2,127.45444,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
369,1,3,28.465265,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
369,2,3,40.53997,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
369,3,3,61.823067,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
369,4,3,112.45438,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
369,5,3,117.241615,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
369,6,3,119.918526,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
369,1,4,36.811,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
369,2,4,39.264957,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
369,3,4,60.12776,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
369,4,4,111.395836,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
369,5,4,140.6489,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
369,6,4,131.40239,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
369,1,5,32.152428,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
369,2,5,42.15307,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
369,3,5,62.218082,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
369,4,5,111.72197,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
369,5,5,105.944374,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
369,6,5,114.698364,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
369,1,6,31.350542,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
369,2,6,46.302,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
369,3,6,67.029915,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
369,4,6,126.24725,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
369,5,6,130.01959,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
369,6,6,130.89671,241,6,NCGC00016854-01,Vinpocetine,"Na channel blocker, also PDE1, IKK inhibitor",NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
370,1,1,26.981297,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
370,2,1,32.477104,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
370,3,1,47.53575,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
370,4,1,109.10427,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
370,5,1,132.6614,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
370,6,1,119.45407,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
370,1,2,32.881493,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
370,2,2,40.039097,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
370,3,2,50.385834,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
370,4,2,91.07759,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
370,5,2,109.63718,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
370,6,2,125.57436,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
370,1,3,31.82412,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
370,2,3,36.25425,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
370,3,3,61.38908,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
370,4,3,90.83933,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
370,5,3,111.364624,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
370,6,3,118.527306,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
370,1,4,34.730877,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
370,2,4,32.771156,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
370,3,4,66.37805,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
370,4,4,122.177475,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
370,5,4,111.3964,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
370,6,4,121.10526,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
370,1,5,29.306318,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
370,2,5,40.400654,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
370,3,5,60.219086,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
370,4,5,118.5254,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
370,5,5,134.55208,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
370,6,5,130.23369,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
370,1,6,32.162178,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
370,2,6,38.33735,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
370,3,6,58.740353,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
370,4,6,108.72545,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
370,5,6,113.441055,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
370,6,6,116.79476,241,6,NCGC00016083-14,Verapamil,Dopamine D2 Receptor (DRD2) Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
371,1,1,13.92991,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
371,2,1,20.075241,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
371,3,1,29.33732,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
371,4,1,66.62216,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
371,5,1,91.68135,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
371,6,1,82.08601,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
371,1,2,18.249117,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
371,2,2,31.53123,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
371,3,2,54.3791,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
371,4,2,88.303505,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
371,5,2,93.8038,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
371,6,2,89.84448,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
371,1,3,25.396338,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
371,2,3,34.955963,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
371,3,3,60.717056,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
371,4,3,102.92094,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
371,5,3,100.32842,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
371,6,3,103.19879,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
371,1,4,29.919323,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
371,2,4,37.437725,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
371,3,4,53.529675,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
371,4,4,98.585365,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
371,5,4,115.7752,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
371,6,4,114.94792,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
371,1,5,33.98644,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
371,2,5,45.042027,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
371,3,5,64.4785,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
371,4,5,104.35642,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
371,5,5,118.466125,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
371,6,5,115.56976,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
371,1,6,39.272293,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
371,2,6,27.096598,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
371,3,6,69.98055,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
371,4,6,104.96919,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
371,5,6,114.18628,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
371,6,6,102.88648,241,6,NCGC00025015-01,(S)-(+)-Niguldipine,L-type Ca2+ channel blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
372,1,1,24.764856,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
372,2,1,28.974894,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
372,3,1,42.36225,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
372,4,1,87.48104,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
372,5,1,111.57087,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
372,6,1,113.744156,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
372,1,2,27.67101,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
372,2,2,49.122505,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
372,3,2,60.171013,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
372,4,2,96.29912,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
372,5,2,124.4632,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
372,6,2,113.62408,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
372,1,3,35.70269,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
372,2,3,29.254105,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
372,3,3,73.087555,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
372,4,3,99.28729,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
372,5,3,110.3677,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
372,6,3,114.364105,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
372,1,4,28.882895,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
372,2,4,42.569115,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
372,3,4,61.034904,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
372,4,4,112.99769,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
372,5,4,104.84602,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
372,6,4,100.80695,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
372,1,5,37.604202,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
372,2,5,33.083405,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
372,3,5,62.34134,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
372,4,5,107.43304,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
372,5,5,108.59208,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
372,6,5,112.146866,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
372,1,6,35.688408,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
372,2,6,37.488495,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
372,3,6,63.33536,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
372,4,6,106.86065,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
372,5,6,106.05733,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
372,6,6,128.69778,241,6,NCGC00025379-01,SR 33805,Ca2+ channel Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
373,1,1,27.33441,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
373,2,1,32.905678,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
373,3,1,45.671513,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
373,4,1,96.07361,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
373,5,1,110.26278,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
373,6,1,118.498955,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
373,1,2,32.868305,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
373,2,2,32.453495,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
373,3,2,63.218487,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
373,4,2,106.30802,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
373,5,2,134.9693,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
373,6,2,118.810135,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
373,1,3,26.526253,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
373,2,3,38.993717,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
373,3,3,57.109703,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
373,4,3,106.61393,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
373,5,3,112.08709,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
373,6,3,121.59772,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
373,1,4,31.479717,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
373,2,4,39.478024,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
373,3,4,60.014282,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
373,4,4,121.89633,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
373,5,4,144.08305,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
373,6,4,129.28801,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
373,1,5,33.076656,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
373,2,5,40.00241,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
373,3,5,61.89599,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
373,4,5,102.854485,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
373,5,5,115.35232,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
373,6,5,128.94696,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
373,1,6,32.129814,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
373,2,6,38.672127,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
373,3,6,62.335503,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
373,4,6,113.544395,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
373,5,6,105.14793,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
373,6,6,115.10198,241,6,NCGC00159544-02,Zaldaride maleate,Calmodulin Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
374,1,1,36.2874,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
374,2,1,36.82573,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
374,3,1,82.756226,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
374,4,1,114.305595,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
374,5,1,122.76178,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
374,6,1,101.16089,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
374,1,2,36.51103,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
374,2,2,36.952366,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
374,3,2,63.22121,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
374,4,2,107.36479,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
374,5,2,128.15483,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
374,6,2,115.768295,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
374,1,3,33.588333,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
374,2,3,46.44474,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
374,3,3,59.801006,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
374,4,3,123.1307,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
374,5,3,129.18027,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
374,6,3,107.57742,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
374,1,4,26.789696,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
374,2,4,43.913612,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
374,3,4,68.74053,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
374,4,4,120.24405,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
374,5,4,122.04962,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
374,6,4,136.71623,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
374,1,5,31.280527,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
374,2,5,40.08087,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
374,3,5,69.99132,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
374,4,5,122.619446,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
374,5,5,116.60658,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
374,6,5,139.07928,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
374,1,6,31.30937,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
374,2,6,40.08982,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
374,3,6,73.908394,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
374,4,6,110.12388,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
374,5,6,107.56691,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
374,6,6,117.57782,241,6,NCGC00015882-11,Riluzole,Glutamate Release Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
375,1,1,32.328503,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
375,2,1,37.433067,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
375,3,1,74.270935,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
375,4,1,97.16241,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
375,5,1,106.66836,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
375,6,1,132.51625,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
375,1,2,31.15305,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
375,2,2,44.946674,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
375,3,2,62.79236,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
375,4,2,109.55885,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
375,5,2,120.78124,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
375,6,2,116.364426,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
375,1,3,30.197214,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
375,2,3,40.550255,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
375,3,3,68.92888,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
375,4,3,99.55493,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
375,5,3,124.910095,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
375,6,3,117.61358,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
375,1,4,45.14536,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
375,2,4,43.6376,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
375,3,4,76.298195,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
375,4,4,113.46217,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
375,5,4,109.6095,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
375,6,4,126.13181,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
375,1,5,35.0779,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
375,2,5,36.329357,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
375,3,5,54.164253,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
375,4,5,117.72543,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
375,5,5,143.45615,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
375,6,5,131.41396,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
375,1,6,38.82143,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
375,2,6,47.4186,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
375,3,6,72.67413,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
375,4,6,114.775734,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
375,5,6,124.50845,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
375,6,6,119.33808,241,6,NCGC00247954-02,SSR-504734,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
376,1,1,18.706419,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
376,2,1,26.212181,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
376,3,1,54.683495,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
376,4,1,70.49449,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
376,5,1,82.152916,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
376,6,1,100.18873,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
376,1,2,24.418184,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
376,2,2,29.830313,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
376,3,2,51.192112,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
376,4,2,87.49966,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
376,5,2,101.18007,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
376,6,2,93.417625,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
376,1,3,25.862759,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
376,2,3,34.022293,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
376,3,3,44.56518,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
376,4,3,76.28384,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
376,5,3,103.90331,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
376,6,3,102.55928,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
376,1,4,26.510147,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
376,2,4,34.873505,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
376,3,4,55.586018,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
376,4,4,100.376625,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
376,5,4,101.41155,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
376,6,4,102.31958,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
376,1,5,26.52196,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
376,2,5,26.14305,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
376,3,5,71.00763,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
376,4,5,100.868286,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
376,5,5,105.97048,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
376,6,5,108.853004,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
376,1,6,30.234278,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
376,2,6,38.687416,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
376,3,6,62.99873,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
376,4,6,104.33628,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
376,5,6,109.62102,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
376,6,6,124.86241,241,6,NCGC00263114-01,SCH-900435,Glycine Transporter 1 (GlyT-1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
377,1,1,34.461487,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
377,2,1,37.531704,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
377,3,1,73.555336,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
377,4,1,105.03506,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
377,5,1,110.414635,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
377,6,1,105.8838,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
377,1,2,29.088846,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
377,2,2,39.683163,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
377,3,2,63.79457,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
377,4,2,94.08063,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
377,5,2,109.458084,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
377,6,2,111.82438,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
377,1,3,40.45703,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
377,2,3,41.0946,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
377,3,3,61.305107,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
377,4,3,108.053734,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
377,5,3,118.76116,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
377,6,3,110.19673,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
377,1,4,33.29713,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
377,2,4,38.214108,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
377,3,4,63.554207,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
377,4,4,111.91398,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
377,5,4,106.41726,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
377,6,4,98.39062,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
377,1,5,34.098904,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
377,2,5,34.2098,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
377,3,5,67.94016,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
377,4,5,97.29648,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
377,5,5,115.245995,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
377,6,5,109.84802,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
377,1,6,32.40758,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
377,2,6,38.20781,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
377,3,6,71.87919,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
377,4,6,96.43515,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
377,5,6,111.91023,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
377,6,6,119.99609,241,6,NCGC00242480-01,Ivacaftor,CFTR Channel Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
378,1,1,25.526943,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
378,2,1,44.688953,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
378,3,1,54.508823,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
378,4,1,105.42348,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
378,5,1,108.79382,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
378,6,1,103.506195,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
378,1,2,29.64195,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
378,2,2,34.980835,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
378,3,2,60.095272,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
378,4,2,100.60627,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
378,5,2,118.526505,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
378,6,2,123.674225,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
378,1,3,34.2917,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
378,2,3,36.144054,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
378,3,3,62.84304,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
378,4,3,92.66314,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
378,5,3,107.700874,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
378,6,3,120.03094,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
378,1,4,32.365116,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
378,2,4,41.97094,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
378,3,4,80.254906,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
378,4,4,104.068954,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
378,5,4,130.84671,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
378,6,4,123.05823,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
378,1,5,29.15652,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
378,2,5,44.474274,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
378,3,5,71.7652,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
378,4,5,108.93377,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
378,5,5,122.107414,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
378,6,5,111.93666,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
378,1,6,32.30422,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
378,2,6,31.57782,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
378,3,6,68.13798,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
378,4,6,103.94218,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
378,5,6,115.91074,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
378,6,6,108.85399,241,6,NCGC00181343-01,Ivabradine hydrochloride,HCN [I(f)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
379,1,1,31.226433,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
379,2,1,23.712969,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
379,3,1,47.03855,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
379,4,1,113.89683,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
379,5,1,116.05675,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
379,6,1,116.63826,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
379,1,2,33.87846,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
379,2,2,39.883392,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
379,3,2,68.01202,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
379,4,2,109.32494,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
379,5,2,119.93968,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
379,6,2,111.877014,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
379,1,3,41.571053,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
379,2,3,46.601437,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
379,3,3,77.188774,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
379,4,3,114.9459,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
379,5,3,114.28626,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
379,6,3,129.13255,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
379,1,4,33.76333,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
379,2,4,39.348076,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
379,3,4,67.85403,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
379,4,4,116.248,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
379,5,4,109.60816,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
379,6,4,120.220985,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
379,1,5,32.011246,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
379,2,5,44.42126,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
379,3,5,68.03443,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
379,4,5,101.972725,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
379,5,5,122.230675,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
379,6,5,114.277695,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
379,1,6,36.131344,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
379,2,6,47.882244,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
379,3,6,64.83189,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
379,4,6,112.2269,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
379,5,6,129.29004,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
379,6,6,130.19327,241,6,NCGC00024929-01,ICI-D7288,HCN [I(h)] Blocker,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
380,1,1,33.327335,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
380,2,1,36.97216,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
380,3,1,51.13135,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
380,4,1,95.8529,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
380,5,1,121.96941,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
380,6,1,124.48507,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
380,1,2,34.907803,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
380,2,2,42.488647,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
380,3,2,89.32452,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
380,4,2,114.434746,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
380,5,2,116.06977,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
380,6,2,107.72838,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
380,1,3,34.209812,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
380,2,3,39.464737,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
380,3,3,57.9194,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
380,4,3,100.6441,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
380,5,3,126.39852,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
380,6,3,134.32883,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
380,1,4,31.47798,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
380,2,4,39.46196,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
380,3,4,67.87908,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
380,4,4,106.98894,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
380,5,4,108.20061,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
380,6,4,123.79074,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
380,1,5,28.933046,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
380,2,5,43.509293,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
380,3,5,71.761986,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
380,4,5,121.192055,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
380,5,5,104.307396,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
380,6,5,126.26733,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
380,1,6,37.158543,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
380,2,6,52.79243,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
380,3,6,62.321293,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
380,4,6,90.287186,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
380,5,6,106.56164,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
380,6,6,129.09035,241,6,NCGC00250409-01,GSK-1016790A,TRPV4 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
381,1,1,19.437826,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
381,2,1,23.349434,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
381,3,1,39.752003,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
381,4,1,65.58126,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
381,5,1,67.778946,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
381,6,1,87.4606,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
381,1,2,26.60278,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
381,2,2,32.28807,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
381,3,2,42.56475,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
381,4,2,75.68605,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
381,5,2,91.307365,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
381,6,2,84.07631,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
381,1,3,22.614716,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
381,2,3,32.46911,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
381,3,3,50.600037,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
381,4,3,91.708725,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
381,5,3,85.72806,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
381,6,3,79.6591,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
381,1,4,26.768919,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
381,2,4,32.14505,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
381,3,4,58.17959,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
381,4,4,95.527306,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
381,5,4,77.16773,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
381,6,4,99.713425,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
381,1,5,25.612223,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
381,2,5,42.636772,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
381,3,5,69.35028,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
381,4,5,63.787655,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
381,5,5,112.68959,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
381,6,5,99.1201,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
381,1,6,32.643723,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
381,2,6,39.80688,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
381,3,6,54.824326,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
381,4,6,79.908134,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
381,5,6,95.864845,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
381,6,6,102.51741,241,6,NCGC00092384-02,Fenobam,mgluR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
382,1,1,22.579617,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
382,2,1,43.195827,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
382,3,1,69.32471,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
382,4,1,105.1019,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
382,5,1,99.72508,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
382,6,1,116.73117,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
382,1,2,38.39231,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
382,2,2,41.33863,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
382,3,2,59.26885,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
382,4,2,95.12109,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
382,5,2,109.77363,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
382,6,2,108.177086,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
382,1,3,28.529446,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
382,2,3,33.614147,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
382,3,3,67.69007,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
382,4,3,89.163246,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
382,5,3,104.43751,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
382,6,3,105.33302,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
382,1,4,22.147636,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
382,2,4,39.09398,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
382,3,4,68.33318,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
382,4,4,87.71654,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
382,5,4,109.32491,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
382,6,4,94.3222,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
382,1,5,31.115116,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
382,2,5,32.19366,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
382,3,5,48.904293,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
382,4,5,91.45445,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
382,5,5,106.402435,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
382,6,5,102.17822,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
382,1,6,28.46396,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
382,2,6,37.621445,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
382,3,6,52.666595,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
382,4,6,91.99979,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
382,5,6,101.01519,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
382,6,6,114.84441,241,6,NCGC00015682-05,MPEP,mgluR5 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
383,1,1,26.915728,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
383,2,1,32.679157,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
383,3,1,54.271336,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
383,4,1,93.22851,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
383,5,1,109.19437,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
383,6,1,108.2422,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
383,1,2,34.317875,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
383,2,2,35.97612,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
383,3,2,50.7298,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
383,4,2,77.28157,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
383,5,2,107.0853,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
383,6,2,112.36274,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
383,1,3,26.58579,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
383,2,3,33.675972,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
383,3,3,55.891926,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
383,4,3,105.666084,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
383,5,3,106.99519,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
383,6,3,108.72047,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
383,1,4,30.920078,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
383,2,4,43.800976,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
383,3,4,68.79732,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
383,4,4,100.93283,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
383,5,4,105.52068,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
383,6,4,113.132484,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
383,1,5,36.227932,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
383,2,5,43.30595,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
383,3,5,65.04066,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
383,4,5,102.28949,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
383,5,5,104.16856,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
383,6,5,112.51673,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
383,1,6,27.352507,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
383,2,6,38.707237,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
383,3,6,61.85717,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
383,4,6,101.364624,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
383,5,6,102.78408,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
383,6,6,100.776146,241,6,NCGC00250378-01,Piboserod hydrochloride,5-HT4 Antagonists,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
384,1,1,15.684026,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
384,2,1,16.094809,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
384,3,1,17.773071,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
384,4,1,25.288319,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
384,5,1,50.83806,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
384,6,1,85.15976,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
384,1,2,37.853012,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
384,2,2,35.7856,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
384,3,2,48.885044,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
384,4,2,68.34255,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
384,5,2,104.37337,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
384,6,2,110.01178,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
384,1,3,33.15167,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
384,2,3,36.223007,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
384,3,3,47.234604,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
384,4,3,91.592636,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
384,5,3,110.91501,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
384,6,3,112.13817,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
384,1,4,35.010494,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
384,2,4,42.217953,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
384,3,4,50.7189,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
384,4,4,106.12545,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
384,5,4,113.57156,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
384,6,4,122.27201,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
384,1,5,33.223495,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
384,2,5,40.169586,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
384,3,5,61.614254,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
384,4,5,84.541374,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
384,5,5,111.82041,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
384,6,5,106.3256,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
384,1,6,36.16507,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
384,2,6,39.155506,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
384,3,6,62.95917,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
384,4,6,102.80547,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
384,5,6,111.67019,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
384,6,6,109.625984,241,6,NCGC00015918-05,SB-224289,5-HT1B Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
385,1,1,44.045452,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
385,2,1,59.07468,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
385,3,1,70.17537,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
385,4,1,108.44367,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
385,5,1,104.52085,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
385,6,1,105.33824,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
385,1,2,32.619034,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
385,2,2,44.745644,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
385,3,2,55.750614,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
385,4,2,100.026405,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
385,5,2,112.22193,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
385,6,2,97.66568,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
385,1,3,29.80415,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
385,2,3,46.073345,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
385,3,3,62.129745,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
385,4,3,95.03425,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
385,5,3,104.581345,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
385,6,3,107.40962,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
385,1,4,27.415047,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
385,2,4,41.11879,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
385,3,4,52.730988,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
385,4,4,116.677795,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
385,5,4,106.66788,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
385,6,4,105.6663,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
385,1,5,35.80427,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
385,2,5,51.53069,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
385,3,5,75.27737,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
385,4,5,98.212326,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
385,5,5,107.60036,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
385,6,5,122.701035,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
385,1,6,37.199394,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
385,2,6,43.068474,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
385,3,6,61.22182,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
385,4,6,102.79539,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
385,5,6,110.07184,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
385,6,6,115.21473,241,6,NCGC00015917-04,SB-206553,5-HT2B Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
386,1,1,25.502655,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
386,2,1,30.609215,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
386,3,1,53.91158,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
386,4,1,83.725586,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
386,5,1,99.69876,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
386,6,1,94.57047,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
386,1,2,24.443876,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
386,2,2,29.554388,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
386,3,2,51.0372,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
386,4,2,92.3443,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
386,5,2,99.16626,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
386,6,2,104.27238,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
386,1,3,23.72929,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
386,2,3,32.708366,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
386,3,3,56.028473,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
386,4,3,107.396515,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
386,5,3,102.81069,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
386,6,3,98.5521,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
386,1,4,21.659826,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
386,2,4,30.581133,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
386,3,4,45.409508,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
386,4,4,102.56902,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
386,5,4,105.83285,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
386,6,4,106.8495,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
386,1,5,28.69612,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
386,2,5,38.488438,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
386,3,5,64.152084,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
386,4,5,104.36077,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
386,5,5,102.21635,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
386,6,5,115.16565,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
386,1,6,28.121716,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
386,2,6,44.25452,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
386,3,6,61.539886,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
386,4,6,119.50286,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
386,5,6,97.97976,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
386,6,6,128.55879,241,6,NCGC00242503-01,Meclinertant,Carboxypeptidase A Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
387,1,1,29.585335,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
387,2,1,34.962505,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
387,3,1,51.462406,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
387,4,1,97.55819,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
387,5,1,124.783226,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
387,6,1,125.46402,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
387,1,2,28.404943,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
387,2,2,45.141308,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
387,3,2,65.73904,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
387,4,2,100.26731,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
387,5,2,115.76574,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
387,6,2,119.377365,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
387,1,3,32.273666,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
387,2,3,43.90968,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
387,3,3,63.797848,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
387,4,3,102.73156,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
387,5,3,104.92887,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
387,6,3,101.23339,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
387,1,4,22.13672,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
387,2,4,40.04214,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
387,3,4,64.09943,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
387,4,4,100.86112,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
387,5,4,114.84484,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
387,6,4,119.03133,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
387,1,5,31.388853,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
387,2,5,34.200294,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
387,3,5,54.183987,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
387,4,5,103.41528,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
387,5,5,109.98552,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
387,6,5,124.74424,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
387,1,6,26.745388,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
387,2,6,40.692055,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
387,3,6,66.476204,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
387,4,6,92.236916,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
387,5,6,102.066795,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
387,6,6,131.6301,241,6,NCGC00242479-02,Zibotentan,Endothelin ETA Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
388,1,1,29.764252,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
388,2,1,39.859722,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
388,3,1,74.47903,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
388,4,1,95.35391,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
388,5,1,128.58372,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
388,6,1,112.95434,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
388,1,2,35.541878,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
388,2,2,39.260372,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
388,3,2,71.37901,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
388,4,2,108.21012,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
388,5,2,115.009766,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
388,6,2,118.266846,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
388,1,3,32.90481,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
388,2,3,41.18926,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
388,3,3,62.245228,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
388,4,3,113.08673,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
388,5,3,127.001495,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
388,6,3,134.21498,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
388,1,4,24.950674,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
388,2,4,43.562893,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
388,3,4,65.662544,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
388,4,4,117.184875,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
388,5,4,123.84593,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
388,6,4,123.32215,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
388,1,5,26.5849,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
388,2,5,46.102562,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
388,3,5,58.59848,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
388,4,5,96.0623,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
388,5,5,109.22261,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
388,6,5,136.24582,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
388,1,6,29.852152,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
388,2,6,39.216175,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
388,3,6,65.55487,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
388,4,6,98.57713,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
388,5,6,120.0906,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
388,6,6,115.18589,241,6,NCGC00167739-01,GW-4064X,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
389,1,1,29.078299,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
389,2,1,35.316055,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
389,3,1,61.658478,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
389,4,1,105.68098,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
389,5,1,105.03806,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
389,6,1,114.37777,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
389,1,2,26.03821,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
389,2,2,35.967957,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
389,3,2,67.54071,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
389,4,2,94.879326,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
389,5,2,107.961296,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
389,6,2,108.98959,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
389,1,3,33.50463,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
389,2,3,45.87915,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
389,3,3,51.213833,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
389,4,3,4.132041,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
389,5,3,120.66826,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
389,6,3,127.56606,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
389,1,4,30.304789,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
389,2,4,35.969116,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
389,3,4,53.268112,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
389,4,4,79.86326,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
389,5,4,120.05185,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
389,6,4,122.636955,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
389,1,5,33.968655,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
389,2,5,36.72571,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
389,3,5,55.850655,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
389,4,5,113.47135,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
389,5,5,112.68494,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
389,6,5,119.806564,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
389,1,6,25.49382,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
389,2,6,33.690067,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
389,3,6,57.1816,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
389,4,6,95.43213,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
389,5,6,124.2464,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
389,6,6,115.96571,241,6,NCGC00263105-01,Turofexorate isopropyl,Farnesoid X Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
390,1,1,22.867338,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
390,2,1,41.88478,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
390,3,1,59.69777,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
390,4,1,94.73881,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
390,5,1,109.43079,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
390,6,1,125.34291,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
390,1,2,30.483849,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
390,2,2,38.428448,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
390,3,2,58.24016,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
390,4,2,102.997345,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
390,5,2,99.6526,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
390,6,2,116.62608,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
390,1,3,22.093145,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
390,2,3,26.058432,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
390,3,3,60.267292,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
390,4,3,110.8087,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
390,5,3,110.819244,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
390,6,3,117.88156,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
390,1,4,19.433685,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
390,2,4,29.634525,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
390,3,4,47.36399,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
390,4,4,101.86107,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
390,5,4,136.53185,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
390,6,4,116.29441,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
390,1,5,24.740683,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
390,2,5,28.071718,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
390,3,5,62.393005,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
390,4,5,102.35389,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
390,5,5,110.28557,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
390,6,5,120.53807,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
390,1,6,27.07448,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
390,2,6,29.402367,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
390,3,6,55.417713,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
390,4,6,94.6596,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
390,5,6,106.2375,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
390,6,6,135.03091,241,6,NCGC00167811-01,GW-9508,Free Fatty Acid Receptor 1 Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
391,1,1,16.975466,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
391,2,1,31.985697,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
391,3,1,53.954266,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
391,4,1,93.591286,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
391,5,1,102.06623,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
391,6,1,108.431526,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
391,1,2,21.088766,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
391,2,2,35.153942,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
391,3,2,48.739346,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
391,4,2,78.13804,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
391,5,2,102.14496,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
391,6,2,106.4316,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
391,1,3,26.464401,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
391,2,3,35.307983,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
391,3,3,62.778908,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
391,4,3,101.613174,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
391,5,3,105.88829,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
391,6,3,120.01114,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
391,1,4,31.52445,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
391,2,4,40.87484,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
391,3,4,60.386814,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
391,4,4,99.04044,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
391,5,4,101.03594,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
391,6,4,100.55301,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
391,1,5,33.1303,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
391,2,5,39.8028,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
391,3,5,47.89729,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
391,4,5,105.40208,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
391,5,5,107.1748,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
391,6,5,112.742,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
391,1,6,36.878494,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
391,2,6,51.825195,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
391,3,6,54.954567,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
391,4,6,111.44646,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
391,5,6,115.988304,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
391,6,6,137.07182,241,6,NCGC00263225-01,AG-041R,gastrin/CCKB receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
392,1,1,35.837147,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
392,2,1,60.1302,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
392,3,1,63.64038,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
392,4,1,112.10821,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
392,5,1,130.41533,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
392,6,1,132.39354,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
392,1,2,33.03434,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
392,2,2,34.26141,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
392,3,2,61.712948,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
392,4,2,109.38837,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
392,5,2,106.601845,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
392,6,2,120.77723,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
392,1,3,23.185114,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
392,2,3,51.788605,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
392,3,3,70.67523,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
392,4,3,110.21295,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
392,5,3,115.26962,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
392,6,3,121.60973,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
392,1,4,34.847374,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
392,2,4,34.59004,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
392,3,4,62.677025,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
392,4,4,90.143036,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
392,5,4,119.61775,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
392,6,4,108.92077,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
392,1,5,30.723446,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
392,2,5,50.808865,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
392,3,5,63.15856,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
392,4,5,107.71238,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
392,5,5,110.84547,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
392,6,5,121.12897,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
392,1,6,28.258526,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
392,2,6,35.51099,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
392,3,6,70.757744,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
392,4,6,106.29921,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
392,5,6,124.35289,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
392,6,6,110.15007,241,6,NCGC00263122-01,MK-0354,Nicotinic Acid Receptor Partial Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
393,1,1,30.465237,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
393,2,1,35.826363,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
393,3,1,54.323647,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
393,4,1,76.80779,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
393,5,1,116.3557,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
393,6,1,111.882484,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
393,1,2,33.70713,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
393,2,2,35.17027,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
393,3,2,59.085407,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
393,4,2,86.21238,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
393,5,2,104.043816,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
393,6,2,112.68703,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
393,1,3,29.415377,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
393,2,3,37.237858,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
393,3,3,65.67977,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
393,4,3,108.20525,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
393,5,3,135.43613,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
393,6,3,107.881096,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
393,1,4,38.872902,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
393,2,4,37.426468,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
393,3,4,53.31568,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
393,4,4,95.561844,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
393,5,4,127.18066,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
393,6,4,134.892,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
393,1,5,34.839073,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
393,2,5,40.629417,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
393,3,5,59.88105,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
393,4,5,95.59057,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
393,5,5,123.03204,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
393,6,5,117.06448,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
393,1,6,33.76366,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
393,2,6,40.402504,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
393,3,6,69.33454,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
393,4,6,111.0359,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
393,5,6,115.48906,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
393,6,6,123.32603,241,6,NCGC00165875-02,PB-28,sigma1/2 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
394,1,1,25.463566,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
394,2,1,33.353203,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
394,3,1,46.819405,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
394,4,1,85.02941,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
394,5,1,105.99298,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
394,6,1,111.60367,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
394,1,2,32.864975,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
394,2,2,33.151733,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
394,3,2,54.426434,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
394,4,2,93.325226,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
394,5,2,121.47942,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
394,6,2,132.43936,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
394,1,3,38.21932,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
394,2,3,44.986534,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
394,3,3,72.93665,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
394,4,3,123.031425,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
394,5,3,132.52663,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
394,6,3,108.78969,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
394,1,4,34.333237,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
394,2,4,45.795456,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
394,3,4,57.171394,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
394,4,4,102.49271,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
394,5,4,117.35145,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
394,6,4,149.50462,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
394,1,5,36.341755,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
394,2,5,43.392044,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
394,3,5,56.04192,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
394,4,5,107.99729,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
394,5,5,124.9184,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
394,6,5,117.44522,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
394,1,6,35.487297,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
394,2,6,35.39289,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
394,3,6,62.05553,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
394,4,6,100.92112,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
394,5,6,111.8418,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
394,6,6,126.06046,241,6,NCGC00263126-01,Cutamesine hydrochloride,sigma1 Receptor Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
395,1,1,37.934322,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
395,2,1,43.7067,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
395,3,1,48.09788,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
395,4,1,91.37589,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
395,5,1,120.57287,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
395,6,1,115.50359,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
395,1,2,31.992046,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
395,2,2,35.78307,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
395,3,2,55.31888,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
395,4,2,91.573425,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
395,5,2,118.19696,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
395,6,2,109.46373,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
395,1,3,27.503918,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
395,2,3,42.08138,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
395,3,3,53.35312,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
395,4,3,103.46528,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
395,5,3,114.57743,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
395,6,3,115.92695,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
395,1,4,29.79833,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
395,2,4,34.560318,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
395,3,4,57.115444,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
395,4,4,101.83021,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
395,5,4,89.6883,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
395,6,4,111.16653,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
395,1,5,34.374485,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
395,2,5,39.26016,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
395,3,5,65.303474,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
395,4,5,83.71125,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
395,5,5,116.77974,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
395,6,5,110.89814,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
395,1,6,27.261738,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
395,2,6,40.90964,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
395,3,6,59.70014,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
395,4,6,108.22607,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
395,5,6,118.2332,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
395,6,6,127.73739,241,6,NCGC00024901-01,BD-1047,sigma Receptor Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
396,1,1,10.034412,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
396,2,1,7.354984,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
396,3,1,6.369515,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
396,4,1,16.771118,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
396,5,1,29.635952,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
396,6,1,39.041447,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
396,1,2,16.689133,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
396,2,2,27.66136,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
396,3,2,35.458256,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
396,4,2,74.93943,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
396,5,2,107.30345,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
396,6,2,103.10356,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
396,1,3,27.509945,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
396,2,3,35.388954,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
396,3,3,50.549965,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
396,4,3,97.889786,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
396,5,3,96.97222,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
396,6,3,105.657104,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
396,1,4,28.002417,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
396,2,4,31.803757,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
396,3,4,69.46878,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
396,4,4,108.216965,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
396,5,4,125.33024,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
396,6,4,100.888466,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
396,1,5,40.777008,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
396,2,5,37.05421,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
396,3,5,69.475555,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
396,4,5,101.88956,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
396,5,5,109.201866,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
396,6,5,113.4564,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
396,1,6,32.357292,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
396,2,6,39.365402,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
396,3,6,64.26313,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
396,4,6,106.72464,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
396,5,6,124.60197,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
396,6,6,134.1258,241,6,NCGC00025225-01,SCH-79797,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
397,1,1,26.70424,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
397,2,1,41.137695,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
397,3,1,52.155262,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
397,4,1,107.80471,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
397,5,1,115.55635,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
397,6,1,97.99285,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
397,1,2,40.80639,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
397,2,2,41.59836,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
397,3,2,64.65519,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
397,4,2,94.69705,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
397,5,2,108.538475,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
397,6,2,124.12845,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
397,1,3,35.894325,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
397,2,3,40.441566,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
397,3,3,70.93858,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
397,4,3,109.00579,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
397,5,3,104.786545,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
397,6,3,130.7626,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
397,1,4,32.152676,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
397,2,4,42.312565,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
397,3,4,66.6987,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
397,4,4,110.768265,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
397,5,4,121.426216,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
397,6,4,119.65927,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
397,1,5,33.477623,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
397,2,5,30.704382,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
397,3,5,62.062035,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
397,4,5,90.416985,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
397,5,5,103.85429,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
397,6,5,113.96754,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
397,1,6,37.048157,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
397,2,6,41.833767,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
397,3,6,64.17753,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
397,4,6,97.114815,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
397,5,6,103.87719,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
397,6,6,100.21894,241,6,NCGC00263108-01,Vorapaxar,PAR1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
398,1,1,32.22796,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
398,2,1,35.97493,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
398,3,1,50.983562,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
398,4,1,82.36332,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
398,5,1,125.30497,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
398,6,1,122.63999,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
398,1,2,32.812283,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
398,2,2,37.712322,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
398,3,2,55.33141,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
398,4,2,102.32272,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
398,5,2,127.314964,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
398,6,2,137.1638,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
398,1,3,31.561974,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
398,2,3,41.35508,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
398,3,3,62.55499,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
398,4,3,108.55702,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
398,5,3,133.33836,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
398,6,3,128.18547,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
398,1,4,34.095505,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
398,2,4,35.373924,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
398,3,4,73.28068,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
398,4,4,107.32672,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
398,5,4,130.31291,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
398,6,4,123.23353,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
398,1,5,40.086636,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
398,2,5,37.20365,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
398,3,5,59.150574,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
398,4,5,107.05078,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
398,5,5,119.91154,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
398,6,5,116.22082,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
398,1,6,39.234337,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
398,2,6,43.721333,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
398,3,6,54.897713,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
398,4,6,109.47223,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
398,5,6,110.59251,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
398,6,6,108.928925,241,6,NCGC00263107-01,GB-83,PAR2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
399,1,1,38.313103,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
399,2,1,45.450657,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
399,3,1,57.79135,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
399,4,1,109.92065,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
399,5,1,109.92432,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
399,6,1,124.59728,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
399,1,2,33.828503,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
399,2,2,38.003765,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
399,3,2,58.941597,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
399,4,2,108.2154,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
399,5,2,104.4208,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
399,6,2,127.82724,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
399,1,3,31.26936,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
399,2,3,30.78524,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
399,3,3,71.7106,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
399,4,3,106.70069,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
399,5,3,117.020386,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
399,6,3,133.94762,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
399,1,4,37.530865,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
399,2,4,45.09389,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
399,3,4,67.41851,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
399,4,4,110.95405,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
399,5,4,118.8604,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
399,6,4,122.485695,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
399,1,5,32.609447,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
399,2,5,38.850323,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
399,3,5,69.70502,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
399,4,5,107.48753,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
399,5,5,116.99975,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
399,6,5,122.99911,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
399,1,6,35.586174,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
399,2,6,46.589504,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
399,3,6,76.54007,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
399,4,6,112.53045,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
399,5,6,102.6076,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
399,6,6,119.41469,241,6,NCGC00181785-01,Aprepitant,Tachykinin NK1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
400,1,1,31.591269,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
400,2,1,34.3988,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
400,3,1,54.7786,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
400,4,1,104.57078,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
400,5,1,113.891396,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
400,6,1,125.790924,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
400,1,2,33.530018,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
400,2,2,39.28179,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
400,3,2,71.03203,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
400,4,2,110.07219,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
400,5,2,113.96237,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
400,6,2,126.42578,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
400,1,3,30.937136,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
400,2,3,34.67482,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
400,3,3,66.5729,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
400,4,3,102.44057,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
400,5,3,121.762825,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
400,6,3,112.50851,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
400,1,4,36.030006,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
400,2,4,37.206882,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
400,3,4,58.311382,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
400,4,4,105.90241,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
400,5,4,109.20541,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
400,6,4,107.54245,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
400,1,5,33.08946,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
400,2,5,37.154205,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
400,3,5,64.82383,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
400,4,5,120.83534,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
400,5,5,123.45172,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
400,6,5,124.68749,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
400,1,6,36.526966,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
400,2,6,39.267582,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
400,3,6,62.103565,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
400,4,6,121.8911,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
400,5,6,115.57291,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
400,6,6,119.23113,241,6,NCGC00025092-01,GR-159897,Tachykinin NK2 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
401,1,1,17.659573,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
401,2,1,26.463486,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
401,3,1,43.327343,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
401,4,1,75.816734,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
401,5,1,102.57486,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
401,6,1,119.006065,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
401,1,2,34.79811,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
401,2,2,34.869442,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
401,3,2,45.624214,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
401,4,2,90.48068,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
401,5,2,101.34367,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
401,6,2,115.45993,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
401,1,3,29.476494,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
401,2,3,37.044205,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
401,3,3,55.967045,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
401,4,3,104.02014,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
401,5,3,113.919914,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
401,6,3,121.41072,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
401,1,4,29.90809,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
401,2,4,41.086243,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
401,3,4,64.95319,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
401,4,4,104.113686,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
401,5,4,127.726456,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
401,6,4,114.5166,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
401,1,5,30.553333,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
401,2,5,40.020412,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
401,3,5,52.675606,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
401,4,5,114.10724,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
401,5,5,112.28329,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
401,6,5,136.44705,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
401,1,6,40.068405,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
401,2,6,39.029987,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
401,3,6,66.38894,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
401,4,6,72.58427,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
401,5,6,115.27194,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
401,6,6,136.621,241,6,NCGC00263110-01,Osanetant,Tachykinin NK3 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
402,1,1,16.445442,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
402,2,1,38.581852,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
402,3,1,61.858437,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
402,4,1,103.82471,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
402,5,1,110.33383,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
402,6,1,112.248245,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
402,1,2,28.245754,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
402,2,2,44.20194,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
402,3,2,62.61376,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
402,4,2,84.78603,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
402,5,2,120.93372,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
402,6,2,100.99804,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
402,1,3,34.773865,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
402,2,3,48.90476,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
402,3,3,69.11639,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
402,4,3,108.32091,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
402,5,3,127.0872,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
402,6,3,127.66497,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
402,1,4,35.179443,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
402,2,4,39.8052,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
402,3,4,68.13501,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
402,4,4,111.85638,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
402,5,4,123.341156,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
402,6,4,114.550186,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
402,1,5,35.839783,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
402,2,5,43.75976,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
402,3,5,59.187546,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
402,4,5,117.03977,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
402,5,5,105.18149,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
402,6,5,131.54095,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
402,1,6,38.07877,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
402,2,6,39.177807,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
402,3,6,54.47475,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
402,4,6,99.579765,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
402,5,6,115.719154,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
402,6,6,100.87069,241,6,NCGC00263139-01,Rolofylline,Adenosine A1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
403,1,1,45.401436,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
403,2,1,39.524128,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
403,3,1,68.469734,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
403,4,1,91.15507,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
403,5,1,108.68699,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
403,6,1,120.63287,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
403,1,2,31.741737,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
403,2,2,47.062405,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
403,3,2,63.789722,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
403,4,2,112.50525,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
403,5,2,126.01915,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
403,6,2,116.61474,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
403,1,3,32.089287,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
403,2,3,39.745308,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
403,3,3,70.63565,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
403,4,3,105.4804,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
403,5,3,113.8157,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
403,6,3,128.47653,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
403,1,4,36.44381,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
403,2,4,50.129288,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
403,3,4,56.343464,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
403,4,4,112.62666,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
403,5,4,131.33475,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
403,6,4,138.60503,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
403,1,5,30.503294,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
403,2,5,43.683277,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
403,3,5,55.132862,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
403,4,5,105.02584,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
403,5,5,122.49916,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
403,6,5,143.2252,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
403,1,6,27.77971,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
403,2,6,32.922806,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
403,3,6,64.56908,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
403,4,6,100.39313,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
403,5,6,122.14451,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
403,6,6,106.85504,241,6,NCGC00242513-01,Maraviroc,Chemokine CCR5 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
404,1,1,27.324533,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
404,2,1,43.42347,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
404,3,1,49.593113,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
404,4,1,98.86481,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
404,5,1,103.831635,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
404,6,1,136.56696,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
404,1,2,31.373783,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
404,2,2,41.034836,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
404,3,2,56.62455,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
404,4,2,112.86069,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
404,5,2,113.27855,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
404,6,2,110.15057,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
404,1,3,38.741524,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
404,2,3,40.05686,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
404,3,3,66.21846,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
404,4,3,113.38849,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
404,5,3,128.53519,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
404,6,3,134.21307,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
404,1,4,34.088955,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
404,2,4,46.515812,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
404,3,4,66.39299,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
404,4,4,98.84939,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
404,5,4,111.80977,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
404,6,4,114.30724,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
404,1,5,44.389606,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
404,2,5,46.951714,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
404,3,5,72.009094,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
404,4,5,116.24043,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
404,5,5,114.36215,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
404,6,5,120.27063,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
404,1,6,33.2599,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
404,2,6,44.57108,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
404,3,6,69.7575,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
404,4,6,109.71001,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
404,5,6,135.61063,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
404,6,6,136.47333,241,6,NCGC00092385-02,LY-320135,Cannabinoid CB1 Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
405,1,1,40.055138,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
405,2,1,48.617435,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
405,3,1,69.28115,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
405,4,1,106.212524,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
405,5,1,124.51013,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
405,6,1,112.26561,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
405,1,2,33.986153,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
405,2,2,46.868584,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
405,3,2,64.01557,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
405,4,2,107.9308,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
405,5,2,129.55937,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
405,6,2,112.3566,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
405,1,3,37.700172,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
405,2,3,42.123684,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
405,3,3,60.787155,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
405,4,3,104.98666,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
405,5,3,124.973564,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
405,6,3,120.56109,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
405,1,4,34.475155,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
405,2,4,35.70076,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
405,3,4,67.76786,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
405,4,4,113.08007,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
405,5,4,125.763954,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
405,6,4,105.50247,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
405,1,5,35.887634,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
405,2,5,40.531116,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
405,3,5,67.753654,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
405,4,5,115.57606,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
405,5,5,118.496254,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
405,6,5,135.65346,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
405,1,6,26.530642,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
405,2,6,33.691467,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
405,3,6,68.24943,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
405,4,6,109.144646,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
405,5,6,119.496506,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
405,6,6,123.4337,241,6,NCGC00162405-01,ACPA,cannabinoid CB1 antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
406,1,1,33.275887,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
406,2,1,47.55125,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
406,3,1,56.502754,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
406,4,1,95.855896,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
406,5,1,101.36427,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
406,6,1,113.46496,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
406,1,2,35.3542,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
406,2,2,43.240417,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
406,3,2,69.47145,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
406,4,2,101.96978,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
406,5,2,134.70474,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
406,6,2,103.07704,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
406,1,3,40.23249,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
406,2,3,40.59511,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
406,3,3,61.845608,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
406,4,3,107.83545,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
406,5,3,111.40048,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
406,6,3,111.22297,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
406,1,4,35.670307,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
406,2,4,39.529053,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
406,3,4,64.52898,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
406,4,4,97.82127,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
406,5,4,108.227165,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
406,6,4,124.46335,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
406,1,5,39.50893,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
406,2,5,42.366287,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
406,3,5,48.536083,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
406,4,5,108.938354,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
406,5,5,125.84394,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
406,6,5,101.657524,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
406,1,6,33.01656,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
406,2,6,44.03544,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
406,3,6,69.28322,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
406,4,6,92.82989,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
406,5,6,110.49777,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
406,6,6,108.8154,241,6,NCGC00025106-01,MK-886,5-lipoxygenase-activating (FLAP) inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
407,1,1,35.05073,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
407,2,1,46.970226,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
407,3,1,59.06596,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
407,4,1,71.76885,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
407,5,1,123.38929,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
407,6,1,146.1635,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
407,1,2,37.904125,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
407,2,2,48.19902,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
407,3,2,56.969585,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
407,4,2,110.59239,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
407,5,2,114.39394,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
407,6,2,116.96696,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
407,1,3,38.315132,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
407,2,3,46.26099,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
407,3,3,72.677284,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
407,4,3,115.00598,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
407,5,3,115.12286,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
407,6,3,106.30917,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
407,1,4,34.763496,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
407,2,4,40.004875,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
407,3,4,63.91078,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
407,4,4,104.153564,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
407,5,4,110.74928,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
407,6,4,116.48603,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
407,1,5,38.63717,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
407,2,5,33.241596,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
407,3,5,54.477757,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
407,4,5,110.3569,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
407,5,5,118.09357,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
407,6,5,121.45454,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
407,1,6,35.979656,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
407,2,6,43.834522,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
407,3,6,70.586174,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
407,4,6,99.339035,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
407,5,6,113.84742,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
407,6,6,129.95169,241,6,NCGC00250411-01,Veliflapon,5-lipoxygenase-activating (FLAP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
408,1,1,33.491,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
408,2,1,52.04196,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
408,3,1,59.127544,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
408,4,1,102.44982,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
408,5,1,120.324196,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
408,6,1,132.23506,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
408,1,2,34.049797,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
408,2,2,38.287926,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
408,3,2,61.095333,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
408,4,2,96.99906,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
408,5,2,108.562386,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
408,6,2,125.21903,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
408,1,3,30.984703,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
408,2,3,38.12439,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
408,3,3,62.44208,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
408,4,3,108.39855,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
408,5,3,120.182304,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
408,6,3,112.032166,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
408,1,4,40.097275,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
408,2,4,46.506443,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
408,3,4,70.00724,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
408,4,4,112.28014,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
408,5,4,127.156555,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
408,6,4,105.73939,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
408,1,5,36.949745,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
408,2,5,50.410248,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
408,3,5,60.284748,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
408,4,5,105.84817,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
408,5,5,133.98586,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
408,6,5,121.93913,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
408,1,6,31.621862,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
408,2,6,38.972103,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
408,3,6,58.51899,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
408,4,6,108.925735,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
408,5,6,120.33278,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
408,6,6,119.255684,241,6,NCGC00250374-01,Licofelone,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
409,1,1,34.876568,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
409,2,1,45.118305,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
409,3,1,63.689163,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
409,4,1,110.00125,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
409,5,1,105.91437,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
409,6,1,141.75992,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
409,1,2,32.344353,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
409,2,2,55.3944,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
409,3,2,52.618988,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
409,4,2,107.781624,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
409,5,2,101.082695,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
409,6,2,108.419716,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
409,1,3,36.876083,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
409,2,3,41.455116,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
409,3,3,70.80871,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
409,4,3,118.289955,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
409,5,3,123.54573,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
409,6,3,130.07118,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
409,1,4,33.61219,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
409,2,4,52.421036,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
409,3,4,68.18063,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
409,4,4,117.48136,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
409,5,4,112.53532,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
409,6,4,137.45212,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
409,1,5,36.348824,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
409,2,5,54.81589,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
409,3,5,56.3762,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
409,4,5,7.659649,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
409,5,5,121.500946,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
409,6,5,125.36027,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
409,1,6,39.68905,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
409,2,6,58.026234,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
409,3,6,48.068165,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
409,4,6,103.367714,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
409,5,6,122.121605,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
409,6,6,126.05081,241,6,NCGC00159453-02,Zileuton,5-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
410,1,1,26.624086,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
410,2,1,32.026787,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
410,3,1,66.02657,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
410,4,1,98.281105,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
410,5,1,124.64125,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
410,6,1,123.57656,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
410,1,2,31.717987,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
410,2,2,42.542652,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
410,3,2,65.39362,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
410,4,2,105.835526,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
410,5,2,115.13708,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
410,6,2,124.67764,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
410,1,3,38.950752,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
410,2,3,45.36119,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
410,3,3,67.53614,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
410,4,3,101.49291,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
410,5,3,113.402,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
410,6,3,119.77665,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
410,1,4,32.150684,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
410,2,4,46.935204,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
410,3,4,55.13052,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
410,4,4,101.692955,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
410,5,4,118.88518,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
410,6,4,111.41826,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
410,1,5,36.072044,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
410,2,5,47.55039,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
410,3,5,69.06333,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
410,4,5,125.16936,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
410,5,5,123.55688,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
410,6,5,127.49303,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
410,1,6,33.5778,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
410,2,6,48.851486,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
410,3,6,73.13862,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
410,4,6,103.21192,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
410,5,6,113.17404,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
410,6,6,123.45277,241,6,NCGC00187940-01,NCGC00185053,15-Lipoxygenase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
411,1,1,25.958439,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
411,2,1,32.377937,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
411,3,1,55.968697,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
411,4,1,98.48383,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
411,5,1,96.603645,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
411,6,1,104.88072,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
411,1,2,29.575583,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
411,2,2,33.822266,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
411,3,2,54.613396,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
411,4,2,101.88696,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
411,5,2,114.252815,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
411,6,2,114.707275,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
411,1,3,32.493763,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
411,2,3,33.59277,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
411,3,3,55.92217,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
411,4,3,100.28065,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
411,5,3,111.19131,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
411,6,3,110.99261,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
411,1,4,32.52352,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
411,2,4,39.444244,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
411,3,4,59.87717,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
411,4,4,93.3876,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
411,5,4,111.17999,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
411,6,4,126.27723,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
411,1,5,43.142853,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
411,2,5,43.156853,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
411,3,5,79.36143,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
411,4,5,108.49596,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
411,5,5,118.9609,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
411,6,5,116.54071,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
411,1,6,32.92183,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
411,2,6,46.408,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
411,3,6,65.918846,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
411,4,6,107.45362,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
411,5,6,118.70431,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
411,6,6,117.17223,241,6,NCGC00091455-07,Celecoxib,Cyclooxygenase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
412,1,1,27.787401,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
412,2,1,38.734764,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
412,3,1,56.927097,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
412,4,1,104.08859,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
412,5,1,109.72409,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
412,6,1,111.14646,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
412,1,2,37.23492,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
412,2,2,41.607857,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
412,3,2,63.984898,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
412,4,2,106.672485,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
412,5,2,122.5169,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
412,6,2,131.25679,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
412,1,3,33.491383,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
412,2,3,41.65574,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
412,3,3,75.38773,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
412,4,3,107.41452,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
412,5,3,114.22219,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
412,6,3,121.428345,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
412,1,4,34.190346,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
412,2,4,35.25765,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
412,3,4,58.735176,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
412,4,4,98.02366,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
412,5,4,112.23572,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
412,6,4,106.25602,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
412,1,5,29.108694,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
412,2,5,42.17391,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
412,3,5,52.483196,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
412,4,5,102.150955,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
412,5,5,108.41496,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
412,6,5,120.46454,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
412,1,6,33.52614,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
412,2,6,38.350456,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
412,3,6,58.293774,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
412,4,6,105.74288,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
412,5,6,122.17565,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
412,6,6,107.535385,241,6,NCGC00160396-03,Pravadoline,COX Inhibitor and cannabinoid (CB) agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
413,1,1,35.490456,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
413,2,1,30.603428,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
413,3,1,57.774094,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
413,4,1,105.007904,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
413,5,1,108.6456,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
413,6,1,107.7618,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
413,1,2,40.026436,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
413,2,2,35.291344,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
413,3,2,62.815754,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
413,4,2,97.88419,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
413,5,2,110.75247,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
413,6,2,121.02939,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
413,1,3,34.486134,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
413,2,3,42.781685,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
413,3,3,64.48762,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
413,4,3,111.62739,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
413,5,3,111.293144,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
413,6,3,117.5483,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
413,1,4,40.54187,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
413,2,4,47.839207,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
413,3,4,60.959484,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
413,4,4,111.2263,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
413,5,4,110.81154,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
413,6,4,116.59845,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
413,1,5,35.89369,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
413,2,5,41.157787,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
413,3,5,83.09084,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
413,4,5,122.37131,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
413,5,5,127.73278,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
413,6,5,119.11842,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
413,1,6,35.8683,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
413,2,6,33.314465,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
413,3,6,54.982914,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
413,4,6,91.23835,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
413,5,6,109.91744,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
413,6,6,117.992516,241,6,NCGC00263131-01,PF-3845,Fatty Acid Amide Hydrolase (FAAH) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
414,1,1,35.667908,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
414,2,1,42.86851,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
414,3,1,68.308044,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
414,4,1,101.59652,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
414,5,1,103.702705,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
414,6,1,111.453354,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
414,1,2,32.06468,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
414,2,2,39.850536,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
414,3,2,68.39548,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
414,4,2,98.93432,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
414,5,2,108.10055,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
414,6,2,114.73859,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
414,1,3,37.129974,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
414,2,3,42.19128,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
414,3,3,56.522778,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
414,4,3,99.376434,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
414,5,3,145.28616,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
414,6,3,127.62021,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
414,1,4,36.75196,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
414,2,4,39.94593,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
414,3,4,69.06501,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
414,4,4,106.64136,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
414,5,4,115.91553,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
414,6,4,123.37514,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
414,1,5,33.909035,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
414,2,5,41.322342,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
414,3,5,63.638996,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
414,4,5,101.577065,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
414,5,5,123.486984,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
414,6,5,113.57963,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
414,1,6,31.678984,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
414,2,6,40.943127,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
414,3,6,58.603897,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
414,4,6,103.41823,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
414,5,6,107.65879,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
414,6,6,118.70764,241,6,NCGC00164604-03,Fluvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
415,1,1,46.04105,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
415,2,1,54.153957,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
415,3,1,69.863365,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
415,4,1,113.77802,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
415,5,1,117.49153,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
415,6,1,110.41067,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
415,1,2,30.495235,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
415,2,2,43.235435,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
415,3,2,73.208145,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
415,4,2,105.65336,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
415,5,2,117.90425,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
415,6,2,119.24387,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
415,1,3,37.99414,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
415,2,3,43.541794,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
415,3,3,56.654552,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
415,4,3,102.29495,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
415,5,3,111.436806,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
415,6,3,108.1003,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
415,1,4,29.092932,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
415,2,4,46.866283,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
415,3,4,58.193794,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
415,4,4,104.273,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
415,5,4,110.208954,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
415,6,4,105.13378,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
415,1,5,42.8985,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
415,2,5,48.560482,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
415,3,5,68.76018,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
415,4,5,91.68584,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
415,5,5,109.37719,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
415,6,5,107.19245,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
415,1,6,31.311523,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
415,2,6,43.958195,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
415,3,6,54.39385,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
415,4,6,99.44875,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
415,5,6,119.495636,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
415,6,6,113.542366,241,6,NCGC00016940-01,Simvastatin,HMG-CoA Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
416,1,1,27.467455,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
416,2,1,31.630314,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
416,3,1,49.3653,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
416,4,1,71.05116,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
416,5,1,96.283005,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
416,6,1,53.33514,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
416,1,2,27.920868,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
416,2,2,32.731625,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
416,3,2,52.60804,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
416,4,2,85.00961,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
416,5,2,83.305336,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
416,6,2,93.88669,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
416,1,3,30.580526,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
416,2,3,37.141167,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
416,3,3,56.35454,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
416,4,3,103.38994,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
416,5,3,99.8996,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
416,6,3,105.4187,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
416,1,4,31.753733,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
416,2,4,35.069725,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
416,3,4,57.774742,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
416,4,4,89.53468,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
416,5,4,99.66959,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
416,6,4,99.64549,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
416,1,5,36.570625,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
416,2,5,37.22246,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
416,3,5,63.75756,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
416,4,5,99.45714,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
416,5,5,104.79069,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
416,6,5,103.41567,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
416,1,6,30.666534,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
416,2,6,48.25435,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
416,3,6,67.16841,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
416,4,6,98.841805,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
416,5,6,100.942696,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
416,6,6,103.707245,241,6,NCGC00263083-01,Dalcetrapib,Cholesteryl Ester Transfer Protein (CETP) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
417,1,1,2.963209,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
417,2,1,1.788661,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
417,3,1,3.103123,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
417,4,1,6.990543,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
417,5,1,9.935435,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
417,6,1,11.96437,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
417,1,2,11.866748,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
417,2,2,10.696787,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
417,3,2,17.127234,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
417,4,2,34.10682,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
417,5,2,38.44558,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
417,6,2,38.229618,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
417,1,3,16.015497,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
417,2,3,19.57031,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
417,3,3,30.800255,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
417,4,3,52.877975,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
417,5,3,72.41824,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
417,6,3,78.202576,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
417,1,4,30.388922,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
417,2,4,32.73377,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
417,3,4,50.30111,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
417,4,4,84.16023,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
417,5,4,87.25539,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
417,6,4,106.53212,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
417,1,5,32.569866,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
417,2,5,41.81456,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
417,3,5,54.498936,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
417,4,5,79.42934,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
417,5,5,102.52976,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
417,6,5,111.19368,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
417,1,6,36.809208,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
417,2,6,48.92518,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
417,3,6,51.67855,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
417,4,6,91.370575,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
417,5,6,102.5383,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
417,6,6,102.98117,241,6,NCGC00263211-01,JK-184,Alcohol dehydrogenase 7 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
418,1,1,36.21863,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
418,2,1,35.4556,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
418,3,1,67.78473,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
418,4,1,77.79602,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
418,5,1,100.3664,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
418,6,1,120.45343,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
418,1,2,30.406378,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
418,2,2,39.467342,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
418,3,2,63.099506,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
418,4,2,108.58297,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
418,5,2,109.370514,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
418,6,2,127.935234,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
418,1,3,36.12746,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
418,2,3,46.64993,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
418,3,3,65.97668,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
418,4,3,112.0893,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
418,5,3,108.28426,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
418,6,3,105.071236,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
418,1,4,40.40859,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
418,2,4,37.755703,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
418,3,4,58.305412,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
418,4,4,110.38174,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
418,5,4,117.8277,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
418,6,4,114.33093,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
418,1,5,45.41607,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
418,2,5,38.5293,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
418,3,5,51.816586,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
418,4,5,111.90667,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
418,5,5,109.9696,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
418,6,5,121.68991,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
418,1,6,30.027487,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
418,2,6,40.596153,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
418,3,6,48.852097,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
418,4,6,104.83888,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
418,5,6,107.272446,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
418,6,6,103.04968,241,6,NCGC00249666-01,NCGC00037850,HPGD Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
419,1,1,4.741328,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
419,2,1,3.021898,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
419,3,1,4.302351,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
419,4,1,10.737343,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
419,5,1,16.728771,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
419,6,1,25.613485,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
419,1,2,23.03257,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
419,2,2,30.511478,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
419,3,2,45.435432,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
419,4,2,85.42323,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
419,5,2,105.60359,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
419,6,2,104.836624,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
419,1,3,32.240505,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
419,2,3,43.13705,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
419,3,3,61.475143,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
419,4,3,103.00166,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
419,5,3,110.09413,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
419,6,3,101.38417,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
419,1,4,33.231293,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
419,2,4,39.328796,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
419,3,4,72.41615,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
419,4,4,119.187256,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
419,5,4,111.210594,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
419,6,4,102.5818,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
419,1,5,32.270462,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
419,2,5,41.409523,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
419,3,5,54.857662,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
419,4,5,103.782486,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
419,5,5,105.33687,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
419,6,5,110.9711,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
419,1,6,40.31195,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
419,2,6,40.05023,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
419,3,6,57.864517,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
419,4,6,104.8742,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
419,5,6,110.16305,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
419,6,6,107.67853,241,6,NCGC00263222-01,CAY-10581,IDO Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
420,1,1,31.70097,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
420,2,1,36.75375,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
420,3,1,65.357285,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
420,4,1,91.24435,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
420,5,1,110.42218,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
420,6,1,107.750565,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
420,1,2,33.44497,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
420,2,2,37.44954,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
420,3,2,56.13322,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
420,4,2,90.25655,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
420,5,2,111.19993,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
420,6,2,108.13779,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
420,1,3,32.22456,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
420,2,3,45.827007,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
420,3,3,54.583294,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
420,4,3,83.83649,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
420,5,3,109.11694,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
420,6,3,103.28749,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
420,1,4,28.261276,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
420,2,4,40.175762,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
420,3,4,56.11952,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
420,4,4,96.57136,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
420,5,4,106.62324,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
420,6,4,109.463974,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
420,1,5,31.762735,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
420,2,5,39.15119,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
420,3,5,59.356133,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
420,4,5,86.0362,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
420,5,5,114.31063,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
420,6,5,114.70514,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
420,1,6,22.794764,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
420,2,6,33.06338,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
420,3,6,61.271317,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
420,4,6,87.02225,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
420,5,6,110.27147,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
420,6,6,101.84063,241,6,NCGC00024631-01,EBPC,Aldose Reductase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
421,1,1,18.236244,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
421,2,1,26.457067,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
421,3,1,40.12272,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
421,4,1,75.53206,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
421,5,1,80.63678,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
421,6,1,91.47004,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
421,1,2,19.956957,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
421,2,2,27.863638,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
421,3,2,48.712,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
421,4,2,75.71447,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
421,5,2,102.32906,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
421,6,2,110.19182,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
421,1,3,17.203686,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
421,2,3,26.838602,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
421,3,3,36.976627,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
421,4,3,81.224525,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
421,5,3,93.16285,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
421,6,3,98.75676,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
421,1,4,22.805037,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
421,2,4,27.874582,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
421,3,4,49.220844,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
421,4,4,75.117874,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
421,5,4,97.35575,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
421,6,4,117.03639,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
421,1,5,30.23451,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
421,2,5,30.913351,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
421,3,5,48.747475,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
421,4,5,93.328606,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
421,5,5,92.74278,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
421,6,5,108.32863,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
421,1,6,23.829693,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
421,2,6,32.829693,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
421,3,6,48.04071,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
421,4,6,98.58106,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
421,5,6,92.923355,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
421,6,6,110.00487,241,6,NCGC00263135-01,Piraxostat,Xanthine Oxidase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
422,1,1,20.452658,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
422,2,1,24.13665,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
422,3,1,35.766113,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
422,4,1,78.80418,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
422,5,1,92.33324,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
422,6,1,112.84573,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
422,1,2,22.87623,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
422,2,2,30.661211,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
422,3,2,60.346966,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
422,4,2,80.00553,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
422,5,2,103.75767,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
422,6,2,89.61227,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
422,1,3,22.042774,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
422,2,3,32.669212,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
422,3,3,46.740833,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
422,4,3,74.54648,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
422,5,3,109.419044,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
422,6,3,98.79501,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
422,1,4,26.249895,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
422,2,4,28.491425,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
422,3,4,46.738457,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
422,4,4,89.27972,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
422,5,4,109.694016,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
422,6,4,99.25686,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
422,1,5,18.824926,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
422,2,5,28.432323,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
422,3,5,44.318214,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
422,4,5,84.453865,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
422,5,5,114.172585,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
422,6,5,104.19408,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
422,1,6,22.457418,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
422,2,6,31.363653,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
422,3,6,45.4669,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
422,4,6,73.56958,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
422,5,6,91.68586,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
422,6,6,103.51898,241,6,NCGC00263237-01,JZL-184,Monoacylglycerol lipase (MAGL) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
423,1,1,23.112034,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
423,2,1,37.646614,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
423,3,1,50.378788,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
423,4,1,105.50582,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
423,5,1,122.18822,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
423,6,1,113.35113,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
423,1,2,24.235678,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
423,2,2,35.815994,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
423,3,2,53.05228,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
423,4,2,87.96276,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
423,5,2,121.85407,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
423,6,2,114.301956,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
423,1,3,24.786743,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
423,2,3,32.43307,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
423,3,3,56.038715,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
423,4,3,103.28573,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
423,5,3,109.26534,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
423,6,3,109.540146,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
423,1,4,22.043257,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
423,2,4,32.58847,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
423,3,4,47.467518,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
423,4,4,84.73355,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
423,5,4,105.15231,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
423,6,4,112.38695,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
423,1,5,26.782782,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
423,2,5,32.072067,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
423,3,5,46.38427,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
423,4,5,86.40913,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
423,5,5,99.77504,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
423,6,5,127.64516,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
423,1,6,23.809982,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
423,2,6,27.057728,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
423,3,6,41.046856,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
423,4,6,91.80743,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
423,5,6,109.70951,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
423,6,6,101.872894,241,6,NCGC00165782-02,GW-4869,Neutral Sphingomyelinase (N-SMase) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
424,1,1,20.374475,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
424,2,1,28.541697,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
424,3,1,37.870205,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
424,4,1,77.025055,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
424,5,1,103.79117,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
424,6,1,117.988716,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
424,1,2,27.089647,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
424,2,2,33.34002,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
424,3,2,42.896496,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
424,4,2,77.5748,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
424,5,2,94.89214,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
424,6,2,106.77734,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
424,1,3,24.560371,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
424,2,3,28.792349,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
424,3,3,44.221905,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
424,4,3,100.57237,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
424,5,3,107.41529,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
424,6,3,115.30369,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
424,1,4,22.538227,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
424,2,4,29.811937,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
424,3,4,51.636932,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
424,4,4,88.99673,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
424,5,4,112.791954,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
424,6,4,106.099686,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
424,1,5,24.068785,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
424,2,5,30.826471,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
424,3,5,2.643049,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
424,4,5,93.47078,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
424,5,5,112.409035,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
424,6,5,116.07082,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
424,1,6,23.237158,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
424,2,6,29.15599,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
424,3,6,50.075016,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
424,4,6,76.759224,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
424,5,6,116.7107,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
424,6,6,114.49259,241,6,NCGC00263221-01,Ezatiostat,Glutathione-s-transferase P1 (GSTP1) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
425,1,1,21.089823,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
425,2,1,32.22125,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
425,3,1,41.49183,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
425,4,1,80.36211,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
425,5,1,101.94332,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
425,6,1,125.11502,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
425,1,2,22.240805,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
425,2,2,31.131117,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
425,3,2,54.35418,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
425,4,2,91.64776,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
425,5,2,99.118164,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
425,6,2,120.281105,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
425,1,3,25.597645,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
425,2,3,35.809685,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
425,3,3,57.316975,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
425,4,3,94.90718,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
425,5,3,109.547295,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
425,6,3,101.89186,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
425,1,4,23.886755,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
425,2,4,34.015465,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
425,3,4,44.453278,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
425,4,4,95.281975,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
425,5,4,95.49552,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
425,6,4,106.09351,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
425,1,5,26.822395,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
425,2,5,30.97035,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
425,3,5,53.580177,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
425,4,5,106.34257,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
425,5,5,92.38938,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
425,6,5,128.82489,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
425,1,6,24.79121,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
425,2,6,33.223557,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
425,3,6,48.80263,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
425,4,6,86.25158,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
425,5,6,105.37454,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
425,6,6,132.2543,241,6,NCGC00025325-01,Vapiprost hydrochloride,Prostanoid TP Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
426,1,1,20.126474,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
426,2,1,26.743076,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
426,3,1,40.44117,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
426,4,1,68.40484,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
426,5,1,84.63669,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
426,6,1,85.91427,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
426,1,2,20.13896,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
426,2,2,28.290678,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
426,3,2,46.58378,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
426,4,2,87.719864,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
426,5,2,104.30761,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
426,6,2,93.35832,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
426,1,3,22.35489,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
426,2,3,29.730972,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
426,3,3,49.271584,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
426,4,3,94.68227,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
426,5,3,99.88128,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
426,6,3,108.66398,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
426,1,4,23.681005,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
426,2,4,28.09005,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
426,3,4,50.347755,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
426,4,4,91.95276,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
426,5,4,101.22445,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
426,6,4,113.095856,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
426,1,5,28.575916,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
426,2,5,37.649227,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
426,3,5,55.345284,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
426,4,5,69.035446,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
426,5,5,110.258484,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
426,6,5,130.38779,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
426,1,6,27.031317,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
426,2,6,38.01083,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
426,3,6,45.563522,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
426,4,6,79.3141,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
426,5,6,98.97016,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
426,6,6,125.4669,241,6,NCGC00095134-03,Ezetimibe,NPC1L1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
427,1,1,25.289642,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
427,2,1,26.62255,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
427,3,1,48.158585,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
427,4,1,82.76539,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
427,5,1,105.17785,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
427,6,1,89.14329,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
427,1,2,26.38104,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
427,2,2,31.14094,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
427,3,2,51.493053,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
427,4,2,79.40068,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
427,5,2,105.76338,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
427,6,2,124.319214,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
427,1,3,30.968052,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
427,2,3,38.900883,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
427,3,3,51.915745,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
427,4,3,78.9433,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
427,5,3,116.82313,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
427,6,3,119.44902,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
427,1,4,26.499031,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
427,2,4,30.611801,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
427,3,4,43.254482,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
427,4,4,79.548965,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
427,5,4,98.8078,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
427,6,4,90.28041,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
427,1,5,27.501171,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
427,2,5,29.628548,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
427,3,5,50.552002,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
427,4,5,88.70662,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
427,5,5,98.58323,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
427,6,5,93.81603,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
427,1,6,25.327936,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
427,2,6,27.573711,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
427,3,6,49.397804,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
427,4,6,99.979965,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
427,5,6,105.81866,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
427,6,6,121.1699,241,6,NCGC00263281-01,GSK-1995010,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
428,1,1,26.73648,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
428,2,1,30.79404,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
428,3,1,58.445087,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
428,4,1,98.76308,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
428,5,1,96.77062,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
428,6,1,112.34204,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
428,1,2,29.999401,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
428,2,2,41.805775,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
428,3,2,50.47485,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
428,4,2,81.91298,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
428,5,2,96.61799,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
428,6,2,118.35178,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
428,1,3,29.123026,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
428,2,3,34.591675,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
428,3,3,55.048737,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
428,4,3,79.64774,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
428,5,3,107.3439,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
428,6,3,110.982544,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
428,1,4,28.638725,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
428,2,4,31.769325,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
428,3,4,49.834435,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
428,4,4,77.712585,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
428,5,4,105.21408,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
428,6,4,116.94624,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
428,1,5,26.960463,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
428,2,5,37.506145,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
428,3,5,64.93333,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
428,4,5,105.02049,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
428,5,5,122.95277,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
428,6,5,93.88799,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
428,1,6,21.117682,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
428,2,6,36.085323,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
428,3,6,61.003056,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
428,4,6,97.16139,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
428,5,6,102.74699,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
428,6,6,95.05878,241,6,NCGC00263228-01,FASN BI,Unknown,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
429,1,1,23.370548,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
429,2,1,31.552814,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
429,3,1,39.827736,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
429,4,1,76.36318,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
429,5,1,99.37985,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
429,6,1,116.55208,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
429,1,2,27.77643,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
429,2,2,33.23373,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
429,3,2,44.48264,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
429,4,2,82.45967,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
429,5,2,94.707214,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
429,6,2,110.56534,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
429,1,3,30.668106,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
429,2,3,38.83994,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
429,3,3,56.629955,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
429,4,3,94.91119,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
429,5,3,122.12314,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
429,6,3,132.10297,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
429,1,4,27.459728,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
429,2,4,37.596027,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
429,3,4,50.894028,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
429,4,4,79.7472,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
429,5,4,102.59201,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
429,6,4,104.351944,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
429,1,5,26.787104,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
429,2,5,36.553974,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
429,3,5,49.89018,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
429,4,5,89.545235,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
429,5,5,113.09788,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
429,6,5,117.88123,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
429,1,6,28.989347,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
429,2,6,35.945217,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
429,3,6,54.915684,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
429,4,6,93.82136,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
429,5,6,96.59938,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
429,6,6,107.52078,241,6,NCGC00263229-01,GSK-837149A,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
430,1,1,34.419468,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
430,2,1,34.857845,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
430,3,1,49.16497,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
430,4,1,81.72528,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
430,5,1,104.87251,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
430,6,1,98.65781,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
430,1,2,30.132465,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
430,2,2,30.21552,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
430,3,2,53.740395,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
430,4,2,71.88494,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
430,5,2,127.551765,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
430,6,2,95.49919,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
430,1,3,22.90635,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
430,2,3,33.298775,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
430,3,3,56.01382,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
430,4,3,87.3368,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
430,5,3,101.90039,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
430,6,3,108.84038,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
430,1,4,27.307034,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
430,2,4,26.417427,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
430,3,4,46.46606,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
430,4,4,102.85712,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
430,5,4,102.72539,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
430,6,4,111.76135,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
430,1,5,30.744709,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
430,2,5,36.795994,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
430,3,5,49.750633,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
430,4,5,104.376076,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
430,5,5,124.61984,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
430,6,5,122.36997,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
430,1,6,28.168062,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
430,2,6,40.029972,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
430,3,6,52.301422,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
430,4,6,104.38607,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
430,5,6,99.33584,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
430,6,6,110.147545,241,6,NCGC00263230-01,FASN MRK,Fatty Acid Synthase (FAS) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
431,1,1,9.105401,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
431,2,1,10.498897,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
431,3,1,14.043817,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
431,4,1,17.45831,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
431,5,1,15.920097,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
431,6,1,13.669725,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
431,1,2,11.515926,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
431,2,2,12.756623,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
431,3,2,22.85105,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
431,4,2,19.409468,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
431,5,2,17.108053,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
431,6,2,17.745049,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
431,1,3,11.282018,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
431,2,3,14.349351,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
431,3,3,20.169693,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
431,4,3,23.803217,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
431,5,3,19.808846,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
431,6,3,15.377364,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
431,1,4,16.314262,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
431,2,4,14.77276,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
431,3,4,26.041063,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
431,4,4,25.193802,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
431,5,4,23.790182,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
431,6,4,18.55847,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
431,1,5,21.683598,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
431,2,5,21.55931,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
431,3,5,31.152994,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
431,4,5,34.74066,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
431,5,5,30.100113,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
431,6,5,29.368193,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
431,1,6,23.293802,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
431,2,6,31.927704,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
431,3,6,55.631737,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
431,4,6,101.77412,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
431,5,6,98.37713,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
431,6,6,113.71126,241,6,NCGC00182868-02,Daporinad,NAMPT Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
432,1,1,35.483517,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
432,2,1,35.71268,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
432,3,1,52.930252,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
432,4,1,75.15751,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
432,5,1,104.52378,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
432,6,1,115.42851,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
432,1,2,28.488003,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
432,2,2,32.871853,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
432,3,2,63.60128,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
432,4,2,75.27451,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
432,5,2,101.923065,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
432,6,2,115.03239,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
432,1,3,29.073786,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
432,2,3,41.97352,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
432,3,3,48.53264,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
432,4,3,96.70862,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
432,5,3,124.933624,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
432,6,3,119.02352,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
432,1,4,25.978828,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
432,2,4,37.000057,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
432,3,4,57.773678,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
432,4,4,90.23686,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
432,5,4,97.023254,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
432,6,4,117.039055,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
432,1,5,29.762293,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
432,2,5,40.294285,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
432,3,5,56.797462,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
432,4,5,86.6644,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
432,5,5,95.85434,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
432,6,5,104.84179,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
432,1,6,19.625496,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
432,2,6,43.611645,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
432,3,6,49.266373,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
432,4,6,98.91265,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
432,5,6,109.394936,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
432,6,6,110.06769,241,6,NCGC00263130-01,cPEPCK Inhibitor,cPEPCK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
433,1,1,24.30605,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
433,2,1,28.863922,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
433,3,1,51.003258,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
433,4,1,92.02939,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
433,5,1,108.90803,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
433,6,1,100.51877,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
433,1,2,31.62367,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
433,2,2,32.64172,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
433,3,2,50.02955,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
433,4,2,89.772995,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
433,5,2,101.86399,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
433,6,2,124.01394,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
433,1,3,22.931087,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
433,2,3,33.864693,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
433,3,3,51.31519,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
433,4,3,87.032036,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
433,5,3,115.0135,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
433,6,3,117.15003,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
433,1,4,28.614433,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
433,2,4,37.190228,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
433,3,4,58.668976,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
433,4,4,99.76218,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
433,5,4,114.865005,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
433,6,4,123.37836,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
433,1,5,28.891808,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
433,2,5,30.859985,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
433,3,5,51.174026,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
433,4,5,103.48631,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
433,5,5,121.02959,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
433,6,5,126.87042,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
433,1,6,27.55655,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
433,2,6,30.945154,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
433,3,6,52.953934,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
433,4,6,91.072464,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
433,5,6,103.87609,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
433,6,6,108.335014,241,6,NCGC00263232-01,GLS-968,Glutaminase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
434,1,1,13.535185,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
434,2,1,14.954333,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
434,3,1,17.10001,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
434,4,1,30.914997,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
434,5,1,44.67619,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
434,6,1,56.048878,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
434,1,2,13.941145,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
434,2,2,15.963172,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
434,3,2,29.754116,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
434,4,2,61.938232,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
434,5,2,87.750244,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
434,6,2,93.10755,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
434,1,3,21.319277,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
434,2,3,28.919758,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
434,3,3,45.496117,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
434,4,3,100.21685,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
434,5,3,110.284515,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
434,6,3,103.651955,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
434,1,4,27.179611,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
434,2,4,32.76833,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
434,3,4,51.31228,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
434,4,4,96.54235,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
434,5,4,117.59993,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
434,6,4,128.70471,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
434,1,5,32.629284,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
434,2,5,38.23753,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
434,3,5,58.26013,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
434,4,5,99.42771,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
434,5,5,109.6101,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
434,6,5,111.32287,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
434,1,6,33.555042,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
434,2,6,43.298798,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
434,3,6,60.810745,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
434,4,6,106.727554,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
434,5,6,115.4696,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
434,6,6,125.30201,241,6,NCGC00263233-01,IPFK2,Inducible phosphofructokinase-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
435,1,1,26.582779,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
435,2,1,34.062366,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
435,3,1,62.12516,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
435,4,1,95.3949,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
435,5,1,100.43539,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
435,6,1,115.003494,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
435,1,2,30.010895,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
435,2,2,34.142994,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
435,3,2,49.04201,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
435,4,2,90.00089,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
435,5,2,107.1484,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
435,6,2,117.37439,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
435,1,3,29.38837,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
435,2,3,33.451077,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
435,3,3,65.16834,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
435,4,3,104.765564,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
435,5,3,97.56936,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
435,6,3,114.25549,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
435,1,4,25.339378,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
435,2,4,33.643215,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
435,3,4,61.212486,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
435,4,4,95.992935,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
435,5,4,104.06682,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
435,6,4,108.628426,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
435,1,5,27.994967,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
435,2,5,34.195328,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
435,3,5,64.920944,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
435,4,5,103.73263,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
435,5,5,114.76652,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
435,6,5,146.92157,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
435,1,6,34.526775,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
435,2,6,43.835484,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
435,3,6,57.488674,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
435,4,6,102.85972,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
435,5,6,111.68433,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
435,6,6,133.47876,241,6,NCGC00186528-04,TEPP-46,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
436,1,1,17.968782,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
436,2,1,22.178347,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
436,3,1,36.86109,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
436,4,1,59.720654,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
436,5,1,65.79005,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
436,6,1,72.51161,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
436,1,2,26.40225,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
436,2,2,33.07901,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
436,3,2,48.87968,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
436,4,2,82.02709,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
436,5,2,94.484436,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
436,6,2,104.16524,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
436,1,3,21.54058,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
436,2,3,29.10384,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
436,3,3,49.648144,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
436,4,3,84.11715,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
436,5,3,94.79907,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
436,6,3,114.68967,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
436,1,4,25.316757,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
436,2,4,33.98033,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
436,3,4,57.461376,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
436,4,4,86.26513,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
436,5,4,97.54149,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
436,6,4,111.26483,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
436,1,5,26.32877,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
436,2,5,45.54482,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
436,3,5,55.509262,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
436,4,5,86.84362,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
436,5,5,124.72679,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
436,6,5,119.48234,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
436,1,6,31.20179,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
436,2,6,35.99528,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
436,3,6,66.2836,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
436,4,6,102.74951,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
436,5,6,135.56012,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
436,6,6,113.71274,241,6,NCGC00185916-06,DASA-58,PKM2 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
437,1,1,31.430592,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
437,2,1,28.010836,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
437,3,1,54.11212,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
437,4,1,87.65516,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
437,5,1,117.88442,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
437,6,1,103.44376,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
437,1,2,29.930555,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
437,2,2,33.696987,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
437,3,2,61.898594,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
437,4,2,88.041504,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
437,5,2,90.37433,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
437,6,2,117.08896,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
437,1,3,25.385836,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
437,2,3,36.990826,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
437,3,3,58.247684,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
437,4,3,85.9001,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
437,5,3,104.35342,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
437,6,3,110.19482,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
437,1,4,28.063692,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
437,2,4,36.881687,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
437,3,4,57.829315,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
437,4,4,91.82839,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
437,5,4,98.04248,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
437,6,4,111.485954,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
437,1,5,24.612368,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
437,2,5,42.14677,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
437,3,5,50.993683,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
437,4,5,97.12993,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
437,5,5,113.562355,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
437,6,5,106.79884,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
437,1,6,27.826715,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
437,2,6,31.005432,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
437,3,6,51.172825,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
437,4,6,93.46405,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
437,5,6,128.3865,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
437,6,6,98.3311,241,6,NCGC00250391-01,AZD-7545,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
438,1,1,29.05883,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
438,2,1,42.095795,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
438,3,1,51.340073,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
438,4,1,92.23525,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
438,5,1,105.29328,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
438,6,1,98.71991,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
438,1,2,30.326223,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
438,2,2,36.527462,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
438,3,2,60.36844,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
438,4,2,101.15099,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
438,5,2,110.88208,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
438,6,2,101.901344,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
438,1,3,33.658707,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
438,2,3,33.706238,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
438,3,3,57.844166,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
438,4,3,81.225685,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
438,5,3,106.8419,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
438,6,3,124.84174,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
438,1,4,28.254736,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
438,2,4,30.46689,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
438,3,4,51.00413,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
438,4,4,94.511246,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
438,5,4,112.33112,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
438,6,4,121.52533,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
438,1,5,31.38429,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
438,2,5,28.282293,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
438,3,5,63.355408,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
438,4,5,96.932304,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
438,5,5,97.4098,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
438,6,5,103.29493,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
438,1,6,29.761417,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
438,2,6,39.53486,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
438,3,6,44.83595,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
438,4,6,97.40807,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
438,5,6,95.905075,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
438,6,6,93.01338,241,6,NCGC00263231-01,PDHK RIKEN,Pyruvate Dehydrogenase Kinase 2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
439,1,1,27.98978,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
439,2,1,26.650787,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
439,3,1,46.51547,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
439,4,1,85.566055,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
439,5,1,114.236084,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
439,6,1,98.779915,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
439,1,2,24.783545,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
439,2,2,34.97607,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
439,3,2,42.676548,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
439,4,2,97.197945,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
439,5,2,105.79196,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
439,6,2,113.6353,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
439,1,3,31.974657,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
439,2,3,44.533825,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
439,3,3,59.22806,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
439,4,3,95.941895,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
439,5,3,98.64216,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
439,6,3,132.60191,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
439,1,4,31.798294,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
439,2,4,40.654587,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
439,3,4,48.609997,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
439,4,4,97.320366,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
439,5,4,128.41911,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
439,6,4,105.78811,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
439,1,5,37.006588,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
439,2,5,32.431725,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
439,3,5,58.94336,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
439,4,5,102.89972,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
439,5,5,100.50778,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
439,6,5,106.97691,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
439,1,6,29.737347,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
439,2,6,34.113255,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
439,3,6,56.37635,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
439,4,6,94.720146,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
439,5,6,119.81331,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
439,6,6,133.62154,241,6,NCGC00262689-01,NCGC00262689,Isocitrate dehydrogenase inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
440,1,1,29.099201,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
440,2,1,35.536358,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
440,3,1,68.665565,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
440,4,1,104.85467,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
440,5,1,113.26158,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
440,6,1,126.12899,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
440,1,2,33.624565,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
440,2,2,39.026344,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
440,3,2,54.033546,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
440,4,2,103.14164,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
440,5,2,112.29309,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
440,6,2,95.956245,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
440,1,3,26.69108,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
440,2,3,39.85732,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
440,3,3,57.119427,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
440,4,3,98.81022,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
440,5,3,103.94601,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
440,6,3,108.13561,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
440,1,4,24.897215,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
440,2,4,31.41096,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
440,3,4,58.53735,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
440,4,4,94.222404,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
440,5,4,104.70111,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
440,6,4,129.11972,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
440,1,5,34.35692,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
440,2,5,37.106297,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
440,3,5,60.02683,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
440,4,5,109.582466,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
440,5,5,132.48917,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
440,6,5,124.567085,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
440,1,6,29.866755,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
440,2,6,33.28131,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
440,3,6,69.817825,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
440,4,6,107.00126,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
440,5,6,116.77978,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
440,6,6,124.75144,241,6,NCGC00263234-01,IDH-001,IDH1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
441,1,1,14.112635,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
441,2,1,17.496735,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
441,3,1,28.100094,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
441,4,1,40.1893,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
441,5,1,58.81399,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
441,6,1,54.526558,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
441,1,2,16.725578,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
441,2,2,17.234053,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
441,3,2,26.463428,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
441,4,2,44.879627,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
441,5,2,63.917732,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
441,6,2,67.17463,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
441,1,3,17.607779,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
441,2,3,19.99132,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
441,3,3,29.347738,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
441,4,3,54.45355,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
441,5,3,67.98779,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
441,6,3,75.43316,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
441,1,4,15.758011,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
441,2,4,18.27117,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
441,3,4,37.214558,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
441,4,4,55.12859,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
441,5,4,76.89291,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
441,6,4,81.35401,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
441,1,5,18.659119,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
441,2,5,27.966688,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
441,3,5,41.560413,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
441,4,5,63.342674,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
441,5,5,76.08633,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
441,6,5,85.574844,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
441,1,6,23.668873,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
441,2,6,43.563644,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
441,3,6,49.775906,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
441,4,6,87.40681,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
441,5,6,130.79788,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
441,6,6,107.59831,241,6,NCGC00250392-01,AR-C155858,MCT1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
442,1,1,32.614132,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
442,2,1,35.39969,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
442,3,1,47.259407,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
442,4,1,98.89236,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
442,5,1,93.993904,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
442,6,1,109.263985,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
442,1,2,30.688927,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
442,2,2,37.61464,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
442,3,2,62.41245,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
442,4,2,104.036934,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
442,5,2,127.63033,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
442,6,2,120.342896,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
442,1,3,26.941328,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
442,2,3,36.209873,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
442,3,3,64.94303,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
442,4,3,105.759674,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
442,5,3,111.2319,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
442,6,3,126.290436,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
442,1,4,25.09489,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
442,2,4,37.511223,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
442,3,4,60.68996,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
442,4,4,102.419586,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
442,5,4,110.30576,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
442,6,4,116.76613,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
442,1,5,27.05446,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
442,2,5,32.89928,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
442,3,5,45.162056,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
442,4,5,99.64618,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
442,5,5,114.204414,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
442,6,5,121.54899,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
442,1,6,25.118347,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
442,2,6,38.747505,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
442,3,6,60.499336,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
442,4,6,94.65667,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
442,5,6,103.824005,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
442,6,6,106.311226,241,6,NCGC00250393-01,CAP-232,Somatostatin srif2B (sst4) Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
443,1,1,26.027573,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
443,2,1,33.555042,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
443,3,1,56.368008,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
443,4,1,99.24431,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
443,5,1,104.72757,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
443,6,1,109.42,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
443,1,2,24.876343,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
443,2,2,32.898495,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
443,3,2,51.76719,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
443,4,2,96.12497,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
443,5,2,112.83839,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
443,6,2,131.01704,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
443,1,3,28.711985,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
443,2,3,36.124546,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
443,3,3,51.38072,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
443,4,3,103.15438,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
443,5,3,116.148575,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
443,6,3,137.16348,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
443,1,4,33.260403,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
443,2,4,36.076847,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
443,3,4,50.845676,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
443,4,4,95.10409,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
443,5,4,117.90697,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
443,6,4,115.09338,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
443,1,5,25.997793,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
443,2,5,36.65427,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
443,3,5,51.046738,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
443,4,5,106.159325,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
443,5,5,109.166275,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
443,6,5,113.47727,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
443,1,6,34.331516,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
443,2,6,34.29386,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
443,3,6,52.806828,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
443,4,6,96.973885,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
443,5,6,112.262344,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
443,6,6,115.74502,241,6,NCGC00238624-04,NCGC00238624,GALK Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
444,1,1,25.568258,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
444,2,1,28.024052,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
444,3,1,49.405304,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
444,4,1,68.71753,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
444,5,1,93.72409,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
444,6,1,108.276474,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
444,1,2,28.527473,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
444,2,2,33.157154,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
444,3,2,45.15943,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
444,4,2,83.034966,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
444,5,2,114.29602,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
444,6,2,99.94562,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
444,1,3,26.683062,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
444,2,3,30.236275,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
444,3,3,58.86118,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
444,4,3,97.97961,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
444,5,3,121.24373,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
444,6,3,113.72615,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
444,1,4,27.695988,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
444,2,4,33.132458,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
444,3,4,58.82354,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
444,4,4,104.281975,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
444,5,4,98.93663,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
444,6,4,141.74486,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
444,1,5,33.542217,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
444,2,5,32.55689,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
444,3,5,59.036053,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
444,4,5,101.96348,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
444,5,5,116.7879,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
444,6,5,127.90039,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
444,1,6,29.32987,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
444,2,6,33.775734,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
444,3,6,56.985226,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
444,4,6,99.531425,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
444,5,6,117.38591,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
444,6,6,123.52958,241,6,NCGC00263235-01,ACC1 BMS,Acetyl-CoA Carboxylase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
445,1,1,23.312164,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
445,2,1,32.95151,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
445,3,1,46.06894,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
445,4,1,97.52329,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
445,5,1,109.62859,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
445,6,1,116.86716,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
445,1,2,26.57045,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
445,2,2,33.753345,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
445,3,2,58.238007,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
445,4,2,93.38989,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
445,5,2,109.84269,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
445,6,2,124.30328,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
445,1,3,29.64349,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
445,2,3,34.885952,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
445,3,3,50.420517,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
445,4,3,103.511375,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
445,5,3,110.23078,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
445,6,3,112.86341,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
445,1,4,27.803518,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
445,2,4,36.266937,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
445,3,4,55.176903,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
445,4,4,97.569664,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
445,5,4,97.72416,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
445,6,4,107.16619,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
445,1,5,35.612465,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
445,2,5,33.395805,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
445,3,5,58.099155,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
445,4,5,100.608734,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
445,5,5,120.12933,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
445,6,5,119.06387,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
445,1,6,31.530102,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
445,2,6,39.2698,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
445,3,6,59.204292,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
445,4,6,104.03217,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
445,5,6,5.273703,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
445,6,6,114.67402,241,6,NCGC00263115-01,Ibutamoren mesilate,Growth Hormone Secretagogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
446,1,1,26.452967,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
446,2,1,27.145823,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
446,3,1,42.22353,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
446,4,1,78.27214,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
446,5,1,98.56872,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
446,6,1,92.922676,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
446,1,2,21.650175,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
446,2,2,1.285992,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
446,3,2,42.278893,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
446,4,2,4.400606,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
446,5,2,95.685074,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
446,6,2,88.5695,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
446,1,3,33.544815,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
446,2,3,37.92907,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
446,3,3,51.301136,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
446,4,3,86.00605,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
446,5,3,88.89688,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
446,6,3,101.27941,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
446,1,4,29.382793,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
446,2,4,32.519417,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
446,3,4,52.466118,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
446,4,4,84.09761,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
446,5,4,120.81336,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
446,6,4,109.96476,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
446,1,5,26.649443,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
446,2,5,33.8591,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
446,3,5,52.366528,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
446,4,5,96.26921,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
446,5,5,100.78082,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
446,6,5,109.058174,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
446,1,6,28.488186,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
446,2,6,40.41284,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
446,3,6,54.426514,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
446,4,6,99.91777,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
446,5,6,125.91671,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
446,6,6,102.57107,241,6,NCGC00263209-01,ML-141,Cdc42 GTPase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
447,1,1,71.26584,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
447,2,1,63.384415,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
447,3,1,79.57526,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
447,4,1,83.864265,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
447,5,1,100.48878,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
447,6,1,89.44659,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
447,1,2,47.723774,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
447,2,2,39.289993,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
447,3,2,64.93252,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
447,4,2,99.73097,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
447,5,2,119.97227,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
447,6,2,86.59615,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
447,1,3,33.546684,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
447,2,3,40.929974,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
447,3,3,57.733006,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
447,4,3,107.37225,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
447,5,3,108.036964,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
447,6,3,108.68619,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
447,1,4,32.276745,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
447,2,4,42.03753,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
447,3,4,45.594673,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
447,4,4,96.92581,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
447,5,4,109.98065,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
447,6,4,107.86488,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
447,1,5,27.974838,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
447,2,5,33.935352,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
447,3,5,53.276745,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
447,4,5,94.731316,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
447,5,5,102.46732,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
447,6,5,90.92652,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
447,1,6,27.652222,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
447,2,6,34.377346,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
447,3,6,56.92239,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
447,4,6,96.38121,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
447,5,6,103.09103,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
447,6,6,110.10454,241,6,NCGC00263207-01,QS11,ADP-ribosylation factor GTPase activating protein 1 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
448,1,1,29.541224,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
448,2,1,31.093801,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
448,3,1,60.78426,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
448,4,1,101.78001,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
448,5,1,105.35126,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
448,6,1,110.77555,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
448,1,2,31.872154,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
448,2,2,34.00994,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
448,3,2,63.693985,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
448,4,2,104.809,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
448,5,2,111.77265,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
448,6,2,113.77557,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
448,1,3,31.141605,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
448,2,3,35.260277,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
448,3,3,51.19968,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
448,4,3,98.269295,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
448,5,3,99.89497,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
448,6,3,95.106125,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
448,1,4,29.2112,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
448,2,4,37.71158,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
448,3,4,59.7249,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
448,4,4,103.97899,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
448,5,4,113.11057,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
448,6,4,111.43295,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
448,1,5,26.746773,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
448,2,5,35.33663,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
448,3,5,51.09356,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
448,4,5,90.61776,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
448,5,5,100.22363,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
448,6,5,111.484695,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
448,1,6,30.433508,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
448,2,6,31.51541,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
448,3,6,58.934727,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
448,4,6,104.93449,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
448,5,6,110.25327,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
448,6,6,131.21417,241,6,NCGC00263106-01,Gavestinel sodium,NMDA Glycine-Site Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
449,1,1,29.695969,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
449,2,1,27.001917,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
449,3,1,38.775013,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
449,4,1,87.58048,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
449,5,1,110.44566,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
449,6,1,97.87239,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
449,1,2,30.557337,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
449,2,2,29.36605,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
449,3,2,51.138607,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
449,4,2,86.902435,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
449,5,2,105.443535,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
449,6,2,97.74794,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
449,1,3,29.392956,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
449,2,3,38.659462,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
449,3,3,50.222656,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
449,4,3,89.10515,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
449,5,3,98.797806,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
449,6,3,111.83174,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
449,1,4,26.527897,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
449,2,4,34.919075,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
449,3,4,55.34203,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
449,4,4,100.282326,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
449,5,4,126.27418,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
449,6,4,116.98378,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
449,1,5,28.181046,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
449,2,5,39.03439,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
449,3,5,61.60906,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
449,4,5,96.04427,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
449,5,5,110.24272,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
449,6,5,115.74451,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
449,1,6,33.722534,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
449,2,6,36.32037,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
449,3,6,55.1245,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
449,4,6,92.138,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
449,5,6,98.034515,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
449,6,6,121.43795,241,6,NCGC00092329-04,Eliprodil,NMDA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
450,1,1,30.277363,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
450,2,1,33.497498,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
450,3,1,43.133904,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
450,4,1,89.923546,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
450,5,1,96.53297,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
450,6,1,118.42042,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
450,1,2,24.897005,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
450,2,2,36.98846,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
450,3,2,52.64231,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
450,4,2,100.24811,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
450,5,2,112.79895,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
450,6,2,116.50739,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
450,1,3,29.186357,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
450,2,3,44.59337,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
450,3,3,54.256657,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
450,4,3,91.68062,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
450,5,3,102.22758,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
450,6,3,108.70656,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
450,1,4,29.627672,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
450,2,4,36.026012,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
450,3,4,50.28676,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
450,4,4,87.30897,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
450,5,4,115.769875,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
450,6,4,110.07172,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
450,1,5,31.124508,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
450,2,5,41.0566,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
450,3,5,50.10993,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
450,4,5,101.19427,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
450,5,5,120.50375,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
450,6,5,111.4866,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
450,1,6,33.232254,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
450,2,6,38.493263,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
450,3,6,57.63706,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
450,4,6,103.81749,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
450,5,6,105.68158,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
450,6,6,111.080124,241,6,NCGC00186046-01,Caroverine,AMPA Antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
451,1,1,4.149235,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
451,2,1,3.545037,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
451,3,1,6.075526,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
451,4,1,24.404203,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
451,5,1,34.59417,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
451,6,1,36.802994,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
451,1,2,15.500659,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
451,2,2,16.301477,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
451,3,2,37.69563,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
451,4,2,73.20327,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
451,5,2,87.275154,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
451,6,2,89.64907,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
451,1,3,20.353983,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
451,2,3,24.747759,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
451,3,3,42.26087,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
451,4,3,80.80582,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
451,5,3,90.41969,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
451,6,3,94.64885,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
451,1,4,22.76695,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
451,2,4,29.293053,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
451,3,4,46.605312,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
451,4,4,92.31456,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
451,5,4,90.88722,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
451,6,4,86.60996,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
451,1,5,25.12672,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
451,2,5,35.627983,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
451,3,5,51.21858,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
451,4,5,96.11461,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
451,5,5,105.42931,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
451,6,5,108.54405,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
451,1,6,28.91469,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
451,2,6,36.92616,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
451,3,6,60.52082,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
451,4,6,93.55857,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
451,5,6,114.00167,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
451,6,6,102.659256,241,6,NCGC00263113-01,GYKI-53655,AMPA receptor antagonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
452,1,1,29.836792,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
452,2,1,32.192043,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
452,3,1,51.215614,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
452,4,1,97.290054,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
452,5,1,121.03403,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
452,6,1,115.44224,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
452,1,2,27.8828,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
452,2,2,33.944584,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
452,3,2,50.14386,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
452,4,2,88.2647,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
452,5,2,112.64434,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
452,6,2,121.56682,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
452,1,3,37.306442,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
452,2,3,33.10354,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
452,3,3,59.244938,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
452,4,3,99.74565,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
452,5,3,105.56866,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
452,6,3,110.184975,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
452,1,4,32.14039,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
452,2,4,29.192797,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
452,3,4,43.158325,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
452,4,4,93.16967,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
452,5,4,97.36066,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
452,6,4,116.72592,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
452,1,5,31.087885,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
452,2,5,36.476013,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
452,3,5,47.40429,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
452,4,5,92.23813,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
452,5,5,110.331024,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
452,6,5,113.68704,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
452,1,6,30.04864,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
452,2,6,33.145466,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
452,3,6,52.655357,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
452,4,6,95.07384,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
452,5,6,113.540764,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
452,6,6,108.08261,241,6,NCGC00250402-01,Dapagliflozin,SGLT-2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
453,1,1,13.01873,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
453,2,1,13.949582,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
453,3,1,18.784203,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
453,4,1,10.521519,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
453,5,1,3.967349,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
453,6,1,4.671699,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
453,1,2,26.27996,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
453,2,2,32.065876,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
453,3,2,54.59982,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
453,4,2,99.55641,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
453,5,2,115.76913,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
453,6,2,118.49593,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
453,1,3,30.13803,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
453,2,3,36.580345,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
453,3,3,54.175274,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
453,4,3,92.67235,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
453,5,3,98.472176,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
453,6,3,108.5319,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
453,1,4,26.463022,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
453,2,4,33.974194,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
453,3,4,52.824562,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
453,4,4,95.5838,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
453,5,4,96.915855,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
453,6,4,96.05106,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
453,1,5,24.50446,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
453,2,5,27.142662,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
453,3,5,53.471626,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
453,4,5,88.37032,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
453,5,5,90.92371,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
453,6,5,109.28636,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
453,1,6,24.436136,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
453,2,6,31.15349,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
453,3,6,47.65105,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
453,4,6,76.32791,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
453,5,6,103.20775,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
453,6,6,102.78494,241,6,NCGC00242476-02,GSK-4112,Rev-erb alpha Agonist,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
454,1,1,-0.607777,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
454,2,1,-2.22459,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
454,3,1,-2.099923,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
454,4,1,-1.670101,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
454,5,1,-1.409196,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
454,6,1,0.071665,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
454,1,2,-0.135468,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
454,2,2,-2.68184,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
454,3,2,-2.588193,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
454,4,2,-2.711423,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
454,5,2,-2.674264,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
454,6,2,-1.30049,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
454,1,3,-0.725286,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
454,2,3,-2.651121,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
454,3,3,-1.59487,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
454,4,3,-2.739909,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
454,5,3,-2.645609,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
454,6,3,-1.363443,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
454,1,4,-0.631757,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
454,2,4,-2.463944,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
454,3,4,-2.441349,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
454,4,4,-2.482295,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
454,5,4,-2.101647,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
454,6,4,-0.534336,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
454,1,5,0.254714,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
454,2,5,-1.129183,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
454,3,5,-0.079319,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
454,4,5,0.53414,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
454,5,5,1.003811,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
454,6,5,2.326152,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
454,1,6,27.17568,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
454,2,6,26.258684,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
454,3,6,53.38408,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
454,4,6,101.409355,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
454,5,6,101.73276,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
454,6,6,105.09179,241,6,NCGC00242514-01,Sepantronium bromide,Survivin Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
455,1,1,29.029757,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
455,2,1,38.30311,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
455,3,1,54.50634,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
455,4,1,87.4452,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
455,5,1,94.964935,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
455,6,1,119.90171,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
455,1,2,30.802048,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
455,2,2,38.615982,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
455,3,2,57.03269,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
455,4,2,90.96996,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
455,5,2,94.4635,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
455,6,2,115.91355,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
455,1,3,29.48885,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
455,2,3,30.723368,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
455,3,3,57.166603,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
455,4,3,100.21536,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
455,5,3,68.07787,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
455,6,3,115.236084,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
455,1,4,26.087757,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
455,2,4,30.157293,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
455,3,4,52.41962,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
455,4,4,99.51748,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
455,5,4,101.51124,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
455,6,4,119.02189,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
455,1,5,32.597206,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
455,2,5,36.735847,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
455,3,5,55.409332,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
455,4,5,103.09624,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
455,5,5,100.300415,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
455,6,5,104.55377,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
455,1,6,23.603922,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
455,2,6,33.987946,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
455,3,6,59.782368,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
455,4,6,104.74574,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
455,5,6,121.91445,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
455,6,6,105.64657,241,6,NCGC00242492-01,BIBR-1532,Telomerase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
456,1,1,22.813465,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
456,2,1,34.816742,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
456,3,1,51.239677,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
456,4,1,83.18391,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
456,5,1,103.136055,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
456,6,1,100.83296,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
456,1,2,23.830696,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
456,2,2,33.6575,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
456,3,2,52.669712,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
456,4,2,87.10404,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
456,5,2,96.87042,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
456,6,2,121.161255,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
456,1,3,24.540346,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
456,2,3,36.031467,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
456,3,3,48.47259,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
456,4,3,86.22651,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
456,5,3,111.818565,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
456,6,3,118.25989,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
456,1,4,24.244896,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
456,2,4,36.49483,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
456,3,4,58.158627,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
456,4,4,90.89742,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
456,5,4,99.64658,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
456,6,4,113.02869,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
456,1,5,28.35736,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
456,2,5,43.546234,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
456,3,5,57.977283,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
456,4,5,88.25813,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
456,5,5,105.36999,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
456,6,5,111.447685,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
456,1,6,34.78298,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
456,2,6,33.696568,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
456,3,6,65.106544,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
456,4,6,87.394325,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
456,5,6,100.78334,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
456,6,6,115.20283,241,6,NCGC00242501-01,ITX3,Triple Functional Domain Protein (TRIO) Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
457,1,1,-0.077624,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
457,2,1,0.064113,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
457,3,1,1.556548,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
457,4,1,9.034335,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
457,5,1,14.652387,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
457,6,1,17.277487,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
457,1,2,-0.697549,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
457,2,2,-0.6144,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
457,3,2,2.073362,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
457,4,2,9.979523,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
457,5,2,27.827023,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
457,6,2,20.927248,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
457,1,3,0.334394,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
457,2,3,1.272163,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
457,3,3,8.762438,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
457,4,3,31.143482,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
457,5,3,45.558426,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
457,6,3,48.007225,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
457,1,4,17.490133,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
457,2,4,20.263573,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
457,3,4,38.446693,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
457,4,4,75.18853,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
457,5,4,83.2411,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
457,6,4,81.51176,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
457,1,5,26.366264,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
457,2,5,38.84494,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
457,3,5,48.195656,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
457,4,5,88.41551,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
457,5,5,93.595505,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
457,6,5,99.408226,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
457,1,6,27.701475,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
457,2,6,35.495476,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
457,3,6,69.568825,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
457,4,6,70.52248,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
457,5,6,91.45079,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
457,6,6,101.639915,241,6,NCGC00168477-01,Salinomycin,Anticoccidial/Antibacterial,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
458,1,1,30.795565,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
458,2,1,40.47675,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
458,3,1,62.870903,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
458,4,1,87.70052,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
458,5,1,113.142006,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
458,6,1,115.055725,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
458,1,2,30.828789,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
458,2,2,38.779446,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
458,3,2,60.31174,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
458,4,2,94.67226,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
458,5,2,103.80705,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
458,6,2,104.278595,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
458,1,3,33.813812,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
458,2,3,43.355347,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
458,3,3,54.420853,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
458,4,3,102.01418,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
458,5,3,109.5815,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
458,6,3,104.75361,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
458,1,4,31.286268,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
458,2,4,42.511307,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
458,3,4,68.30055,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
458,4,4,92.97493,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
458,5,4,114.07575,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
458,6,4,100.627754,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
458,1,5,33.4024,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
458,2,5,45.672974,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
458,3,5,76.88749,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
458,4,5,92.86969,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
458,5,5,91.735245,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
458,6,5,87.18094,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
458,1,6,31.444405,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
458,2,6,32.032322,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
458,3,6,65.95362,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
458,4,6,89.1424,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
458,5,6,100.93118,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
458,6,6,106.72676,241,6,NCGC00159337-02,Efavirenz,Reverse Transcriptase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
459,1,1,28.763134,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
459,2,1,36.25696,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
459,3,1,51.54614,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
459,4,1,90.46674,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
459,5,1,107.69736,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
459,6,1,111.548,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
459,1,2,26.31544,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
459,2,2,36.03373,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
459,3,2,60.98803,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
459,4,2,90.24347,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
459,5,2,101.6836,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
459,6,2,84.87571,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
459,1,3,34.500446,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
459,2,3,46.917606,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
459,3,3,62.08649,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
459,4,3,100.742325,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
459,5,3,116.0754,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
459,6,3,113.32908,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
459,1,4,30.883135,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
459,2,4,40.660095,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
459,3,4,53.095448,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
459,4,4,96.95971,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
459,5,4,93.68466,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
459,6,4,109.61438,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
459,1,5,27.66288,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
459,2,5,36.386898,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
459,3,5,64.71257,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
459,4,5,99.7499,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
459,5,5,98.829895,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
459,6,5,113.79804,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
459,1,6,27.426306,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
459,2,6,35.791798,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
459,3,6,57.37823,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
459,4,6,94.62359,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
459,5,6,98.31803,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
459,6,6,111.11705,241,6,NCGC00167805-02,Ivachtin,Caspase 3 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
460,1,1,24.672539,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
460,2,1,39.58244,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
460,3,1,53.3821,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
460,4,1,74.59648,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
460,5,1,94.085464,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
460,6,1,97.49315,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
460,1,2,23.990849,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
460,2,2,34.3041,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
460,3,2,49.00177,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
460,4,2,93.37497,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
460,5,2,98.953125,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
460,6,2,108.070206,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
460,1,3,25.126593,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
460,2,3,40.743866,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
460,3,3,56.34495,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
460,4,3,90.97625,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
460,5,3,107.19227,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
460,6,3,106.20609,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
460,1,4,19.90072,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
460,2,4,26.396877,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
460,3,4,44.69289,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
460,4,4,96.30015,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
460,5,4,116.021095,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
460,6,4,118.209885,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
460,1,5,24.487091,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
460,2,5,33.415592,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
460,3,5,53.26027,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
460,4,5,99.76735,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
460,5,5,103.105804,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
460,6,5,101.95015,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
460,1,6,29.083506,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
460,2,6,41.337654,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
460,3,6,56.74956,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
460,4,6,88.16783,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
460,5,6,107.83733,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
460,6,6,101.81466,241,6,NCGC00167785-01,PAC-1,Procaspase 3 Activator,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
461,1,1,29.177307,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
461,2,1,36.362846,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
461,3,1,49.611572,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
461,4,1,91.56604,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
461,5,1,99.72768,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
461,6,1,90.404175,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
461,1,2,28.683977,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
461,2,2,32.845634,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
461,3,2,47.05836,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
461,4,2,90.411705,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
461,5,2,93.50633,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
461,6,2,93.58138,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
461,1,3,30.374084,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
461,2,3,36.56421,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
461,3,3,52.16692,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
461,4,3,99.2414,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
461,5,3,99.11259,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
461,6,3,104.42506,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
461,1,4,29.840885,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
461,2,4,33.276756,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
461,3,4,57.485226,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
461,4,4,87.164246,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
461,5,4,96.420555,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
461,6,4,99.05281,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
461,1,5,31.475044,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
461,2,5,36.611908,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
461,3,5,63.620354,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
461,4,5,102.18157,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
461,5,5,104.20784,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
461,6,5,104.65888,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
461,1,6,34.654507,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
461,2,6,38.564808,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
461,3,6,79.80975,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
461,4,6,97.7874,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
461,5,6,98.96351,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
461,6,6,99.55773,241,6,NCGC00092372-01,Necrostatin-1,RIP1 Kinase Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
462,1,1,44.930984,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
462,2,1,37.585625,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
462,3,1,65.326775,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
462,4,1,87.80227,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
462,5,1,91.66537,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
462,6,1,99.225876,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
462,1,2,33.21719,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
462,2,2,43.73505,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
462,3,2,57.594444,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
462,4,2,85.15675,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
462,5,2,106.179596,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
462,6,2,112.682106,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
462,1,3,23.78381,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
462,2,3,42.303757,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
462,3,3,56.490566,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
462,4,3,97.64242,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
462,5,3,112.507034,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
462,6,3,85.03893,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
462,1,4,29.785006,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
462,2,4,34.213367,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
462,3,4,55.18706,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
462,4,4,94.22295,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
462,5,4,108.466736,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
462,6,4,103.93354,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
462,1,5,24.63144,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
462,2,5,41.668167,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
462,3,5,60.378353,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
462,4,5,96.052574,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
462,5,5,101.62466,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
462,6,5,108.23337,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
462,1,6,33.031483,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
462,2,6,37.36861,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
462,3,6,55.471443,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
462,4,6,91.10511,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
462,5,6,102.125206,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
462,6,6,110.07495,241,6,NCGC00262398-01,NCGC00262398,USP2 Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
463,1,1,26.629333,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
463,2,1,40.19531,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
463,3,1,72.60044,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
463,4,1,86.73532,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
463,5,1,99.693665,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
463,6,1,105.46619,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
463,1,2,25.177044,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
463,2,2,39.215084,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
463,3,2,52.253,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
463,4,2,90.26625,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
463,5,2,91.62452,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
463,6,2,107.27108,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
463,1,3,28.592,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
463,2,3,34.309723,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
463,3,3,54.939102,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
463,4,3,96.931206,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
463,5,3,101.54762,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
463,6,3,107.48998,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
463,1,4,29.177418,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
463,2,4,39.317436,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
463,3,4,59.712234,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
463,4,4,93.69628,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
463,5,4,107.14099,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
463,6,4,105.744705,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
463,1,5,24.679016,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
463,2,5,38.095806,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
463,3,5,62.72889,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
463,4,5,105.73731,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
463,5,5,101.48133,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
463,6,5,126.45298,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
463,1,6,27.770287,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
463,2,6,37.11245,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
463,3,6,63.928623,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
463,4,6,86.62772,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
463,5,6,109.11208,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
463,6,6,114.69924,241,6,NCGC00263142-01,Tiplasinin,PAI Inhibitor,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
464,1,1,0.775656,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
464,2,1,-0.301184,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
464,3,1,-0.001022,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
464,4,1,0.469071,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
464,5,1,1.541629,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
464,6,1,3.892497,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
464,1,2,0.317333,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
464,2,2,-0.840253,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
464,3,2,-0.708946,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
464,4,2,-0.405276,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
464,5,2,-0.154722,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
464,6,2,1.923986,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
464,1,3,2.82972,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
464,2,3,1.59259,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
464,3,3,1.987754,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
464,4,3,5.8055,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
464,5,3,11.069086,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
464,6,3,10.266989,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
464,1,4,23.750793,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
464,2,4,34.771156,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
464,3,4,48.59296,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
464,4,4,91.106064,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
464,5,4,80.4885,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
464,6,4,88.42416,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
464,1,5,35.363052,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
464,2,5,40.804512,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
464,3,5,55.614094,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
464,4,5,97.424355,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
464,5,5,113.746155,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
464,6,5,118.66166,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
464,1,6,28.604338,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
464,2,6,40.391182,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
464,3,6,50.751072,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
464,4,6,104.22591,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
464,5,6,109.01994,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
464,6,6,117.54144,241,6,NCGC00263265-01,ASR-isobudimer-SO2Ph-4-CH2OC(O)NMe2,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
465,1,1,11.544691,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
465,2,1,18.681164,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
465,3,1,36.255524,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
465,4,1,58.30774,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
465,5,1,81.0348,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
465,6,1,79.45364,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
465,1,2,2.795197,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
465,2,2,2.165022,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
465,3,2,6.306704,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
465,4,2,42.447952,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
465,5,2,18.150383,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
465,6,2,23.733358,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
465,1,3,26.628063,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
465,2,3,19.820541,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
465,3,3,51.154346,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
465,4,3,61.799023,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
465,5,3,51.843594,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
465,6,3,86.56069,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
465,1,4,30.902117,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
465,2,4,41.48467,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
465,3,4,48.131844,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
465,4,4,75.618385,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
465,5,4,100.827225,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
465,6,4,111.9994,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
465,1,5,38.621586,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
465,2,5,43.82534,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
465,3,5,67.781944,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
465,4,5,101.42346,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
465,5,5,99.79454,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
465,6,5,100.722404,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
465,1,6,26.50528,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
465,2,6,40.148476,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
465,3,6,62.880726,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
465,4,6,99.57319,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
465,5,6,109.75902,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
465,6,6,116.18185,241,6,NCGC00263268-01,BTM-2C-dimer ketone,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
466,1,1,0.477388,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,50,nM,nM,TMD8,Lymphoma,1
466,2,1,-1.067515,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,12.5,nM,nM,TMD8,Lymphoma,1
466,3,1,-0.810096,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,3.125,nM,nM,TMD8,Lymphoma,1
466,4,1,-0.506426,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.7812,nM,nM,TMD8,Lymphoma,1
466,5,1,-0.477457,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0.1954,nM,nM,TMD8,Lymphoma,1
466,6,1,1.359733,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,2500,0,nM,nM,TMD8,Lymphoma,1
466,1,2,1.647489,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,50,nM,nM,TMD8,Lymphoma,1
466,2,2,-1.156398,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,12.5,nM,nM,TMD8,Lymphoma,1
466,3,2,-1.172063,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,3.125,nM,nM,TMD8,Lymphoma,1
466,4,2,-0.838996,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.7812,nM,nM,TMD8,Lymphoma,1
466,5,2,-0.308105,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0.1954,nM,nM,TMD8,Lymphoma,1
466,6,2,1.313455,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,625,0,nM,nM,TMD8,Lymphoma,1
466,1,3,1.319533,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,50,nM,nM,TMD8,Lymphoma,1
466,2,3,-0.482872,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,12.5,nM,nM,TMD8,Lymphoma,1
466,3,3,-0.131818,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,3.125,nM,nM,TMD8,Lymphoma,1
466,4,3,1.582174,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.7812,nM,nM,TMD8,Lymphoma,1
466,5,3,1.57879,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0.1954,nM,nM,TMD8,Lymphoma,1
466,6,3,4.897142,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,156.25,0,nM,nM,TMD8,Lymphoma,1
466,1,4,10.846617,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,50,nM,nM,TMD8,Lymphoma,1
466,2,4,14.1888,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,12.5,nM,nM,TMD8,Lymphoma,1
466,3,4,21.222961,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,3.125,nM,nM,TMD8,Lymphoma,1
466,4,4,38.518295,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.7812,nM,nM,TMD8,Lymphoma,1
466,5,4,41.60223,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0.1954,nM,nM,TMD8,Lymphoma,1
466,6,4,34.544434,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,39.0626,0,nM,nM,TMD8,Lymphoma,1
466,1,5,36.07107,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,50,nM,nM,TMD8,Lymphoma,1
466,2,5,47.6344,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,12.5,nM,nM,TMD8,Lymphoma,1
466,3,5,60.46605,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,3.125,nM,nM,TMD8,Lymphoma,1
466,4,5,105.292,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.7812,nM,nM,TMD8,Lymphoma,1
466,5,5,105.031296,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0.1954,nM,nM,TMD8,Lymphoma,1
466,6,5,98.82255,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,9.7656,0,nM,nM,TMD8,Lymphoma,1
466,1,6,35.215733,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,50,nM,nM,TMD8,Lymphoma,1
466,2,6,48.654408,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,12.5,nM,nM,TMD8,Lymphoma,1
466,3,6,70.58309,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,3.125,nM,nM,TMD8,Lymphoma,1
466,4,6,99.04082,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.7812,nM,nM,TMD8,Lymphoma,1
466,5,6,105.18187,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0.1954,nM,nM,TMD8,Lymphoma,1
466,6,6,114.861565,241,6,NCGC00263270-01,BTM-2C-dimer allyl oxime,artemesinin analogue,NCGC00187912,Ibrutinib (PCI-32765),Tyrosine-protein kinase BTK,0,0,0,0,nM,nM,TMD8,Lymphoma,1
